Study Status,Study Results,Interventions,Sex,Age,Phases,Enrollment,Funder Type,Study Design,Start Date,Completion Date
COMPLETED,NO,BIOLOGICAL: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|OTHER: Standard treatment according to the Clinical protocols,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,32,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-11,2021-06-30
ACTIVE_NOT_RECRUITING,NO,DRUG: S-217622|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,2093,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-08-03,2024-05-24
UNKNOWN,NO,BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,696,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-08-01,2021-12-30
UNKNOWN,NO,DRUG: MethylPREDNISolone 80 Mg/mL Injectable Suspension,ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-04-14,2021-04-30
NOT_YET_RECRUITING,NO,BIOLOGICAL: COVI-MSC|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-02,2024-09
UNKNOWN,NO,BIOLOGICAL: Mesenchymal Stromal Cells infusion,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-25,2020-12-30
COMPLETED,NO,DIAGNOSTIC_TEST: Take home saliva kits,ALL,"CHILD, ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-09-14,2022-06-30
NOT_YET_RECRUITING,NO,BIOLOGICAL: LVRNA009|BIOLOGICAL: CoronaVac®,ALL,"ADULT, OLDER_ADULT",PHASE3,1100,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-04,2024-10
UNKNOWN,NO,DIETARY_SUPPLEMENT: propolis,ALL,ADULT,NA,45,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-05-15,2021-08-15
ACTIVE_NOT_RECRUITING,NO,DRUG: RSLV-132|DRUG: Sodium Chloride 0.9%,ALL,"ADULT, OLDER_ADULT",PHASE2,70,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-25,2023-03-31
RECRUITING,NO,OTHER: Virtual vs On Site Pulmonary Rehabilitation,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-02,2025-02-02
TERMINATED,NO,BIOLOGICAL: Asunercept|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,34,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-11-03,2023-08-18
WITHDRAWN,NO,BIOLOGICAL: UC-MSCs|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-02-24,2020-02-25
RECRUITING,NO,DEVICE: Transcranial Direct Current Stimulation (tDCS)|BEHAVIORAL: Motor Training|BEHAVIORAL: Cognitive Training,ALL,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-08-25,2024-06-28
TERMINATED,NO,DRUG: UNIKINON (Chloroquine phosphate) 200mg tablets,ALL,"ADULT, OLDER_ADULT",PHASE2,29,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-04-06,2020-11-30
WITHDRAWN,NO,"BIOLOGICAL: candidate vaccine, SCB-2020S",ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-08,2022-04
UNKNOWN,NO,OTHER: Concentrated rehabilitation for patients with persistent symptoms post COVID-19,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2023-12-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: mRNA-1273|BIOLOGICAL: Placebo|BIOLOGICAL: mRNA-1273.222,ALL,"CHILD, ADULT",PHASE2|PHASE3,4331,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-12-09,2024-12-09
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: anti-SARS-Cov-2 vaccination,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-12-21,2024-03-31
UNKNOWN,NO,DRUG: Favipiravir (3200 mg + 1200 mg)|DRUG: Favipiravir (3600 mg + 1600 mg)|DRUG: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|DRUG: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|DRUG: Hydroxychloroquine|DRUG: Hydroxychloroquine combined with Azithromycin,ALL,"ADULT, OLDER_ADULT",PHASE3,1008,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-08,2021-06-01
COMPLETED,NO,COMBINATION_PRODUCT: Cupping therapy with convential medical treatment|DRUG: Convential medical treatment,ALL,"ADULT, OLDER_ADULT",NA,76,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-03-07,2023-06-01
UNKNOWN,NO,BIOLOGICAL: Novaferon|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,222,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-10-28,2022-06
UNKNOWN,NO,DRUG: Hydroxychloroquine Sulfate 200 MG|OTHER: Placebo,ALL,ADULT,PHASE2,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-05-01,2020-09-25
COMPLETED,NO,BIOLOGICAL: NBP2001 adjuvanted with alum (RBD 30μg/dose)|BIOLOGICAL: NBP2001 adjuvanted with alum (RBD 50μg/dose)|OTHER: Normal Saline,ALL,ADULT,PHASE1,50,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-12-17,2022-03-02
UNKNOWN,NO,BIOLOGICAL: Covid-19 vaccine (0-1-4 schedule)|BIOLOGICAL: Covid-19 vaccine (0-1-6 schedule),ALL,"ADULT, OLDER_ADULT",PHASE4,1440,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-11,2022-12
UNKNOWN,NO,DRUG: PD-1 blocking antibody+standard treatment|DRUG: Thymosin+standard treatment|OTHER: standard treatment,ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-02-10,2020-10-31
WITHDRAWN,NO,"DRUG: NT-I7|DRUG: Placebo|PROCEDURE: Blood for research purposes|PROCEDURE: Blood for pharmacokinetic samples|PROCEDURE: Nasopharyngeal, oropharyngeal, or saliva swab|PROCEDURE: Blood for anti-drug antibody (ADA)",ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-07-31,2022-04-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Niclosamide|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,166,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-30,2023-05
NOT_YET_RECRUITING,NO,BIOLOGICAL: AdCLD-CoV19-1 OMI|BIOLOGICAL: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran),ALL,"ADULT, OLDER_ADULT",PHASE3,4000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-09,2025-05
TERMINATED,YES,DRUG: TNKase|DRUG: Placebo|DRUG: Enoxaparin,ALL,"ADULT, OLDER_ADULT",PHASE4,2,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-08,2021-08-08
COMPLETED,NO,BEHAVIORAL: Strength RMT|BEHAVIORAL: Strength RMT and nasal breathing|BEHAVIORAL: Endurance RMT|BEHAVIORAL: Endurance RMT and nasal breathing|BEHAVIORAL: Low dose RMT,ALL,"ADULT, OLDER_ADULT",NA,2268,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-11-01,2023-07-01
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|BIOLOGICAL: Saline placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,300,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-12-15,2022-06-20
COMPLETED,YES,DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE2,221,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-04-03,2020-06-30
COMPLETED,NO,OTHER: CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|OTHER: placebo rinse,ALL,"ADULT, OLDER_ADULT",NA,23,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2020-06-18,2020-10-23
COMPLETED,NO,"DIAGNOSTIC_TEST: BinaxNOW Test|DIAGNOSTIC_TEST: ""Lollipop"" swab",ALL,"CHILD, ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-10-11,2023-05-21
RECRUITING,NO,DRUG: Jinzhen oral liquid or Jinhuaqinggan granules,ALL,"CHILD, ADULT",NA,240,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-18,2023-03-17
WITHDRAWN,NO,COMBINATION_PRODUCT: Hyperbaric oxygen therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-08,2023-12-31
COMPLETED,NO,DIAGNOSTIC_TEST: Data collection and rhinopharyngeal swab,ALL,CHILD,NA,605,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-14,2020-06-01
COMPLETED,NO,OTHER: Circuit Training Exercise Program|OTHER: Aerobic Training Exercise Program,ALL,ADULT,NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-04-01,2022-12-01
COMPLETED,NO,DEVICE: Inogen One® G4,ALL,"ADULT, OLDER_ADULT",NA,21,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2022-06-08,2023-03-02
WITHDRAWN,NO,DRUG: RESP301 (a nitric oxide generating solution)|DRUG: Standard of Care (SOC),ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-09,2022-01
RECRUITING,NO,DEVICE: surgical mask (5 different types),ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-02-06,2023-10-30
UNKNOWN,NO,BIOLOGICAL: Vaxzevria|BIOLOGICAL: Comirnaty,ALL,"ADULT, OLDER_ADULT",PHASE2,3000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-05-10,2021-12-30
UNKNOWN,NO,BIOLOGICAL: ChAdOx1 nCoV-19 single dose + paracetamol|BIOLOGICAL: MenACWY single dose + paracetamol|BIOLOGICAL: ChAdOx1 nCoV-19 two dose + paracetamol|BIOLOGICAL: MenACWY prime & saline placebo boost + paracetamol,ALL,"ADULT, OLDER_ADULT",PHASE3,10300,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-06-02,2021-09
UNKNOWN,NO,DRUG: Cholecalciferol,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-04,2020-12-30
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Positive Affect Regulation sKills (PARK),ALL,"ADULT, OLDER_ADULT",NA,555,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-01,2024-03-31
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Rehabilitation based on CBT principles,ALL,"CHILD, ADULT, OLDER_ADULT",NA,310,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2022-02-21,2024-03-31
NOT_YET_RECRUITING,NO,DRUG: Ensitrelvir|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-01-01,2025-12-31
UNKNOWN,NO,BIOLOGICAL: Sputnik Light,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,110,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-01-15,2021-07-31
UNKNOWN,NO,DRUG: JS016,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-01-20,2022-12-31
RECRUITING,NO,DEVICE: COVIDReApp Group|OTHER: Control Group,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-03-15,2024-09-15
WITHDRAWN,NO,BIOLOGICAL: Convalescent Plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-04-01,2022-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: SNO|DRUG: Nitrogen gas,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,24,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-05,2025-04-30
COMPLETED,YES,DRUG: EIDD-2801|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,71,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-16,2022-02-21
UNKNOWN,NO,BIOLOGICAL: Gam-COVID-Vac|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,2000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-11,2021-12
RECRUITING,NO,BEHAVIORAL: Self-Affirmation Implementation Intentions (SAII) Intervention|BEHAVIORAL: Promotores de Salud (Health Education),ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2023-04-22,2024-10-31
SUSPENDED,NO,DEVICE: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|DEVICE: vv-ECMO only (no cytokine adsorption),ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-01,2021-10-31
ACTIVE_NOT_RECRUITING,NO,DRUG: SOC,ALL,"ADULT, OLDER_ADULT",NA,66,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE,2023-01-19,2023-11-30
NOT_YET_RECRUITING,NO,DEVICE: VR Headset|OTHER: Traditional Theatre-based simulation,ALL,"CHILD, ADULT, OLDER_ADULT",NA,45,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2023-07,2025-12
UNKNOWN,NO,OTHER: Water (E) Mouth rinse with the solution provided|OTHER: Chlorhexidine gluconate (A) Mouth rinse with the solution provided|OTHER: Hydrogen peroxide (B) Mouth rinse with the solution provided|OTHER: Betadine (C) Mouth rinse with the solution provided|OTHER: Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-10-06,2023-12
NOT_YET_RECRUITING,NO,BIOLOGICAL: BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|BIOLOGICAL: influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent),ALL,"ADULT, OLDER_ADULT",PHASE3,8825,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-10-01,2024-09-30
RECRUITING,NO,COMBINATION_PRODUCT: Shampoo and saline|COMBINATION_PRODUCT: Saline and Listerine|COMBINATION_PRODUCT: Shampoo and Listerine|COMBINATION_PRODUCT: Saline and Saline,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,200,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-10-01,2025-05-30
ACTIVE_NOT_RECRUITING,NO,DRUG: AER002|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-08-01,2025-07-31
COMPLETED,NO,DRUG: Poly-ICLC (Hiltonol®) or Placebo|DRUG: Poly-ICLC (Hiltonol®) or Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,43,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-07-21,2023-04-01
COMPLETED,YES,BIOLOGICAL: CoV2 preS dTM-AF03 (low-dose)|BIOLOGICAL: CoV2 preS dTM-AF03 (high-dose)|BIOLOGICAL: CoV2 preS dTM-AS03 (low-dose)|BIOLOGICAL: CoV2 preS dTM-AS03 (high-dose)|BIOLOGICAL: CoV2 preS dTM (high-dose) without adjuvant|BIOLOGICAL: Placebo (0.9% normal saline),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,441,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-09-03,2021-11-19
NOT_YET_RECRUITING,NO,DEVICE: Acupuncture|DEVICE: Sham-acupuncture,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-30,2025-04-30
RECRUITING,NO,BEHAVIORAL: CBT/ACT,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-01,2025-11-15
COMPLETED,NO,BIOLOGICAL: Experimental Group,ALL,CHILD,PHASE4,31041,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-07-24,2023-08-31
COMPLETED,NO,DRUG: glenzocimab|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-16,2021-08-06
COMPLETED,NO,OTHER: Balneotherapy and aquatic exercises,ALL,"ADULT, OLDER_ADULT",NA,98,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-03-29,2023-01-31
COMPLETED,YES,DRUG: CT-P59|DRUG: Placebo,ALL,ADULT,PHASE1,32,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING",2020-07-18,2020-11-05
COMPLETED,NO,DRUG: HH-120 nasal spray 1|DRUG: HH-120 nasal spray 2|DRUG: Placebo Comparator 1|DRUG: Placebo Comparator 2,ALL,"ADULT, OLDER_ADULT",NA,281,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2022-10-20,2022-12-06
RECRUITING,NO,DIAGNOSTIC_TEST: Levels of inflammatory cytokine ( IL-6) in post-COVID-19 POTS and controls|DIAGNOSTIC_TEST: Levels of inflammatory cytokine ( IL-6) in controls|DIAGNOSTIC_TEST: Effect on inflammation after chronic PNS stimulation,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2022-06-01,2026-07-01
COMPLETED,NO,DRUG: hydroxychloroquine|DRUG: azithromycin|DRUG: hydroxychloroquine placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,122,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-04-17,2020-06-18
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Breathing and Wellness Webinar|OTHER: Routine Daily Activity,ALL,"ADULT, OLDER_ADULT",NA,189,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-09-15,2024-03-31
RECRUITING,NO,DEVICE: RDX-19,ALL,"ADULT, OLDER_ADULT",NA,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-10-30,2024-03-30
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 convalescent plasma|OTHER: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,59,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-03,2022-01-26
TERMINATED,NO,DRUG: Tocilizumab (TCZ)|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,5,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-26,2020-09-27
RECRUITING,NO,PROCEDURE: Enhanced external counterpulsation,ALL,"ADULT, OLDER_ADULT",NA,32,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04-01,2024-07
UNKNOWN,NO,DRUG: Dialyzable Leukocyte Extract|DRUG: Placebo oral,ALL,"ADULT, OLDER_ADULT",PHASE2,562,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-05,2020-12
UNKNOWN,NO,BIOLOGICAL: GLS-5130|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-11,2022-12
COMPLETED,YES,"BIOLOGICAL: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)|OTHER: Placebo|BIOLOGICAL: Pfizer-BioNTech COVID-19 Vaccine, Bivalent",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,20,NIH,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-09-08,2023-02-22
COMPLETED,NO,BEHAVIORAL: Childbirth preparation education,FEMALE,"ADULT, OLDER_ADULT",NA,44,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2021-11-08,2021-12-10
UNKNOWN,NO,DRUG: Ivermectin 0.6mg/kg/day|DRUG: Ivermectin 1.0mg/kg/day|DRUG: Placebo|DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,294,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-01-25,2021-04-20
COMPLETED,NO,BIOLOGICAL: COVAX,ALL,"ADULT, OLDER_ADULT",PHASE4,1440,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-10-05,2022-01-05
COMPLETED,NO,DRUG: Transfusion of COVID-19 convalescent plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-15,2021-05-28
UNKNOWN,NO,DRUG: Anakinra Prefilled Syringe|DRUG: Tocilizumab Prefilled Syringe|DRUG: Standard-of-care treatment,ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-11,2021-06
TERMINATED,YES,DEVICE: Continuous Positive Airway Pressure,ALL,"ADULT, OLDER_ADULT",NA,4,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-07,2021-07-07
ENROLLING_BY_INVITATION,NO,OTHER: BrainHQ/Active Comparator Activity|OTHER: BrainHQ|OTHER: PASC CoRE|DEVICE: tDCS-active|DEVICE: tDCS-sham,ALL,"ADULT, OLDER_ADULT",NA,315,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-09-01,2024-12
UNKNOWN,NO,"BIOLOGICAL: SARS-CoV-2 Vaccine (Vero Cells), Inactivated|BIOLOGICAL: Placebo",ALL,CHILD,PHASE1,84,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-08,2022-10
COMPLETED,NO,BIOLOGICAL: ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001),ALL,ADULT,PHASE1,38,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2022-07-01,2023-08-22
UNKNOWN,NO,DEVICE: CPAP helmet|OTHER: Standard of care non-helmet based CPAP ventilation,ALL,"ADULT, OLDER_ADULT",NA,370,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-11-13,2021-12
COMPLETED,NO,DRUG: Dutasteride 0.5 mg|DRUG: Azithromycin|DRUG: Nitazoxanide|DRUG: Placebo,MALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,138,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-30,2020-10-07
NOT_YET_RECRUITING,NO,BIOLOGICAL: Intramuscularly administered Ad5-nCoV vaccine|BIOLOGICAL: Aerosolized Ad5-nCoV|BIOLOGICAL: DelNS1-2019-nCoV-RBD-OPT1|BIOLOGICAL: SYS6006,ALL,"ADULT, OLDER_ADULT",PHASE4,10000,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-05-18,2024-12-31
NOT_YET_RECRUITING,NO,BEHAVIORAL: 12-weeks of Weight Loss|BEHAVIORAL: 12-weeks of Weight Stability,ALL,"ADULT, OLDER_ADULT",NA,150,FED,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-03-01,2028-09-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Blood collection on admission and longitudinally|BIOLOGICAL: Blood collection on their first consultation and 10 to 14 days later,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-03-04,2025-01-07
UNKNOWN,NO,BIOLOGICAL: SARS-CoV-2 Inactivated Vaccine|BIOLOGICAL: The SARS-CoV-2 Inactivated Vaccine,ALL,ADULT,PHASE4,1400,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-06-19,2021-12-19
COMPLETED,NO,BIOLOGICAL: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|BIOLOGICAL: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|BIOLOGICAL: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|BIOLOGICAL: Placebo on a 0- and 28-day schedule,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,471,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-10,2021-10-27
COMPLETED,NO,"DIAGNOSTIC_TEST: iStatis COVID-19 Ag Rapid Test|DIAGNOSTIC_TEST: ""COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America (""Labcorp"")",ALL,"ADULT, OLDER_ADULT",NA,129,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2022-01-13,2022-01-27
UNKNOWN,NO,DRUG: Reduction in antimetabolite immunosuppression,ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-09-24,2023-01-24
COMPLETED,NO,BIOLOGICAL: ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2),ALL,ADULT,PHASE1,80,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-04-20,2023-10-29
COMPLETED,NO,BIOLOGICAL: COVID-19 vaccine HIPRA 10|BIOLOGICAL: COVID-19 vaccine HIPRA 20|BIOLOGICAL: COVID-19 vaccine HIPRA 40|BIOLOGICAL: Commercial COVID-19 vaccine,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,30,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-08-16,2022-09-30
UNKNOWN,NO,DRUG: Aspirin 100mg,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,128,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-10,2020-06
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: EXERCISE,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-03,2022-10-31
RECRUITING,NO,BIOLOGICAL: SARS-CoV-2 subunit protein recombinant vaccine|BIOLOGICAL: Active Comparator,ALL,"ADULT, OLDER_ADULT",PHASE2,900,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-09-01,2023-03-30
COMPLETED,NO,BIOLOGICAL: Ad26.COV2.S|BIOLOGICAL: BNT162b2|BIOLOGICAL: mRNA-1273|BIOLOGICAL: mRNA-1273.211|BIOLOGICAL: mRNA-1273.222|BIOLOGICAL: SARS-CoV-2 rS/M1,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,867,NIH,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-05-28,2023-06-16
UNKNOWN,NO,BIOLOGICAL: ChAdOx1 nCoV-19 vaccine (AZD1222),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,550,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-01-15,2023-12-30
RECRUITING,NO,OTHER: Standard of Care|BIOLOGICAL: SARS-CoV2-CTLS,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-20,2025-12-31
UNKNOWN,NO,BEHAVIORAL: Home exercise program,ALL,OLDER_ADULT,NA,88,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2020-08-01,2020-11-20
TERMINATED,NO,DRUG: Chloroquine|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE2,8,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-04-21,2021-02-10
WITHDRAWN,NO,DRUG: Ruxolitinib,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07,2021-10
UNKNOWN,NO,OTHER: High tone power therapy group,ALL,ADULT,NA,56,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-11-10,2022-11-20
COMPLETED,NO,DRUG: Hydroxychloroquine|DRUG: Favipiravir|DRUG: Favipiravir + Hydroxychloroquine|DRUG: Placebo,ALL,ADULT,PHASE3,1120,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-16,2021-02-16
COMPLETED,YES,BEHAVIORAL: insurance navigation,ALL,"CHILD, ADULT",NA,56,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-12-08,2021-09-01
UNKNOWN,NO,PROCEDURE: Prone Positioning (PP),ALL,"ADULT, OLDER_ADULT",NA,596,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-10,2022-06-01
COMPLETED,YES,DRUG: Dipyridamole 100 Milligram(mg)|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE2,99,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-05-31,2021-02-22
SUSPENDED,NO,DRUG: nirmatrelvir|DRUG: ritonavir,ALL,CHILD,PHASE2|PHASE3,160,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-07,2027-07-03
COMPLETED,YES,"DRUG: Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable|OTHER: Placebo oral tablet without BSS",ALL,"ADULT, OLDER_ADULT",PHASE4,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-10-27,2021-08-15
UNKNOWN,NO,BIOLOGICAL: Inactivated SARS-CoV-2 Vaccine (Vero cell)|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,34020,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-01-28,2022-07
COMPLETED,YES,BIOLOGICAL: COVID-HIGIV|OTHER: Placebo (saline),ALL,ADULT,PHASE1,28,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-24,2021-07-27
NOT_YET_RECRUITING,NO,BEHAVIORAL: Concordant Care Training|BEHAVIORAL: Education Packet Training,ALL,"CHILD, ADULT, OLDER_ADULT",NA,348,FED,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2024-10-01,2027-09-30
COMPLETED,NO,"DEVICE: Exposure to ""TOR"" device|DEVICE: Exposure to switched off ""TOR"" device",ALL,"ADULT, OLDER_ADULT",NA,236,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-29,2021-08-12
UNKNOWN,NO,BIOLOGICAL: mRNA-1273,ALL,"ADULT, OLDER_ADULT",PHASE2,180,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-02-10,2023-01-25
COMPLETED,YES,BIOLOGICAL: BNT162b1|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,144,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-28,2021-08-10
COMPLETED,NO,DEVICE: Device: Physiomer undiluted seawater nasal spray,ALL,"ADULT, OLDER_ADULT",NA,370,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-07-29,2022-03-18
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: VBI-2901a,ALL,ADULT,PHASE1,103,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2022-10-05,2024-02
UNKNOWN,NO,BIOLOGICAL: SAB-185|OTHER: Normal Saline,ALL,ADULT,PHASE1,21,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-20,2021-11
UNKNOWN,NO,BIOLOGICAL: BCG vaccine|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,908,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-21,2021-01-01
TERMINATED,NO,DRUG: Apixaban 2.5 MG|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE4,411,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-03-04,2022-05-30
RECRUITING,NO,BEHAVIORAL: Compassion Focused Therapy (CFT) combined with Breathing Pattern Retraining (BPR),ALL,"ADULT, OLDER_ADULT",NA,160,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-03-25,2023-06
TERMINATED,NO,DRUG: Favipiravir HU 200 mg hard capsules|DRUG: Placebo HU,ALL,"ADULT, OLDER_ADULT",PHASE2,1,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-25,2021-11-29
WITHDRAWN,NO,BIOLOGICAL: Mesenchymal cells|DRUG: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-07,2021-05-31
COMPLETED,NO,DRUG: Enoxaparin|DRUG: Apixaban,ALL,"ADULT, OLDER_ADULT",PHASE4,3460,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-08,2022-12-30
RECRUITING,NO,BEHAVIORAL: Mindfulness-Based Cognitive Therapy|BEHAVIORAL: Muscle Relaxation Therapy,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-19,2024-06-30
COMPLETED,YES,DRUG: Cyclosporine|OTHER: Standard of Care Treatment,ALL,"ADULT, OLDER_ADULT",PHASE2,47,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-23,2021-12-10
TERMINATED,NO,BIOLOGICAL: Equine COVID-19 Antiserum|DRUG: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,7,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-07-27,2022-05-25
COMPLETED,NO,BIOLOGICAL: Peginterferon beta-1a,ALL,"ADULT, OLDER_ADULT",PHASE3,1173,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-12-01,2021-06-30
COMPLETED,NO,DRUG: Echinaforce Chewable tablets,ALL,"ADULT, OLDER_ADULT",PHASE4,122,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-11-20,2021-05-29
UNKNOWN,NO,DRUG: Anti-SARS-CoV-2|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,200,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-01,2021-12-31
COMPLETED,NO,BIOLOGICAL: Convalescent plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,61,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-01,2021-03-31
UNKNOWN,NO,BIOLOGICAL: Half dose of ChAdOx1 nCoV-19 (AZD1222)|BIOLOGICAL: Standard dose of ChAdOx1 nCoV-19 (AZD1222),ALL,ADULT,PHASE2|PHASE3,29637,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-06-01,2022-10-30
UNKNOWN,NO,DIAGNOSTIC_TEST: PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test),ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-06,2021-08
COMPLETED,NO,DIAGNOSTIC_TEST: Innova Lateral Flow Test,ALL,CHILD,NA,449,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-03-26,2022-04-20
COMPLETED,NO,OTHER: Escola L'Horitzó|OTHER: Escola John Talabot,ALL,"CHILD, ADULT, OLDER_ADULT",NA,153,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-04-22,2021-06-17
TERMINATED,YES,BIOLOGICAL: anti-CD14|OTHER: Placebo|DRUG: remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE2,49,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-12,2022-02-04
NOT_YET_RECRUITING,NO,DRUG: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE4,72,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2024-04-01,2025-12-01
NOT_YET_RECRUITING,NO,BIOLOGICAL: SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose|BIOLOGICAL: SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",NA,350,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-04,2024-04
COMPLETED,NO,BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),ALL,ADULT,PHASE1,108,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-03-16,2021-02-20
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 antibody based IVIG therapy,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,50,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-06-19,2021-02-08
COMPLETED,NO,BIOLOGICAL: mRNA-1273|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,30000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-27,2022-12-29
WITHDRAWN,NO,DRUG: HCQ|DRUG: Azithromycin|DRUG: Doxycycline|DIETARY_SUPPLEMENT: Zinc,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-15,2020-07-15
COMPLETED,YES,BIOLOGICAL: COVID-19 Convalescent Plasma (CCP)|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,34,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-09,2021-04-30
UNKNOWN,NO,BIOLOGICAL: SCTV01C|BIOLOGICAL: SCTV01E|BIOLOGICAL: Sinopharm inactivated COVID-19 vaccine|BIOLOGICAL: Comirnaty|BIOLOGICAL: SCTV01E,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,400,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-04-01,2023-08-01
COMPLETED,NO,DRUG: BDB-001 injection|DRUG: BDB-001 injection|DRUG: BDB-001 injection,ALL,ADULT,PHASE1,18,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-21,2020-04-14
COMPLETED,NO,DRUG: Clarithromycin,ALL,"ADULT, OLDER_ADULT",PHASE2,90,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-05-06,2020-11-30
NOT_YET_RECRUITING,NO,"OTHER: Xltranplus, Xltran",ALL,"ADULT, OLDER_ADULT",NA,111,OTHER,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-10,2023-10
COMPLETED,NO,OTHER: music therapy group,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-04-15,2021-06-30
COMPLETED,NO,DIAGNOSTIC_TEST: Blood group determination|DIAGNOSTIC_TEST: Antibody titration|DIETARY_SUPPLEMENT: Probiotic,ALL,"ADULT, OLDER_ADULT",NA,566,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-04-14,2022-04-11
COMPLETED,NO,BIOLOGICAL: Intramuscular Vaccine,ALL,ADULT,PHASE1,180,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-07-10,2021-08-30
TERMINATED,YES,BIOLOGICAL: SARS-CoV-2 mRNA vaccine formulation 1|BIOLOGICAL: SARS-CoV-2 mRNA vaccine formulation 2|BIOLOGICAL: SARS-CoV-2 mRNA vaccine formulation 3|BIOLOGICAL: Placebo (0.9% normal saline),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,182,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-03-12,2022-06-27
UNKNOWN,NO,DRUG: STAT-205,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-05,2022-09-30
COMPLETED,YES,BIOLOGICAL: COVID-19 Convalescent Plasma,ALL,"ADULT, OLDER_ADULT",PHASE1,32,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-30,2021-01-30
UNKNOWN,NO,DRUG: Mouthwash Product|OTHER: Water rinse,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,90,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-07,2022-02
RECRUITING,NO,DEVICE: Transcranial Magnetic Stimulation,ALL,"ADULT, OLDER_ADULT",NA,125,FED,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-11-01,2024-10-31
COMPLETED,NO,DRUG: Progesterone 100 MG,MALE,"ADULT, OLDER_ADULT",PHASE1,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-27,2020-08-20
COMPLETED,NO,DEVICE: Fit test|DEVICE: Filtration Test,ALL,ADULT,NA,43,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-05-01,2020-05-31
COMPLETED,NO,DRUG: MIR 19 ®|COMBINATION_PRODUCT: Standard COVID-19 therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,156,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-27,2021-09-07
COMPLETED,NO,PROCEDURE: Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice|OTHER: Usual emergency department practice with physician-directed diagnostic testing,ALL,"ADULT, OLDER_ADULT",NA,138352,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SCREENING,2021-03-12,2021-06-15
COMPLETED,NO,COMBINATION_PRODUCT: Insulin film|DEVICE: Fast dissolving film,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-10-01,2021-03-20
TERMINATED,NO,DRUG: FSD201|DRUG: Placebo|OTHER: Standard of Care for Covid-19,ALL,"ADULT, OLDER_ADULT",PHASE2,53,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-14,2021-08-24
UNKNOWN,NO,DRUG: Artecom® (pyronaridine-artesunate)|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,402,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-29,2022-04-15
WITHDRAWN,NO,DEVICE: Monitoring of vital signs,ALL,"ADULT, OLDER_ADULT",NA,0,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-01-27,2022-07-31
COMPLETED,NO,BIOLOGICAL: AdCOVID|OTHER: Placebo,ALL,ADULT,PHASE1,92,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-02-25,2022-12-21
ENROLLING_BY_INVITATION,NO,OTHER: Device,ALL,"CHILD, ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-04-16,2025-12-31
COMPLETED,NO,DRUG: NBT-NM108|OTHER: Usual Care Only,ALL,"ADULT, OLDER_ADULT",PHASE2,44,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-02,2022-03-14
NOT_YET_RECRUITING,NO,BEHAVIORAL: iENDURE,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-07-01,2025-01-01
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine|BIOLOGICAL: Prototype/XBB.1.5 Bivalent Vaccine (5 µg),ALL,"CHILD, ADULT",PHASE3,400,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-08-16,2024-03-22
COMPLETED,YES,DRUG: Recombinant human plasma gelsolin (Rhu-pGSN)|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,64,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-30,2022-01-28
UNKNOWN,NO,DIETARY_SUPPLEMENT: Bioarginina®,ALL,"ADULT, OLDER_ADULT",NA,290,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-11-18,2021-09-18
ACTIVE_NOT_RECRUITING,NO,OTHER: symptom-focused rehabilitation|OTHER: usual care,ALL,"ADULT, OLDER_ADULT",NA,132,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-05-20,2023-12-31
COMPLETED,NO,BEHAVIORAL: Telehealth coaching sessions,ALL,OLDER_ADULT,NA,75,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-07-28,2021-06-30
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Microdosing of mindfulness,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2023-01-12,2025-04
TERMINATED,YES,DRUG: Famotidine|DRUG: N-Acetyl cysteine,ALL,"ADULT, OLDER_ADULT",PHASE1,2,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-20,2021-06-02
UNKNOWN,NO,OTHER: blood draw,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-03,2020-07-31
NOT_YET_RECRUITING,NO,DRUG: Calcium Dobesilate|DRUG: Mannitol,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,74,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-05,2023-03
UNKNOWN,NO,DRUG: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1378,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-31,2020-11-15
COMPLETED,NO,BIOLOGICAL: CAP-1002|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,63,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-15,2022-02-04
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Spikogen/Covax-19,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,200,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-03-01,2024-02-25
NOT_YET_RECRUITING,NO,DRUG: Jaktinib hydrochloride tablets|DRUG: placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-04,2025-03
COMPLETED,NO,"DIAGNOSTIC_TEST: SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics",MALE,ADULT,NA,129,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-07-10,2023-12-31
WITHDRAWN,NO,"BIOLOGICAL: Candidate vaccine, SCB-2019",ALL,CHILD,PHASE2|PHASE3,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-10-05,2022-12-15
TERMINATED,NO,DRUG: Transfusion of SARS-CoV-2 Convalescent Plasma.|DRUG: Transfusion of standard Plasma.,ALL,"ADULT, OLDER_ADULT",PHASE3,18,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-14,2021-06-01
RECRUITING,NO,OTHER: Mindfulness - Mindful Awareness Practices ( MAPs),FEMALE,ADULT,NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-02-28,2023-06
RECRUITING,NO,DRUG: [11C]CPPC Injection|DRUG: [11C]CPPC Injection,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,6,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-02,2024-08
RECRUITING,NO,BIOLOGICAL: Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|BIOLOGICAL: CoronaVac Biofarma COVID-1 9 Vaccine 3 µg,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,350,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-09-05,2023-09-05
COMPLETED,NO,DRUG: STI-1558,ALL,"ADULT, OLDER_ADULT",PHASE1,79,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-09-16,2023-03-29
COMPLETED,YES,DRUG: Ensifentrine Dose 1|DRUG: Placebo pMDI,ALL,"ADULT, OLDER_ADULT",PHASE2,45,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-04,2021-05-01
COMPLETED,NO,DIETARY_SUPPLEMENT: Magnesium chloride|DIETARY_SUPPLEMENT: Vitamin D|DIETARY_SUPPLEMENT: Inert placebo,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2022-01-30,2023-09-01
COMPLETED,YES,OTHER: Placebo|DRUG: Remdesivir|DRUG: Baricitinib,ALL,"ADULT, OLDER_ADULT",PHASE3,1033,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-05-08,2020-07-31
WITHDRAWN,NO,DRUG: Bicalutamide 150 Mg Oral Tablet,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04,2022-01
COMPLETED,NO,BIOLOGICAL: TURKOVAC-Dollvet|BIOLOGICAL: TURKOVAC-Koçak,ALL,ADULT,PHASE2,65,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-01-24,2023-05-02
COMPLETED,NO,BEHAVIORAL: Adhera® Fatigue Digital Program,ALL,"ADULT, OLDER_ADULT",NA,58,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-12-13,2023-06-30
ACTIVE_NOT_RECRUITING,NO,DRUG: CIC Vaccine|DRUG: CIC Vaccine|DRUG: qNIV Vaccine|DRUG: SARS-CoV-2 rS Vaccine|DRUG: Influenza Vaccine|DRUG: CIC Vaccine,ALL,"ADULT, OLDER_ADULT",PHASE2,1579,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-12-30,2023-12-24
UNKNOWN,NO,BIOLOGICAL: anti-SARS-CoV-2 convalescent plasma,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-14,2021-09-01
COMPLETED,NO,BIOLOGICAL: VPM1002|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,2038,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-06-18,2021-10-12
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Recombinant COVID-19 vaccine (Sf9 cells)|OTHER: Placebo control,ALL,"ADULT, OLDER_ADULT",PHASE3,40000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-06-15,2023-12-31
COMPLETED,NO,BIOLOGICAL: Gam-COVID-Vac,ALL,ADULT,PHASE1|PHASE2,38,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-06-17,2020-08-10
COMPLETED,NO,DRUG: Remdesivir|DRUG: Tocilizumab,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,205,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-15,2021-02-10
COMPLETED,NO,DIAGNOSTIC_TEST: LumiraDx SARS-CoV-2 & Flu A/B test|DIAGNOSTIC_TEST: LumiraDx SARS-CoV-2 & RSV test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,668,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-01-04,2023-03-14
RECRUITING,NO,"BIOLOGICAL: blood samples, urine samples and nasopharyngeal swabs",ALL,"ADULT, OLDER_ADULT",NA,275,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-02-07,2024-09-30
RECRUITING,NO,OTHER: Breathing techniques over 12 sessions / 6 weeks inc yoga,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-02-10,2024-06-30
UNKNOWN,NO,OTHER: Analysis of genetic polymorphisms of vasoactive peptides in COVID-19,ALL,"ADULT, OLDER_ADULT",NA,151,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-01,2022-02
UNKNOWN,NO,DIETARY_SUPPLEMENT: Acacia Senegal|DIETARY_SUPPLEMENT: Pectin,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,110,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-01,2020-09-01
COMPLETED,YES,BIOLOGICAL: Sotrovimab (Gen1)|BIOLOGICAL: Sotrovimab (Gen2)|BIOLOGICAL: Sotrovimab (Gen2),ALL,"ADULT, OLDER_ADULT",PHASE2,354,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-18,2022-04-06
COMPLETED,YES,OTHER: PRO-SERO-COV,ALL,"ADULT, OLDER_ADULT",NA,526,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-06-18,2021-10-04
UNKNOWN,NO,DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE2,2300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-14,2021-09
COMPLETED,NO,OTHER: patients COVID 19,ALL,"ADULT, OLDER_ADULT",NA,950,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-06-01,2022-07-19
RECRUITING,NO,BIOLOGICAL: Ad5-triCoV/Mac|BIOLOGICAL: ChAd-triCoV/Mac,ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-01-03,2024-09-30
COMPLETED,YES,DRUG: Losartan|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,205,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-13,2021-02-01
COMPLETED,NO,BIOLOGICAL: NDV-HXP-S 1μg|BIOLOGICAL: NDV-HXP-S 3μg|BIOLOGICAL: NDV-HXP-S 10μg|OTHER: Adsorbed inactivated COVID-19 vaccine (CoronaVac),ALL,"ADULT, OLDER_ADULT",PHASE1,320,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-07-09,2022-11-04
COMPLETED,NO,DRUG: Gam-COVID-Vac / Gam-COVID-Vac,ALL,"ADULT, OLDER_ADULT",PHASE2,192,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-07-05,2021-08-15
RECRUITING,NO,DRUG: Stellate Ganglion Block|DRUG: Placebo Sham Injection,ALL,"ADULT, OLDER_ADULT",PHASE2,140,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2023-10-25,2025-08
UNKNOWN,NO,DRUG: Suspension of heat killed (autoclaved) Mycobacterium w|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,480,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-30,2021-04-30
NOT_YET_RECRUITING,NO,DRUG: ACEIs|DRUG: Conventional treatment,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-15,2029-12-01
TERMINATED,NO,BIOLOGICAL: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,6,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-27,2020-11-01
UNKNOWN,NO,DRUG: Oseltamivir|DRUG: Azithromycin|BIOLOGICAL: Umbilical Cord Mesenchymal Stem Cells,ALL,"ADULT, OLDER_ADULT",PHASE1,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07,2020-09
NOT_YET_RECRUITING,NO,OTHER: Blood sampling|OTHER: Skin biopsy,ALL,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-01,2023-03
WITHDRAWN,NO,DRUG: Hydroxychloroquine and Azithromycin|DIETARY_SUPPLEMENT: Azinc,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04,2020-09
NOT_YET_RECRUITING,NO,"DEVICE: Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|DEVICE: OLO-1 Medical Molecular Sieve Oxygen Generator",ALL,"ADULT, OLDER_ADULT",NA,218,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04-01,2024-12-31
COMPLETED,YES,"BIOLOGICAL: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|DRUG: Placebo",ALL,"ADULT, OLDER_ADULT",PHASE2,124,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-01,2021-01-12
TERMINATED,NO,BIOLOGICAL: CONVALESCENT PLASMA,ALL,"ADULT, OLDER_ADULT",PHASE2,1,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-01,2020-09-30
WITHDRAWN,NO,DRUG: Camostat Mesilate|DRUG: Placebo|DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05,2021-12
ACTIVE_NOT_RECRUITING,NO,"DRUG: GRT-R912, samRNA-Spikebeta-TCE11|DRUG: GRT-R914, samRNA-Spikebeta-TCE9|DRUG: GRT-R918, samRNA-SpikeOmicron-N-TCE11",ALL,"ADULT, OLDER_ADULT",PHASE1,342,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-02-28,2024-03
COMPLETED,NO,BIOLOGICAL: COVID-HIG,ALL,ADULT,PHASE1,23,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-07,2022-05-31
RECRUITING,NO,DEVICE: vagal nerve stimulator,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-21,2024-07
COMPLETED,NO,DRUG: MIR 19 ®|COMBINATION_PRODUCT: Standard therapy,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,984,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-10,2023-07-28
COMPLETED,NO,COMBINATION_PRODUCT: Immunofree tablets and Reginmune capsule,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,100,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-07,2020-12-20
COMPLETED,NO,BIOLOGICAL: Convalescent anti-SARS-CoV-2 MBT Plasma|DRUG: Standard Medical Treatment,ALL,"ADULT, OLDER_ADULT",PHASE2,200,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-29,2021-02-04
COMPLETED,NO,DIAGNOSTIC_TEST: rapid salivary test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,122,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC,2020-04-16,2020-07-31
COMPLETED,NO,BIOLOGICAL: Inactivated SARS-CoV-2 Vaccine (Vero cell）,ALL,ADULT,PHASE4,1080,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-05-11,2021-11-30
COMPLETED,NO,DRUG: Chloroquine diphosphate,ALL,"ADULT, OLDER_ADULT",PHASE2,278,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-03-23,2020-06-07
RECRUITING,NO,DRUG: Montelukast|OTHER: placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,284,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-01,2023-08-31
COMPLETED,NO,DRUG: Ethyl methyl hydroxypyridine succinate + Meldonium|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE4,160,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-04-05,2022-11-10
COMPLETED,NO,OTHER: Gown personal protective equipment (PPE-G) suit|OTHER: Coverall personal protective equipment (PPE-C) suit,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2020-09-01,2020-11-18
TERMINATED,YES,DRUG: DUR-928|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,2,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-21,2021-03-04
RECRUITING,NO,BIOLOGICAL: mRNA COVID-19 Vaccine|BIOLOGICAL: Routine Childhood Vaccinations,ALL,CHILD,PHASE4,600,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-10-30,2024-12
RECRUITING,NO,DRUG: Nirmatrelvir|DRUG: Ritonavir|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04-14,2024-10-31
COMPLETED,NO,DIAGNOSTIC_TEST: NG test|DIAGNOSTIC_TEST: Blood test|BEHAVIORAL: Self-questionnary,ALL,"ADULT, OLDER_ADULT",NA,9453,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC,2020-05-29,2020-10-12
UNKNOWN,NO,DRUG: Nivolumab,ALL,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-14,2021-08-31
COMPLETED,NO,PROCEDURE: Direct laryngoscopy|PROCEDURE: Vie Scope laryngoscopy,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-03-20,2020-12-10
UNKNOWN,NO,DRUG: Ivermectin|DRUG: ASP|DRUG: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,1200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-01-22,2022-07
COMPLETED,NO,DRUG: Double-Stranded RNA sodium salt|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,800,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-06-09,2023-01-17
COMPLETED,NO,DIAGNOSTIC_TEST: vaccination against COVID19,ALL,"ADULT, OLDER_ADULT",NA,43,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-12-24,2021-12-24
RECRUITING,NO,DRUG: BC 007 or matching placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,114,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-06-16,2025-05-31
ACTIVE_NOT_RECRUITING,NO,DEVICE: gammaCore® Sapphire (non-invasive vagus nerve stimulator)|OTHER: Standard of care therapies,ALL,"ADULT, OLDER_ADULT",NA,21,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-08,2023-12-01
TERMINATED,NO,DRUG: Hydroxychloroquine Sulfate Regular dose|DRUG: Hydroxychloroquine Sulfate Loading Dose|DRUG: Chloroquine|DRUG: Placebo,ALL,ADULT,PHASE4,137,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-15,2020-08-30
UNKNOWN,NO,DRUG: Silymarin|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-08-16,2021-02-28
TERMINATED,YES,DRUG: Silmitasertib,ALL,"ADULT, OLDER_ADULT",PHASE2,31,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-21,2022-10-19
UNKNOWN,NO,BIOLOGICAL: VPM1002|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,59,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-05-25,2021-05-01
TERMINATED,NO,DRUG: Varespladib|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,18,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-30,2022-11-22
COMPLETED,YES,DRUG: Ivermectin,ALL,"ADULT, OLDER_ADULT",PHASE3,66,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-11,2020-09-02
COMPLETED,NO,DRUG: Sarilumab|OTHER: Standar of care,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-13,2020-12-04
COMPLETED,NO,DRUG: Placebo|DRUG: DuACT,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-12-09,2022-02-28
ACTIVE_NOT_RECRUITING,NO,DRUG: Sodium Chloride|BIOLOGICAL: NDV-HXP-S IN low dose|BIOLOGICAL: NDV-HXP-S IM low dose|BIOLOGICAL: NDV-HXP-S IN high dose|BIOLOGICAL: NDV-HXP-S IM high dose,ALL,ADULT,PHASE1,35,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2022-02-01,2024-04-20
COMPLETED,NO,BIOLOGICAL: SCB-2019|BIOLOGICAL: SCB-2019 with AS03 adjuvant|BIOLOGICAL: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant|BIOLOGICAL: SCB-2019 with Alum adjuvant,ALL,"ADULT, OLDER_ADULT",PHASE1,166,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-06-19,2021-12-08
COMPLETED,NO,BIOLOGICAL: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|BIOLOGICAL: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|BIOLOGICAL: Two doses of placebo at the emergency vaccination schedule|BIOLOGICAL: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|BIOLOGICAL: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|BIOLOGICAL: Two doses of placebo at the routine vaccination schedule|BIOLOGICAL: Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|BIOLOGICAL: Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|BIOLOGICAL: Three doses of placebo at the emergency vaccination schedule|BIOLOGICAL: Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|BIOLOGICAL: Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|BIOLOGICAL: Three doses of placebo at the routine vaccination schedule,ALL,ADULT,PHASE1|PHASE2,744,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-04-16,2021-07-24
UNKNOWN,NO,DEVICE: TCC-COVID mHealth solution,ALL,"ADULT, OLDER_ADULT",NA,2000,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-05-20,2021-05-19
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: COVAC-2|BIOLOGICAL: Saline Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,150,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-08-24,2024-08
ACTIVE_NOT_RECRUITING,NO,"BIOLOGICAL: BNT162b2|BIOLOGICAL: CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK|BIOLOGICAL: CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK",ALL,"ADULT, OLDER_ADULT",PHASE3,247,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-12-08,2022-12
COMPLETED,NO,DEVICE: ARC intellicare,ALL,"ADULT, OLDER_ADULT",NA,31,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2021-03-26,2022-03-30
TERMINATED,YES,DRUG: Hydroxychloroquine|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,3,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-17,2020-07-08
UNKNOWN,NO,DRUG: CBD|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,50,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-01-20,2022-01
COMPLETED,NO,DRUG: DEXAMETHASONE|DRUG: PREDNISOLONE,ALL,"ADULT, OLDER_ADULT",PHASE3,89,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-03,2022-05-13
COMPLETED,NO,DIETARY_SUPPLEMENT: Probiotics (2 strains 10x10^9 UFC)|DIETARY_SUPPLEMENT: Placebo (potato starch and magnesium stearate),ALL,"ADULT, OLDER_ADULT",NA,17,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-12,2021-10-12
UNKNOWN,NO,DRUG: Interferon Beta-1A|DRUG: Lopinavir / Ritonavir|DRUG: Single Dose of Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE4,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-15,2020-04-24
TERMINATED,NO,"BIOLOGICAL: ARCT-021 single dose priming|BIOLOGICAL: ARCT-021 two lower dose priming|BIOLOGICAL: ARCT-021 two higher dose priming|BIOLOGICAL: Placebo (two doses), priming|BIOLOGICAL: Randomized booster|BIOLOGICAL: Placebo booster",ALL,"ADULT, OLDER_ADULT",PHASE2,581,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-01-07,2022-03-01
UNKNOWN,NO,BIOLOGICAL: Infusion IV of Mesenchymal Stem cells,ALL,"ADULT, OLDER_ADULT",PHASE2,10,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-01,2021-05-01
RECRUITING,NO,DIAGNOSTIC_TEST: COVID-19 vaccinated people,ALL,"ADULT, OLDER_ADULT",NA,5000,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-08-20,2024-02-20
COMPLETED,NO,DRUG: Favipiravir|DRUG: Azithromycin,ALL,ADULT,PHASE3,130,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-15,2021-11-08
COMPLETED,NO,DIAGNOSTIC_TEST: Breath Biopsy,ALL,"ADULT, OLDER_ADULT",NA,54,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-07-03,2021-01-30
COMPLETED,YES,DEVICE: RD-X19,ALL,"ADULT, OLDER_ADULT",NA,31,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-18,2021-01-30
COMPLETED,NO,BIOLOGICAL: Sinovac|BIOLOGICAL: AZD1222|BIOLOGICAL: BNT162b2,ALL,ADULT,PHASE4,2354,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-07-05,2024-01-11
UNKNOWN,NO,BIOLOGICAL: Blood plasma,ALL,"ADULT, OLDER_ADULT",NA,11,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-20,2021-06-30
COMPLETED,NO,OTHER: Prone decubitus,ALL,"ADULT, OLDER_ADULT",NA,405,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-27,2021-02-21
UNKNOWN,NO,OTHER: Yoga,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-05-20,2020-12-31
RECRUITING,NO,"DEVICE: percutaneous electrical nerve-field stimulation, PENFS|DEVICE: percutaneous electrical nerve-field stimulation, PENFS (sham device)|DEVICE: percutaneous electrical nerve-field stimulation, PENFS (COVID active device)",ALL,"CHILD, ADULT",NA,125,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-01,2026-12
COMPLETED,NO,BEHAVIORAL: Resistance training|BEHAVIORAL: Standard care,ALL,ADULT,NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-03-08,2022-09-18
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: BCG (Bacillus Calmette-Guérin) vaccine|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,556,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-05-27,2023-12-31
RECRUITING,NO,DEVICE: Volatile Organic Compounds analysis (e-noses)|OTHER: Canine odor detection of Volatile Organic Compounds|DEVICE: Volatile Organic Compounds analysis (mass spectrometry)|DEVICE: Volatile Organic Compounds analysis in sweat (mass spectrometry),ALL,"ADULT, OLDER_ADULT",NA,192,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-03-01,2022-09
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: VXCO-100,ALL,"ADULT, OLDER_ADULT",PHASE1,121,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2023-05-11,2024-07-31
COMPLETED,NO,BEHAVIORAL: Opt-out Recruitment Email|BEHAVIORAL: Opt-in Recruitment Email,ALL,"ADULT, OLDER_ADULT",NA,412,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING",2020-09-09,2020-10-30
COMPLETED,NO,DEVICE: TaffiX™,ALL,"CHILD, ADULT, OLDER_ADULT",NA,693,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-05-19,2021-12-02
COMPLETED,YES,BEHAVIORAL: Hospital: DD-CA|BEHAVIORAL: Hospital: Usual Care (UC),ALL,"ADULT, OLDER_ADULT",PHASE3,172,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-02-01,2022-08-31
WITHDRAWN,NO,DRUG: Hydroxychloroquine plus standard preventive measures|DRUG: Placebo plus standard preventive measures,ALL,ADULT,PHASE3,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-12,2021-05
COMPLETED,NO,DIAGNOSTIC_TEST: Rapid detection test|DIAGNOSTIC_TEST: Nasopharyngeal swab|DIAGNOSTIC_TEST: Stool collection,ALL,"CHILD, ADULT, OLDER_ADULT",NA,600,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-06-02,2020-10-02
COMPLETED,YES,DRUG: Efzofitimod 1 mg/kg|DRUG: Efzofitimod 3 mg/kg|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,36,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-04,2020-10-23
UNKNOWN,NO,DRUG: Therapeutic plasma exchange,ALL,"ADULT, OLDER_ADULT",PHASE3,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-22,2022-03-22
COMPLETED,YES,DRUG: Baricitinib|DRUG: Dexamethasone|OTHER: Placebo|DRUG: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE3,1010,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-02,2021-06-18
COMPLETED,NO,BIOLOGICAL: Umbilical cord Wharton's jelly-derived human|OTHER: NaCl 0.9%,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,47,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-06,2021-10-26
COMPLETED,NO,DRUG: CT-P63|DRUG: Placebo,ALL,ADULT,PHASE1,24,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-10-11,2022-01-25
RECRUITING,NO,BIOLOGICAL: Novaferon|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,914,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-06-10,2022-08
NOT_YET_RECRUITING,NO,BIOLOGICAL: platelets rich plasma,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,88,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-01,2023-01-01
UNKNOWN,NO,BIOLOGICAL: Convalescent plasma,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-11,2022-01-30
UNKNOWN,NO,BIOLOGICAL: ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)|BIOLOGICAL: CoronaVac (Sinovac Biotech)|BIOLOGICAL: Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover),ALL,"ADULT, OLDER_ADULT",PHASE2,520,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-12-01,2022-04-01
WITHDRAWN,NO,DRUG: SCTA01 and SCTA01C|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-15,2022-12-01
RECRUITING,NO,DIETARY_SUPPLEMENT: Vitamin D supplementation in pregnant women,FEMALE,"ADULT, OLDER_ADULT",NA,500,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-09-29,2024-12-30
COMPLETED,NO,DRUG: Canakinumab|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,116,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-23,2021-08-17
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: 20 μg dose of SYS6006|BIOLOGICAL: 30 μg dose of SYS6006|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,40,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-06-01,2023-10-01
TERMINATED,NO,DRUG: Janus Kinase Inhibitor (ruxolitinib)|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,5,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-14,2021-03-29
COMPLETED,NO,DRUG: MBS-COV|OTHER: Placebo,ALL,ADULT,PHASE1,44,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-11-07,2023-03-30
TERMINATED,NO,DIETARY_SUPPLEMENT: Zinc Picolinate|DIETARY_SUPPLEMENT: Resveratrol|DIETARY_SUPPLEMENT: Zinc Picolinate Placebo|DIETARY_SUPPLEMENT: Resveratrol Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,45,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2020-09-08,2021-02-05
ENROLLING_BY_INVITATION,NO,BIOLOGICAL: 0.3ml of mRNA vaccine,ALL,"ADULT, OLDER_ADULT",NA,800,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-09-21,2023-03-21
COMPLETED,NO,DRUG: Nitric Oxide Gas,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-03-21,2022-06-15
RECRUITING,NO,BIOLOGICAL: BNT162b2 (Omi XBB.1.5)/RIV|BIOLOGICAL: BNT162b2 (Omi XBB.1.5)|BIOLOGICAL: RIV|OTHER: Normal saline placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,640,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2024-01-31,2024-09-13
COMPLETED,NO,BIOLOGICAL: ABNCoV2|BIOLOGICAL: Comirnaty,ALL,"ADULT, OLDER_ADULT",PHASE3,4223,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-08-31,2023-10-05
UNKNOWN,NO,DRUG: Bromhexine Hydrochloride Tablets|DRUG: Arbidol Hydrochloride Granules|DRUG: Recombinant Human Interferon α2b Spray,ALL,"ADULT, OLDER_ADULT",NA,18,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-16,2020-06-01
NOT_YET_RECRUITING,NO,DRUG: VIX001,ALL,"ADULT, OLDER_ADULT",PHASE1,9,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-01,2025-09-01
COMPLETED,NO,DRUG: Meplazumab for Injection,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,17,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-03,2020-03-09
COMPLETED,NO,DEVICE: Training with a Robotic Hand Exoskeleton,ALL,"ADULT, OLDER_ADULT",NA,13,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-01,2023-02-01
RECRUITING,NO,DIAGNOSTIC_TEST: COVID19 immunization testing,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-01-10,2023-12-10
ENROLLING_BY_INVITATION,NO,OTHER: Magnetic Resonance Imaging|OTHER: Ultra-High Resolution Computed Tomography (CT) Scan,ALL,"ADULT, OLDER_ADULT",NA,210,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-10-14,2026-10-31
WITHDRAWN,NO,BIOLOGICAL: VBI-2901e,ALL,ADULT,PHASE1,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2023-03,2024-06
NOT_YET_RECRUITING,NO,DRUG: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)|DRUG: MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)|DRUG: MSC-exosomes delivered intravenously every other day (8:8:8),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,55,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2023-09,2024-12
WITHDRAWN,NO,BIOLOGICAL: ResCure™,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01,2021-11
COMPLETED,NO,OTHER: Staff Wellbeing Centres,ALL,"CHILD, ADULT, OLDER_ADULT",NA,819,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-05-25,2020-10-30
COMPLETED,NO,BEHAVIORAL: Culturally Targeted SARS-CoV-2 Communication|BEHAVIORAL: General SARS-CoV-2 Communication,ALL,"ADULT, OLDER_ADULT",NA,525,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SCREENING,2021-08-04,2022-12-19
COMPLETED,NO,BIOLOGICAL: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19),ALL,"ADULT, OLDER_ADULT",PHASE3,150,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-11-19,2021-01-30
COMPLETED,NO,DIAGNOSTIC_TEST: SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen,ALL,"ADULT, OLDER_ADULT",NA,60,FED,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-02-03,2021-08-18
TERMINATED,YES,DRUG: Colchicine|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE3,4506,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-03-23,2021-01-21
WITHDRAWN,NO,DRUG: Hydroxychloroquine|OTHER: Placebo,ALL,OLDER_ADULT,PHASE2|PHASE3,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-21,2021-05-01
COMPLETED,NO,DRUG: Hydrocortisone|DRUG: Sodium Chloride 9mg/mL,ALL,"ADULT, OLDER_ADULT",PHASE3,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-17,2021-09-08
COMPLETED,YES,BEHAVIORAL: Opt-In (Call-Back)|BEHAVIORAL: Opt-in (In-Bound)|BEHAVIORAL: Standard Message|BEHAVIORAL: Clinician Endorsement|BEHAVIORAL: Scarcity|BEHAVIORAL: Opt-Out Framing|BEHAVIORAL: Phone Call,ALL,"CHILD, ADULT, OLDER_ADULT",NA,19554,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2021-04-29,2021-07-06
UNKNOWN,NO,BIOLOGICAL: Lenzilumab|DRUG: Standard of Care,ALL,"ADULT, OLDER_ADULT",PHASE3,520,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-05-05,2021-03
RECRUITING,NO,DRUG: Pregabalin|BEHAVIORAL: Independent walking training|DRUG: Placebo|BEHAVIORAL: Gradual movement therapy in the ward|BEHAVIORAL: Telerehabilitation|BEHAVIORAL: Psychotherapy,ALL,"ADULT, OLDER_ADULT",PHASE2,132,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-10-24,2028-03-01
NOT_YET_RECRUITING,NO,BEHAVIORAL: ENGAGE,ALL,"ADULT, OLDER_ADULT",NA,21,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-04-01,2023-12-30
UNKNOWN,NO,DRUG: Remdesivir|DRUG: Baricitinib|DRUG: Tocilizumab,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,150,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-10,2021-03-05
WITHDRAWN,NO,OTHER: Best Practice|BIOLOGICAL: Tocilizumab,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-07,2020-06-02
UNKNOWN,NO,DRUG: hydroxychloroquine in combination with camostat mesylate|DRUG: Hydroxychloroquine in combination of Azithromycin,ALL,"ADULT, OLDER_ADULT",PHASE3,250,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-11,2020-12-11
UNKNOWN,NO,COMBINATION_PRODUCT: Stem Cell Educator-Treated Mononuclear Cells Apheresis,ALL,ADULT,PHASE2,20,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: TREATMENT,2021-11-10,2022-06-10
RECRUITING,NO,PROCEDURE: Online-based self-help psychological intervention|PROCEDURE: Provide online mental health knowledge,ALL,"ADULT, OLDER_ADULT",NA,110,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-18,2023-09-20
COMPLETED,NO,OTHER: Hypertonic seawater solution,ALL,"ADULT, OLDER_ADULT",NA,56,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2022-06-01,2022-12-31
TERMINATED,YES,DIAGNOSTIC_TEST: Dräger Antigen Test SARS-CoV-2,ALL,"ADULT, OLDER_ADULT",NA,388,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-02-12,2021-03-22
WITHDRAWN,NO,DRUG: Lovenox 40 MG in 0.4 mL Prefilled Syringe|DEVICE: Ultrasound of the lower limbs,ALL,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-02,2020-07-10
COMPLETED,YES,DRUG: Enoxaparin|DRUG: Prophylactic/Intermediate Dose Enoxaparin,ALL,"ADULT, OLDER_ADULT",PHASE3,257,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-26,2021-05-14
COMPLETED,NO,DRUG: Pyramax,ALL,"ADULT, OLDER_ADULT",PHASE2,20,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-24,2022-11-20
ACTIVE_NOT_RECRUITING,NO,OTHER: Screening testing strategy|OTHER: No screening testing strategy,ALL,"CHILD, ADULT, OLDER_ADULT",NA,2474,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-05-07,2023-12-31
UNKNOWN,NO,DRUG: Hydroxychloroquine|DRUG: Azithromycin,ALL,"ADULT, OLDER_ADULT",PHASE4,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-20,2020-05-05
RECRUITING,NO,BIOLOGICAL: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|BIOLOGICAL: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|BIOLOGICAL: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|BIOLOGICAL: Variant-adapted BNT162b2 (Omicron XBB.1.5) Substudy A Ph 2/3 Selected Dose|BIOLOGICAL: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose|BIOLOGICAL: Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose|BIOLOGICAL: Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose,ALL,CHILD,PHASE2|PHASE3,3692,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2022-09-23,2025-08-11
UNKNOWN,NO,BIOLOGICAL: Gam-COVID-Vac|OTHER: Placebo,ALL,ADULT,PHASE3,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-09-28,2021-04-10
COMPLETED,YES,DRUG: Omega-3 Fatty Acid Supplement|DRUG: Placebo/Control,ALL,"ADULT, OLDER_ADULT",PHASE2,139,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07-15,2021-12-31
NOT_YET_RECRUITING,NO,DEVICE: Pulsed ectromagnetid field therapy|OTHER: Pulmonary rehabilitation program (PRP),ALL,"ADULT, OLDER_ADULT",NA,33,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-09-15,2022-12-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Fluarix|BIOLOGICAL: mRNA-1083.1|BIOLOGICAL: mRNA-1083.2|BIOLOGICAL: mRNA-1083.3|BIOLOGICAL: mRNA-1010.4|BIOLOGICAL: mRNA-1283.222|BIOLOGICAL: mRNA-1273.222|BIOLOGICAL: mRNA-1010|BIOLOGICAL: Fluzone HD,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,1231,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-04-14,2024-11-29
COMPLETED,NO,BEHAVIORAL: psychological assessment,FEMALE,"ADULT, OLDER_ADULT",NA,287,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-04-27,2021-02-17
UNKNOWN,NO,PROCEDURE: Pulmonary rehabilitation,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-01,2021-03-31
ACTIVE_NOT_RECRUITING,NO,OTHER: Extension for Community Healthcare Outcomes,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-30,2024-10-31
COMPLETED,NO,BEHAVIORAL: healthcare workers,ALL,"CHILD, ADULT, OLDER_ADULT",NA,183,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-02-25,2021-10-27
UNKNOWN,NO,DIAGNOSTIC_TEST: Neurology test,ALL,"ADULT, OLDER_ADULT",NA,2,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2021-01-12,2021-04-12
COMPLETED,NO,OTHER: COVID-19 patients,ALL,"ADULT, OLDER_ADULT",NA,99,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-05-11,2022-12-30
UNKNOWN,NO,DEVICE: Cytokine Adsorption,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-17,2020-07
NOT_YET_RECRUITING,NO,PROCEDURE: Adipose Tissue Biopsy|DIAGNOSTIC_TEST: Steady State Plasma Glucose (SSPG) Test,ALL,"ADULT, OLDER_ADULT",NA,55,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-05-02,2025-12-31
COMPLETED,NO,DRUG: Angiotensin Receptor Blockers|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE4,787,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-06-19,2022-01-17
UNKNOWN,NO,DRUG: Abidol hydrochloride|DRUG: Oseltamivir|DRUG: Lopinavir/ritonavir,ALL,"ADULT, OLDER_ADULT",PHASE4,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-02-01,2020-07-01
RECRUITING,NO,BEHAVIORAL: RehabCovid_Telematic|BEHAVIORAL: RehabCovid_ImmersiveVR|BEHAVIORAL: Control_Condition,ALL,"ADULT, OLDER_ADULT",NA,158,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-05-01,2024-12-31
RECRUITING,NO,BEHAVIORAL: Cardiac Rehabilitation,ALL,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12,2024-09
COMPLETED,NO,"BIOLOGICAL: ChAdV68-S|BIOLOGICAL: ChAdV68-S-TCE|BIOLOGICAL: SAM-LNP-S|BIOLOGICAL: SAM-LNP-S-TCE|OTHER: Sodium Chloride, 0.9%",ALL,"ADULT, OLDER_ADULT",PHASE1,81,NIH,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-03-18,2023-09-15
UNKNOWN,NO,BIOLOGICAL: Pasocovac vaccine,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-11-01,2023-07-01
COMPLETED,YES,BIOLOGICAL: VLA2001,ALL,ADULT,PHASE1|PHASE2,153,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-12-16,2022-04-06
UNKNOWN,NO,BIOLOGICAL: High-dosage SARS-CoV-2 vaccine|BIOLOGICAL: Medium-dosage SARS-CoV-2 vaccine,ALL,"ADULT, OLDER_ADULT",PHASE4,1200,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-12-17,2022-06-01
COMPLETED,YES,DRUG: Veru-111,ALL,"ADULT, OLDER_ADULT",PHASE2,39,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-18,2021-08-13
UNKNOWN,NO,DRUG: Intravenous Immunoglobulin|OTHER: Standard care,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-10,2020-06-30
RECRUITING,NO,OTHER: Osteopathic Manipulative Treatment in addition to Physiotherapy|OTHER: Physiotherapy,ALL,"ADULT, OLDER_ADULT",NA,104,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-09-20,2023-07-06
COMPLETED,NO,DIAGNOSTIC_TEST: AAZ Covid-19 rapid test,ALL,"ADULT, OLDER_ADULT",NA,75,NETWORK,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-25,2020-10-25
WITHDRAWN,NO,BIOLOGICAL: CLBS119,ALL,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-05,2021-05
UNKNOWN,NO,DRUG: Cyclosporin A,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,200,OTHER_GOV,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-09,2020-09-30
UNKNOWN,NO,BIOLOGICAL: SARS-CoV-2 Specific T Cells,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,18,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-01,2022-12
COMPLETED,NO,DIAGNOSTIC_TEST: Cytokines dosage|DIAGNOSTIC_TEST: Complement dosage,ALL,"CHILD, ADULT, OLDER_ADULT",NA,63,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-03-20,2020-11-23
ENROLLING_BY_INVITATION,NO,DRUG: Paxlovid 25 day dosing|DRUG: Paxlovid 15 day dosing|DRUG: Control,ALL,"ADULT, OLDER_ADULT",PHASE2,900,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-07-26,2024-07
WITHDRAWN,NO,"BEHAVIORAL: Coaching, Cleaning, Communication, Collaboration",ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-12-04,2022-03
UNKNOWN,NO,DRUG: Pyridostigmine Bromide|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,436,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-04,2021-04-30
COMPLETED,YES,DRUG: SNG001|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,623,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-01-12,2022-02-10
UNKNOWN,NO,BIOLOGICAL: Convalescent Plasma,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-28,2020-09-30
UNKNOWN,NO,BEHAVIORAL: exercise group|OTHER: control group,MALE,"ADULT, OLDER_ADULT",NA,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-19,2021-03-01
COMPLETED,NO,BIOLOGICAL: Mesenchymal stem cell|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,15,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-15,2023-05-18
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)|BIOLOGICAL: Placebo|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination,ALL,"ADULT, OLDER_ADULT",PHASE3,23726,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-05-26,2025-01-31
COMPLETED,NO,DRUG: Nitazoxanide|DRUG: Sofosbuvir/Daclatasvir,ALL,"ADULT, OLDER_ADULT",PHASE2,1950,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-12-08,2022-02-28
NOT_YET_RECRUITING,NO,OTHER: Home-based physical training,ALL,"ADULT, OLDER_ADULT",NA,94,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05,2024-02
COMPLETED,NO,OTHER: Body odor samples|OTHER: Body odor samples,ALL,"ADULT, OLDER_ADULT",NA,160,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-06-21,2022-01-14
COMPLETED,YES,BIOLOGICAL: mRNA-1273 vaccine (Pfizer/BioNTech)|BIOLOGICAL: mRNA-1273 vaccine (Moderna),ALL,"ADULT, OLDER_ADULT",PHASE2,81,NIH,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-08-10,2023-03-10
NOT_YET_RECRUITING,NO,OTHER: IV normal saline (1500mL infusion)|OTHER: IV normal saline (50mL infusion),ALL,ADULT,NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-11-01,2027-12-31
UNKNOWN,NO,DRUG: Sofosbuvir|DRUG: Daclatasvir,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-01,2021-04-10
COMPLETED,NO,DRUG: AXA1125|DRUG: Placebo,ALL,ADULT,PHASE2,41,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-12-15,2022-06-29
COMPLETED,YES,DRUG: Fluvoxamine|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,152,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-10,2020-12-12
COMPLETED,NO,DIETARY_SUPPLEMENT: Jing Si Herbal Tea Liquid Packet|DIETARY_SUPPLEMENT: Jing Si Herbal Tea Liquid Packet Placebo,ALL,"ADULT, OLDER_ADULT",NA,32,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-01-01,2023-12-31
UNKNOWN,NO,"DRUG: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,100,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-10,2022-05
TERMINATED,NO,DRUG: Hydroxychloroquine Sulfate|DRUG: Azithromycin|DRUG: Chloroquine Sulfate,ALL,"ADULT, OLDER_ADULT",PHASE3,31,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-04,2021-04-01
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: NVX-CoV2373 (5μg)|BIOLOGICAL: NVX-CoV2601 (5μg)|BIOLOGICAL: NVX-CoV2601(5μg)|BIOLOGICAL: NVX-CoV2601 (35μg)|BIOLOGICAL: NVX-CoV2601(35μg)|BIOLOGICAL: NVX-CoV2601(50μg)|BIOLOGICAL: Bivalent BA.4/5,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1980,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-10-16,2024-11-14
TERMINATED,NO,DRUG: APX-115|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,16,INDIV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-10-20,2022-04-28
COMPLETED,YES,DRUG: Mavrilimumab|DRUG: Placebos,ALL,"ADULT, OLDER_ADULT",PHASE2,2,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-02,2020-11-30
COMPLETED,YES,DRUG: Defibrotide,ALL,"ADULT, OLDER_ADULT",PHASE1,13,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-01,2021-04-09
TERMINATED,YES,COMBINATION_PRODUCT: INOpulse|COMBINATION_PRODUCT: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,191,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-12,2021-01-22
WITHDRAWN,NO,DIAGNOSTIC_TEST: SARS-CoV-2 antigen rapid test,ALL,ADULT,NA,0,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-05,2021-12
WITHDRAWN,NO,DRUG: Peginterferon Lambda-1A,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09,2021-02-05
RECRUITING,NO,BEHAVIORAL: Personalized multidisciplinary day-hospital intervention,ALL,"ADULT, OLDER_ADULT",NA,130,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-18,2025-09
COMPLETED,NO,DIAGNOSTIC_TEST: Blood sample,FEMALE,"CHILD, ADULT",NA,16,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-09-10,2022-01-01
COMPLETED,NO,DRUG: Peginterferon Lambda-1A|OTHER: placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,157,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-13,2022-12-08
COMPLETED,NO,BIOLOGICAL: Gam-COVID-Vac Lyo,ALL,ADULT,PHASE1|PHASE2,38,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-06-17,2020-08-10
COMPLETED,NO,OTHER: Exercise,ALL,"ADULT, OLDER_ADULT",NA,46,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2021-04-01,2021-12-22
RECRUITING,NO,DRUG: Bronchipret,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-14,2022-11-30
COMPLETED,NO,DIAGNOSTIC_TEST: Saliva collection,ALL,"ADULT, OLDER_ADULT",NA,130,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-16,2020-05-17
COMPLETED,NO,BIOLOGICAL: VPM1002|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,122,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2020-06-24,2021-09-09
COMPLETED,NO,DIETARY_SUPPLEMENT: Vitamin D3,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-10-05,2021-04-15
UNKNOWN,NO,DIETARY_SUPPLEMENT: Natural Honey|OTHER: Standard Care,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,1000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-04-15,2021-01-15
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Recombinant SARS-CoV-2 fusion protein vaccine (V-01)|OTHER: Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01),ALL,"ADULT, OLDER_ADULT",PHASE3,22500,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-08-25,2023-06-14
COMPLETED,NO,BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cell) group,ALL,"ADULT, OLDER_ADULT",NA,360,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-08-31,2021-09-30
COMPLETED,NO,DIAGNOSTIC_TEST: Direct Antigen Tests for COVID-19,ALL,"ADULT, OLDER_ADULT",NA,200,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-24,2020-09-24
COMPLETED,YES,DRUG: Niclosamide|DRUG: Placebo|OTHER: Telehealth monitoring,ALL,"ADULT, OLDER_ADULT",PHASE2,73,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-01,2021-08-19
COMPLETED,NO,"BIOLOGICAL: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|BIOLOGICAL: Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|BIOLOGICAL: Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28|BIOLOGICAL: Two doses of placebo at the schedule of day 0, 28（middle-dose group）|BIOLOGICAL: Two doses of placebo at the schedule of day 0, 28（high-dose group）|BIOLOGICAL: Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）",ALL,"ADULT, OLDER_ADULT",PHASE1,168,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-08-28,2021-11-23
ENROLLING_BY_INVITATION,NO,BEHAVIORAL: Brief Behavioral Intervention in Insomnia,ALL,ADULT,NA,36,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-23,2024-02-01
UNKNOWN,NO,OTHER: Physiology,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-10-04,2023-05-04
RECRUITING,NO,PROCEDURE: An Oropharyngeal swab,ALL,"ADULT, OLDER_ADULT",NA,1000,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-11-10,2023-03-02
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: ZR202-CoV|BIOLOGICAL: ZR202a-CoV|BIOLOGICAL: Comirnaty®,ALL,ADULT,PHASE1|PHASE2,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-06-02,2023-08
TERMINATED,YES,DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,1,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-04-14,2020-07-15
COMPLETED,NO,DEVICE: Mouthwash and nose rinse with the AgNPs solution|DEVICE: Mouthwashes and nose rinse in a conventional way,ALL,"ADULT, OLDER_ADULT",NA,231,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2020-04-24,2020-09-29
TERMINATED,YES,BIOLOGICAL: Convalescent plasma,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,940,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-14,2021-06-16
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 inactivated vaccine,ALL,"ADULT, OLDER_ADULT",PHASE3,2300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-11-27,2022-11-01
UNKNOWN,NO,DRUG: AMY-101|OTHER: WFI 5% glucose,ALL,"ADULT, OLDER_ADULT",PHASE2,144,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-09,2022-12
COMPLETED,NO,OTHER: Exercise,ALL,"ADULT, OLDER_ADULT",NA,76,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2021-01-18,2021-07-08
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Advax-CpG55.2 adjuvanted recombinant spike protein,ALL,"ADULT, OLDER_ADULT",PHASE3,39,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-08-15,2023-12-31
COMPLETED,YES,BIOLOGICAL: BNT162b3,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,96,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-09-09,2022-02-07
COMPLETED,NO,"DIETARY_SUPPLEMENT: OL-1, standard dose|DIETARY_SUPPLEMENT: OL-1, high dose|DIETARY_SUPPLEMENT: Placebo",ALL,ADULT,NA,54,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-04-13,2022-01-31
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: Buccal Swabc- Copan flocked swab|DIAGNOSTIC_TEST: Standard of Care COVID-19 swab,ALL,CHILD,NA,2882,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-11-10,2023-12-31
WITHDRAWN,NO,DRUG: INNA-051|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-03-01,2022-12-31
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®),ALL,"CHILD, ADULT",NA,101,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-09-01,2022-03-01
COMPLETED,YES,DRUG: MP0420|DRUG: Placebo|BIOLOGICAL: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE3,485,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-06-11,2023-06-08
COMPLETED,NO,BIOLOGICAL: Convalescent Plasma (CP)|DRUG: Standard COVID-19 therapies,ALL,"CHILD, ADULT",EARLY_PHASE1,3,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-04,2020-09-01
COMPLETED,NO,BIOLOGICAL: C144-LS and C-135-LS,ALL,"ADULT, OLDER_ADULT",PHASE1,23,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-11,2022-02-02
COMPLETED,NO,BIOLOGICAL: Convalescent Plasma|OTHER: Placebo,ALL,OLDER_ADULT,NA,165,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-06-04,2020-10-25
COMPLETED,NO,BEHAVIORAL: Mindfulness session,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-09-01,2022-07-05
RECRUITING,NO,BIOLOGICAL: AZD9838|BIOLOGICAL: Licensed mRNA vaccine,ALL,ADULT,PHASE1,90,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-11-27,2025-04-10
RECRUITING,NO,BIOLOGICAL: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine|DRUG: Saline solution,ALL,"ADULT, OLDER_ADULT",NA,3200,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-01-04,2023-11
COMPLETED,NO,DIAGNOSTIC_TEST: BinaxNOW Rapid Antigen System,ALL,"ADULT, OLDER_ADULT",NA,71,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-05-04,2023-09-01
COMPLETED,YES,DRUG: Weight-based dexamethasone dose,ALL,"ADULT, OLDER_ADULT",PHASE3,142,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-19,2022-03-29
COMPLETED,NO,DEVICE: mouthrinse with bêta-cyclodextrin and citrox|DEVICE: mouthrinse without bêta-cyclodextrin and citrox,ALL,"ADULT, OLDER_ADULT",NA,176,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-04-27,2020-12-11
COMPLETED,NO,"BIOLOGICAL: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|OTHER: Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)",ALL,ADULT,PHASE1|PHASE2,100,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-07-27,2021-12-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Placebo|BIOLOGICAL: mRNA-1345|BIOLOGICAL: Afluria® Quadrivalent|BIOLOGICAL: mRNA-1273.214,ALL,"ADULT, OLDER_ADULT",PHASE3,3800,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-04-01,2025-01-06
TERMINATED,YES,DRUG: Convalescent Plasma|OTHER: Masked Saline Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,75,FED,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-16,2021-09-30
TERMINATED,YES,DRUG: EDP1815|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,16,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-26,2021-05-19
COMPLETED,NO,BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cell) group|BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cells) placebo group,ALL,CHILD,PHASE1,75,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-07-03,2023-04-06
COMPLETED,YES,DRUG: M5049|DRUG: M5049|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,149,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07-29,2021-08-16
COMPLETED,NO,DRUG: Treamid|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-09-01,2021-02-10
RECRUITING,NO,BEHAVIORAL: Restoring Energy with Sub-symptom Threshold Aerobic Rehabilitation Exercise|BEHAVIORAL: Light Stretching/Breathing Exercises,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-10-01,2024-01
COMPLETED,NO,OTHER: ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE|OTHER: PLACEBO,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-02-03,2021-06-30
SUSPENDED,NO,DRUG: KIN001|DRUG: KIN001-Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,400,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-25,2025-10-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Betuvax-CoV-2|DRUG: Placebo,ALL,ADULT,PHASE1|PHASE2,116,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-10-14,2022-07-24
UNKNOWN,NO,BIOLOGICAL: ACT-20-MSC|BIOLOGICAL: ACT-20-CM|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,70,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-05,2020-10
UNKNOWN,NO,DRUG: Carrimycin|DRUG: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|DRUG: basic treatment,ALL,"ADULT, OLDER_ADULT",PHASE4,520,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-23,2021-02-28
TERMINATED,NO,BIOLOGICAL: Convalescent Plasma (anti-SARS-CoV-2 plasma)|BIOLOGICAL: Control (albumin 5%),ALL,"ADULT, OLDER_ADULT",PHASE2,89,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-12,2022-01-06
COMPLETED,NO,DRUG: ensovibep,ALL,"ADULT, OLDER_ADULT",PHASE2,12,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-01,2021-08-20
COMPLETED,NO,OTHER: Homeopathy,ALL,"ADULT, OLDER_ADULT",NA,69,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-06,2023-01-12
RECRUITING,NO,BEHAVIORAL: Psychology interventions,ALL,"CHILD, ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-30,2024-03-30
RECRUITING,NO,"BIOLOGICAL: Recombinant COVID-19 Vaccine (Sf9 Cell)|BIOLOGICAL: COVID-19 Vaccine (Vero Cell), Inactivated",ALL,"ADULT, OLDER_ADULT",PHASE2,450,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-07-11,2023-07
COMPLETED,YES,DIAGNOSTIC_TEST: Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol,ALL,"ADULT, OLDER_ADULT",NA,151,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-10-26,2021-01-20
WITHDRAWN,NO,"DRUG: Combination regimen: Fluoxetine, Prednisolone, Ivermectin|DRUG: Combination regimen: Albendazole, Vitamin C",ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2022-05-01,2022-07-30
UNKNOWN,NO,BEHAVIORAL: Protect Your Elders Campaign,ALL,"ADULT, OLDER_ADULT",NA,4000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-02-17,2022-06-30
ACTIVE_NOT_RECRUITING,NO,DIETARY_SUPPLEMENT: Vitamin D3,ALL,"ADULT, OLDER_ADULT",NA,2000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-11-30,2024-12-30
UNKNOWN,NO,OTHER: Inspiratory Muscle Training,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-10,2022-03-10
WITHDRAWN,NO,DRUG: Melatonin|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-01,2022-12-31
TERMINATED,NO,DRUG: Merimepodib|DRUG: Matching Placebo|DRUG: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE2,44,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-16,2020-12-01
UNKNOWN,NO,OTHER: Convalescent/Vaccine-boosted Plasma (CP/PVP),ALL,"ADULT, OLDER_ADULT",PHASE2,174,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2020-09-03,2022-06
TERMINATED,NO,"DRUG: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies",ALL,"ADULT, OLDER_ADULT",NA,2,NETWORK,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-06-26,2022-11-25
UNKNOWN,NO,BIOLOGICAL: Convalescent COVID 19 Plasma,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-01,2020-12-30
COMPLETED,NO,OTHER: Olfactory Training,ALL,"ADULT, OLDER_ADULT",NA,63,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-03,2021-08-08
TERMINATED,NO,COMBINATION_PRODUCT: Hyperbaric Oxygen,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-06,2020-12-30
NOT_YET_RECRUITING,NO,BIOLOGICAL: Autologous Adipose MSC's,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-04,2026-04
COMPLETED,NO,DEVICE: Volatile Organic Compounds analysis,ALL,"ADULT, OLDER_ADULT",NA,65,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-04-14,2021-06-01
COMPLETED,NO,DRUG: Vitamin C|DRUG: Vitamin E|DRUG: Melatonin|DRUG: N-acetyl cysteine|DRUG: Pentoxifylline,ALL,"CHILD, ADULT, OLDER_ADULT",NA,110,OTHER,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-19,2020-12-01
COMPLETED,NO,DEVICE: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol),ALL,"ADULT, OLDER_ADULT",NA,107,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-20,2022-04-01
COMPLETED,NO,DRUG: Elsulfavirine,ALL,ADULT,PHASE1,15,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-23,2021-08-16
SUSPENDED,NO,DRUG: Hydroxychloroquine|DRUG: Azithromycin|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE3,300,FED,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-30,2021-08
COMPLETED,NO,BIOLOGICAL: Experimental Group,ALL,"ADULT, OLDER_ADULT",PHASE4,131650,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-06-05,2023-08-31
NOT_YET_RECRUITING,NO,DEVICE: whole body hyperthermia,ALL,"ADULT, OLDER_ADULT",NA,21,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-10-01,2024-12-01
UNKNOWN,NO,DRUG: Favipiravir,ALL,"ADULT, OLDER_ADULT",PHASE2,190,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-30,2021-12
COMPLETED,YES,DRUG: PF-07304814|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,26,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-09-09,2021-06-07
NOT_YET_RECRUITING,NO,OTHER: Sessions of cognitive stimulation,ALL,"ADULT, OLDER_ADULT",NA,88,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-12-14,2023-11
COMPLETED,NO,DRUG: Chloroquine,ALL,"ADULT, OLDER_ADULT",PHASE2,3217,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-03-28,2021-09-30
NOT_YET_RECRUITING,NO,OTHER: Overall uncertainty language,ALL,"ADULT, OLDER_ADULT",NA,960,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: OTHER,2022-12,2023-03
RECRUITING,NO,BIOLOGICAL: Pfizer-BioNTech COVID-19 Vaccine 2023-2024|BIOLOGICAL: Moderna COVID-19 Vaccine 2023-2024|DRUG: SOC IS Regimen|DRUG: SOC IS Reduction,ALL,"ADULT, OLDER_ADULT",PHASE2,400,NIH,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-06,2025-03-04
COMPLETED,NO,DRUG: Dornase Alfa Inhalation Solution [Pulmozyme],ALL,"ADULT, OLDER_ADULT",PHASE2,41,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-16,2021-11-05
COMPLETED,NO,BEHAVIORAL: The Kaleidescope|BEHAVIORAL: The visual illusion cards,ALL,CHILD,NA,114,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-03-01,2022-07-01
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: inactive SARS-CoV-2 vaccine (Vero cell)|BIOLOGICAL: Low dose aerosolized Ad5-nCoV|BIOLOGICAL: High dose aerosolized Ad5-nCoV,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,420,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-09-13,2022-12-30
COMPLETED,NO,DRUG: Vit-D 0.2 MG/ML Oral Solution [Calcidol]|DRUG: Physiological Irrigating Solution,ALL,"ADULT, OLDER_ADULT",PHASE3,130,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-04-22,2020-10-31
TERMINATED,NO,DEVICE: Hemopurifier,ALL,"ADULT, OLDER_ADULT",NA,1,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-01,2022-11-14
UNKNOWN,NO,DRUG: MRG-001|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,40,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-12-01,2022-07-01
RECRUITING,NO,DRUG: TAZCOV|DRUG: Vidicine,ALL,"ADULT, OLDER_ADULT",PHASE2,510,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-03-03,2024-01
UNKNOWN,NO,BIOLOGICAL: Adsorbed SARS-CoV-2 (inactivated) vaccine,ALL,ADULT,PHASE4,6233,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-18,2022-03
UNKNOWN,NO,BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV),ALL,"ADULT, OLDER_ADULT",PHASE2,876,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-06-24,2022-09-30
COMPLETED,YES,DEVICE: Rapid Onsite COVID-19 Detection,ALL,"CHILD, ADULT, OLDER_ADULT",NA,93,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-07-13,2021-03-31
WITHDRAWN,NO,DIETARY_SUPPLEMENT: Nicotinamide riboside|DIETARY_SUPPLEMENT: Placebo,ALL,OLDER_ADULT,PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-01,2022-05-01
UNKNOWN,NO,DRUG: Eculizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-16,2020-12-31
RECRUITING,NO,OTHER: Sampling of tissue,ALL,"CHILD, ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-05-07,2024-12-31
ENROLLING_BY_INVITATION,NO,DIAGNOSTIC_TEST: Humoral immunity,ALL,"ADULT, OLDER_ADULT",NA,350,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-01-23,2024-12-31
UNKNOWN,NO,DRUG: Mavrilimumab|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-22,2020-11-22
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 (LVRNA009) 50μg group|BIOLOGICAL: SARS-CoV-2 (LVRNA009) 100μg group|OTHER: Placebo,ALL,ADULT,PHASE2,420,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-03-16,2023-06-21
COMPLETED,NO,DRUG: Nigella|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,500,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-01,2021-12-31
COMPLETED,NO,DIETARY_SUPPLEMENT: NLC-V,ALL,"ADULT, OLDER_ADULT",PHASE2,31,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-30,2022-01-20
RECRUITING,NO,DRUG: NP-101|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,308,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-02-22,2023-12-22
UNKNOWN,NO,BEHAVIORAL: Guided online support program|BEHAVIORAL: WHO recommendations (waiting condition),ALL,"ADULT, OLDER_ADULT",NA,600,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: TREATMENT,2020-04-08,2021-12
TERMINATED,YES,DRUG: LY3127804|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,95,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-20,2020-10-12
COMPLETED,YES,DRUG: PUL-042 Inhalation Solution|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,101,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-16,2021-07-02
COMPLETED,NO,OTHER: 16-hour PP,ALL,"ADULT, OLDER_ADULT",NA,61,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-25,2021-10-27
COMPLETED,NO,DRUG: TNX-102 SL|DRUG: Placebo SL Tablet,ALL,"ADULT, OLDER_ADULT",PHASE2,63,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-18,2023-07-27
WITHDRAWN,NO,"DRUG: Povidone Iodine 5% Soln,Top,Kit",ALL,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2024-07-03,2026-04-01
COMPLETED,NO,BIOLOGICAL: SARS-COV2 Pfizer Vaccine,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-07,2022-05-08
COMPLETED,YES,DRUG: Ibrutinib|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,46,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-06,2021-06-08
WITHDRAWN,NO,BIOLOGICAL: SARS-CoV-2 mRNA Vaccine (CVnCoV)|BIOLOGICAL: Quadrivalent influenza vaccine (QIV)|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-10-01,2022-11-15
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: STEP-COVID,FEMALE,"ADULT, OLDER_ADULT",PHASE1,100,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-09-01,2022-12-10
TERMINATED,NO,DRUG: Hydroxychloroquine Sulfate Regular dose|DRUG: Hydroxychloroquine Sulfate Loading Dose|DRUG: Chloroquine|DRUG: Placebo,ALL,ADULT,PHASE4,125,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-14,2020-08-30
TERMINATED,NO,BIOLOGICAL: AZD1222,ALL,"ADULT, OLDER_ADULT",PHASE4,34,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-01-31,2023-04-19
RECRUITING,NO,BEHAVIORAL: CARE Program and Valera Application with care manager functionality|BEHAVIORAL: Valera Application with care manager functionality|BEHAVIORAL: CARE Program|BEHAVIORAL: Valera Application|BEHAVIORAL: CARE Program and Valera Application,ALL,"ADULT, OLDER_ADULT",NA,360,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-17,2026-03-31
COMPLETED,NO,DIAGNOSTIC_TEST: Diagnostic Test: IN Vitro,ALL,"CHILD, ADULT, OLDER_ADULT",NA,202,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-04-11,2023-04-30
RECRUITING,NO,DRUG: Sirolimus,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-07-09,2024-06
TERMINATED,NO,DRUG: Isavuconazonium Injection [Cresemba]|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,8,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-03-16,2021-10-25
RECRUITING,NO,RADIATION: Thoracic CT scan,ALL,"ADULT, OLDER_ADULT",NA,500,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-06-13,2025-06
COMPLETED,NO,BIOLOGICAL: Low-dose SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|BIOLOGICAL: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant,ALL,"CHILD, ADULT",PHASE3,581,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-02-23,2022-09-30
COMPLETED,NO,DRUG: BAF312|DRUG: Baseline disease modifying therapies (DMTs),ALL,"ADULT, OLDER_ADULT",PHASE4,41,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-19,2022-08-15
UNKNOWN,NO,BIOLOGICAL: Pfizer|BIOLOGICAL: Moderna,ALL,"ADULT, OLDER_ADULT",NA,418,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-05-28,2022-01
WITHDRAWN,NO,BIOLOGICAL: Recombinant COVID-19 vaccine (Sf9 cells)|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-02-01,2022-03-15
NOT_YET_RECRUITING,NO,DRUG: Nitazoxanide|DIETARY_SUPPLEMENT: Vitamin Super-B Complex|DRUG: Placebo|OTHER: Standard of Care,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,2000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-08,2025-05
COMPLETED,NO,DRUG: Icatibant|DRUG: 0.9% Sodium Chloride Injection,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,32,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-05-16,2023-07-07
UNKNOWN,NO,DRUG: Aerosolized 13 cis retinoic acid|DRUG: Aerosolized All trans retinoic acid|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,360,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10,2020-12
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: ABNCoV2 100ug|BIOLOGICAL: ABNCoV2 50ug,ALL,"ADULT, OLDER_ADULT",PHASE2,197,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-19,2024-02-01
ACTIVE_NOT_RECRUITING,NO,DEVICE: Cereset Research,ALL,"ADULT, OLDER_ADULT",NA,144,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-12-14,2025-03
COMPLETED,NO,DRUG: IVIG,ALL,"ADULT, OLDER_ADULT",PHASE3,76,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-07,2020-09-15
COMPLETED,NO,DRUG: nirmatrelvir/ritonavir|DRUG: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE3,264,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-17,2022-06-01
COMPLETED,NO,DEVICE: COVVR_Synch|DEVICE: COVVR_Asynch,ALL,"ADULT, OLDER_ADULT",NA,26,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: SUPPORTIVE_CARE",2020-11-26,2021-04-06
COMPLETED,NO,BIOLOGICAL: avdoralimab|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,208,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-27,2021-03-30
TERMINATED,YES,DRUG: Resveratrol|DIETARY_SUPPLEMENT: Vitamin D3,ALL,"ADULT, OLDER_ADULT",PHASE2,105,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-13,2021-03-01
WITHDRAWN,NO,DRUG: T89,ALL,"ADULT, OLDER_ADULT",NA,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-26,2020-04-20
COMPLETED,NO,DRUG: FOY-305|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,155,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-09,2021-04-09
COMPLETED,NO,BIOLOGICAL: COVAXIN,ALL,"CHILD, ADULT",PHASE2|PHASE3,525,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-05-26,2022-01-25
ACTIVE_NOT_RECRUITING,NO,DEVICE: Low-field thoracic magnetic stimulation (LF-ThMS),ALL,"ADULT, OLDER_ADULT",NA,17,OTHER,"Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: BASIC_SCIENCE",2020-07-03,2022-09-17
ACTIVE_NOT_RECRUITING,NO,DRUG: GLS-5310 (Group 1)|DRUG: GLS-5310 (Group 2)|DRUG: GLS-5310 (Group 3)|DRUG: GLS-5310 (Group 4),ALL,"ADULT, OLDER_ADULT",PHASE1,69,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-05-23,2023-12
COMPLETED,NO,BIOLOGICAL: BCG vaccine|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE4,301,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-05-26,2021-05-07
COMPLETED,NO,"OTHER: Collection of blood, salivary and nasopharyngeal samples.",ALL,"ADULT, OLDER_ADULT",NA,189,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-11-23,2021-05-12
WITHDRAWN,NO,BIOLOGICAL: BACMUNE (MV130)|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-10,2021-12
COMPLETED,NO,BIOLOGICAL: BNT162b2s01|BIOLOGICAL: BNT162b2,ALL,"ADULT, OLDER_ADULT",PHASE2,137,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-07-26,2022-09-16
COMPLETED,NO,DIAGNOSTIC_TEST: Serological tests for SARS Cov-2,ALL,"ADULT, OLDER_ADULT",NA,2817,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-06-20,2020-12-31
COMPLETED,YES,DIETARY_SUPPLEMENT: Nutritional support system (NSS)|OTHER: Conventional nutritional support designed by hospital nutritionists,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-07,2021-04-10
NOT_YET_RECRUITING,NO,OTHER: intensive combined rehabilitation therapy,ALL,ADULT,NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-10-01,2023-10-01
RECRUITING,NO,DIETARY_SUPPLEMENT: Mitoquinone|DIETARY_SUPPLEMENT: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",NA,300,FED,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-11-01,2028-10-31
SUSPENDED,NO,DRUG: Hydroxychloroquine|DIETARY_SUPPLEMENT: Vitamin C,ALL,"ADULT, OLDER_ADULT",PHASE4,13,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-03-30,2022-05-27
COMPLETED,NO,DRUG: Cerebrolysin,ALL,ADULT,PHASE3,250,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-01,2022-10-30
COMPLETED,NO,DRUG: Ivermectin Oral Product|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,476,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-14,2020-12-21
UNKNOWN,NO,DRUG: sofosbuvir|DRUG: Sofosbuvir ledipsavir|DRUG: Daclatasvir,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-01,2021-08-31
UNKNOWN,NO,DRUG: Resveratrol|DRUG: Placebo capsules,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-01,2022-05
COMPLETED,YES,DRUG: Ivermectin|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,66,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: TREATMENT,2020-07-01,2021-01-29
COMPLETED,YES,BIOLOGICAL: LY3819253|BIOLOGICAL: Placebo|BIOLOGICAL: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE3,314,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-05,2021-02-01
COMPLETED,NO,"DRUG: Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins|DRUG: Oral low dose steroid|DRUG: Intravenous Antibiotics with Low dose steroid.|DRUG: Oral anti-coagulant",ALL,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-04-15,2021-06-06
TERMINATED,YES,BIOLOGICAL: Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells,ALL,"ADULT, OLDER_ADULT",PHASE1,7,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-23,2022-03-02
NOT_YET_RECRUITING,NO,DRUG: Metformin|OTHER: Placebo,ALL,"CHILD, ADULT",PHASE3,16,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-01,2024-12
COMPLETED,NO,BIOLOGICAL: MAD0004J08|OTHER: Placebo,ALL,ADULT,PHASE1,30,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-01,2021-10-20
COMPLETED,NO,BIOLOGICAL: Moderna mRNA-1273 COVID-19 vaccine|BIOLOGICAL: Pfizer BNT162b2 COVID-19 vaccine,ALL,"ADULT, OLDER_ADULT",PHASE4,66,NETWORK,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-25,2022-12-21
UNKNOWN,NO,DIETARY_SUPPLEMENT: Ketogenic diet with phytoextracts,ALL,"ADULT, OLDER_ADULT",NA,28,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-01,2021-08-30
UNKNOWN,NO,COMBINATION_PRODUCT: stem cells,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-05-25,2020-09-01
COMPLETED,NO,DEVICE: Face mask|BEHAVIORAL: Face mask awareness,ALL,"ADULT, OLDER_ADULT",NA,350000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2020-11-15,2021-06-29
WITHDRAWN,NO,BIOLOGICAL: SII B.1.351|BIOLOGICAL: SII B.1.351|BIOLOGICAL: SII Bivalent|BIOLOGICAL: SII Bivalent|BIOLOGICAL: SII B.1.617.2,ALL,ADULT,PHASE1|PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-02-04,2022-08
RECRUITING,NO,DRUG: CI-581a|DRUG: CI-581b,ALL,"ADULT, OLDER_ADULT",PHASE2,12,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-03-20,2023-12-31
COMPLETED,NO,COMBINATION_PRODUCT: AZD7442|OTHER: Placebo,ALL,ADULT,PHASE1,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-18,2021-10-19
RECRUITING,NO,DRUG: Ramatroban|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,324,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-11-10,2026-05-31
COMPLETED,NO,BIOLOGICAL: Convalescent plasma,ALL,"ADULT, OLDER_ADULT",NA,474,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-16,2021-05-31
COMPLETED,NO,DRUG: HCQ|OTHER: Standard therapy,ALL,"ADULT, OLDER_ADULT",PHASE3,325,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-03-01,2020-07-31
UNKNOWN,NO,OTHER: Standard administration of oxygen flow|DEVICE: Automated oxygen administration - FreeO2,ALL,"ADULT, OLDER_ADULT",NA,216,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-04-20,2021-10-31
COMPLETED,NO,DIETARY_SUPPLEMENT: Probiotic: Lactobacillus salivarius + Vit D + Zinc|DIETARY_SUPPLEMENT: Placebo,ALL,"ADULT, OLDER_ADULT",NA,41,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-10-25,2022-04-30
TERMINATED,NO,OTHER: blood sample analyses,ALL,"ADULT, OLDER_ADULT",NA,139,NETWORK,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-12-16,2022-12-31
COMPLETED,NO,BEHAVIORAL: 1: Prone positioning|BEHAVIORAL: 2: No instruction regarding positioning,ALL,"ADULT, OLDER_ADULT",NA,446,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-26,2021-09-23
WITHDRAWN,NO,DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04,2020-08
UNKNOWN,NO,OTHER: Cryo lung biopsies,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-08-01,2022-06-01
COMPLETED,NO,DRUG: Chloroquine Diphosphate|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE2,152,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-08,2020-06-08
COMPLETED,YES,BIOLOGICAL: sotrovimab|BIOLOGICAL: sotrovimab|BIOLOGICAL: sotrovimab|BIOLOGICAL: sotrovimab|BIOLOGICAL: Sotrovimab|BIOLOGICAL: Sotrovimab|BIOLOGICAL: Sotrovimab,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,1065,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-10,2023-03-24
NOT_YET_RECRUITING,NO,DRUG: Treamid|DRUG: Treamid twice a day|DRUG: Treamid once a day|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,412,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-08,2022-12
COMPLETED,NO,BIOLOGICAL: SCTA01|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,33,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07-24,2020-11-17
RECRUITING,NO,BIOLOGICAL: BioBlock® antiviral nasal spray,ALL,ADULT,PHASE4,2000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2022-05-01,2023-12-30
COMPLETED,NO,OTHER: diaphragmatic positioning|OTHER: incentive spirometer|OTHER: Control,ALL,ADULT,NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-01,2023-02-02
TERMINATED,YES,DRUG: Razuprotafib Subcutaneous Solution|DRUG: Placebo Subcutaneous Solution,ALL,"ADULT, OLDER_ADULT",PHASE2,31,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-21,2021-02-26
WITHDRAWN,NO,DRUG: Budesonide|BEHAVIORAL: High-Concentration Essential Oil|DRUG: Placebo|BEHAVIORAL: Low-Concentration Essential Oil,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-01,2023-12-31
WITHDRAWN,NO,BIOLOGICAL: SCTV01C|BIOLOGICAL: Comirnaty,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-04-25,2023-02-01
COMPLETED,NO,DRUG: REGN10933+REGN10987|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,974,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-26,2021-11-22
COMPLETED,YES,DEVICE: PneumoniaCheck,ALL,"ADULT, OLDER_ADULT",NA,69,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-04-14,2022-08-05
COMPLETED,NO,BIOLOGICAL: CpG 1018/Alum-adjuvanted SCB-2019 vaccine|BIOLOGICAL: Placebo; 0.9% saline|BIOLOGICAL: SCB-2019 vaccine|BIOLOGICAL: SCB-2019 vaccine for Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,31454,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-03-24,2023-04-23
UNKNOWN,NO,DEVICE: BioStation T101 and TeraTube,ALL,"ADULT, OLDER_ADULT",NA,500,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-01-01,2022-08-01
COMPLETED,NO,DRUG: Favipiravir|DRUG: Chloroquine,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,92,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-20,2020-09-28
UNKNOWN,NO,DRUG: Heparin sodium|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-01,2021-12-31
COMPLETED,NO,OTHER: endurance training|OTHER: concurrent training,ALL,"ADULT, OLDER_ADULT",NA,66,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-02-10,2023-05-31
UNKNOWN,NO,DRUG: Ivermectin,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,100,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-31,2020-08-15
COMPLETED,NO,DRUG: Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly|DRUG: Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaled|DRUG: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE3,313,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-28,2022-11-22
TERMINATED,NO,DRUG: XAV-19|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,290,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-04-28,2022-11-28
TERMINATED,NO,DEVICE: Nitric Oxide delivered via LungFit™ system,ALL,"ADULT, OLDER_ADULT",NA,4,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2020-06-13,2020-09-30
COMPLETED,NO,DRUG: Hydroxychloroquine|DRUG: Azithromycin|OTHER: Placebo Tablet|OTHER: Placebo capsules,ALL,"ADULT, OLDER_ADULT",NA,456,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-14,2020-08-30
COMPLETED,NO,BEHAVIORAL: a wake prone positioning,ALL,"ADULT, OLDER_ADULT",NA,93,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-03-08,2023-05-01
RECRUITING,NO,DEVICE: Auricular Acupuncture,ALL,ADULT,NA,280,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-03-01,2025-05-01
COMPLETED,NO,BIOLOGICAL: BNT162b2|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,950,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-12-04,2022-01-09
COMPLETED,NO,DEVICE: Inspiratory muscle trainer|OTHER: diaphragmatic release,MALE,ADULT,NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-08-01,2022-12-01
WITHDRAWN,NO,BIOLOGICAL: COVI-MSC,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08,2022-01
RECRUITING,NO,DIAGNOSTIC_TEST: Perfusion brain scintigraphy imaging,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-08-10,2023-12-31
RECRUITING,NO,DIETARY_SUPPLEMENT: Nutritional blend (ImmuneRecov).,ALL,"ADULT, OLDER_ADULT",PHASE3,58,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-10,2024-12-15
WITHDRAWN,NO,DRUG: Famotidine 20 milligram tablet,ALL,"ADULT, OLDER_ADULT",PHASE4,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-05-01,2022-01-31
RECRUITING,NO,DRUG: IMM-BCP-01|DRUG: Placebo,ALL,ADULT,PHASE1,36,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-06-03,2023-04
UNKNOWN,NO,DIAGNOSTIC_TEST: Serological testing,ALL,"ADULT, OLDER_ADULT",NA,3500,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-05-12,2021-12-25
UNKNOWN,NO,BIOLOGICAL: Covi Vax,ALL,ADULT,PHASE1,72,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-11-14,2023-05-23
COMPLETED,NO,DRUG: Quercetin,ALL,"ADULT, OLDER_ADULT",PHASE1,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-01-04,2021-06-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: PHH-1V81|BIOLOGICAL: Comirnaty Omicron XBB1.5,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,612,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-11-13,2024-06-01
UNKNOWN,NO,BIOLOGICAL: Gam-COVID-vac M|BIOLOGICAL: Placebo,ALL,CHILD,PHASE2|PHASE3,3000,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-07-05,2023-12-31
COMPLETED,NO,BEHAVIORAL: Tele-delivered psychological intervention,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-05-29,2022-05-31
NOT_YET_RECRUITING,NO,DRUG: CX-4945 (SARS-CoV-2 domain)|DRUG: Placebo (SARS-CoV-2 domain)|DRUG: CX-4945 (Influenza virus domain)|DRUG: Placebo (Influenza virus domain),ALL,"ADULT, OLDER_ADULT",PHASE2,136,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-03,2025-06
RECRUITING,NO,BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cell),ALL,"ADULT, OLDER_ADULT",PHASE4,100000,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-04-02,2023-06
RECRUITING,NO,COMBINATION_PRODUCT: Institutional standard treatment for xerostomia and Long Covid|RADIATION: Photobiomodulation Therapy|RADIATION: Placebo Photobiomodulation Therapy,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,10,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-03-01,2024-12
UNKNOWN,NO,DRUG: Niclosamide suspension|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,200,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-08,2021-02-14
RECRUITING,NO,"BEHAVIORAL: Intervention 1: According to DGP|BEHAVIORAL: Intervention 2: According to Cacioppo ""E.A.S.E.""",ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-01-18,2025-09-30
UNKNOWN,NO,OTHER: 3D Telemedicine|OTHER: 2D Telemedicine,ALL,"CHILD, ADULT, OLDER_ADULT",NA,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2021-09-30,2021-12-31
COMPLETED,NO,DRUG: Ivermectin,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,164,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2020-12-01
NOT_YET_RECRUITING,NO,BIOLOGICAL: RQ3013|BIOLOGICAL: Comirnaty,ALL,ADULT,PHASE1,120,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-12,2023-06
COMPLETED,NO,DRUG: Orally Suspension of CoV2-OGEN1,ALL,ADULT,PHASE1,45,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-06-30,2022-11-11
NOT_YET_RECRUITING,NO,BIOLOGICAL: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|BIOLOGICAL: Recombinant novel coronavirus protein vaccine (CHO cells),ALL,"ADULT, OLDER_ADULT",NA,160,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-09-20,2024-06-30
COMPLETED,NO,DRUG: N-acetylcysteine,ALL,"ADULT, OLDER_ADULT",PHASE2,165,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-23,2021-05-14
NOT_YET_RECRUITING,NO,"DIAGNOSTIC_TEST: IL-6|DIAGNOSTIC_TEST: cytokines (IL-17, and IFN-ɣ)|BEHAVIORAL: Compass 31",ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-01-30,2026-10-31
COMPLETED,NO,BEHAVIORAL: Participate in a massive musical event,ALL,ADULT,NA,1000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-11-30,2021-01-08
UNKNOWN,NO,DRUG: Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)|OTHER: Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE),ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,950,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-08-30,2021-04-01
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|BIOLOGICAL: ChAdOx1-S not less than 2.5 × 10^8 infectious units|BIOLOGICAL: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose),ALL,"ADULT, OLDER_ADULT",PHASE3,4036,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-08-30,2023-11
WITHDRAWN,NO,DRUG: Hydroxychloroquine and azithromycin treatment arm.|DRUG: Hydroxychloroquine|DRUG: Control arm,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-02,2020-06-02
RECRUITING,NO,DEVICE: Wearable device,ALL,"ADULT, OLDER_ADULT",NA,100500,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-11-16,2025-12-01
COMPLETED,NO,DRUG: Reparixin|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,312,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-14,2021-10-31
TERMINATED,NO,DIAGNOSTIC_TEST: conjunctival swab,ALL,"ADULT, OLDER_ADULT",NA,534,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-01-19,2021-04-29
COMPLETED,NO,BIOLOGICAL: Group A (AG0302-COVID19)|BIOLOGICAL: Group A (Placebo)|BIOLOGICAL: Group B (AG0302-COVID19)|BIOLOGICAL: Group B (Placebo),ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,500,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-11-23,2022-02-01
COMPLETED,NO,"BIOLOGICAL: Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)|BIOLOGICAL: Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)",ALL,"ADULT, OLDER_ADULT",PHASE3,610,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-04-19,2023-09-23
TERMINATED,NO,BIOLOGICAL: PLX-PAD,ALL,"ADULT, OLDER_ADULT",PHASE2,23,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-19,2023-02-07
UNKNOWN,NO,DIAGNOSTIC_TEST: real time PCR,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-12-15,2022-12
COMPLETED,NO,BIOLOGICAL: 9vHPV Vaccine|BIOLOGICAL: mRNA-1273 Vaccine,ALL,CHILD,PHASE3,165,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-03-28,2023-12-12
RECRUITING,NO,OTHER: Placebo|DRUG: Metformin,ALL,"ADULT, OLDER_ADULT",PHASE3,15000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2023-09-05,2024-06
NOT_YET_RECRUITING,NO,BEHAVIORAL: Incentive Spirometer respiratory training,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-07-01,2026-08-01
WITHDRAWN,NO,DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10,2022-06-01
COMPLETED,NO,BEHAVIORAL: exercise,ALL,"ADULT, OLDER_ADULT",NA,401,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-09-01,2021-12-25
ACTIVE_NOT_RECRUITING,NO,DRUG: Peginterferon Lambda-1A|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,763,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-27,2022-06-30
COMPLETED,NO,DEVICE: iCura COVID-19 Antigen Rapid Home Test|DIAGNOSTIC_TEST: RT-PCR Test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,100,NETWORK,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-08-04,2022-12-20
COMPLETED,NO,BIOLOGICAL: AZD1222|BIOLOGICAL: rAd26-S,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,100,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-07-13,2022-07-26
COMPLETED,NO,BIOLOGICAL: Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,62,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-30,2021-08-31
UNKNOWN,NO,DEVICE: Bone conduction headphones,ALL,CHILD,NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-22,2021-06-01
COMPLETED,NO,BIOLOGICAL: Convalescent plasma|DRUG: Camostat Mesilate|DRUG: Placebo for Camostat Mesilate|OTHER: Standard of Care (SoC),ALL,"ADULT, OLDER_ADULT",PHASE2,22,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-08,2021-10-29
UNKNOWN,NO,OTHER: Aerobic Exercises,FEMALE,ADULT,NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-12-10,2021-02-25
TERMINATED,YES,BIOLOGICAL: Emapalumab|BIOLOGICAL: Anakinra,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,16,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-02,2020-11-13
COMPLETED,NO,DRUG: HFB30132A|OTHER: Placebo,ALL,ADULT,PHASE1,24,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-20,2021-07-26
COMPLETED,NO,DRUG: BTL-TML-COVID|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,28,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-30,2021-02-28
TERMINATED,NO,DRUG: ABBV-990|DRUG: Placebo for ABBV-990,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2022-07-25,2022-09-26
COMPLETED,NO,COMBINATION_PRODUCT: RQ-001|OTHER: Placebo,ALL,ADULT,PHASE1,66,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-09-27,2024-01-03
NOT_YET_RECRUITING,NO,PROCEDURE: Active tDCS and cognitive training|PROCEDURE: Sham tDCS and cognitive training,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-06-30,2023-03-30
UNKNOWN,NO,BIOLOGICAL: Anti SARS-CoV-2 equine hyperimmune serum|BIOLOGICAL: placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,156,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-29,2021-09-29
UNKNOWN,NO,DRUG: Trimetazidine,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-10,2021-04-30
RECRUITING,NO,BEHAVIORAL: Cognitive Rehabilitation|OTHER: Education,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-05-01,2024-12-01
COMPLETED,YES,DRUG: VERU-111,ALL,"ADULT, OLDER_ADULT",PHASE3,204,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-05-18,2022-07-06
WITHDRAWN,NO,DIETARY_SUPPLEMENT: Ozonized oil (HOO,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-07,2021-12
COMPLETED,NO,DRUG: Lithium|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-11-28,2023-07-21
COMPLETED,NO,DRUG: Therapeutic Anticoagulation,ALL,"ADULT, OLDER_ADULT",PHASE3,465,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-11,2021-10-14
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: ABO1009-DP|BIOLOGICAL: ABO-CoV.617.2|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-07-08,2023-08-30
COMPLETED,NO,DRUG: Nirmatrelvir/ ritonavir|DRUG: Nirmatrelvir/Ritonavir|DRUG: Nirmatrelvir/Ritonavir|DRUG: Nirmatrelvir/ritonavir|DRUG: Nirmatrelvir/ritonavir,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-09-28,2022-11-29
UNKNOWN,NO,BIOLOGICAL: Recombinant COVID-19 vaccine (Sf9 cell),ALL,ADULT,NA,892,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-07,2023-04
TERMINATED,NO,DRUG: Tocilizumab,ALL,"ADULT, OLDER_ADULT",PHASE3,129,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-08,2020-07-21
COMPLETED,NO,PROCEDURE: haemodialysis,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-06-01,2022-01-01
RECRUITING,NO,BIOLOGICAL: the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine,ALL,ADULT,EARLY_PHASE1,63,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-07-13,2023-12-09
COMPLETED,NO,DRUG: Metformin Glycinate|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE2,20,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-14,2021-03-18
RECRUITING,NO,DRUG: Montelukast Oral Tablet|DRUG: Montelukast plus Favicovir (Favipiravir)|DRUG: Favicovir (Standard Treatment),ALL,"ADULT, OLDER_ADULT",PHASE2,380,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-15,2022-06-01
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: Capillary Collection & Testing|DIAGNOSTIC_TEST: Venous Draw & Testing,ALL,"CHILD, ADULT, OLDER_ADULT",NA,153,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-07-09,2023-09-30
COMPLETED,NO,BIOLOGICAL: Serology SARS-CoV2|BEHAVIORAL: Data collection,ALL,"CHILD, ADULT, OLDER_ADULT",NA,563,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-06-19,2021-04-30
UNKNOWN,NO,BIOLOGICAL: Inactivated Coronavac/Butantan vaccine|BIOLOGICAL: BNT162b2 (Pfizer),ALL,"CHILD, ADULT",PHASE3,1120,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-01-21,2023-03-21
RECRUITING,NO,BEHAVIORAL: General SARS-CoV-2 Communication|BEHAVIORAL: Rural-Targeted SARS-CoV-2 Communication,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SCREENING,2023-05-01,2024-06-30
COMPLETED,NO,BIOLOGICAL: UQSC2 Vaccine|BIOLOGICAL: NVX-CoV2373 vaccine,ALL,ADULT,PHASE1,70,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-05-08,2023-06-16
RECRUITING,NO,DRUG: Sotrovimab,ALL,"ADULT, OLDER_ADULT",PHASE4,500,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-01,2023-11-15
UNKNOWN,NO,RADIATION: Low Dose Radiotherapy,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,5,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-05-04,2020-12
COMPLETED,NO,DRUG: rhDNase I,ALL,"ADULT, OLDER_ADULT",PHASE1,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-25,2021-08-01
NOT_YET_RECRUITING,NO,"BIOLOGICAL: ""Sputnik Lite"" vaccine for the prevention of COVID-19 with altered antigenic composition",ALL,"ADULT, OLDER_ADULT",PHASE3,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-09,2024-12
COMPLETED,NO,DRUG: Botulinum Neurotoxin|DRUG: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,45,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-07-20,2020-12-01
WITHDRAWN,NO,DRUG: Rapamycin|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-04,2023-01
COMPLETED,NO,DRUG: Control group (standard hospital treatment)|DRUG: Group Hydroxychloroquine|DRUG: Group Hydroxychloroquine and apixaban|DRUG: Group Apixaban,ALL,"ADULT, OLDER_ADULT",PHASE3,176,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-01,2020-12-23
COMPLETED,NO,BIOLOGICAL: MVC-COV1901 (High-Dose)|BIOLOGICAL: MVC-COV1901(Mid-Dose),ALL,OLDER_ADULT,PHASE2,420,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-05-20,2022-01-28
COMPLETED,NO,OTHER: Respiratory Music Therapy Protocol,ALL,"ADULT, OLDER_ADULT",NA,33,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-01-13,2023-03-13
COMPLETED,NO,RADIATION: Low dose Radiotherapy,ALL,"ADULT, OLDER_ADULT",NA,2,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-11-25,2022-06-30
UNKNOWN,NO,PROCEDURE: Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells|DRUG: Antibiotics|DRUG: Hormones|DRUG: Anticoagulant Therapy|DEVICE: Оxygen therapy,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,30,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-02,2021-12
WITHDRAWN,NO,DRUG: HCQ01|DRUG: standard of care (SOC) for COVID-19,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10,2022-12
TERMINATED,NO,DRUG: VIB7734|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,10,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-28,2021-05-19
TERMINATED,NO,DRUG: Losartan|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,15,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-06,2021-12-01
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Omalizumab|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-10-15,2022-12-16
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: 25 Baiya SARS-CoV-2 Vax 2|BIOLOGICAL: 50 Baiya SARS-CoV-2 Vax 2,ALL,ADULT,PHASE1,24,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2022-03-28,2024-04-10
UNKNOWN,NO,BIOLOGICAL: Anti-SARS-CoV-2 immunoglobulin,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,41,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-01,2021-03-31
NOT_YET_RECRUITING,NO,BIOLOGICAL: Allogeneic Mesenchymal Stromal Cells,ALL,"ADULT, OLDER_ADULT",PHASE1,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-09,2027-05
UNKNOWN,NO,DRUG: Jing-Si-Herbal-Tea,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-01,2021-09-30
COMPLETED,NO,DRUG: Ivermectin and Doxycyline|DRUG: Standard of care,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,140,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-07-01,2020-10-14
UNKNOWN,NO,OTHER: Chest physiotherapy post-covid19,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2021-08-01
COMPLETED,YES,DRUG: Ivermectin|DRUG: Placebo,ALL,ADULT,PHASE2,24,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07-31,2020-10-09
RECRUITING,NO,"OTHER: Anhydrous Enol-Oxaloacetate, a ""Medical Food""|OTHER: White Rice Flour",ALL,"ADULT, OLDER_ADULT",NA,70,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-06-01,2024-04-30
TERMINATED,NO,DRUG: Bevacizumab|DRUG: BAT,ALL,"ADULT, OLDER_ADULT",PHASE2,21,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-01,2021-08-31
COMPLETED,NO,DRUG: Maraviroc,ALL,"ADULT, OLDER_ADULT",PHASE1,9,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-01,2020-12-31
ACTIVE_NOT_RECRUITING,NO,DIETARY_SUPPLEMENT: MOLECULAR HYDROGEN|DIETARY_SUPPLEMENT: PLACEBO MAGNESIUM,ALL,"ADULT, OLDER_ADULT",NA,700,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-01-22,2023-05-22
TERMINATED,NO,BIOLOGICAL: ARCT-021,ALL,"ADULT, OLDER_ADULT",PHASE2,65,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-04,2021-12-28
COMPLETED,NO,"BIOLOGICAL: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|BIOLOGICAL: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|OTHER: Two doses of placebo at the schedule of day 0,28",ALL,CHILD,PHASE1|PHASE2,552,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-10-31,2023-02-08
WITHDRAWN,NO,BIOLOGICAL: CVnCoV Vaccine,ALL,"ADULT, OLDER_ADULT",PHASE3,0,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-10-01,2022-09
COMPLETED,NO,BIOLOGICAL: AV-COVID-19|OTHER: GM-CSF,ALL,"ADULT, OLDER_ADULT",PHASE1,27,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-12-07,2021-01-15
COMPLETED,YES,DRUG: Bamlanivimab|DRUG: Placebo|DRUG: Etesevimab,ALL,"ADULT, OLDER_ADULT",PHASE3,1180,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-08-02,2021-05-20
TERMINATED,NO,BIOLOGICAL: CpG 1018/Alum-adjuvanted SCB-2019 vaccine|BIOLOGICAL: Havrix|OTHER: Placebo; 0.9% saline,ALL,"ADULT, OLDER_ADULT",PHASE3,1,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-11-12,2022-05-04
COMPLETED,NO,OTHER: Exercise,ALL,"ADULT, OLDER_ADULT",NA,12,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-05-08,2022-04-20
UNKNOWN,NO,"COMBINATION_PRODUCT: Tomeka®|DRUG: ""Vernonia amygdalina""",ALL,"CHILD, ADULT, OLDER_ADULT",NA,2000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-11,2022-12
UNKNOWN,NO,DRUG: Nuvastatic,ALL,"ADULT, OLDER_ADULT",PHASE1,10,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-01,2020-09-30
COMPLETED,YES,BIOLOGICAL: CVnCoV 6 μg|BIOLOGICAL: CVnCoV 12 μg|BIOLOGICAL: Hepatitis A vaccine|BIOLOGICAL: Pneumococcal vaccine|BIOLOGICAL: CVnCoV 12μg,ALL,"ADULT, OLDER_ADULT",PHASE2,668,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-09-21,2022-02-21
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Low-dose of LVRNA009|BIOLOGICAL: Middle-dose of LVRNA009|BIOLOGICAL: High-dose of LVRNA009|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,144,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-07-31,2023-10
TERMINATED,NO,DEVICE: nasal spray,ALL,"ADULT, OLDER_ADULT",NA,13,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-01-14,2022-11-08
COMPLETED,NO,DRUG: tenofovir disoproxil and emtricitabine,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-11-18,2021-05-01
COMPLETED,NO,BEHAVIORAL: Contain COVID Anxiety SSI|BEHAVIORAL: Remain COVID Free SSI,ALL,"ADULT, OLDER_ADULT",NA,500,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-19,2020-10-15
TERMINATED,YES,BIOLOGICAL: Convalescent Plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,52,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-09,2023-04-26
COMPLETED,NO,BEHAVIORAL: Antimicrobial stewardship prospective audit and feedback,ALL,"ADULT, OLDER_ADULT",NA,833,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-03-01,2021-11-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Hyperbaric oxygen|PROCEDURE: Sham treatment,ALL,ADULT,PHASE2,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-09-15,2024-06-30
COMPLETED,NO,DRUG: Firazyr|OTHER: SoC,ALL,"ADULT, OLDER_ADULT",PHASE2,73,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-12,2022-03-17
WITHDRAWN,NO,DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-04-10,2020-10-01
RECRUITING,NO,DIETARY_SUPPLEMENT: β-hydroxy β-methyl butyrate (HMB) enriched amino acid|DIETARY_SUPPLEMENT: Balanced amino acid,ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-04-01,2025-03-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: LYB001|BIOLOGICAL: CoronaVac,ALL,ADULT,EARLY_PHASE1,120,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-05-14,2023-06-30
NOT_YET_RECRUITING,NO,DRUG: Tafenoquine Oral Tablet|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,148,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-08-01,2024-04-27
TERMINATED,NO,BIOLOGICAL: Convalescent Plasma,ALL,"ADULT, OLDER_ADULT",PHASE1,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-08,2020-08-20
RECRUITING,NO,"OTHER: Low sugar diet and 10-12 hour eating window|OTHER: Low sugar diet, 8 hour eating window and fasting",ALL,"ADULT, OLDER_ADULT",NA,180,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-11-04,2025-07-30
COMPLETED,NO,DEVICE: MLS Laser|OTHER: Regular Inpatient Medical Care,ALL,"ADULT, OLDER_ADULT",PHASE2,10,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-30,2020-07-16
RECRUITING,NO,DRUG: Hydroxychloroquine|DRUG: Azithromycin|DIETARY_SUPPLEMENT: Vitamin C|DIETARY_SUPPLEMENT: Vitamin D|DIETARY_SUPPLEMENT: Zinc,ALL,"ADULT, OLDER_ADULT",PHASE2,600,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-22,2024-09
NOT_YET_RECRUITING,NO,BEHAVIORAL: Psychological measurement,ALL,"CHILD, ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-05-20,2022-11-15
NOT_YET_RECRUITING,NO,BIOLOGICAL: SCTV01E|BIOLOGICAL: Comirnaty,ALL,"ADULT, OLDER_ADULT",PHASE2,400,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-07-01,2023-03-01
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: High-Intensity-Interval-Exercise|PROCEDURE: Moderate-Intensity-Continuous-Exercise|PROCEDURE: Strength training|PROCEDURE: Baseline assessment|PROCEDURE: 1 year follow-up,ALL,ADULT,NA,62,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2022-09-01,2024-12-31
COMPLETED,NO,DEVICE: UVC Irradiation|DRUG: UVC Irradiation|DEVICE: Fit test|DEVICE: Tensile strength,ALL,ADULT,NA,20,OTHER_GOV,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-04-01,2021-02-05
ACTIVE_NOT_RECRUITING,NO,DRUG: Ivermectin|DRUG: Fluvoxamine|DRUG: Fluticasone|OTHER: Placebo|DRUG: Montelukast|DRUG: Metformin,ALL,"ADULT, OLDER_ADULT",PHASE3,15000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-06-08,2024-06
WITHDRAWN,NO,"DIAGNOSTIC_TEST: Xiamen Wiz Biotech Co., Ltd. SARS-CoV-2 Antigen Rapid Test",ALL,"CHILD, ADULT, OLDER_ADULT",NA,0,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-01-09,2021-01-28
TERMINATED,YES,DRUG: Disulfiram|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,11,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-18,2022-02-28
COMPLETED,YES,DRUG: Alteplase 50 MG [Activase]|DRUG: Alteplase 50 MG [Activase],ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-14,2021-09-30
RECRUITING,NO,DRUG: TriCor® 145mg tablets|OTHER: Placebo|OTHER: Usual care,ALL,"ADULT, OLDER_ADULT",PHASE3,55,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-01,2022-07-01
RECRUITING,NO,DRUG: Allopurinol 200 mg|DRUG: Optional intervention,ALL,"ADULT, OLDER_ADULT",PHASE3,1116,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-09-01,2028-07-31
UNKNOWN,NO,BIOLOGICAL: COVAX,ALL,"ADULT, OLDER_ADULT",PHASE4,1440,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-10,2022-03
RECRUITING,NO,"BIOLOGICAL: Comvigen (Bivalent, ChulaCov19 BNA159.2)|BIOLOGICAL: BIVALENT Pfizer/BNT vaccine",ALL,ADULT,PHASE2,450,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-10-09,2024-02
TERMINATED,NO,DEVICE: NOWDx COVID-19 Test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,50,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-04-01,2021-10-28
COMPLETED,NO,DIAGNOSTIC_TEST: Test all,ALL,"CHILD, ADULT, OLDER_ADULT",NA,152082,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-05-17,2023-03-31
UNKNOWN,NO,"OTHER: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )|OTHER: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)",ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-06-01,2021-03-01
NOT_YET_RECRUITING,NO,BEHAVIORAL: Standard MI|BEHAVIORAL: Intensive MI|BEHAVIORAL: MOTIVACC|BEHAVIORAL: Ecological momentary assessment (EMA) messages,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-12-01,2023-12-31
COMPLETED,NO,BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation|BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|BIOLOGICAL: Placebo for Inhalation|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,840,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-04-21,2022-08-09
COMPLETED,NO,OTHER: Diaphragmatic breathing with Resistance Training|OTHER: diaphragmatic breathing with out resistance training,ALL,ADULT,NA,42,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-09-02,2022-12-10
WITHDRAWN,NO,DEVICE: Face mask|BEHAVIORAL: Face mask awareness|BEHAVIORAL: Face mask promotion through community values or individual information,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2023-02-04,2023-05-30
UNKNOWN,NO,BIOLOGICAL: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group|BIOLOGICAL: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group|BIOLOGICAL: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group,ALL,"ADULT, OLDER_ADULT",PHASE1,50,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-08-19,2021-12-31
COMPLETED,YES,DRUG: Ivermectin (IVM),ALL,"ADULT, OLDER_ADULT",PHASE1,16,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-18,2020-06-01
COMPLETED,NO,DRUG: Neosporin|OTHER: Vaseline,ALL,ADULT,PHASE1,67,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-09-01,2023-09-22
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|BIOLOGICAL: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|BIOLOGICAL: placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,3100,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-04-25,2023-03
TERMINATED,YES,BIOLOGICAL: NasoVAX|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,48,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-10,2021-02-15
COMPLETED,NO,BIOLOGICAL: Convalescent plasma|DRUG: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE2,38,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-06,2022-04-07
COMPLETED,NO,BEHAVIORAL: Inspiratory muscle training,ALL,"ADULT, OLDER_ADULT",NA,26,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2022-01-30,2022-08-01
COMPLETED,NO,DIETARY_SUPPLEMENT: ubiquinol (reduced coenzyme Q10)|OTHER: mountain spa rehabilitation|DIAGNOSTIC_TEST: 2x14 ml of peripheral blood collected in a tube with anticoagulant,ALL,"ADULT, OLDER_ADULT",NA,51,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-05-01,2022-01-01
NOT_YET_RECRUITING,NO,DRUG: Xagrotin|DRUG: Green tea,ALL,"ADULT, OLDER_ADULT",PHASE3,3000,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-01,2022-12-07
COMPLETED,NO,DRUG: Nirmatrelvir and ritonavir stage 1|DRUG: Nirmatrelvir and ritonavir stage 2,ALL,"ADULT, OLDER_ADULT",PHASE4,18,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-06,2022-06-08
WITHDRAWN,NO,DRUG: Hydroxychloroquine|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-05-05,2020-09-25
ENROLLING_BY_INVITATION,NO,DRUG: Ebselen|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-10-12,2023-12-31
COMPLETED,NO,DRUG: Enoxaparin,ALL,"ADULT, OLDER_ADULT",PHASE3,142,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-27,2023-04-30
COMPLETED,NO,BIOLOGICAL: Kamada Anti-SARS-CoV-2,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,12,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-05,2020-11-26
UNKNOWN,NO,BIOLOGICAL: UC-MSCs,ALL,"ADULT, OLDER_ADULT",PHASE2,16,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-02-06,2020-12-30
UNKNOWN,NO,DRUG: Ivermectin,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-09,2020-09-01
RECRUITING,NO,BIOLOGICAL: Adeno-viral vector vaccine,ALL,ADULT,PHASE1,36,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-01-21,2023-03-01
UNKNOWN,NO,DRUG: Hydroxychloroquine (HCQ)|OTHER: Standard care|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1000,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-03-22,2021-06-30
UNKNOWN,NO,DRUG: Aprotinin,ALL,"ADULT, OLDER_ADULT",NA,30,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-11,2020-08-31
COMPLETED,YES,BIOLOGICAL: High-titer Convalescent COVID-19 Plasma (CCP1)|BIOLOGICAL: Standard-titer Convalescent COVID-19 plasma (CCP2),ALL,"ADULT, OLDER_ADULT",PHASE2,56,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-27,2021-06-04
TERMINATED,YES,DRUG: Melatonin|OTHER: Placebo (Methylcellulose) capsule,ALL,"ADULT, OLDER_ADULT",PHASE2,8,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-06,2022-07-22
UNKNOWN,NO,BIOLOGICAL: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|BIOLOGICAL: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|BIOLOGICAL: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,216,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-07-13,2022-02-02
UNKNOWN,NO,DRUG: nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1|DRUG: nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV|DRUG: nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,66,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-22,2021-04-30
TERMINATED,NO,DRUG: GLS-1200|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,184,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-06-10,2023-01-10
COMPLETED,NO,DRUG: Defibrotide|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,156,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-08,2023-02-28
UNKNOWN,NO,DRUG: Hydroxychloroquine - Daily dosing|DRUG: Hydroxychloroquine - Weekly Dosing|OTHER: Matched Placebo Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE3,1000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-05-11,2021-04
COMPLETED,NO,DRUG: Enoxaparin|DRUG: Enoxaparin,ALL,"ADULT, OLDER_ADULT",PHASE4,1000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2020-05-13,2021-09-14
COMPLETED,NO,DRUG: Casirivimab+Imdevimab,ALL,"ADULT, OLDER_ADULT",PHASE1,45,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-07,2022-06-03
TERMINATED,NO,DRUG: Ivermectin|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,75,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-10,2021-12-09
COMPLETED,NO,BIOLOGICAL: MVA-SARS-2-S vaccinations (days 0 & 28)|BIOLOGICAL: Comirnaty,ALL,ADULT,PHASE1,30,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-10-05,2021-08-24
TERMINATED,NO,DRUG: Telacebec|DRUG: COVID-19 Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE2,1,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-07-29,2022-02-11
COMPLETED,NO,DIETARY_SUPPLEMENT: Zinc Acetate,ALL,"ADULT, OLDER_ADULT",PHASE4,75,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-05-01,2022-05-25
TERMINATED,NO,DRUG: VC|DRUG: Sterile Water for Injection,ALL,"ADULT, OLDER_ADULT",PHASE2,56,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-02-14,2020-03-29
UNKNOWN,NO,BIOLOGICAL: SARS-CoV-2 convalescent plasma treatment|OTHER: Standard care,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,236,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-07,2021-02
UNKNOWN,NO,DRUG: Gam-COVID-Vac / Gam-COVID-Vac,ALL,OLDER_ADULT,PHASE2,120,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-07-26,2021-09-26
COMPLETED,NO,DRUG: Alisporivir|OTHER: Standard of care (SOC),ALL,"ADULT, OLDER_ADULT",PHASE2,26,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-08,2022-04-13
RECRUITING,NO,BEHAVIORAL: Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM),ALL,"ADULT, OLDER_ADULT",NA,500,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-01-03,2026-06
UNKNOWN,NO,DRUG: Recombinant cytokine gene derived protein injection,ALL,"ADULT, OLDER_ADULT",PHASE3,300,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-31,2022-08-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: COVID-19 Vaccine HIPRA|BIOLOGICAL: Cominarty (Pfizer-BioNtech),ALL,ADULT,PHASE2,256,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-11-11,2022-12-27
COMPLETED,NO,BEHAVIORAL: Video Chat +Personalized Feedback|BEHAVIORAL: Video Chat + Basic Feedback|BEHAVIORAL: Discussion Board for Social Support +Basic Feedback|BEHAVIORAL: Discussion Board for Social Support+Personalized Feedback,ALL,"ADULT, OLDER_ADULT",NA,73,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-23,2021-03-08
UNKNOWN,NO,BIOLOGICAL: WJ-MSCs,ALL,"ADULT, OLDER_ADULT",PHASE1,5,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-16,2020-09-30
COMPLETED,YES,DRUG: Trans Sodium Crocetinate|DRUG: Normal saline,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,25,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-10,2021-04-29
UNKNOWN,NO,DIETARY_SUPPLEMENT: Vitamin C,ALL,"CHILD, ADULT, OLDER_ADULT",NA,500,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-13,2021-03-13
UNKNOWN,NO,DRUG: favipiravir tablets+chloroquine phosphatetablets tablets|DRUG: Favipiravir tablets|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,150,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-03-05,2020-06-25
COMPLETED,NO,BIOLOGICAL: Blood samples collection|OTHER: Saliva collection,ALL,"ADULT, OLDER_ADULT",NA,71,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-05-25,2021-03-09
TERMINATED,YES,DRUG: Peginterferon lambda alfa-1a subcutaneous injection|OTHER: Saline,ALL,"ADULT, OLDER_ADULT",PHASE2,6,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-06-29,2021-09-24
COMPLETED,NO,BIOLOGICAL: COVID-19 Vaccine 40 ug/dose,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,2646,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-02-03,2023-03-03
COMPLETED,NO,DIAGNOSTIC_TEST: Blood count|DIAGNOSTIC_TEST: Blood collection|DIAGNOSTIC_TEST: Nasopharyngeal swab|DIAGNOSTIC_TEST: Saliva samples|DIAGNOSTIC_TEST: Faeces samples|GENETIC: Genetic blood collection|OTHER: Data collection,ALL,"ADULT, OLDER_ADULT",NA,57,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-02-05,2021-09-15
UNKNOWN,NO,DRUG: Dapsone 100 MG,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-18,2021-12-31
COMPLETED,NO,OTHER: Intervention group_rehabilitation program,ALL,"ADULT, OLDER_ADULT",NA,160,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-07-30,2023-01-13
COMPLETED,YES,DRUG: Ruxolitinib|DRUG: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,432,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-05-02,2020-10-17
COMPLETED,YES,DRUG: Methylprednisolone|OTHER: Usual Care,ALL,"ADULT, OLDER_ADULT",PHASE2,44,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2019-12-02,2020-11-17
SUSPENDED,NO,DRUG: Thiazide or Thiazide-like diuretics|DRUG: Calcium Channel Blockers|DRUG: ACE inhibitor|DRUG: Angiotensin receptor blocker,ALL,"ADULT, OLDER_ADULT",PHASE4,2414,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-04-30,2021-12-01
RECRUITING,NO,BIOLOGICAL: LEM-mR203|BIOLOGICAL: Placebo,ALL,ADULT,PHASE1,20,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-11-06,2025-02
COMPLETED,YES,BIOLOGICAL: Ad26.COV2.S|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,44325,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-09-07,2023-03-31
COMPLETED,YES,BIOLOGICAL: CT-P59|BIOLOGICAL: CT-P59|BIOLOGICAL: Placebo|BIOLOGICAL: CT-P59|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1642,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-05,2021-10-20
UNKNOWN,NO,"DEVICE: PS membrane versus PMMA membrane,",ALL,"ADULT, OLDER_ADULT",NA,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-04-17,2021-12-31
TERMINATED,NO,DEVICE: CareSuperb COVID-19 Antigen Home Test Kit,ALL,"CHILD, ADULT, OLDER_ADULT",NA,786,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-01-09,2023-05-11
RECRUITING,NO,BIOLOGICAL: BBIBP-CorV,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-04-25,2024-07
RECRUITING,NO,"DIAGNOSTIC_TEST: Cardiac Magnetic Resonance, Blood Tests",ALL,"CHILD, ADULT, OLDER_ADULT",NA,162,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-10-04,2024-10-31
NOT_YET_RECRUITING,NO,DEVICE: laser acupuncture,ALL,ADULT,NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-03-15,2022-07-30
UNKNOWN,NO,DRUG: Mavrilimumab|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-20,2021-05-31
NOT_YET_RECRUITING,NO,DRUG: Nivolumab and Ipilimumab,ALL,"ADULT, OLDER_ADULT",PHASE2,105,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-01,2027-03-30
RECRUITING,NO,OTHER: Phone-based monitoring|OTHER: Oxygen saturation monitoring|OTHER: Alcohol-based hand sanitizer,ALL,"ADULT, OLDER_ADULT",NA,1892,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-03-28,2023-02-28
RECRUITING,NO,DRUG: Methylprednisolone,ALL,"ADULT, OLDER_ADULT",PHASE2,418,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-10-01,2025-03-31
ENROLLING_BY_INVITATION,NO,RADIATION: [18F]DPA-714 positron emission tomography (PET) scan,ALL,ADULT,PHASE2|PHASE3,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-02-03,2023-09
COMPLETED,YES,DEVICE: Testing for SARS CoV2 RNA,ALL,"ADULT, OLDER_ADULT",NA,11,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-01-31,2021-02-25
COMPLETED,NO,BIOLOGICAL: AVX-COVID/12|BIOLOGICAL: ChAdOx-1-S[recombinant],ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,4065,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-11-09,2023-09-10
COMPLETED,NO,DRUG: Remdesivir|DRUG: Conventional,ALL,"CHILD, ADULT, OLDER_ADULT",NA,66,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-01,2020-12-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: HDT-301,ALL,"ADULT, OLDER_ADULT",PHASE1,63,INDUSTRY,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-01-24,2023-11
COMPLETED,NO,DIAGNOSTIC_TEST: Blood sample,ALL,"ADULT, OLDER_ADULT",NA,79,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-07-28,2021-01-27
UNKNOWN,NO,BIOLOGICAL: Recombinant novel coronavirus vaccine (CHO cells),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,480,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-11-10,2022-07
UNKNOWN,NO,BIOLOGICAL: Gam-COVID-Vac|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1600,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-11-30,2021-09
UNKNOWN,NO,BIOLOGICAL: Covid-19 vaccine (0-1-4 schedule)|BIOLOGICAL: Covid-19 vaccine (0-1-6 schedule),ALL,"ADULT, OLDER_ADULT",PHASE4,1440,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-11,2022-12
COMPLETED,NO,DEVICE: Transcutaneous Auricular Vagus Nerve Stimulation,ALL,"ADULT, OLDER_ADULT",NA,50,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-27,2020-11-01
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 Virus|DRUG: Remdesivir,ALL,ADULT,NA,36,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-03-06,2022-07-11
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1|BIOLOGICAL: GBP510 (RBD 10μg/dose) - Stage 1|OTHER: Normal saline (0.9% sodium chloride solution) - Stage 1|BIOLOGICAL: GBP510 adjuvanted with AS03 (RBD 25μg/dose) - Stage 1|BIOLOGICAL: GBP510 (RBD 25μg/dose) - Stage 1|OTHER: Normal saline (0.9% sodium chloride solution) - Stage 1|BIOLOGICAL: GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 2|BIOLOGICAL: GBP510 adjuvanted with AS03 (RBD 25μg/dose)- Stage 2|BIOLOGICAL: GBP510 (RBD 25μg/dose)- Stage 2|OTHER: Normal saline (0.9% sodium chloride solution)- Stage 2,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,328,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-02-03,2022-06
TERMINATED,NO,DEVICE: Helmet CPAP|DEVICE: HFNC,ALL,"ADULT, OLDER_ADULT",NA,2,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-06-03,2021-04-12
COMPLETED,NO,BIOLOGICAL: Inactivated SARS-CoV-2 Vaccine (Vero cell)|BIOLOGICAL: Inactivated SARS-CoV-2 Vaccine (Vero cell)|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,44101,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-16,2021-12-31
RECRUITING,NO,DRUG: Azvudine|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1550,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-12-29,2024-07-15
COMPLETED,NO,DRUG: Colchicine|DRUG: Ruxolitinib 5 MG|DRUG: Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|OTHER: standard therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-08,2020-08-23
TERMINATED,NO,DRUG: ASC09/ritonavir group|DRUG: lopinavir/ritonavir group,ALL,"ADULT, OLDER_ADULT",NA,6,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-11,2020-04-13
ACTIVE_NOT_RECRUITING,NO,DRUG: CST-2: EIDD-2801|DRUG: CST-2: Placebo|DRUG: Nitazoxanide|DRUG: VIR-7832|DRUG: VIR-7831|DRUG: CST-5: Placebo|DRUG: Favipiravir|DRUG: Molnupiravir|DRUG: Paxlovid,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,600,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-03,2024-04-30
ACTIVE_NOT_RECRUITING,NO,DEVICE: Muse S™ Headband system,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-01,2024-12
UNKNOWN,NO,DRUG: Ethanol with Asprin,ALL,ADULT,PHASE3,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-01,2022-06-01
COMPLETED,YES,OTHER: mHealth Assessments,ALL,"ADULT, OLDER_ADULT",NA,128,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-07-22,2021-11-12
COMPLETED,NO,"BIOLOGICAL: Candidate vaccine, SCB-2020S|BIOLOGICAL: Candidate vaccine, SCB-2019|OTHER: Squalene based adjuvant|OTHER: CpG/alum adjuvant",ALL,"ADULT, OLDER_ADULT",PHASE1,153,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-05-30,2023-04-23
TERMINATED,NO,BIOLOGICAL: COVID-19 convalescent plasma treatment,ALL,"ADULT, OLDER_ADULT",NA,396,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-22,2022-01-04
UNKNOWN,NO,PROCEDURE: Medical Ozone procedure,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-04-08,2020-10-08
COMPLETED,NO,PROCEDURE: Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection|PROCEDURE: Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection,ALL,"CHILD, ADULT, OLDER_ADULT",NA,48,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2021-03-16,2021-03-23
TERMINATED,YES,DRUG: CUROSURF® (poractant alfa),ALL,"ADULT, OLDER_ADULT",PHASE2,22,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-06,2022-03-17
COMPLETED,NO,"DRUG: AS03|BIOLOGICAL: BNT162b2|BIOLOGICAL: BNT162b2 (B.1.1.529)|BIOLOGICAL: BNT162b2 (B.1.351)|BIOLOGICAL: BNT162b2 bivalent (wildtype and Omicron BA.1)|BIOLOGICAL: BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)|BIOLOGICAL: CoV2 preS dTM [B.1.351]|BIOLOGICAL: CoV2 preS dTM/D614|BIOLOGICAL: CoV2 preS dTM/D614+B.1.351|BIOLOGICAL: mRNA-1273|BIOLOGICAL: mRNA-1273.351|BIOLOGICAL: mRNA-1273.529|BIOLOGICAL: mRNA-1273.617.2|OTHER: Sodium Chloride, 0.9%",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,1270,NIH,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-03-30,2023-11-10
COMPLETED,NO,BIOLOGICAL: ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine|OTHER: Placebo (normal saline)|BIOLOGICAL: Astra Zeneca COVID-19 vaccine,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,19494,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-08-15,2023-01-18
UNKNOWN,NO,DRUG: Nitazoxanide|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE4,456,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-12-01,2022-04-30
RECRUITING,NO,DRUG: Masitinib Mesylate|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,78,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-23,2023-12
ACTIVE_NOT_RECRUITING,NO,DRUG: PBI-0451 (Pomotrelvir)|DRUG: Placebo,ALL,ADULT,PHASE2,210,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-09-21,2023-07-02
COMPLETED,NO,DRUG: Fuzheng Huayu tablet,ALL,"ADULT, OLDER_ADULT",PHASE4,66,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-01,2020-04-15
TERMINATED,NO,BIOLOGICAL: convalescent plasma infusion covid 19,ALL,OLDER_ADULT,PHASE3,93,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-03-31,2021-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Efgartigimod|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,53,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-09-23,2024-11-30
RECRUITING,NO,OTHER: Collection of biological samples,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-12-01,2026-12-01
COMPLETED,NO,OTHER: Physiotherapy,ALL,"ADULT, OLDER_ADULT",NA,34,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-27,2020-12-01
COMPLETED,NO,OTHER: Pulmonary rehabilitation exercises at the Rehabilitation Center|OTHER: Home Intervention,ALL,"ADULT, OLDER_ADULT",NA,106,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2022-06-30,2023-03-23
ACTIVE_NOT_RECRUITING,NO,DRUG: inhaled beclametasone|DRUG: Inahaled beclomethasone / formoterol / glycopyrronium,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-28,2022-05-20
UNKNOWN,NO,DRUG: Hydroxychloroquine|DRUG: Azithromycin,ALL,"ADULT, OLDER_ADULT",PHASE2,1000,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-03,2022-04
TERMINATED,NO,DRUG: NTR-441|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,52,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-04-14,2023-06-06
TERMINATED,YES,DRUG: Azithromycin|DRUG: Placebos,ALL,"ADULT, OLDER_ADULT",PHASE3,263,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-22,2021-03-30
COMPLETED,NO,BIOLOGICAL: Plasma|OTHER: Best Available Therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,31,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-27,2021-05-01
ACTIVE_NOT_RECRUITING,NO,RADIATION: Low dose radiation 35 cGy|RADIATION: High dose radiation 100 cGy,ALL,"ADULT, OLDER_ADULT",PHASE2,37,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-28,2025-12-31
WITHDRAWN,NO,OTHER: Symptoms entered into the CovidX application,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-06,2021-11
ACTIVE_NOT_RECRUITING,NO,"BIOLOGICAL: 2nd booster with Comirnaty® (Pfizer-BioNTech)|BIOLOGICAL: CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK",ALL,"ADULT, OLDER_ADULT",PHASE3,189,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2022-06-08,2023-07
RECRUITING,NO,DRUG: Ceftriaxone|DRUG: Moxifloxacin or Levofloxacin|DRUG: Piperacillin-tazobactam|DRUG: Ceftaroline|DRUG: Amoxicillin-clavulanate|DRUG: Standard course macrolide|DRUG: Extended course macrolide|OTHER: No systemic corticosteroid|DRUG: Fixed-duration Hydrocortisone|DRUG: Shock-dependent hydrocortisone|DRUG: Fixed-duration higher dose Hydrocortisone|OTHER: No antiviral agent for influenza|DRUG: Five-days oseltamivir|DRUG: Ten-days oseltamivir|OTHER: No antiviral agent for COVID-19|DRUG: Lopinavir / Ritonavir|DRUG: Hydroxychloroquine|DRUG: Hydroxychloroquine + lopinavir/ritonavir|DRUG: Ivermectin|OTHER: No immune modulation for COVID-19|DRUG: Interferon beta-1a|DRUG: Anakinra|DRUG: Tocilizumab|DRUG: Sarilumab|DRUG: Local standard venous thromboprophylaxis|DRUG: Therapeutic dose anticoagulation|DRUG: Conventional low dose thromboprophylaxis|DRUG: Intermediate dose thromboprophylaxis|DRUG: Continuation of therapeutic dose anticoagulation|OTHER: No immunoglobulin|BIOLOGICAL: Convalescent plasma|BIOLOGICAL: Delayed administration of convalescent plasma|OTHER: No vitamin C|DRUG: Vitamin C|OTHER: No antiplatelet|DRUG: Aspirin|DRUG: P2Y12 inhibitor|OTHER: No simvastatin|DRUG: Simvastatin|OTHER: Placebo|DRUG: Eritoran|DRUG: Apremilast|PROCEDURE: Clinician-preferred mechanical ventilation strategy|PROCEDURE: Protocolised mechanical ventilation strategy|OTHER: No renin-angiotensin system inhibitor|DRUG: Angiotensin converting enzyme inhibitor|DRUG: Angiotensin Receptor Blockers|DRUG: ARB + DMX-200|OTHER: No cysteamine|DRUG: Cysteamine|DRUG: Fixed-duration dexamethasone|DRUG: Baloxavir Marboxil|DRUG: Five-days oseltamivir + baloxavir marboxil|DRUG: Ten-days oseltamivir + baloxavir marboxil|OTHER: No endothelial modulator|DRUG: Imatinib,ALL,"ADULT, OLDER_ADULT",PHASE3,10000,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2016-04-11,2028-02
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|BIOLOGICAL: Recombinant novel coronavirus protein vaccine (CHO cells),ALL,"ADULT, OLDER_ADULT",NA,450,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-03-17,2023-11-10
COMPLETED,NO,"BIOLOGICAL: Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|BIOLOGICAL: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|BIOLOGICAL: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly",ALL,"ADULT, OLDER_ADULT",PHASE3,1040,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-10-31,2021-05-31
COMPLETED,NO,BIOLOGICAL: CV2CoV (2 µg)|BIOLOGICAL: CV2CoV (4 µg)|BIOLOGICAL: CV2CoV (8 µg)|BIOLOGICAL: CV2CoV (12 µg)|BIOLOGICAL: CV2CoV (16 µg)|BIOLOGICAL: CV2CoV (20 µg),ALL,"ADULT, OLDER_ADULT",PHASE1,98,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2022-03-24,2023-03-07
RECRUITING,NO,OTHER: High Definition-transcranial Direct Current Stimulation|DIETARY_SUPPLEMENT: Chlorella Pyrenoidosa,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-10,2024-06-28
COMPLETED,NO,DRUG: Therapeutic anticoagulation,ALL,"ADULT, OLDER_ADULT",PHASE3,465,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-04,2021-10-14
RECRUITING,NO,DRUG: Fluvoxamine,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,300,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-15,2025-05-15
RECRUITING,NO,BIOLOGICAL: SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)|DRUG: 0.9% sodium chloride solution,ALL,"ADULT, OLDER_ADULT",PHASE3,9800,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-03-25,2024-06
TERMINATED,NO,BIOLOGICAL: Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,3000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-12-29,2023-07-12
COMPLETED,NO,DIAGNOSTIC_TEST: Rapid antigen testing kit,ALL,"CHILD, ADULT, OLDER_ADULT",NA,70000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING,2021-11-01,2023-01-13
RECRUITING,NO,BIOLOGICAL: B/HPIV3/S-6P,ALL,ADULT,PHASE1,30,NIH,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2023-09-18,2025-06
COMPLETED,NO,DRUG: Baricitinib 4 MG Oral Tablet,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,12,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2020-03-16,2020-04-07
COMPLETED,NO,DRUG: Autophagy inhibitor (GNS651)|OTHER: Standard of care|DRUG: Avdoralimab|DRUG: Monalizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,19,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-15,2021-12-31
COMPLETED,NO,DRUG: MTx-COVAB36|DRUG: Placebo,ALL,ADULT,PHASE1,32,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-04-26,2022-11-02
UNKNOWN,NO,BIOLOGICAL: SCTV01C|BIOLOGICAL: Sinopharm inactivated COVID-19 vaccine|BIOLOGICAL: Comirnaty,ALL,"ADULT, OLDER_ADULT",PHASE2,600,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-03-20,2022-12-01
UNKNOWN,NO,DIETARY_SUPPLEMENT: glycophosphopeptical AM3|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-01,2022-12-31
UNKNOWN,NO,BIOLOGICAL: AV-COVID-19,ALL,"ADULT, OLDER_ADULT",PHASE1,27,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-12-07,2022-01-31
RECRUITING,NO,DRUG: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE4,202,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-07-24,2023-12-31
COMPLETED,YES,DRUG: Povidone-Iodine 2%|DRUG: Povidone-Iodine 0.5%|DRUG: Isotonic saline 0.9%,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,47,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-15,2020-12-13
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: Nasal and mouth swab,ALL,"CHILD, ADULT, OLDER_ADULT",NA,61,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-03-14,2023-09-30
WITHDRAWN,NO,DEVICE: Hypothermia|DRUG: Neuromuscular Blocking Agents|DEVICE: Standard of Care,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-05-01,2021-04-27
WITHDRAWN,NO,DRUG: [14C]PF-07321332,MALE,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-02-22,2022-04-01
COMPLETED,YES,DIAGNOSTIC_TEST: Home-based SARS-CoV-2 test kit,ALL,"ADULT, OLDER_ADULT",NA,273,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2021-04-26,2022-03-09
NOT_YET_RECRUITING,NO,BIOLOGICAL: AstraZeneca/Fiocruz|BIOLOGICAL: Pfizer/Wyeth|BIOLOGICAL: Clover SCB-2019,ALL,"ADULT, OLDER_ADULT",PHASE3,360,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2022-08,2023-08
NOT_YET_RECRUITING,NO,DEVICE: Box Fan|DEVICE: UV Germicidal Irradiation Lamp Unit|DEVICE: Combined: Box Fan and UV Germicidal Irradiation Lamp Units,ALL,CHILD,NA,20000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2024-12,2026-03
COMPLETED,NO,DRUG: Ursodeoxycholic acid,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,95,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-12-16,2023-03-08
RECRUITING,NO,BEHAVIORAL: No video|BEHAVIORAL: Video Text,ALL,"ADULT, OLDER_ADULT",NA,500,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2022-06-21,2025-04-01
COMPLETED,NO,DRUG: Lacer Clorhexidina Colutorio|DRUG: Lacer Clorhexidine 0.20% Colutorio|DRUG: Gingilacer Encías Delicadas Colutorio|DRUG: Distilled water,ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-04-13,2022-01-08
WITHDRAWN,NO,DIAGNOSTIC_TEST: Blood draw,ALL,"CHILD, ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-05-10,2023-09-01
NOT_YET_RECRUITING,NO,OTHER: Cardiac coherence,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-10-01,2026-06-01
RECRUITING,NO,OTHER: questionnaire,ALL,"ADULT, OLDER_ADULT",NA,134,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-06-11,2022-06-11
ACTIVE_NOT_RECRUITING,NO,DRUG: Intramuscular injection|BIOLOGICAL: Intramuscular vaccine,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,30918,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-11-19,2022-04-30
COMPLETED,NO,BIOLOGICAL: Convalescent COVID 19 Plasma,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,22,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-28,2020-08-12
NOT_YET_RECRUITING,NO,BEHAVIORAL: Speed of Processing Training|BEHAVIORAL: In-lab Instrumental Activities of Daily Living Training|BEHAVIORAL: In-lab Brain Health Training|BEHAVIORAL: Transfer Package|BEHAVIORAL: Follow Up Phone Calls|BEHAVIORAL: Vocational Rehabilitation|BEHAVIORAL: Peer Mentoring,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-02,2027-02
RECRUITING,NO,DRUG: Aspirin 300 Mg Oral Tablet|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,76,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-12-07,2025-02-28
UNKNOWN,NO,"BIOLOGICAL: 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|DRUG: Sodium chloride, USP, for injection (0.9% NaCl)|BIOLOGICAL: 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)",ALL,ADULT,PHASE1,29,FED,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-04-05,2023-10-30
UNKNOWN,NO,BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cell) group|BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cells) placebo group,ALL,"ADULT, OLDER_ADULT",PHASE3,28904,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-12-16,2022-12
UNKNOWN,NO,BIOLOGICAL: ARCT-165|BIOLOGICAL: ARCT-154|BIOLOGICAL: ARCT-021,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,72,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-30,2023-03
COMPLETED,NO,BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,44247,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-09-15,2022-10-21
COMPLETED,YES,DRUG: Brilacidin|DRUG: Placebo|DRUG: Standard of Care (SoC),ALL,"ADULT, OLDER_ADULT",PHASE2,120,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-22,2021-07-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Janssen Ad26.CoV2.S Vaccine|OTHER: Reduction in Immunosuppression Medication|OTHER: Maintenance in Immunosuppression Medication,ALL,"ADULT, OLDER_ADULT",PHASE3,1200,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION,2022-04-11,2025-03
ACTIVE_NOT_RECRUITING,NO,DRUG: Artesunate|DRUG: Imatinib|DRUG: Infliximab|DRUG: Dexamethasone|DRUG: LSALT Peptide,ALL,"ADULT, OLDER_ADULT",PHASE3,2900,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-18,2024-05-18
RECRUITING,NO,DRUG: Reparixin|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,526,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-04-06,2024-10
COMPLETED,NO,DIETARY_SUPPLEMENT: Kunamin®|DRUG: Favipiravir|DRUG: Enoxaparin|DRUG: Lansoprazole|DRUG: Paracetamol|DRUG: Ceftriaxone/ Clarithromycin|DRUG: Methylprednisolone,ALL,"ADULT, OLDER_ADULT",PHASE3,71,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-29,2021-12-02
COMPLETED,NO,BIOLOGICAL: Low Dose of KBP-COVID-19|BIOLOGICAL: High Dose of KBP-COVID-19|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,101,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-12-30,2022-10-14
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: BNT162b2 (Omi XBB.1.5),ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,730,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-08-10,2024-03-19
COMPLETED,NO,BEHAVIORAL: Wearing glasses (any type),ALL,"ADULT, OLDER_ADULT",NA,3717,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-02-02,2022-12-01
RECRUITING,NO,DEVICE: Baldachin,ALL,"ADULT, OLDER_ADULT",NA,104,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-09-13,2024-11-30
UNKNOWN,NO,DRUG: GX-19N|DRUG: Placebo,ALL,ADULT,PHASE1|PHASE2,170,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-12-30,2022-06-30
NOT_YET_RECRUITING,NO,BEHAVIORAL: Virtual Intervention Program,ALL,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-12,2023-12
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 mRNA vaccine (RBMRNA-405)|BIOLOGICAL: CoronaVac®,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-05-16,2023-05-12
UNKNOWN,NO,PROCEDURE: Biospecimen Collection|OTHER: Questionnaire Administration,ALL,"CHILD, ADULT, OLDER_ADULT",NA,257,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-09,2023-04-30
COMPLETED,NO,DRUG: Ruxolitinib administration,ALL,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-01,2021-07-30
NOT_YET_RECRUITING,NO,DIETARY_SUPPLEMENT: Lithium,ALL,"ADULT, OLDER_ADULT",PHASE1,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11,2024-07
ACTIVE_NOT_RECRUITING,NO,OTHER: Multimodal intervention in Long Covid19,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-05-03,2024-11-18
RECRUITING,NO,BEHAVIORAL: Exercise (Resistance Training,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-02,2024-05-05
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 convalescent plasma,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-07,2020-12-01
RECRUITING,NO,DEVICE: Dexcom G6,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,100,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-01,2024-08-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: CV0701 Bivalent High dose|BIOLOGICAL: CV0701 Bivalent Medium dose|BIOLOGICAL: CV0701 Bivalent Low dose|BIOLOGICAL: CV0601 Monovalent High dose|BIOLOGICAL: Control vaccine|BIOLOGICAL: CV0801 Monovalent,ALL,"ADULT, OLDER_ADULT",PHASE2,664,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-08-01,2024-09-05
COMPLETED,NO,OTHER: blood sample,ALL,"CHILD, ADULT, OLDER_ADULT",NA,1177,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-03-16,2021-07-07
RECRUITING,NO,BIOLOGICAL: Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation|BIOLOGICAL: Bivalent COVID-19 mRNA Vaccine|BIOLOGICAL: Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation,ALL,"ADULT, OLDER_ADULT",NA,450,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-05-30,2024-05-29
TERMINATED,NO,DRUG: Colchicine|DRUG: Standard treatment,ALL,"ADULT, OLDER_ADULT",PHASE2,105,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-03,2020-04-27
TERMINATED,NO,BIOLOGICAL: MVA-SARS-2-ST,ALL,ADULT,PHASE1,23,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-02-24,2023-11-21
COMPLETED,NO,DEVICE: Biosensors,ALL,"ADULT, OLDER_ADULT",NA,138,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-04-22,2022-09-20
WITHDRAWN,NO,DRUG: Plasmapheresis|OTHER: Blood collection|OTHER: Stool samples|OTHER: PET scan|OTHER: Cycle ergometer stress test|OTHER: Questionnaires at baseline|OTHER: Medical consultations,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02,2025-10
UNKNOWN,NO,DRUG: Isoquercetin (IQC-950AN),ALL,"ADULT, OLDER_ADULT",PHASE2,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-01,2023-06
COMPLETED,NO,BIOLOGICAL: mRNA-1273,ALL,"ADULT, OLDER_ADULT",PHASE3,234,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-04-16,2023-05-22
UNKNOWN,NO,OTHER: Systemic indirect endovenous ozone therapy,ALL,"ADULT, OLDER_ADULT",PHASE3,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07,2020-12
COMPLETED,NO,DRUG: Tanreqing capsule|DRUG: Tanreqing capsule simulator,ALL,"ADULT, OLDER_ADULT",PHASE3,480,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-28,2022-08-31
TERMINATED,NO,DRUG: Remdesivir|DRUG: Remdesivir placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,237,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-02-06,2020-04-10
RECRUITING,NO,PROCEDURE: Rehabilitation|PROCEDURE: Standard of Care,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-02-01,2024-03-27
UNKNOWN,NO,BIOLOGICAL: COVID-19 Vaccine,ALL,ADULT,NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-03-09,2022-12-25
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose|BIOLOGICAL: COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",NA,54,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-09-13,2024-03
COMPLETED,NO,DIAGNOSTIC_TEST: Sequence of testing.,ALL,"CHILD, ADULT, OLDER_ADULT",NA,27947,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2021-01-22,2021-05-31
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: Cardiac PET/MRI|DIAGNOSTIC_TEST: Blood Biomarkers,ALL,"CHILD, ADULT, OLDER_ADULT",NA,57,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-08-05,2024-08-05
COMPLETED,NO,OTHER: blood sample,ALL,"ADULT, OLDER_ADULT",NA,238,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-10-23,2022-12-14
COMPLETED,NO,DEVICE: LungFit™,ALL,"ADULT, OLDER_ADULT",NA,40,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-25,2022-08-07
UNKNOWN,NO,DIAGNOSTIC_TEST: Venous and Capillary blood sampling,ALL,"ADULT, OLDER_ADULT",NA,1467,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-07-15,2022-12-30
TERMINATED,NO,DRUG: Aspirin 75mg|DRUG: Clopidogrel 75mg|DRUG: Rivaroxaban 2.5 MG|DRUG: Atorvastatin 40mg|DRUG: Omeprazole 20mg,ALL,"ADULT, OLDER_ADULT",NA,320,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-03,2021-11-30
COMPLETED,NO,DRUG: Favipiravir|DRUG: Standard of care (SOC)|DRUG: standard concomitant therapy,ALL,ADULT,PHASE3,168,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-20,2020-08-04
RECRUITING,NO,BEHAVIORAL: Exercise,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-01,2023-12-31
ACTIVE_NOT_RECRUITING,NO,"BIOLOGICAL: SARS-CoV-2 mRNA Vaccine, Bivalent Low dose|BIOLOGICAL: SARS-CoV-2 mRNA Vaccine, Bivalent High dose|DRUG: Placebo",ALL,"ADULT, OLDER_ADULT",NA,350,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-09-26,2024-03
COMPLETED,NO,BIOLOGICAL: Biological/Vaccine: BNT162b2 10mcg|BIOLOGICAL: BNT162b2 20mcg|BIOLOGICAL: BNT162b2 30mcg|OTHER: Placebo|BIOLOGICAL: Biological/Vaccine: BNT162b2 3mcg,ALL,CHILD,PHASE2|PHASE3,11837,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-03-24,2023-12-08
RECRUITING,NO,BIOLOGICAL: one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)|OTHER: Cellular Immunity|OTHER: Humoral Immunity|OTHER: Safety,ALL,"ADULT, OLDER_ADULT",NA,1000,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-08-13,2023-03-01
COMPLETED,NO,DRUG: Chloroquine|DRUG: Hydroxychloroquine|OTHER: standard care,ALL,"ADULT, OLDER_ADULT",PHASE3,142,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-16,2020-09-03
COMPLETED,NO,BIOLOGICAL: MSCs-derived exosomes,ALL,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-15,2020-07-31
UNKNOWN,NO,BIOLOGICAL: COVID-19 Specific T Cell derived exosomes (CSTC-Exo),ALL,"ADULT, OLDER_ADULT",PHASE1,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-05-01,2021-05-31
COMPLETED,YES,DIETARY_SUPPLEMENT: Investigational Product - ViraCide|OTHER: Placebo - Starch Powder Soft gels,ALL,"ADULT, OLDER_ADULT",NA,118,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2020-09-16,2020-12-12
TERMINATED,NO,DRUG: Enoxaparin,ALL,"ADULT, OLDER_ADULT",PHASE3,160,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-04-28,2021-06-02
RECRUITING,NO,BIOLOGICAL: SARS-CoV-2 virus,ALL,ADULT,PHASE1,132,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: OTHER,2021-05-27,2024-03
UNKNOWN,NO,OTHER: blood samples|OTHER: feces samples (COVI-BIOME ancillary study)|OTHER: sweat samples (COVIDOG ancillary study)|OTHER: saliva samples|OTHER: 6 minutes walk test|OTHER: Phone call|OTHER: Urine samples,ALL,"ADULT, OLDER_ADULT",NA,2003,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-03-31,2022-05-31
WITHDRAWN,NO,DRUG: Hydroxychloroquine|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-04,2020-08
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Nurse-Community-Family Partnership Intervention,ALL,"CHILD, ADULT, OLDER_ADULT",NA,392,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-07-23,2023-04
SUSPENDED,NO,DIAGNOSTIC_TEST: Sample Collection/Performance Evaluation (A)|DIAGNOSTIC_TEST: Sample Collection/Performance Evaluation (B),ALL,"ADULT, OLDER_ADULT",NA,2000,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-30,2024-07-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Placebo Administration|BIOLOGICAL: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1,ALL,ADULT,PHASE1|PHASE2,189,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-19,2024-09
TERMINATED,NO,DRUG: Hydroxychloroquine (HCQ),ALL,"ADULT, OLDER_ADULT",PHASE3,7,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-03,2020-05-28
COMPLETED,NO,DIAGNOSTIC_TEST: Blood samples (collection of 5 mL of blood in a dry tube)|DIAGNOSTIC_TEST: Nasopharyngeal swabs,ALL,"ADULT, OLDER_ADULT",NA,1971,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-04-28,2022-05-13
COMPLETED,NO,BIOLOGICAL: COVAX+IIV4; COVAX+PPV23|BIOLOGICAL: COVAX only (1st and 2nd dose)|BIOLOGICAL: IIV4 for the 1st dose and PPV23 for the 2nd dose,ALL,"ADULT, OLDER_ADULT",PHASE4,1133,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-03-10,2021-09-05
TERMINATED,NO,DRUG: Tofacitinib 10 mg|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,24,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-14,2021-02-28
COMPLETED,NO,OTHER: Osteopathic Manipulative Therapy,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-31,2021-09-13
WITHDRAWN,NO,DRUG: BAT2020,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-20,2021-08-18
COMPLETED,NO,BIOLOGICAL: Ad26.COV2.S|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,31831,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-11-12,2023-06-18
COMPLETED,NO,"DRUG: The drug ""Rutan 0.1"".|OTHER: Basic treatment",ALL,"ADULT, OLDER_ADULT",PHASE2,57,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-12,2021-09-30
TERMINATED,NO,OTHER: samling of oropharynx and nasopharynx,ALL,"CHILD, ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-20,2020-06-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: SARS-CoV-2 Bivalent mRNA Vaccine|OTHER: Saline,ALL,"ADULT, OLDER_ADULT",PHASE2,450,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-10-09,2024-12-30
COMPLETED,NO,BIOLOGICAL: NVX-CoV2373,ALL,"ADULT, OLDER_ADULT",PHASE2,384,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-02-28,2022-11-30
ENROLLING_BY_INVITATION,NO,DEVICE: the multi-domain Tai Chi Digital therapy Software Application,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2022-06-01,2023-12-31
COMPLETED,NO,BIOLOGICAL: Comirnaty(BTN162b2)|BIOLOGICAL: Spikevax (mRNA-1273),ALL,OLDER_ADULT,PHASE2,323,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-11-08,2023-09-13
UNKNOWN,NO,OTHER: hyper immunoglobulins containing anti-Corona VS2 immunoglobulin,ALL,ADULT,NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2021-01-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Ad26COVS1|DRUG: ChAdOx1 SARS2 Vaccine|DRUG: BNT162B2|DRUG: mRNA-1273,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-06-15,2022-12-31
TERMINATED,YES,DRUG: Sodium bicarbonate|OTHER: Standard of Care,ALL,"ADULT, OLDER_ADULT",PHASE4,3,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-05,2021-07-15
COMPLETED,YES,DRUG: Plitidepsin 1.5 mg/day|DRUG: Plitidepsin 2.0 mg/day|DRUG: Plitidepsin 2.5 mg/day,ALL,"ADULT, OLDER_ADULT",PHASE1,46,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-12,2020-11-26
COMPLETED,NO,DRUG: Omega-3 (EPA+DHA)|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,32,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-10,2023-04-21
TERMINATED,NO,DRUG: Apabetalone|OTHER: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-14,2022-06-22
TERMINATED,NO,DRUG: Losmapimod oral tablet|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE3,52,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-28,2021-03-31
NOT_YET_RECRUITING,NO,DRUG: Trauma,ALL,"ADULT, OLDER_ADULT",PHASE1,30,NETWORK,"Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-09-03,2025-10-03
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Psychoeducation,ALL,"ADULT, OLDER_ADULT",NA,130,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-15,2024-05-31
COMPLETED,NO,DRUG: REGN14284|DRUG: Matching Placebo,ALL,ADULT,PHASE1,48,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-09-15,2023-05-30
UNKNOWN,NO,BIOLOGICAL: Homologous mRNA booster vaccine|BIOLOGICAL: Heterologous mRNA booster vaccine|BIOLOGICAL: Non-mRNA booster vaccine A|BIOLOGICAL: Non-mRNA booster vaccine B|BIOLOGICAL: Non-mRNA booster vaccine C,ALL,"ADULT, OLDER_ADULT",PHASE3,600,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-10-12,2023-04
TERMINATED,NO,DRUG: Camostat Mesylate|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,70,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-03,2021-12-02
UNKNOWN,NO,DRUG: Hydroxychloroquine Only Product in Oral Dose Form,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1930,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-09,2021-04-01
UNKNOWN,NO,DRUG: Angiotensin 1-7|DRUG: Placebos,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-30,2023-06-15
COMPLETED,NO,DRUG: Lopinavir and Ritonavir Tablets|DRUG: Arbidol,ALL,"ADULT, OLDER_ADULT",PHASE4,86,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-28,2020-05-31
UNKNOWN,NO,DRUG: S-1226 (8%)|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,48,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-09,2022-01
RECRUITING,NO,BEHAVIORAL: CRT|BEHAVIORAL: CBT|BEHAVIORAL: Modifiable lifestyle factors|BEHAVIORAL: Usual care Psychoeducation,ALL,"ADULT, OLDER_ADULT",NA,56,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: TREATMENT,2023-09-01,2025-03-30
UNKNOWN,NO,BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cell) low-dose group|BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cells) high-dose group|BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cells) placebo group,ALL,ADULT,PHASE2,900,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-07-12,2021-12-15
UNKNOWN,NO,DRUG: Ivermectin Injectable Solution|OTHER: Injectable Placebo|DRUG: Zinc|DRUG: Placebo empty capsule|DRUG: Oral Ivermectin,ALL,ADULT,PHASE1|PHASE2,180,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-14,2021-10-30
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: BinaxNOW Rapid Antigen System,ALL,"ADULT, OLDER_ADULT",NA,51,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-04-27,2023-09-15
UNKNOWN,NO,DRUG: Recombinant human interferon α1β,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,328,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-01,2020-06-30
TERMINATED,NO,DRUG: Maraviroc 300 mg|OTHER: Standard care therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-26,2021-02-08
RECRUITING,NO,DRUG: Sodium Thiosulfate 25% Solution for Injection,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-01,2023-12-31
COMPLETED,YES,DRUG: Fluvoxamine|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1331,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-06-08,2022-09-04
TERMINATED,NO,DRUG: human SARS-CoV 2 specific T lymphocytes,ALL,"ADULT, OLDER_ADULT",PHASE1,1,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-08,2022-08-03
UNKNOWN,NO,DEVICE: Oxygen theraphy with high flow nasal cannule|DEVICE: Oxygen theraphy with mask with reservoir,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2022-01-18,2022-12-31
COMPLETED,YES,DEVICE: Testing for SARS CoV2 Antigen and Antibody,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-01-26,2021-02-11
COMPLETED,NO,BIOLOGICAL: CVXGA1 low dose|BIOLOGICAL: CVXGA1 high dose,ALL,ADULT,PHASE1,72,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-06,2023-06-10
UNKNOWN,NO,DRUG: Convalescent Plasma|OTHER: Standard Care Therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-09,2021-08-09
COMPLETED,YES,DRUG: Standard of care|DRUG: Apremilast|DRUG: Apremilast placebo|DRUG: Lanadelumab|DRUG: Lanadelumab placebo|DRUG: Zilucoplan|DRUG: Zilucoplan placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,515,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-24,2021-08-03
COMPLETED,NO,DIAGNOSTIC_TEST: Serological test for the detection of IgG anti-SARS-CoV-2,ALL,"CHILD, ADULT, OLDER_ADULT",NA,2817,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-05-10,2021-10-12
TERMINATED,YES,DRUG: fosmanogepix,ALL,"ADULT, OLDER_ADULT",PHASE2,21,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-04,2022-05-09
TERMINATED,NO,DRUG: Valsartan (Diovan)|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE4,23,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-17,2021-05-25
COMPLETED,NO,DIETARY_SUPPLEMENT: Vitamin D3,ALL,"ADULT, OLDER_ADULT",PHASE1,41,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-19,2020-11-30
COMPLETED,NO,OTHER: Blood sample collection|OTHER: Questionnaires,ALL,"ADULT, OLDER_ADULT",NA,680,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-12-01,2022-09-17
UNKNOWN,NO,DRUG: Ivermectin|DRUG: Doxycycline Hcl|DIETARY_SUPPLEMENT: Zinc|DIETARY_SUPPLEMENT: Vitamin D3|DIETARY_SUPPLEMENT: Vitamin C,ALL,"ADULT, OLDER_ADULT",PHASE1,31,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-09,2022-07
UNKNOWN,NO,BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,500,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-09-11,2021-07-31
UNKNOWN,NO,BIOLOGICAL: Dental pulp mesenchymal stem cells,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,24,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-05,2021-07-30
COMPLETED,NO,BIOLOGICAL: DZIF-10c|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,57,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-08,2021-08-11
COMPLETED,YES,DRUG: TD-0903|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,235,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-24,2021-04-21
COMPLETED,YES,DRUG: MAS825|OTHER: Placebo|DRUG: Standard of Care (SoC),ALL,"ADULT, OLDER_ADULT",PHASE2,140,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-11,2021-04-21
UNKNOWN,NO,DRUG: Baricitinib Oral Tablet,ALL,"ADULT, OLDER_ADULT",PHASE2,126,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-20,2020-07-30
ACTIVE_NOT_RECRUITING,NO,"BIOLOGICAL: randomized, double-blinded, placebo-controlled",ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,3300,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-12-27,2023-12-31
RECRUITING,NO,RADIATION: Radiation therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-23,2021-12-31
COMPLETED,YES,DRUG: Hydroxychloroquine|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE3,1360,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-04-22,2021-01-09
COMPLETED,NO,DRUG: Remdesivir|DRUG: Lopinavir/ritonavir|DRUG: Interferon Beta-1A|DRUG: Hydroxychloroquine|OTHER: Standard of care|DRUG: AZD7442|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1552,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-03-22,2023-09-25
COMPLETED,NO,BIOLOGICAL: Vaccine for intramuscular injection|OTHER: Placebo comparator (without active ingredient) for intramuscular injection,ALL,ADULT,PHASE1|PHASE2,400,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-10-03,2021-10-01
WITHDRAWN,NO,BIOLOGICAL: Allogeneic NK transfer,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-30,2020-10-30
NOT_YET_RECRUITING,NO,BEHAVIORAL: Exercise session|BEHAVIORAL: Control session,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-02-15,2024-11-30
UNKNOWN,NO,OTHER: blood sampling|OTHER: additional blood tubes,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-05-05,2021-10-22
COMPLETED,YES,BEHAVIORAL: Connect2Test Intervention,ALL,"ADULT, OLDER_ADULT",NA,205,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-04-14,2021-06-30
COMPLETED,NO,DRUG: S-268019-b|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,9902,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-12-25,2023-07-19
NOT_YET_RECRUITING,NO,DRUG: Unfractionated heparin,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,180,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-20,2022-10-20
COMPLETED,NO,DIAGNOSTIC_TEST: ELISA test for Cytokines,ALL,"ADULT, OLDER_ADULT",NA,320,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2022-03-01,2023-08-10
COMPLETED,YES,DRUG: PF-07321332|DRUG: Ritonavir,ALL,"ADULT, OLDER_ADULT",PHASE1,17,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-08-31,2021-12-07
RECRUITING,NO,BEHAVIORAL: yoga|BEHAVIORAL: social contact,ALL,ADULT,NA,320,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-07-24,2027-01-01
WITHDRAWN,NO,BEHAVIORAL: Communication about the COVID-19 vaccination from the Massachusetts Department of Public Health,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-10-28,2022-09-01
COMPLETED,NO,DRUG: Anakinra|DRUG: Tocilizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,102,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-02,2021-01-08
UNKNOWN,NO,BIOLOGICAL: high-titer anti-Sars-CoV-2 plasma|OTHER: oxygen therapy,ALL,"ADULT, OLDER_ADULT",PHASE1,115,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-01,2022-12-31
COMPLETED,NO,BIOLOGICAL: Blood draw,ALL,"ADULT, OLDER_ADULT",NA,1044,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2021-01-14,2021-07-08
NOT_YET_RECRUITING,NO,BIOLOGICAL: SCTV01E-2|BIOLOGICAL: SCTV01E,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,600,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-08-10,2024-11-10
WITHDRAWN,NO,RADIATION: Phase 1|RADIATION: Phase 1|RADIATION: Phase 2|RADIATION: Phase 2|RADIATION: Phase 2,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-19,2021-09
COMPLETED,YES,BIOLOGICAL: 20-valent pneumococcal conjugate vaccine (20vPnC)|BIOLOGICAL: BNT162b2|OTHER: Saline,ALL,OLDER_ADULT,PHASE3,570,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-05-20,2021-12-08
UNKNOWN,NO,DRUG: Favipiravir|DRUG: Standard of Care,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,330,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-23,2020-07
NOT_YET_RECRUITING,NO,DRUG: Cetirizine|DRUG: Famotidine|DRUG: Cetirizine Placebo|DRUG: Famotidine Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,36,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-02,2024-08
TERMINATED,YES,DRUG: Acalabrutinib,ALL,"ADULT, OLDER_ADULT",PHASE1,9,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-21,2020-11-18
RECRUITING,NO,BIOLOGICAL: Glycovax-002,ALL,ADULT,PHASE1,36,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-04-28,2024-08
TERMINATED,NO,DRUG: RESP301,ALL,"ADULT, OLDER_ADULT",PHASE2,39,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-03-01,2022-05-20
UNKNOWN,NO,BIOLOGICAL: Gam-COVID-Vac,ALL,"ADULT, OLDER_ADULT",PHASE2,110,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-10-22,2021-04-30
WITHDRAWN,NO,DRUG: Hydroxychloroquine|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08,2021-09
RECRUITING,NO,DEVICE: Splenic Ultrasound,ALL,"ADULT, OLDER_ADULT",NA,15,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2024-01-03,2024-09-25
COMPLETED,NO,BIOLOGICAL: Biological samples,ALL,"ADULT, OLDER_ADULT",PHASE4,196,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-03-26,2022-02-06
UNKNOWN,NO,DIAGNOSTIC_TEST: conjunctival RT PCR,ALL,"ADULT, OLDER_ADULT",NA,68,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-05-15,2021-12-15
COMPLETED,NO,OTHER: physiotherapy,ALL,"ADULT, OLDER_ADULT",NA,122,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-04-04,2022-09-30
COMPLETED,YES,DRUG: RPH-104 80 mg|DRUG: Olokizumab 64 mg|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,372,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-23,2020-07-24
TERMINATED,NO,DRUG: Ivermectin|OTHER: Standard of Care,ALL,"ADULT, OLDER_ADULT",PHASE2,32,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-01,2020-12-01
UNKNOWN,NO,DIETARY_SUPPLEMENT: Placebo|DIETARY_SUPPLEMENT: Lactobacillus,ALL,"ADULT, OLDER_ADULT",NA,201,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2021-01-01,2021-12-31
COMPLETED,YES,BIOLOGICAL: Convalescent Plasma|OTHER: Saline solution,ALL,"ADULT, OLDER_ADULT",PHASE2,941,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-17,2022-12-12
TERMINATED,YES,DRUG: Ivermectin|DRUG: Camostat Mesilate|DIETARY_SUPPLEMENT: Artemesia annua|DRUG: Artesunate,ALL,"ADULT, OLDER_ADULT",PHASE2,13,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-01,2022-01-12
COMPLETED,NO,BIOLOGICAL: serology test|BIOLOGICAL: nasopharyngeal swab|BIOLOGICAL: rectal swab|BIOLOGICAL: saliva sample,ALL,"CHILD, ADULT, OLDER_ADULT",NA,1056,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-07-29,2022-05-24
TERMINATED,YES,DRUG: casirivimab+imdevimab|DRUG: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,66,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-10-25,2022-05-18
RECRUITING,NO,"DRUG: Prednisolone 20 mg/ 5 mg|DRUG: Vitamin B compound (100mg B1, 50 mg B6, 500 µg B12)|DRUG: Placebo for Vitamin B compound|DRUG: Placebo for Prednisolon",ALL,"ADULT, OLDER_ADULT",PHASE3,340,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-11-11,2024-12-31
UNKNOWN,NO,OTHER: Longan nasal spray|OTHER: Placebo,ALL,ADULT,NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: SUPPORTIVE_CARE",2021-07-01,2022-06-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205,ALL,"ADULT, OLDER_ADULT",PHASE1,7,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-17,2025-06-30
TERMINATED,YES,OTHER: Water|OTHER: Peroxyl|DRUG: Periogard|OTHER: Colgate Total Zero,ALL,"ADULT, OLDER_ADULT",PHASE2,2,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-26,2021-04-07
COMPLETED,NO,DRUG: VXA-CoV2-1.1-S|OTHER: Placebo Tablets,ALL,"ADULT, OLDER_ADULT",PHASE2,66,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-10-01,2023-08-01
COMPLETED,NO,DIETARY_SUPPLEMENT: Probiotics daily|DIETARY_SUPPLEMENT: Placebo daily,ALL,ADULT,NA,31,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2022-03-09,2022-05-19
UNKNOWN,NO,DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",NA,582,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-07,2022-06
RECRUITING,NO,"BIOLOGICAL: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|BIOLOGICAL: Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|BIOLOGICAL: Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|BIOLOGICAL: Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|BIOLOGICAL: Two doses of placebo at the schedule of day 0, 14 #middle-dose group#|BIOLOGICAL: Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|BIOLOGICAL: Two doses of placebo at the schedule of day 0, 14 #High-dose group#|BIOLOGICAL: Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#",ALL,"ADULT, OLDER_ADULT",PHASE1,216,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-10-30,2022-07-07
COMPLETED,NO,BIOLOGICAL: COVIVAC|BIOLOGICAL: Phosphate-buffered saline,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,420,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-03-10,2022-03-11
RECRUITING,NO,DRUG: DAS181|DRUG: Placebo|DRUG: DAS181 COVID-19|DRUG: DAS181 OL,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,274,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-05-23,2024-12-31
COMPLETED,YES,BIOLOGICAL: Anti- SARS-CoV-2 Plasma|BIOLOGICAL: SARS-CoV-2 non-immune Plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,180,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-10,2021-06-22
COMPLETED,NO,DEVICE: VESTA respirator|DEVICE: Conventional N95 respirator,ALL,ADULT,NA,300,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-03-01,2023-06-28
COMPLETED,NO,DIETARY_SUPPLEMENT: Probiotics|OTHER: Placebo,ALL,ADULT,NA,300,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2020-08-19,2021-02-02
COMPLETED,NO,BIOLOGICAL: Normal Saline|BIOLOGICAL: NDV-HXP-S vaccine,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,455,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-03-20,2022-09-12
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: GBP510 adjuvanted with AS03|OTHER: Placebo (Normal Saline),ALL,"ADULT, OLDER_ADULT",PHASE3,840,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-12-09,2024-08
COMPLETED,YES,BIOLOGICAL: Moderna COVID-19 Vaccine|BIOLOGICAL: Pfizer-BioNTech COVID-19 Vaccine|BIOLOGICAL: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,746,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-07,2022-04-27
COMPLETED,NO,DIAGNOSTIC_TEST: Dried blood spot and venous blood collection,ALL,"ADULT, OLDER_ADULT",NA,440,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-08-01,2020-09-30
UNKNOWN,NO,"DRUG: Human fecal microbiota, MBiotix HBI|DRUG: Placebo|DRUG: SOC",ALL,"ADULT, OLDER_ADULT",PHASE3,366,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-04,2022-12
UNKNOWN,NO,DRUG: BCG-10 vaccine|DRUG: 0.9% saline,ALL,"ADULT, OLDER_ADULT",PHASE3,1000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-07,2021-04
COMPLETED,NO,DRUG: Lopinavir/ritonavir,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,326,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-04-23,2021-03-24
COMPLETED,NO,DRUG: Sofosbuvir plus Ledipasvir,ALL,"ADULT, OLDER_ADULT",PHASE3,250,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-04-15,2020-07-23
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: ZR-202-CoV|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,84,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-01-18,2023-06
COMPLETED,NO,BIOLOGICAL: Biological,ALL,"ADULT, OLDER_ADULT",PHASE2,150,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-23,2020-09-30
RECRUITING,NO,OTHER: tai chi exercise|OTHER: no intervention,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-11-10,2023-12-28
WITHDRAWN,NO,OTHER: washed microbiota transplantation|OTHER: placebo,ALL,"CHILD, ADULT, OLDER_ADULT",NA,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-02-05,2020-04-30
COMPLETED,YES,DRUG: Octagam,ALL,"ADULT, OLDER_ADULT",PHASE4,34,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-28,2020-06-23
ACTIVE_NOT_RECRUITING,NO,OTHER: Aerobic Exercises|DEVICE: Incentive Spirometer Device|OTHER: Traditional Chest Physiotherapy,ALL,"ADULT, OLDER_ADULT",NA,45,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-01,2024-02
COMPLETED,NO,BIOLOGICAL: SCTV01E|BIOLOGICAL: Placebo (normal saline),ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,518,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-01-05,2024-01-15
UNKNOWN,NO,BIOLOGICAL: SARS-CoV-2 DNA Vaccine|BIOLOGICAL: Matching placebo,ALL,ADULT,PHASE1,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-11-18,2022-12
COMPLETED,NO,DEVICE: Medical Mask|DEVICE: N95 respirator,ALL,"ADULT, OLDER_ADULT",PHASE4,1009,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-03-01,2022-12-08
WITHDRAWN,NO,DRUG: Nirmatrelvir|DRUG: Ritonavir|DRUG: Placebo for nirmatrelvir,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-12-13,2024-01-06
COMPLETED,NO,DRUG: Propranolol Hydrochloride,ALL,"ADULT, OLDER_ADULT",PHASE3,72,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-01-08,2022-11-30
COMPLETED,NO,DRUG: Ciclesonide Metered Dose Inhaler [Alvesco],ALL,"ADULT, OLDER_ADULT",PHASE2,68,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-01,2021-03-31
COMPLETED,NO,BIOLOGICAL: BBV152A - Phase I|BIOLOGICAL: BBV152B - Phase I|BIOLOGICAL: BBV152C - Phase I|BIOLOGICAL: Placebo - Phase I|BIOLOGICAL: BBV152A - Phase II|BIOLOGICAL: BBV152B - Phase II,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,755,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-15,2021-06-30
COMPLETED,YES,DRUG: Duvelisib|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,47,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-11-18,2021-06-10
COMPLETED,NO,BIOLOGICAL: AG0302-COVID19 for Intramuscular Injection|BIOLOGICAL: AG0302-COVID19 for Intramuscular Injection|BIOLOGICAL: AG0302-COVID19 for Intramuscular Injection|BIOLOGICAL: AG0302-COVID19 for Intradermal Injection|BIOLOGICAL: AG0302-COVID19 for Intradermal Injection,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,422,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-07-29,2022-09-23
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: ABO1020|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,14168,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-11-23,2024-07-31
COMPLETED,NO,BIOLOGICAL: Mesenchymal stem cell,ALL,"ADULT, OLDER_ADULT",PHASE1,6,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-21,2021-02-02
COMPLETED,NO,DRUG: Nitric Oxide,ALL,"ADULT, OLDER_ADULT",PHASE3,306,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-11-01,2022-02-02
COMPLETED,NO,BIOLOGICAL: ChAdOx1 nCov-19,ALL,ADULT,PHASE1,42,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-04-01,2022-09-30
COMPLETED,NO,OTHER: low-intensity aerobic training,MALE,"ADULT, OLDER_ADULT",NA,76,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-03-30,2020-12-15
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: SCTV01C|BIOLOGICAL: SCTV01E|BIOLOGICAL: Sinopharm inactivated COVID-19 vaccine|BIOLOGICAL: Comirnaty,ALL,"ADULT, OLDER_ADULT",PHASE3,1800,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-05-30,2023-05-01
COMPLETED,NO,DRUG: Effects in oxygenation and hypoxic pulmonary vasoconstriction,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,24,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: TREATMENT,2020-10-01,2021-05-15
WITHDRAWN,NO,BIOLOGICAL: UB-612,ALL,ADULT,PHASE1,0,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-02-15,2022-10-31
TERMINATED,NO,DIAGNOSTIC_TEST: Q16 testing|DIAGNOSTIC_TEST: Nasopharyngeal swab and main laboratory,ALL,"ADULT, OLDER_ADULT",NA,461,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-07-02,2020-10-27
RECRUITING,NO,OTHER: Resistance Exercise,ALL,"CHILD, ADULT, OLDER_ADULT",NA,220,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-01,2033-07-31
UNKNOWN,NO,OTHER: Immunological analyses,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-09-20,2022-08-20
TERMINATED,NO,DRUG: Dornase Alfa Inhalation Solution [Pulmozyme]|PROCEDURE: standard procedure,ALL,"ADULT, OLDER_ADULT",PHASE3,77,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-04-21,2021-12-20
RECRUITING,NO,"DIAGNOSTIC_TEST: COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support|OTHER: Telemedicine",ALL,"ADULT, OLDER_ADULT",NA,200,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-16,2022-04
COMPLETED,NO,BEHAVIORAL: Promotores de Salud|BEHAVIORAL: Services as usual,ALL,"CHILD, ADULT, OLDER_ADULT",NA,1627,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-02-04,2022-12-31
COMPLETED,NO,DRUG: Fluvoxamine|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1188,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2022-08-25,2023-05-30
RECRUITING,NO,OTHER: Smell training,ALL,"ADULT, OLDER_ADULT",NA,105,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-05,2023-03
TERMINATED,NO,DRUG: Hydroxychloroquine + placebo|DRUG: hydroxychloroquine + azithromycin,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,7,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-11,2021-04-09
UNKNOWN,NO,DIAGNOSTIC_TEST: Sit to stand test,ALL,"ADULT, OLDER_ADULT",NA,146,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2020-12-21,2021-12-28
SUSPENDED,NO,DRUG: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-06,2021-09-30
COMPLETED,NO,DEVICE: Home Pulse Oximetry Monitoring,ALL,"ADULT, OLDER_ADULT",NA,209,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-03-20,2020-04-22
UNKNOWN,NO,DRUG: Tofacitinib|DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE2,116,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06,2020-10
COMPLETED,NO,BIOLOGICAL: Remdesivir|DRUG: Remdesivir Placebo|BIOLOGICAL: Aviptadil|DRUG: Aviptadil Placebo|DRUG: Corticosteroid,ALL,"ADULT, OLDER_ADULT",PHASE3,473,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-04-20,2022-11-20
ACTIVE_NOT_RECRUITING,NO,DRUG: Tocilizumab 20 MG/ML,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2024-12-31
UNKNOWN,NO,OTHER: nasopharyngeal swabbing procedure (self swabbing first)|OTHER: nasopharyngeal swabbing procedure (conventionnal swabbing first),ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-04,2021-12
TERMINATED,NO,DRUG: Carrimycin|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,93,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-30,2022-05-09
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: QTP104 1ug|BIOLOGICAL: QTP104 5ug|BIOLOGICAL: QTP104 25ug,ALL,ADULT,PHASE1,36,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-11-19,2023-08-30
COMPLETED,YES,DRUG: Sirukumab|DRUG: Placebo|OTHER: Standard of Care (SOC),ALL,"ADULT, OLDER_ADULT",PHASE2,212,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-24,2021-06-24
COMPLETED,NO,BEHAVIORAL: Connect2Test,ALL,"ADULT, OLDER_ADULT",NA,349,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION,2022-08-08,2023-06-30
UNKNOWN,NO,DEVICE: VibroLUNG,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-03-22,2021-02-01
NOT_YET_RECRUITING,NO,OTHER: Blood sampling|OTHER: Nasal Brushing,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2022-12,2025-12
COMPLETED,NO,"BEHAVIORAL: ""Stay at Home Take a Step Program (SHTSP)""",ALL,OLDER_ADULT,NA,32,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-06-01,2021-09-01
COMPLETED,NO,DRUG: Arbidol|OTHER: basic treatment,ALL,"ADULT, OLDER_ADULT",PHASE4,236,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-08,2020-12-30
COMPLETED,NO,DIAGNOSTIC_TEST: Evolution of antibodies titre,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-09-08,2022-02-01
RECRUITING,NO,DEVICE: Bright light therapy|DEVICE: Dim red light therapy,ALL,"ADULT, OLDER_ADULT",NA,36,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-02-15,2024-04-30
RECRUITING,NO,OTHER: blood sampling,ALL,"ADULT, OLDER_ADULT",NA,1000,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-07-28,2025-12-31
UNKNOWN,NO,BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cell) low-dose group|BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cells) high-dose group|BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cells) placebo group,ALL,ADULT,PHASE1,50,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-06-22,2021-09-20
COMPLETED,NO,DRUG: PF-07321332/ritonavir|DRUG: PF-07321332/ritonavir|DRUG: PF-07321332/ritonavir|DRUG: PF-07321332/ritonavir|DRUG: PF-07321332,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-03-03,2022-05-16
NOT_YET_RECRUITING,NO,DRUG: Nitazoxanide|DRUG: Placebo|DIETARY_SUPPLEMENT: Vitamin Super-B Complex,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,600,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-08,2025-03
UNKNOWN,NO,DRUG: acetylsalicylic acid|DRUG: Unfractionated heparin nebulized,ALL,"ADULT, OLDER_ADULT",PHASE2,379,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-11,2022-05-30
UNKNOWN,NO,BIOLOGICAL: recovered covid 19 patients plasma,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-29,2020-09-01
UNKNOWN,NO,BIOLOGICAL: BM-Allo.MSC|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,45,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-03,2022-06
COMPLETED,NO,DIETARY_SUPPLEMENT: Vitamins|DRUG: Telmisartan|DRUG: Ciclesonide|DRUG: interferon β-1b,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,412,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-29,2021-10-22
RECRUITING,NO,BIOLOGICAL: SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,16,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-18,2024-03-31
COMPLETED,NO,BIOLOGICAL: AV-COVID-19,ALL,"ADULT, OLDER_ADULT",PHASE2,145,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-04-14,2021-05-31
RECRUITING,NO,"OTHER: ""Tomando control de su salud"" (Spanish Chronic Disease Self-Management)",ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-11-02,2024-06
COMPLETED,NO,DRUG: MediCabilis Cannabis sativa 50,ALL,"ADULT, OLDER_ADULT",PHASE2,12,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04-14,2023-01-06
COMPLETED,NO,DRUG: BAT2022,ALL,ADULT,PHASE1,32,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-06-09,2022-11-07
COMPLETED,NO,DRUG: Emtricitabine/tenofovir|DRUG: Colchicine Pill|DRUG: Rosuvastatin|OTHER: Standard treatment,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,650,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-18,2021-06-30
UNKNOWN,NO,DRUG: Acetylsalicylic acid|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,204,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-01,2021-08-31
UNKNOWN,NO,DIAGNOSTIC_TEST: AP-23,ALL,"CHILD, ADULT, OLDER_ADULT",NA,4400,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-02-11,2021-05-15
COMPLETED,YES,DRUG: Hydroxychloroquine|DRUG: Azithromycin,ALL,"ADULT, OLDER_ADULT",PHASE2,85,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-30,2021-01-01
COMPLETED,NO,BEHAVIORAL: Positive feedback,ALL,"ADULT, OLDER_ADULT",NA,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-15,2020-07-30
SUSPENDED,NO,OTHER: Decision tool for clinicians,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-03-01,2025-01-31
RECRUITING,NO,DIETARY_SUPPLEMENT: Immulina TM|DIETARY_SUPPLEMENT: Placebo,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-07-20,2025-03-31
RECRUITING,NO,BIOLOGICAL: COMIRNATY - BioNTech Manufacturing GmbH|BIOLOGICAL: COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH|BIOLOGICAL: COVID-19 Vaccine AstraZeneca suspension for injection,ALL,"ADULT, OLDER_ADULT",PHASE4,10000,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-02-08,2024-12-31
TERMINATED,YES,DRUG: Antithrombin III,ALL,"ADULT, OLDER_ADULT",PHASE2,52,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-07-06,2022-03-31
UNKNOWN,NO,"DEVICE: Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|DEVICE: OLO-1 Medical Molecular Sieve Oxygen Generator",ALL,"ADULT, OLDER_ADULT",NA,198,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-31,2021-12-31
WITHDRAWN,NO,DRUG: RLS-0071 10 mg/kg|DRUG: RLS-0071 40 mg/kg|DRUG: Placebo|DRUG: RLS-0071 10 mg/kg|DRUG: RLS-0071 40 mg/kg,ALL,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-01,2022-12
COMPLETED,NO,DEVICE: PEP flute,ALL,"ADULT, OLDER_ADULT",NA,378,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2020-10-06,2021-09-01
UNKNOWN,NO,BIOLOGICAL: Gam-COVID-Vac|OTHER: placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,33758,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-09-07,2021-05-01
COMPLETED,NO,"DRUG: Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO)",ALL,"ADULT, OLDER_ADULT",PHASE4,75,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-09-01,2021-12-07
NOT_YET_RECRUITING,NO,DEVICE: eBAM Cov Testing,ALL,"ADULT, OLDER_ADULT",NA,250,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-01,2025-06
RECRUITING,NO,DEVICE: Trigeminal Nerve Stimulation (TNS)|OTHER: Active Smell Training (ST)|OTHER: Placebo Smell Training (PBO),ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,180,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-10-02,2028-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Psilocybin (Usona Institute)|DRUG: Active placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-03,2024-03-30
TERMINATED,NO,DRUG: ZYESAMI™ (aviptadil acetate)|DRUG: Placebo|DEVICE: Nebulized administration of ZYESAMI™ or Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,144,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-15,2021-12-31
COMPLETED,NO,BIOLOGICAL: Recombinant novel coronavirus vaccine (CHO cells),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,480,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-11-10,2022-07-31
COMPLETED,NO,DRUG: CPI-006|OTHER: Standard of Care,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-01,2021-07-09
NOT_YET_RECRUITING,NO,BIOLOGICAL: PTX-COVID19-B|BIOLOGICAL: Vaxzevria®,ALL,"ADULT, OLDER_ADULT",PHASE3,450,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-02-03,2023-10-18
COMPLETED,NO,DRUG: siCoV/KK46,MALE,ADULT,PHASE1,10,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-22,2021-03-26
TERMINATED,YES,DRUG: Normal Saline intranasal and placebo inhaler|DRUG: Ciclesonide|DRUG: Ciclesonide nasal,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,215,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-09-15,2021-07-08
RECRUITING,NO,DEVICE: Abbott Panbio rapid antigen self-tests|OTHER: COVIDSmart CARE! app,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,600,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING,2023-02-02,2024-03
COMPLETED,NO,DRUG: Favipiravir|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1231,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-30,2021-10-20
TERMINATED,NO,DRUG: Famotidine|DRUG: Celecoxib|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,9,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-12-29,2022-07-08
TERMINATED,YES,BIOLOGICAL: Ravulizumab|OTHER: BSC,ALL,"ADULT, OLDER_ADULT",PHASE3,202,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-10,2021-04-08
COMPLETED,NO,BEHAVIORAL: Phase II Promotores de Salud|BEHAVIORAL: Phase I Promotores de Salud Outreach,ALL,"CHILD, ADULT, OLDER_ADULT",NA,1463,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-09-15,2023-04-30
RECRUITING,NO,DRUG: Molnupiravir 200 mg,ALL,"ADULT, OLDER_ADULT",PHASE3,4000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-08-12,2027-07
UNKNOWN,NO,DRUG: Eicosapentaenoic acid gastro-resistant capsules|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,284,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-01-08,2021-12-01
UNKNOWN,NO,BIOLOGICAL: V-SARS,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-15,2021-06-15
COMPLETED,NO,DRUG: MR or M-M-R II ® vaccine|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,3545,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-09-04,2021-12-03
TERMINATED,NO,DRUG: Anakinra alone (stages 2b/3)|DRUG: Anakinra and Ruxolitinib (overcome stage 3)|OTHER: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE2,2,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-19,2020-10-02
COMPLETED,NO,DRUG: TL-895,ALL,"ADULT, OLDER_ADULT",PHASE1,7,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-09,2020-12-15
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|BIOLOGICAL: ZF2001,ALL,"ADULT, OLDER_ADULT",PHASE3,1200,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-12-28,2023-12-31
WITHDRAWN,NO,DRUG: Baricitinib,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03,2021-10
COMPLETED,YES,BEHAVIORAL: Mobile Mental Health App - 1|BEHAVIORAL: Mobile Mental Health App - 2|BEHAVIORAL: Mobile Mental Health App - 3|BEHAVIORAL: Mobile Mental Health App - 4,ALL,"ADULT, OLDER_ADULT",NA,838,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-30,2021-06-20
TERMINATED,YES,DRUG: GC4419|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,16,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-09,2021-05-28
COMPLETED,NO,DEVICE: Sentinox--Group A|DEVICE: Sentinox--Group B,ALL,ADULT,NA,57,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-20,2021-11-30
RECRUITING,NO,OTHER: Clinical examination|OTHER: Blood collection|OTHER: Olfactory evoked potentials|OTHER: Brushing of olfactory slits|OTHER: Neurological examination and neuropsychological assessment|OTHER: Nasal endoscopy|OTHER: Assessment of olfactory and taste functions,ALL,ADULT,NA,30,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-06-20,2024-01-09
COMPLETED,NO,OTHER: severity of lung involvement with COVID-19.,ALL,"ADULT, OLDER_ADULT",NA,29,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: DIAGNOSTIC",2020-06-05,2020-09-05
COMPLETED,NO,DRUG: SNG001|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,221,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-03-16,2021-11-16
RECRUITING,NO,BIOLOGICAL: JCXH-221|BIOLOGICAL: Active Comparator|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,262,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-03-20,2024-10-04
COMPLETED,NO,DEVICE: Lucira COVID-19 All-In-One test kit,ALL,"CHILD, ADULT, OLDER_ADULT",NA,304,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-12-09,2021-03-30
NOT_YET_RECRUITING,NO,BIOLOGICAL: GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile),ALL,"ADULT, OLDER_ADULT",PHASE3,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-10,2024-12
RECRUITING,NO,BEHAVIORAL: External Qigong,ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-01-04,2024-07-30
COMPLETED,NO,DRUG: Carrageenan nasal spray and 1% PVP- mouthwash and gargle,ALL,"ADULT, OLDER_ADULT",PHASE4,7,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-24,2022-08-01
COMPLETED,NO,BIOLOGICAL: Anti-SARS-CoV-2 IgT seropositivity,ALL,"CHILD, ADULT, OLDER_ADULT",NA,2006,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-06-26,2020-07-24
RECRUITING,NO,BIOLOGICAL: CVXGA,ALL,"ADULT, OLDER_ADULT",PHASE2,400,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-30,2024-10
COMPLETED,NO,DRUG: AZVUDINE|DRUG: AZVUDINE placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,180,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-23,2022-08-10
COMPLETED,NO,DIAGNOSTIC_TEST: miRNA analysis in plasma,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2020-12-07,2021-07-12
RECRUITING,NO,BIOLOGICAL: Coronavirus-2-specific T cells|OTHER: standard of care (SOC),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,182,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-02,2022-12-31
COMPLETED,YES,BIOLOGICAL: BNT162b2,ALL,ADULT,PHASE3,629,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-04-01,2021-12-02
COMPLETED,NO,PROCEDURE: Internal jugular vein cannulation,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: PREVENTION,2020-03-20,2020-09-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Vaccine for intramuscular injection|OTHER: Placebo comparator (without active ingredient) for intramuscular injection,ALL,CHILD,PHASE3,300,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-04-01,2024-02-01
COMPLETED,NO,BIOLOGICAL: Baiya SARS-CoV-2 Vax 1,ALL,"ADULT, OLDER_ADULT",PHASE1,48,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-09-11,2022-11-04
COMPLETED,YES,DRUG: REGN10933 + REGN10987|DRUG: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,3303,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-13,2021-10-04
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|OTHER: Placebo (Initial Vaccination Period)|BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)|OTHER: Placebo (Crossover Vaccination period)|BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination),ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,33000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-12-27,2023-12-15
ACTIVE_NOT_RECRUITING,NO,OTHER: Intervention Group: Virtual home-based rehabilitation plus usual outpatient care,ALL,"ADULT, OLDER_ADULT",NA,132,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-08-01,2024-03
COMPLETED,NO,OTHER: 0.07% cetylpyridinium chloride (CPC) in mouthwash|OTHER: Distilled water with the same colorant as the experimental product,ALL,"ADULT, OLDER_ADULT",NA,118,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2021-02-17,2021-06-03
COMPLETED,NO,DRUG: Nirmatrelvir|DRUG: Ritonavir|DRUG: Placebo for nirmatrelvir|DRUG: Placebo for ritonavir,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,157,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-08-03,2023-11-13
UNKNOWN,NO,DRUG: Heparin sodium|DRUG: Enoxaparin,ALL,"ADULT, OLDER_ADULT",PHASE4,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2021-06-01
UNKNOWN,NO,OTHER: PROTECTIVE VENTILATION|OTHER: ULTRAPROTECTIVE VENTILATION,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-15,2023-04-15
ACTIVE_NOT_RECRUITING,NO,DIETARY_SUPPLEMENT: Açaí palm berry extract - natural product|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,480,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-04,2022-12
TERMINATED,NO,DRUG: Colchicine 1 MG Oral Tablet,ALL,"ADULT, OLDER_ADULT",PHASE2,227,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-18,2021-10-31
COMPLETED,NO,BIOLOGICAL: Administration of Equine immunoglobulin anti SARS-CoV-2,ALL,"ADULT, OLDER_ADULT",PHASE2,26,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-06,2020-12-06
TERMINATED,YES,DRUG: FP-025 100 mg|DRUG: FP-025 300 mg|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,90,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-06,2022-04-18
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 convalescent plasma,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-10,2020-12-31
TERMINATED,NO,BIOLOGICAL: NGM621|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,16,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-09,2021-03-11
RECRUITING,NO,DRUG: HH-120 Nasal Spray|DRUG: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,1200,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-03-31,2024-06-01
UNKNOWN,NO,DRUG: pirfenidone,ALL,"ADULT, OLDER_ADULT",PHASE3,294,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-04,2020-06-01
COMPLETED,NO,BIOLOGICAL: BCG vaccine (Freeze-dried),ALL,"ADULT, OLDER_ADULT",PHASE3,2175,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-07-01,2021-09-20
UNKNOWN,NO,BIOLOGICAL: SARS-CoV-2 mRNA Vaccine|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,28000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-07-22,2023-05-30
COMPLETED,NO,BIOLOGICAL: cAd3-Marburg|BIOLOGICAL: cAd3-EBO-S,ALL,ADULT,PHASE1,32,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-01-06,2021-12-14
ENROLLING_BY_INVITATION,NO,OTHER: Comprehensive Rehabilitation|OTHER: Augmented Usual Care,ALL,"CHILD, ADULT, OLDER_ADULT",NA,216,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-11-15,2026-03-30
UNKNOWN,NO,"OTHER: Mini Nutritional Assessment ,Pıtsburg Sleep Qualıty Scale, Short Physical Activity Survey",ALL,"ADULT, OLDER_ADULT",NA,66,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-01-01,2022-02-01
RECRUITING,NO,DRUG: Upadacitinib|DRUG: Abatacept|DRUG: Secukinumab|DRUG: Tofacitinib|DRUG: TNF Inhibitor|DRUG: Canakinumab Injection|DRUG: Baricitinib|DRUG: Ixekizumab,ALL,"ADULT, OLDER_ADULT",PHASE4,1000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-11-15,2024-09-30
COMPLETED,NO,DRUG: Rintatolimod|OTHER: Placebo / Normal Saline,ALL,ADULT,PHASE2,80,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-30,2023-11-30
RECRUITING,NO,DRUG: Low-dose acetylsalicylic acid|DRUG: Placebo,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE3,400,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-09-14,2024-02-28
TERMINATED,NO,DRUG: LYT-100|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,185,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-11,2022-07-18
ACTIVE_NOT_RECRUITING,NO,DEVICE: transcranial current direct stimulation,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-03-01,2024-06-30
RECRUITING,NO,DRUG: Efgartigimod,ALL,"ADULT, OLDER_ADULT",PHASE2,38,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-16,2025-05
COMPLETED,NO,DRUG: Hydroxychloroquine + azithromycin|DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE3,440,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-28,2020-06-14
UNKNOWN,NO,DRUG: Ribavirin Capsules|DRUG: Favipiravir,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04,2021-12-31
COMPLETED,NO,DIETARY_SUPPLEMENT: Cretan IAMA,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-01,2020-10-15
COMPLETED,YES,DRUG: Sargramostim|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,600,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-04-27,2022-01-31
UNKNOWN,NO,BIOLOGICAL: Sputnik Light|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,6000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-02-19,2022-01-31
TERMINATED,NO,OTHER: Postural Positioning,ALL,"ADULT, OLDER_ADULT",NA,7,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-25,2022-05-01
UNKNOWN,NO,BEHAVIORAL: At-home COVID-19 testing|BEHAVIORAL: Family-based model|BEHAVIORAL: Onsite COVID-19 testing,ALL,"CHILD, ADULT, OLDER_ADULT",NA,3000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-10-17,2023-07-30
UNKNOWN,NO,DRUG: Nitazoxanide|DRUG: Placebo,ALL,ADULT,PHASE2|PHASE3,135,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-06-26,2020-12-26
COMPLETED,NO,DRUG: Ivermectin|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,72,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-09-01,2021-12-01
WITHDRAWN,NO,BIOLOGICAL: Viral Specific T-cells (VSTs),ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01,2025-06
TERMINATED,NO,DIAGNOSTIC_TEST: In Vitro,ALL,"CHILD, ADULT, OLDER_ADULT",NA,64,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-10-07,2022-11-18
TERMINATED,NO,DRUG: Ensovibep|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,53,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2020-11-18,2022-01-06
COMPLETED,YES,BIOLOGICAL: Convalescent Plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-10,2020-08-13
COMPLETED,YES,BIOLOGICAL: mRNA-1273,ALL,"ADULT, OLDER_ADULT",PHASE1,120,NIH,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-03-16,2022-04-26
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Biological: AZD3152|BIOLOGICAL: Biological: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,116,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-09-29,2024-05-27
UNKNOWN,NO,DRUG: Ciclesonide Inhalation Aerosol,ALL,"ADULT, OLDER_ADULT",PHASE2,98,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-29,2022-01-31
RECRUITING,NO,DRUG: Experimental: Primary Cohort|OTHER: Placebo Comparator: Primary Cohort - Placebo,ALL,"ADULT, OLDER_ADULT",PHASE4,280,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-07-01,2025-07
RECRUITING,NO,"OTHER: Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation|OTHER: Exercise booklet",ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-10-01,2024-12-01
COMPLETED,YES,DRUG: DFV890|DRUG: Standard of Care (SoC),ALL,"ADULT, OLDER_ADULT",PHASE2,143,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-27,2020-12-24
TERMINATED,NO,BIOLOGICAL: High-Titer COVID-19 Convalescent Plasma (HT-CCP)|BIOLOGICAL: Standard Plasma (FFP),ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,45,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-30,2021-06-30
COMPLETED,YES,DRUG: PF-07321332/ritonavir,ALL,"ADULT, OLDER_ADULT",PHASE1,35,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-06-15,2021-10-07
UNKNOWN,NO,DRUG: SARS-CoV-2 convalescent plasma,ALL,"ADULT, OLDER_ADULT",PHASE3,100,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-04-08,2021-12-31
COMPLETED,YES,DRUG: APL-9|OTHER: Vehicle Control,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,72,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-05-28,2021-02-13
UNKNOWN,NO,DRUG: Ivermectin Powder,ALL,"ADULT, OLDER_ADULT",PHASE3,80,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-25,2021-12-31
COMPLETED,NO,DRUG: Hydroxychloroquine|DRUG: Favipiravir|OTHER: Routine care for COVID-19 patients,ALL,"ADULT, OLDER_ADULT",PHASE2,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-11,2021-04-07
WITHDRAWN,NO,DIAGNOSTIC_TEST: Lollipop Swab,ALL,"CHILD, ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-07,2023-09
ENROLLING_BY_INVITATION,NO,BIOLOGICAL: Protein subunit vaccine Soberana Plus (FINLAY-FR-1A) is a vaccine against COVID-19 produced by The Finlay Vaccine Institute and The Centre of Molecular Immunology (Republic of Cuba),ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-12-09,2023-07-28
COMPLETED,NO,DIAGNOSTIC_TEST: conjunctival swab,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-03-26,2020-05-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Hydroxychloroquine Sulfate,ALL,"ADULT, OLDER_ADULT",PHASE4,53,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-25,2025-03-03
RECRUITING,NO,DEVICE: Tens Eco Plus,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-01-09,2023-03
UNKNOWN,NO,DRUG: Tocilizumab|DRUG: Hydroxychloroquine|DRUG: Azithromycin,ALL,"ADULT, OLDER_ADULT",PHASE2,276,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-02,2021-07
COMPLETED,YES,DRUG: BGB DXP593|DRUG: Placebo,ALL,ADULT,PHASE1,18,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2020-09-08,2021-02-13
COMPLETED,YES,DRUG: Proxalutamide|OTHER: Standard of Care,MALE,"ADULT, OLDER_ADULT",NA,268,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-21,2021-01-21
COMPLETED,NO,DRUG: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|DRUG: Group 2: control group with enoxaparin 40mg/d,ALL,"ADULT, OLDER_ADULT",PHASE4,615,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-06-21,2021-05-30
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 Protein Subunit Recombinant Vaccine|BIOLOGICAL: SARS-CoV-2 Inactivated Vaccine,ALL,"ADULT, OLDER_ADULT",PHASE1,54,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-12-10,2022-08-06
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: mRNA-1010|BIOLOGICAL: mRNA-1345|BIOLOGICAL: mRNA-1273.214|BIOLOGICAL: mRNA-1045|BIOLOGICAL: mRNA-1230,ALL,"ADULT, OLDER_ADULT",PHASE1,392,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-10-14,2024-02-14
TERMINATED,NO,DRUG: Estradiol patch,ALL,"ADULT, OLDER_ADULT",PHASE2,2,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-20,2020-07-30
COMPLETED,YES,DRUG: Apilimod Dimesylate Capsule|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,142,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-15,2021-04-19
COMPLETED,NO,DRUG: HH-120 Nasal Spray,ALL,"ADULT, OLDER_ADULT",NA,14,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-06-14,2023-02-06
UNKNOWN,NO,DRUG: captopril 25mg,ALL,"ADULT, OLDER_ADULT",PHASE2,230,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-05,2020-08
COMPLETED,NO,BIOLOGICAL: mRNA-1273.529|BIOLOGICAL: mRNA-1273|BIOLOGICAL: mRNA-1273.214,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,3557,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-02-16,2023-06-23
COMPLETED,NO,DRUG: Methylprednisolone Sodium Succinate|DRUG: Placebo solution,ALL,"ADULT, OLDER_ADULT",PHASE2,416,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-18,2020-10-20
COMPLETED,NO,OTHER: lung ultrasound assessment,ALL,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-12-01,2022-05-31
COMPLETED,NO,DRUG: TQ Formula/Tab,ALL,"ADULT, OLDER_ADULT",PHASE2,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-06-08,2022-01-01
RECRUITING,NO,BIOLOGICAL: Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|BIOLOGICAL: CoronaVac Biofarma COVID-19 Vaccine,ALL,"ADULT, OLDER_ADULT",PHASE3,4005,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-06-28,2023-05-28
ACTIVE_NOT_RECRUITING,NO,OTHER: Virtual Realty Exercises|OTHER: Aerobic exercises|OTHER: conventional exercises,ALL,"ADULT, OLDER_ADULT",NA,63,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-01,2022-05-01
COMPLETED,YES,DRUG: Favipiravir|DRUG: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE3,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-21,2020-08-20
COMPLETED,NO,DEVICE: Lucira COVID-19 All-In-One test kit,ALL,"ADULT, OLDER_ADULT",NA,101,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-09-25,2020-10-20
WITHDRAWN,NO,DRUG: Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|DRUG: Comparator,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-12-15,2022-04-09
ACTIVE_NOT_RECRUITING,YES,DRUG: Metformin|DRUG: Placebo|DRUG: Fluvoxamine|DRUG: Ivermectin,ALL,"ADULT, OLDER_ADULT",PHASE3,1323,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-01,2024-02-14
COMPLETED,NO,DRUG: Sargramostim|OTHER: Normal Saline 0.9%,ALL,"ADULT, OLDER_ADULT",PHASE2,2,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-02,2022-02-04
COMPLETED,YES,DRUG: Losartan|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,117,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-09,2021-02-01
WITHDRAWN,NO,DRUG: Hydroxychloroquine|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2020-03-30,2020-10-30
COMPLETED,NO,DRUG: Ganovo+ritonavir+/-Interferon nebulization,ALL,"ADULT, OLDER_ADULT",PHASE4,11,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-17,2020-03-19
COMPLETED,YES,DIAGNOSTIC_TEST: SARS-CoV2 serum antibody testing,ALL,"ADULT, OLDER_ADULT",NA,143,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-05-05,2020-09-04
COMPLETED,NO,DRUG: Aerolized Hydroxychloroquine Sulfate|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-25,2020-08-17
COMPLETED,YES,BIOLOGICAL: BNT162b2|BIOLOGICAL: BNT162b2.B.1.351,ALL,"CHILD, ADULT",PHASE3,1574,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-02-15,2021-07-22
ENROLLING_BY_INVITATION,NO,DRUG: Placebo|DRUG: Fisetin,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-03,2025-09
UNKNOWN,NO,DEVICE: Remote Ischemic Conditioning,ALL,"CHILD, ADULT, OLDER_ADULT",NA,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-15,2021-09-01
ACTIVE_NOT_RECRUITING,NO,OTHER: Immunosuppression reduction|OTHER: No immunosuppression reduction,ALL,"ADULT, OLDER_ADULT",PHASE1,40,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-11-15,2022-11-14
COMPLETED,YES,DEVICE: Transcutaneous Non-Invasive Vagus Nerve Stimulation,ALL,"CHILD, ADULT, OLDER_ADULT",NA,17,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-06,2022-12-05
COMPLETED,NO,DRUG: Enisamium Iodide|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,592,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-15,2021-03-26
COMPLETED,NO,BEHAVIORAL: Remote Problem Management Plus,ALL,"ADULT, OLDER_ADULT",NA,45,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-04,2023-05-20
COMPLETED,NO,BEHAVIORAL: Theory of planned behaviours (TPB) based intervention,ALL,"ADULT, OLDER_ADULT",NA,310,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-03-15,2023-05-30
ACTIVE_NOT_RECRUITING,NO,"DEVICE: Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|DEVICE: the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen)",ALL,"ADULT, OLDER_ADULT",NA,188,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-16,2022-12-30
UNKNOWN,NO,BIOLOGICAL: Astrazeneca/Oxford Vaccine|BIOLOGICAL: Sinopharm vaccine,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,4000,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-02-23,2021-12-01
UNKNOWN,NO,DIAGNOSTIC_TEST: Salivary test for COVID19,ALL,"CHILD, ADULT, OLDER_ADULT",NA,1159,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-08-10,2021-11-12
COMPLETED,YES,BIOLOGICAL: Ampion|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,32,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-07-26,2022-02-21
UNKNOWN,NO,DRUG: Iodine Complex|DRUG: Iodine Complex|DRUG: Placebo|DRUG: Idoine Complex,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,200,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-14,2021-10-15
TERMINATED,NO,"DRUG: Vitamin D3 50,000 IU|DIETARY_SUPPLEMENT: Vitamin C/Zinc|DIETARY_SUPPLEMENT: Vitamin K2/D|OTHER: Microcrystalline Cellulose Capsule|OTHER: Medium Chain Triglyceride Oil",ALL,"ADULT, OLDER_ADULT",PHASE3,90,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-07-12,2022-07-07
COMPLETED,NO,DIAGNOSTIC_TEST: Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus,ALL,"CHILD, ADULT, OLDER_ADULT",NA,28,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2020-05-23,2022-06-17
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg|BIOLOGICAL: BNT162b4 5 µg|BIOLOGICAL: BNT162b4 10 µg|BIOLOGICAL: BNT162b4 15 µg|BIOLOGICAL: BNT162b4 30 µg|BIOLOGICAL: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg,ALL,"ADULT, OLDER_ADULT",PHASE1,360,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-11-08,2024-10
COMPLETED,YES,DRUG: Ivermectin|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1800,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-06-08,2022-05-16
COMPLETED,NO,DRUG: Methylene Blue and Photodynamic Therapy,ALL,"ADULT, OLDER_ADULT",PHASE1,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-04-24,2020-07-30
SUSPENDED,NO,DRUG: Remdesivir|DRUG: Remdesivir placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,308,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-02-12,2020-04-27
TERMINATED,NO,DRUG: Pacritinib|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,200,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-05-22,2021-09-21
TERMINATED,YES,DRUG: ensovibep|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,407,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-05-10,2022-01-27
COMPLETED,NO,DRUG: Covidir injections|DIAGNOSTIC_TEST: One Step Test|DIAGNOSTIC_TEST: IgM and IgG dosage|DIAGNOSTIC_TEST: RT-PCR SARS-CoV-2|DIAGNOSTIC_TEST: Screening blood test|DIAGNOSTIC_TEST: ECG|DIAGNOSTIC_TEST: Medical evaluation|DIAGNOSTIC_TEST: NEWS-2 score|DIAGNOSTIC_TEST: WHO score,ALL,ADULT,PHASE1,12,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-29,2021-08-09
COMPLETED,YES,DRUG: Hydroxychloroquine Sulfate|DRUG: Ascorbic Acid,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,943,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-03-31,2020-10-08
NOT_YET_RECRUITING,NO,BIOLOGICAL: CoronaVac|BIOLOGICAL: SCTV01E,ALL,"ADULT, OLDER_ADULT",PHASE3,6000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-01-25,2024-08-25
WITHDRAWN,NO,DRUG: Hydroxychloroquine Sulfate|DRUG: Hydroxychloroquine Sulfate + Azythromycin,ALL,"ADULT, OLDER_ADULT",PHASE3,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-30,2020-11-04
RECRUITING,NO,OTHER: PVP-I Nasal Irrigation and gargling,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-16,2022-10-31
RECRUITING,NO,OTHER: Tele-exercise,ALL,"ADULT, OLDER_ADULT",NA,80,FED,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-29,2028-01-30
COMPLETED,NO,DIETARY_SUPPLEMENT: LCLT : 68% elemental L-carnitine and 32 % Tartric acid|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,224,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-01,2022-02-03
UNKNOWN,NO,OTHER: survey work,ALL,ADULT,NA,300,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-07-24,2021-04-24
TERMINATED,NO,DRUG: Hydroxychloroquine|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE3,70,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-03-25,2020-08-17
COMPLETED,NO,DEVICE: reusable respirators,ALL,CHILD,NA,52,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-04-01,2022-05-01
COMPLETED,NO,BIOLOGICAL: VLA2001|BIOLOGICAL: AZD1222|BIOLOGICAL: VLA2001 - adolescent part|BIOLOGICAL: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,4034,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-04-26,2023-03-13
UNKNOWN,NO,OTHER: Standard of Care (SoC)|DRUG: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-29,2022-11
COMPLETED,YES,DRUG: Ivermectin Tablets,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,340,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-05-31,2020-07-27
NOT_YET_RECRUITING,NO,DEVICE: HIGH FREQUENCY CHEST WALL OSCILLATION,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-02-15,2023-03-15
COMPLETED,NO,OTHER: Triphala capsule supplementation and high-intensity interval training,ALL,ADULT,PHASE2,141,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2023-05-09,2023-11-06
NOT_YET_RECRUITING,NO,PROCEDURE: Adipose Tissue Harvest|BIOLOGICAL: ATCell,ALL,"ADULT, OLDER_ADULT",PHASE1,20,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-08-01,2024-02-01
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: low-dose LYB001|BIOLOGICAL: Recombinant COVID-19 Vaccine (CHO Cell)|BIOLOGICAL: high-dose LYB001,ALL,"ADULT, OLDER_ADULT",PHASE1,100,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-07-19,2023-12-01
NOT_YET_RECRUITING,NO,DRUG: Jaktinib hydrochloride tablets,ALL,"ADULT, OLDER_ADULT",PHASE2,120,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-04,2025-03
UNKNOWN,NO,RADIATION: Single fraction whole lung radiotherapy,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-10,2022-08-30
TERMINATED,YES,BIOLOGICAL: Abatacept|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,61,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-14,2021-09-13
COMPLETED,NO,BEHAVIORAL: Adhera® Fatigue for Long COVID program,ALL,"ADULT, OLDER_ADULT",NA,15,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-08-01,2022-08-28
UNKNOWN,NO,DRUG: Nafamostat Mesilate,ALL,"ADULT, OLDER_ADULT",PHASE3,186,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-13,2021-08-12
COMPLETED,NO,"BIOLOGICAL: Candidate vaccine, SCB-2019|BIOLOGICAL: Comirnaty Vaccine|BIOLOGICAL: Vaxzevria Vaccine|BIOLOGICAL: CoronaVac Vaccine",ALL,"ADULT, OLDER_ADULT",PHASE3,1831,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-06-13,2023-06-06
COMPLETED,NO,OTHER: Placebo|DRUG: Montelukast,ALL,"ADULT, OLDER_ADULT",PHASE3,1403,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2023-01-27,2024-01-01
COMPLETED,NO,"DRUG: Patch, Nicotine|DRUG: Patch, Placebo",ALL,"ADULT, OLDER_ADULT",PHASE3,220,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-06,2021-06-20
COMPLETED,NO,BEHAVIORAL: Tough Talks COVID,ALL,ADULT,NA,360,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-03-13,2023-12-15
RECRUITING,NO,DRUG: Ivabradine,ALL,"ADULT, OLDER_ADULT",PHASE4,250,FED,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-06-14,2024-09-01
COMPLETED,NO,BIOLOGICAL: BNT162b2|OTHER: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE3,683,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-02-16,2022-07-15
COMPLETED,NO,DRUG: Dexamethasone 2 MG/ML|DRUG: Methylprednisolone Injection,ALL,"ADULT, OLDER_ADULT",PHASE3,100,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-30,2020-07-01
COMPLETED,NO,BEHAVIORAL: Smell Training,ALL,"ADULT, OLDER_ADULT",NA,240,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-01-11,2022-03-11
COMPLETED,NO,DRUG: Q-Griffithsin|OTHER: Placebo,ALL,ADULT,PHASE1,18,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-11-11,2022-02-14
UNKNOWN,NO,RADIATION: Low-dose radiotherapy|DRUG: Hydroxychloroquine Sulfate|DRUG: Ritonavir/lopinavir|DRUG: Tocilizumab Injection [Actemra]|DRUG: Azithromycin|DRUG: Corticosteroid|DRUG: Low molecular weight heparin|DEVICE: Oxygen supply,ALL,"ADULT, OLDER_ADULT",NA,106,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-06-05,2021-11-01
RECRUITING,NO,BIOLOGICAL: SARS-CoV-2 Protein Subunit Recombinant Vaccine|BIOLOGICAL: Active Comparator,ALL,CHILD,PHASE3,1050,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-10-09,2024-01-31
COMPLETED,YES,DRUG: Povidone-Iodine Nasal Spray and Gargle|DRUG: Povidone-Iodine Nasal Spray and Gargle|DRUG: Povidone-Iodine Nasal Spray and Gargle,ALL,"ADULT, OLDER_ADULT",PHASE2,98,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-04-29,2022-01-28
WITHDRAWN,NO,DRUG: SARS-CoV-2 plasma,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-07,2021-04-07
TERMINATED,NO,DIAGNOSTIC_TEST: Sona Saliva C-19 Rapid Test,ALL,"ADULT, OLDER_ADULT",NA,20,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-04-29,2022-01-05
ACTIVE_NOT_RECRUITING,NO,DRUG: Famotidine|DRUG: Celecoxib|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,2000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-12-29,2025-01
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: Nasal Swab|DIAGNOSTIC_TEST: Nasopharyngeal swab,ALL,"CHILD, ADULT, OLDER_ADULT",NA,400,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-06-30,2023-04-30
COMPLETED,NO,BIOLOGICAL: RBMRNA-176|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,480,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-01-08,2023-07-19
RECRUITING,NO,DIAGNOSTIC_TEST: Serological testing,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-05-05,2028-06
UNKNOWN,NO,DRUG: Nintedanib 150 MG|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,96,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-02,2020-08-01
UNKNOWN,NO,BIOLOGICAL: Recombinant SARS-CoV-2 Fusion Protein Vaccine,ALL,"ADULT, OLDER_ADULT",PHASE2,34,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-08-05,2022-08-05
RECRUITING,NO,OTHER: home-based concurrent exercise,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-09-04,2024-04-30
COMPLETED,NO,BIOLOGICAL: AZD1222,ALL,"ADULT, OLDER_ADULT",PHASE4,75012,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-08-30,2022-09-30
COMPLETED,YES,DRUG: Opaganib|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,42,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-02,2020-12-23
UNKNOWN,NO,BIOLOGICAL: Ligilactobacillus salivarius MP101,ALL,OLDER_ADULT,NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-10-01,2021-07-01
COMPLETED,NO,BIOLOGICAL: VXA-CoV2-1,ALL,ADULT,PHASE1,35,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-09-21,2021-10-10
WITHDRAWN,NO,DRUG: hydroxychloroquine|DRUG: Azithromycin|DRUG: Ritonavir|DRUG: Lopinavir,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07,2021-12
COMPLETED,NO,BIOLOGICAL: MSC Treatment|BIOLOGICAL: Saline Control,ALL,ADULT,PHASE1|PHASE2,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-01,2020-11-30
UNKNOWN,NO,OTHER: Breathing exercise,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-01-20,2021-04-20
COMPLETED,NO,BIOLOGICAL: SAB-185|OTHER: Normal saline,ALL,ADULT,PHASE1,28,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-01,2020-12-23
WITHDRAWN,NO,DRUG: Hydroxychloroquine and Azithromycin,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-30,2020-10-30
WITHDRAWN,NO,DRUG: Doxycycline|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-22,2021-04-13
COMPLETED,NO,BIOLOGICAL: Convalescent anti-SARS-CoV-2 MBT plasma|OTHER: Control Group,ALL,"ADULT, OLDER_ADULT",PHASE2,384,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-10,2021-07-28
COMPLETED,NO,BIOLOGICAL: anti-SARS-CoV-2 convalescent plasma,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-30,2021-05-10
NOT_YET_RECRUITING,NO,BIOLOGICAL: LYB001|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,18000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-12,2024-02
UNKNOWN,NO,DRUG: Nebulised heparin,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-23,2022-01
COMPLETED,NO,BIOLOGICAL: BCG-Denmark|BIOLOGICAL: Saline,ALL,"ADULT, OLDER_ADULT",PHASE4,668,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-12-03,2022-07-13
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Ad5-nCov,ALL,"ADULT, OLDER_ADULT",PHASE2,450,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-10-01,2023-04-15
NOT_YET_RECRUITING,NO,BEHAVIORAL: vimida,ALL,"ADULT, OLDER_ADULT",NA,160,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-04-15,2025-04-15
TERMINATED,NO,DRUG: GT0918|DRUG: Standard of care|DRUG: Matching placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,139,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-09-30,2023-07-14
COMPLETED,NO,BEHAVIORAL: EMDR,ALL,"ADULT, OLDER_ADULT",NA,900,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-20,2023-01-31
RECRUITING,NO,BIOLOGICAL: PHH1-V,ALL,"ADULT, OLDER_ADULT",PHASE3,400,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-05-12,2023-10-20
TERMINATED,NO,DRUG: Cenicriviroc (CVC)|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,45,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-25,2021-07-27
COMPLETED,NO,BIOLOGICAL: Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|BIOLOGICAL: Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01),ALL,"ADULT, OLDER_ADULT",PHASE3,10381,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-11-03,2023-04-14
RECRUITING,NO,BEHAVIORAL: Telerehabilitation|BEHAVIORAL: Standard rehabilitation care,ALL,ADULT,NA,22,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-05,2023-11
ACTIVE_NOT_RECRUITING,NO,OTHER: Rehabilitation program,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2023-03-27,2023-09-30
RECRUITING,NO,BIOLOGICAL: mRNA-1273.214|OTHER: Placebo,ALL,CHILD,PHASE2,700,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-09-30,2025-03-08
UNKNOWN,NO,DRUG: EOM613,ALL,"ADULT, OLDER_ADULT",PHASE1,40,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-09,2022-03-30
UNKNOWN,NO,COMBINATION_PRODUCT: JS016 (anti-SARS-CoV-2 monoclonal antibody),ALL,"CHILD, ADULT",PHASE1,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-05,2020-12-11
UNKNOWN,NO,DRUG: Cannabidiol|OTHER: PLACEBO,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-06,2021-11-16
RECRUITING,NO,OTHER: Comprehensive Well-Being Intervention,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2023-10-12,2026-03-01
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)|BIOLOGICAL: Sequential Vaccination (Influenza vaccine then mRNA COVID booster)|BIOLOGICAL: Sequential Vaccination (mRNA COVID booster then Influenza vaccine),ALL,"CHILD, ADULT",PHASE4,800,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-09-25,2024-05-15
COMPLETED,NO,OTHER: Normal saline,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2021-06-01,2021-10-01
COMPLETED,NO,DRUG: Convalescent Plasma,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,159,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-05,2021-09-21
UNKNOWN,NO,OTHER: Track U,ALL,"ADULT, OLDER_ADULT",NA,180,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-12-27,2022-05-15
TERMINATED,YES,DRUG: casirivimab+imdevimab combination therapy,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,10078,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-16,2022-06-09
COMPLETED,NO,OTHER: PSG,ALL,"ADULT, OLDER_ADULT",NA,17,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-04-28,2020-12-09
WITHDRAWN,NO,DRUG: Methylprednisolone|DRUG: Heparin,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-20,2022-12-31
COMPLETED,NO,DRUG: Molgramostim nebuliser solution|OTHER: Placebo nebuliser solution,ALL,"ADULT, OLDER_ADULT",PHASE2,63,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-09-24,2022-09-20
NOT_YET_RECRUITING,NO,BIOLOGICAL: SCTV01E-1 on D0|BIOLOGICAL: SCTV01E-1 on D28|BIOLOGICAL: SCTV01E-1 on D150|BIOLOGICAL: SCTV01E on D0|BIOLOGICAL: SCTV01E on D28|BIOLOGICAL: SCTV01E on D150|BIOLOGICAL: SCTV01E-1 on D120|BIOLOGICAL: SCTV01E on D120,ALL,"ADULT, OLDER_ADULT",PHASE2,400,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-10-15,2023-12-15
UNKNOWN,NO,DIAGNOSTIC_TEST: Ejaculated semen sample,MALE,ADULT,NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-08-31,2021-08-31
NOT_YET_RECRUITING,NO,BEHAVIORAL: Acupuncture and TCM-based lifestyle management,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-09-30,2024-08-31
COMPLETED,NO,BIOLOGICAL: Combination [RSVpreF+BNTb162b2]|BIOLOGICAL: Bivalent BNT162b2 (original/Omi BA.4/BA.5)|BIOLOGICAL: RSVpreF|BIOLOGICAL: QIV|BIOLOGICAL: Normal Saline Placebo,ALL,OLDER_ADULT,PHASE2,1084,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-06-05,2024-01-01
UNKNOWN,NO,DIAGNOSTIC_TEST: Sars-Cov-2 serology,ALL,"ADULT, OLDER_ADULT",NA,900,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-06-08,2020-06-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: ABO1009-DP,ALL,"ADULT, OLDER_ADULT",PHASE1,48,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-08-22,2023-08-25
TERMINATED,YES,COMBINATION_PRODUCT: Hydroxychloroquine Sulfate + Azithromycin|DRUG: Hydroxychloroquine Sulfate,ALL,"ADULT, OLDER_ADULT",PHASE2,75,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-01,2020-10-14
NOT_YET_RECRUITING,NO,BIOLOGICAL: Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)|BIOLOGICAL: Recombinant COVID-19 Variant Vaccine (Sf9 Cell)|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,4800,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-12-19,2025-01-31
UNKNOWN,NO,COMBINATION_PRODUCT: autologous activated platelet-rich plasma|DRUG: Avigan,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-12-29,2021-12-27
RECRUITING,NO,OTHER: Multicomponent exercise program|OTHER: Tele-health primary care rehabilitation program,ALL,"ADULT, OLDER_ADULT",NA,62,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-20,2024-11-20
UNKNOWN,NO,PROCEDURE: Prone positioning,ALL,"ADULT, OLDER_ADULT",NA,56,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-03,2021-06-30
UNKNOWN,NO,DRUG: alpha one antitrypsin inhalation,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,150,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-06-01,2020-09-01
COMPLETED,NO,DIAGNOSTIC_TEST: diagnostic,MALE,"ADULT, OLDER_ADULT",NA,52,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-05-07,2021-05-12
TERMINATED,NO,BIOLOGICAL: CSL760,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: OTHER,2021-02-02,2021-06-09
UNKNOWN,NO,DRUG: Estetrol monohydrate 15 mg|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,162,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-19,2022-08-05
COMPLETED,NO,BIOLOGICAL: Bacillus subtilis,ALL,"CHILD, ADULT, OLDER_ADULT",NA,35,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-08-28,2021-12-30
COMPLETED,NO,BIOLOGICAL: NK Cells,ALL,"ADULT, OLDER_ADULT",PHASE1,2,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-15,2022-12-31
TERMINATED,YES,DRUG: RO7496998|DRUG: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,216,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-04-28,2021-12-02
UNKNOWN,NO,DRUG: Hydroxychloroquine Pill + Azithromycin Pill|DRUG: SOC,ALL,"ADULT, OLDER_ADULT",PHASE2,132,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-10,2021-12
TERMINATED,YES,DIAGNOSTIC_TEST: BinaxNOW Ag Card,ALL,"CHILD, ADULT, OLDER_ADULT",NA,65,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-01-09,2021-04-08
TERMINATED,YES,BIOLOGICAL: Convalescent Plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,8,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-14,2021-09-14
COMPLETED,NO,BIOLOGICAL: Determination of COVID-19 vacciantion efficacy,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-05-21,2022-06-27
TERMINATED,NO,DRUG: PF-07321332 (nirmatrelvir)/ritonavir,ALL,"ADULT, OLDER_ADULT",PHASE1,15,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-07,2023-07-11
UNKNOWN,NO,DRUG: Sirolimus,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-08-15,2020-11-30
UNKNOWN,NO,OTHER: Ointment and dressing for external use,ALL,"CHILD, ADULT, OLDER_ADULT",NA,170,OTHER,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2021-06-01,2022-01-01
WITHDRAWN,NO,DRUG: Sirolimus 1 MG/ML|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-06,2021-07-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: SYS6006 20 μg|BIOLOGICAL: SYS6006 30 μg|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,450,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-06-28,2023-06-28
UNKNOWN,NO,OTHER: Blood sample and data record,ALL,"ADULT, OLDER_ADULT",NA,270,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-05-28,2022-10-28
ACTIVE_NOT_RECRUITING,NO,"BIOLOGICAL: BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|BIOLOGICAL: Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein),|BIOLOGICAL: Placebo - Normal saline (0.9% sodium chloride solution)",ALL,"ADULT, OLDER_ADULT",PHASE2,360,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-12-29,2024-02-28
TERMINATED,NO,DRUG: Rivaroxaban 10 mg,ALL,"ADULT, OLDER_ADULT",PHASE4,660,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-29,2022-08-30
COMPLETED,NO,DIETARY_SUPPLEMENT: Best Standard of Care + CARDIO|DIETARY_SUPPLEMENT: Best Standard of Care,ALL,"ADULT, OLDER_ADULT",NA,14,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-31,2021-10-04
UNKNOWN,NO,BIOLOGICAL: Gam-COVID-Vac|OTHER: placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2020-12,2021-12
UNKNOWN,NO,DRUG: Ivermectin 6 MG Oral Tablet (2 tablets),ALL,"CHILD, ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-15,2020-07
ACTIVE_NOT_RECRUITING,NO,"BIOLOGICAL: mRNA-1273 SARS-CoV-2 vaccine|BIOLOGICAL: BNT162b2|BIOLOGICAL: ChAdOx1-S [recombinant]|OTHER: 0, 28 day schedule|OTHER: 0, 112 day schedule|BIOLOGICAL: Covifenz",ALL,"ADULT, OLDER_ADULT",PHASE2,669,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-05-20,2024-03
COMPLETED,NO,BEHAVIORAL: Assigned Strategies: Opt-in|BEHAVIORAL: Assigned Strategies: Active Choice|BEHAVIORAL: Assigned Strategies: Enhanced Active Choice|BEHAVIORAL: Choice of Assignment: Opt-in|BEHAVIORAL: Choice of Assignment: Active Choice|BEHAVIORAL: Choice of Assignment: Enhanced Active Choice,ALL,"ADULT, OLDER_ADULT",NA,148,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-09-07,2020-12-16
RECRUITING,NO,DIETARY_SUPPLEMENT: Remolacha,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-13,2024-05-31
RECRUITING,NO,DRUG: LNP-nCOV saRNA-02 Vaccine,ALL,ADULT,PHASE1,42,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-12-02,2022-12-31
COMPLETED,NO,DIAGNOSTIC_TEST: COVID 19 diagnostic test by PCR,FEMALE,"ADULT, OLDER_ADULT",NA,2494,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-04-17,2022-03-31
COMPLETED,NO,DRUG: Rayaldee 30Mcg Extended-Release (ER) Capsule|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,171,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-26,2021-10-08
UNKNOWN,NO,OTHER: Prone positioning,ALL,"ADULT, OLDER_ADULT",NA,340,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-05-15,2021-06-01
WITHDRAWN,NO,DRUG: Methylprednisolone|DRUG: Tocilizumab,ALL,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-02-01,2021-04-01
UNKNOWN,NO,DRUG: Camostat Mesilate|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,580,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-04,2022-05-01
TERMINATED,NO,BIOLOGICAL: SARS-CoV-2 vaccine|BIOLOGICAL: Placebo,ALL,ADULT,PHASE1,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-04-25,2021-09-05
RECRUITING,NO,BIOLOGICAL: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,820,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-06,2024-08-01
UNKNOWN,NO,BIOLOGICAL: BCG vaccine|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE4,2014,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-04-16,2021-05
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 protein subunit recombinant vaccine|BIOLOGICAL: placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,360,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-04-13,2023-02-28
RECRUITING,NO,BIOLOGICAL: BBV152,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,400,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-02-20,2023-10-31
COMPLETED,NO,BIOLOGICAL: mRNA-1283|BIOLOGICAL: mRNA-1273|BIOLOGICAL: Placebo,ALL,ADULT,PHASE1,104,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-03-11,2023-07-25
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,4422,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-08-17,2022-01-19
UNKNOWN,NO,DRUG: Ivermectin,ALL,"ADULT, OLDER_ADULT",PHASE3,550,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-09-07,2020-12-16
COMPLETED,NO,DEVICE: SCD,ALL,"ADULT, OLDER_ADULT",NA,22,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-10,2021-07-21
RECRUITING,NO,"DRUG: LAU-7b for 3 cycles|DRUG: LAU-7b for 1 cycle, then placebo|OTHER: Placebo for 3 cycles",ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,204,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-20,2024-06-30
TERMINATED,NO,DRUG: 1: discontinuation of RAS blocker therapy|DRUG: 2: continuation of RAS blocker therapy,ALL,"ADULT, OLDER_ADULT",PHASE3,44,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-09,2021-01-09
COMPLETED,NO,BIOLOGICAL: ARCT-021 Dose 1|BIOLOGICAL: ARCT-021 Dose 2|BIOLOGICAL: ARCT-021 Dose 3|BIOLOGICAL: ARCT-021 Dose 4|BIOLOGICAL: ARCT-021 Dose Regimen 1|BIOLOGICAL: ARCT-021 Dose Regimen 2|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,106,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-04,2021-01-29
COMPLETED,NO,DIAGNOSTIC_TEST: Phase-1: Breath Holding Test|DIAGNOSTIC_TEST: Phase 2: 6-Minute Walk Test (6MWT),ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-06-29,2022-04-21
TERMINATED,YES,DRUG: Azithromycin|DRUG: Hydroxychloroquine|DRUG: Placebo oral tablet|DRUG: Placebo oral tablet,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,117,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-06,2021-02-02
WITHDRAWN,NO,DRUG: ZYESAMI™ (aviptadil acetate)|DRUG: Placebo|DEVICE: Nebulized administration of ZYESAMI™ or Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-15,2022-08-15
COMPLETED,YES,DRUG: REGN10933+REGN10987 combination therapy|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,2252,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-10,2021-10-22
COMPLETED,NO,BIOLOGICAL: COVI-VAC|OTHER: Placebo,ALL,ADULT,PHASE1,48,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-12-11,2022-05-30
WITHDRAWN,NO,DRUG: Hydroxychloroquine (HCQ)|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2020-04-28,2020-07-15
COMPLETED,NO,DRUG: RP7214 + Standard of care (SOC)|DRUG: Placebo + Standard of care (SOC),ALL,"ADULT, OLDER_ADULT",PHASE2,163,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-09-20,2022-03-25
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Subunit recombinant vaccine for the prevention of coronavirus infection|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,16304,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-10-24,2023-12-30
COMPLETED,NO,DRUG: HLX71|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,32,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2021-04-08,2021-07-20
COMPLETED,NO,OTHER: Telerehabilitation program based on cardiorespiratory principles,ALL,"ADULT, OLDER_ADULT",NA,7,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04-01,2022-08-08
UNKNOWN,NO,BIOLOGICAL: Ozone auto-hemotherapy,ALL,"ADULT, OLDER_ADULT",PHASE3,208,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-25,2020-12-25
NOT_YET_RECRUITING,NO,BIOLOGICAL: Stem Cell,ALL,ADULT,PHASE1,12,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-01,2026-02
UNKNOWN,NO,OTHER: COVID-19 Testing Home-based (Aim 1)|OTHER: COVID-19 Testing Mobile (Aim 1)|OTHER: COVID-19 Testing Mobile Approach 1 (Aim 2)|OTHER: COVID-19 Testing Mobile Approach 2 (Aim 2),ALL,"CHILD, ADULT, OLDER_ADULT",NA,42000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-10-25,2022-06
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: mRNA-1273|BIOLOGICAL: mRNA-1010|BIOLOGICAL: mRNA-1345|BIOLOGICAL: FLUAD®|BIOLOGICAL: mRNA-1647,ALL,"ADULT, OLDER_ADULT",PHASE1,308,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-05-24,2024-03-25
COMPLETED,NO,DRUG: cyclosporine,ALL,"ADULT, OLDER_ADULT",PHASE3,102,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-03,2022-12-09
COMPLETED,NO,DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE3,68,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-06-25,2020-11-23
SUSPENDED,NO,DRUG: S-1226,ALL,"ADULT, OLDER_ADULT",PHASE2,30,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-15,2021-12-31
COMPLETED,NO,BEHAVIORAL: Behaviour Change Technique Intervention to Improve Quality of Life,ALL,"ADULT, OLDER_ADULT",NA,274,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2020-05-22,2021-09-01
COMPLETED,NO,GENETIC: Whole Genome Analysis|GENETIC: T-cell receptor (TCR) repertoire|GENETIC: SARS-CoV-2 viral composition,ALL,"ADULT, OLDER_ADULT",NA,1000,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-10-21,2023-08-31
COMPLETED,YES,DRUG: Molnupiravir|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,2441,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-08-11,2022-11-16
TERMINATED,NO,DRUG: BIO101|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,238,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-26,2022-09-30
COMPLETED,NO,OTHER: HOME-CoV rule implementation,ALL,"ADULT, OLDER_ADULT",NA,3133,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-09,2020-06-17
RECRUITING,NO,OTHER: Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)|OTHER: Usual care,ALL,"ADULT, OLDER_ADULT",NA,820,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING,2021-11-18,2024-12
COMPLETED,YES,DRUG: L-Citrulline|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,65,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-15,2021-09-30
COMPLETED,NO,OTHER: Probiotics,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-10,2021-04-10
COMPLETED,NO,DRUG: IV Dexamethasone|DRUG: Nasal Dexamethasone,ALL,"ADULT, OLDER_ADULT",PHASE2,66,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-11-05,2021-11-13
RECRUITING,NO,OTHER: Inspiratory muscle strength training,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-10-16,2024-10-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: BCG vaccine|BIOLOGICAL: 0.9% sodium chloride (NaCl) saline solution,ALL,"ADULT, OLDER_ADULT",PHASE2,752,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2020-10-01,2024-04-01
COMPLETED,NO,DIETARY_SUPPLEMENT: Ascorbic Acid|DIETARY_SUPPLEMENT: Zinc Gluconate|DIETARY_SUPPLEMENT: Ascorbic Acid and Zinc Gluconate|OTHER: Standard of Care,ALL,"ADULT, OLDER_ADULT",NA,214,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-04-08,2021-02-11
COMPLETED,NO,DIETARY_SUPPLEMENT: Bovine Plasma-Derived Immunoglobulin Concentrate|OTHER: Standard of care,ALL,"ADULT, OLDER_ADULT",NA,200,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-22,2022-02-21
COMPLETED,NO,OTHER: Prone Positioning,ALL,"ADULT, OLDER_ADULT",NA,35,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-01,2021-12-31
COMPLETED,NO,BIOLOGICAL: Subunit recombinant vaccine for the prevention of coronavirus infection|BIOLOGICAL: Placebo,ALL,ADULT,PHASE1|PHASE2,155,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-07-19,2022-12-31
TERMINATED,NO,OTHER: Saline|DRUG: 1.5% w/v Hydrogen Peroxide|DRUG: 0.12% Chlorohexidine Gluconate|DRUG: 27% Ethanol plus essential oils|DRUG: 0.5% w/v Povidone-iodide|DRUG: 0.075% Cetylpyridinium Chloride,ALL,"ADULT, OLDER_ADULT",PHASE2,129,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-18,2021-10-21
TERMINATED,YES,DRUG: Ascorbic Acid|DRUG: Hydroxychloroquine Sulfate|DRUG: Azithromycin|DRUG: Folic Acid|DRUG: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra],ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,289,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-16,2020-11-30
RECRUITING,NO,DEVICE: Experimental group|DEVICE: Sham Control,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-02-07,2022-07-31
WITHDRAWN,NO,OTHER: Maintenance or reduction of immunosuppression,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-05-03,2021-05-04
WITHDRAWN,NO,DRUG: GLB-COV2-043|DRUG: BNT162b2/COMIRNATY®,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-02-21,2024-09
WITHDRAWN,NO,DRUG: TAK-671|DRUG: TAK-671 Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-25,2020-10-30
COMPLETED,NO,BIOLOGICAL: COVAC-2|BIOLOGICAL: Saline Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,61,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-02-10,2022-11-02
TERMINATED,NO,DIAGNOSTIC_TEST: Spartan COVID-19 Platform,ALL,"ADULT, OLDER_ADULT",NA,89,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-03-19,2021-08-31
RECRUITING,NO,OTHER: mild hyperthermia group|OTHER: sham group,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2024-01-08,2025-03-31
UNKNOWN,NO,DRUG: Methylprednisolone|DRUG: Methylprednisolone,ALL,"ADULT, OLDER_ADULT",PHASE4,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-02-01,2020-07-01
NOT_YET_RECRUITING,NO,DRUG: Traditional Chinese medicine treatment|DRUG: Western medicine treatment,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,162,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-12-01,2026-02-28
RECRUITING,NO,DIAGNOSTIC_TEST: Respiratory pathogen panel PCR test|DIAGNOSTIC_TEST: COVID-19 antibody test,ALL,"ADULT, OLDER_ADULT",NA,1000,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-08-21,2024-12
UNKNOWN,NO,BEHAVIORAL: Cognitive Behavioral Brief-Telepsychotherapy|BEHAVIORAL: Brief Interpersonal Telepsychotherapy|BEHAVIORAL: Telepsychoeducation,ALL,"CHILD, ADULT, OLDER_ADULT",NA,999,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-05,2021-07-20
COMPLETED,NO,DIAGNOSTIC_TEST: biological samples day of delivery,FEMALE,"ADULT, OLDER_ADULT",NA,160,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-05-17,2021-08-02
NOT_YET_RECRUITING,NO,BIOLOGICAL: Blood sample collection|OTHER: Saliva sample collection|OTHER: Nasopharyngeal and nasal sample collection|OTHER: Exhaled Breath Condensate (EBC),ALL,"ADULT, OLDER_ADULT",NA,90,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-11-01,2024-06-18
COMPLETED,YES,DRUG: PF-07321332|DRUG: Ritonavir|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,2246,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-07-16,2022-04-25
UNKNOWN,NO,DRUG: Imatinib Mesylate|DRUG: Standard of Care,ALL,"ADULT, OLDER_ADULT",PHASE3,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06,2020-10
COMPLETED,NO,DRUG: Placebo|DRUG: Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS),ALL,ADULT,PHASE1,32,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-07,2022-08-01
UNKNOWN,NO,DIETARY_SUPPLEMENT: Taxifolin Aqua,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-05-10,2021-10-01
NOT_YET_RECRUITING,NO,BIOLOGICAL: SARS-CoV-2 variant mRNA vaccine low dose|BIOLOGICAL: SARS-CoV-2 variant mRNA vaccine high dose,ALL,"ADULT, OLDER_ADULT",PHASE1,144,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-02,2024-05
UNKNOWN,NO,DIAGNOSTIC_TEST: molecular testing for virus RNA using RT-PCR,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-05-17,2020-12-30
COMPLETED,YES,BIOLOGICAL: Study-provided Moderna mRNA-1273 COVID-19 vaccine|BIOLOGICAL: Community-provided Moderna mRNA-1273 COVID-19 Vaccine|BIOLOGICAL: Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine,ALL,"ADULT, OLDER_ADULT",PHASE4,43,NIH,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-07-09,2023-01-10
NOT_YET_RECRUITING,NO,DEVICE: Monoplace Hyperbaric Chamber (Class III medical device).,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-12,2025-12-30
TERMINATED,NO,DRUG: Linagliptin 5 MG,ALL,"ADULT, OLDER_ADULT",PHASE3,64,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-01,2021-05-04
COMPLETED,NO,DIAGNOSTIC_TEST: Collection of nasal and oropharyngeal specimen for COVID19 antigen test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,3070,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-02-04,2022-05-06
COMPLETED,YES,DIETARY_SUPPLEMENT: Nigella sativa oil,ALL,"ADULT, OLDER_ADULT",PHASE2,183,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-21,2020-12-31
TERMINATED,NO,DRUG: Ozanimod|OTHER: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE2,43,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-16,2022-05-12
COMPLETED,NO,BIOLOGICAL: CVnCoV|BIOLOGICAL: Placebo|BIOLOGICAL: Authorized/licensed vaccines for preventing COVID-19 (AV),ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,39693,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-12-14,2022-06-03
NOT_YET_RECRUITING,NO,"BIOLOGICAL: Recombinant COVID-19 variant Vaccine (Sf9 Cell)|BIOLOGICAL: COVID-19 Vaccine (Vero Cell), Inactivated|BIOLOGICAL: mRNA COVID-19 vaccine (Moderna)|BIOLOGICAL: Viral Vector COVID-19 vaccine (AstraZeneca)",ALL,"ADULT, OLDER_ADULT",PHASE2,600,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-07,2023-12
UNKNOWN,NO,OTHER: Respiratory physiotherapy,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-09-25,2022-04-15
TERMINATED,YES,BIOLOGICAL: CVnCoV Vaccine,ALL,"ADULT, OLDER_ADULT",PHASE3,129,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-04-22,2021-09-21
RECRUITING,NO,DEVICE: PrO2,ALL,"ADULT, OLDER_ADULT",NA,16,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-10-20,2024-04-20
COMPLETED,NO,DRUG: Alveavax-v1.2|DRUG: Janssen Ad26.COV2.S,ALL,"ADULT, OLDER_ADULT",PHASE1,130,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-06-27,2023-03-02
UNKNOWN,NO,BIOLOGICAL: Novaferon|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,385,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-25,2023-04-30
RECRUITING,NO,BIOLOGICAL: Coronavirus-specific T cell (CST),ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,24,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-10-19,2027-12-15
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: CYNK-001,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,86,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-13,2022-06-30
ACTIVE_NOT_RECRUITING,NO,"BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1|BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2|BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03",ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,3385,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-02-24,2024-07-16
RECRUITING,NO,DRUG: Lopinavir / Ritonavir|DRUG: Remdesivir (RDV)|DRUG: Tocilizumab|OTHER: Corticosteroid Therapy-enhanced Standard Care (CTSC),ALL,"ADULT, OLDER_ADULT",PHASE1,1000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-03-28,2025-12-30
COMPLETED,YES,BIOLOGICAL: SARILUMAB,ALL,"ADULT, OLDER_ADULT",PHASE2,50,FED,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-10,2021-08-02
RECRUITING,NO,DRUG: Nintedanib 150 MG [Ofev]|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,250,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-29,2024-05
TERMINATED,YES,BIOLOGICAL: Liquid Alpha1-Proteinase Inhibitor (Human)|DRUG: Placebo|DRUG: Standard Medical Treatment,ALL,"ADULT, OLDER_ADULT",PHASE2,57,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-01-29,2022-01-28
WITHDRAWN,NO,DRUG: Aspirin 81 mg|DIETARY_SUPPLEMENT: Vitamin D,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05,2020-12
UNKNOWN,NO,DRUG: Ivermectin Tablets|DRUG: Doxycycline Tablets|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE4,150,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-28,2022-03-28
ACTIVE_NOT_RECRUITING,NO,DRUG: Nintedanib|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE4,103,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-18,2024-04
WITHDRAWN,NO,DRUG: EG-009A|DRUG: EG-009A Placebo|DRUG: Standard of Care|DRUG: Dexamethasone,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-04,2023-05-01
COMPLETED,NO,DRUG: ZYIL1 capsule,ALL,ADULT,PHASE1,30,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-28,2021-06-12
COMPLETED,NO,RADIATION: Angiography scanner,ALL,"ADULT, OLDER_ADULT",NA,117,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-05-26,2022-03-05
COMPLETED,YES,DRUG: Mavrilimumab|DRUG: Placebos,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-20,2021-04-23
UNKNOWN,NO,DRUG: Ivermectin,ALL,"ADULT, OLDER_ADULT",PHASE3,200,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-05-28,2022-06
COMPLETED,YES,DRUG: NP-120 (Ifenprodil),ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,168,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-05,2021-01-26
RECRUITING,NO,DRUG: REGN17092|DRUG: Matching Placebo,ALL,ADULT,PHASE1,128,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-28,2025-04-30
COMPLETED,NO,BEHAVIORAL: Family Risk Messaging|BEHAVIORAL: Personal Risk Messaging|BEHAVIORAL: Loss Protection|BEHAVIORAL: Lottery Incentive,ALL,"CHILD, ADULT, OLDER_ADULT",NA,2161,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-06-29,2023-06-03
COMPLETED,NO,OTHER: Pulmonary Physiotherapy Techniques,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-04-02,2020-05-30
WITHDRAWN,NO,BIOLOGICAL: UB-612|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-02-01,2023-03-22
COMPLETED,NO,OTHER: BREATHE,ALL,"ADULT, OLDER_ADULT",NA,27,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-01-03,2022-10-13
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: TURKOVAC|BIOLOGICAL: CoronaVac,ALL,"CHILD, ADULT",PHASE2,644,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-02-18,2023-12-31
UNKNOWN,NO,DRUG: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|DRUG: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|DRUG: Isotretinoin (13 cis retinoic acid ) capsules|DRUG: Aerosolized 13 cis retinoic acid|DRUG: Standard treatment,ALL,"ADULT, OLDER_ADULT",PHASE3,100000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08,2021-11
COMPLETED,NO,BEHAVIORAL: Low Intensity Nudges|BEHAVIORAL: High Intensity Activities|BEHAVIORAL: BRAC's business-as-usual,ALL,"CHILD, ADULT, OLDER_ADULT",NA,855,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-01-03,2021-05-06
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: bivalent BNT162b2 (original/Omi BA.4/BA.5)|BIOLOGICAL: qIRV (22/23)|BIOLOGICAL: QIV|BIOLOGICAL: bIRV|BIOLOGICAL: tIRV,ALL,"ADULT, OLDER_ADULT",PHASE2,1018,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2022-10-28,2023-12-29
COMPLETED,NO,DIAGNOSTIC_TEST: identify SARS-CoV-2 infection by serology|BIOLOGICAL: collection of biological samples,FEMALE,"ADULT, OLDER_ADULT",NA,2446,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2020-05-04,2021-08-31
COMPLETED,NO,DRUG: Chloroquine or hydroxychloroquine|DRUG: zinc,ALL,"ADULT, OLDER_ADULT",PHASE3,191,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-06-23,2020-08-15
RECRUITING,NO,DIETARY_SUPPLEMENT: Probiotic|DIETARY_SUPPLEMENT: Placebo,ALL,"ADULT, OLDER_ADULT",NA,240,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-12,2023-12-11
UNKNOWN,NO,DRUG: Basiliximab Injection|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,300,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-10-15,2022-12-01
COMPLETED,NO,DRUG: PF-07321332/ritonavir,ALL,ADULT,PHASE1,14,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-03-10,2022-04-21
COMPLETED,NO,OTHER: Blood and derivatives.|DRUG: Standard of Care,ALL,"ADULT, OLDER_ADULT",PHASE2,350,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-03,2021-04-05
RECRUITING,NO,"DRUG: anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)",ALL,"ADULT, OLDER_ADULT",PHASE3,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-03-22,2023-01-01
COMPLETED,YES,DRUG: PUL-042 Inhalation Solution|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,217,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-06-09,2021-07-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Open Label Crossover Vaccination period)|BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|OTHER: Placebo,ALL,CHILD,PHASE2|PHASE3,3600,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-07-22,2025-09-08
COMPLETED,NO,DRUG: INM005|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,242,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-27,2020-12-30
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant,ALL,"ADULT, OLDER_ADULT",NA,43,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-02-04,2022-03-30
UNKNOWN,NO,DRUG: Voclosporin|DRUG: Tacrolimus,ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-15,2022-10-25
NOT_YET_RECRUITING,NO,DRUG: SCTA01|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,690,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-28,2022-03-01
WITHDRAWN,NO,DRUG: hydroxychloroquine sulfate 200 MG|DRUG: Placebo oral tablet,FEMALE,ADULT,PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05,2020-05
UNKNOWN,NO,"BIOLOGICAL: Biological collection with nasopharyngeal samples, saliva, blood, stool and urine",ALL,"CHILD, ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-11,2022-02
COMPLETED,NO,BIOLOGICAL: Bacille Calmette-Guérin (BCG)|OTHER: Placebo Comparator,ALL,"ADULT, OLDER_ADULT",PHASE3,1000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-05-04,2022-01-02
COMPLETED,NO,DEVICE: Nasal lavages with Tonimer Panthexyl®,ALL,"ADULT, OLDER_ADULT",NA,107,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-08,2022-04-14
UNKNOWN,NO,DRUG: Leukotriene Receptor Antagonist|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,66,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-02-28,2021-12
RECRUITING,NO,DEVICE: Electric pad for human external pain therapy,ALL,"ADULT, OLDER_ADULT",NA,274,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-27,2022-06
TERMINATED,NO,BIOLOGICAL: blood tests|BIOLOGICAL: Nasopharyngeal swabs|BIOLOGICAL: Stools,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-06-11,2022-02-21
COMPLETED,NO,BIOLOGICAL: ICC Vaccine|BIOLOGICAL: qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant|BIOLOGICAL: SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,642,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-09-08,2022-04-22
COMPLETED,NO,DRUG: Colchicine plus symptomatic treatment (paracetamol)|DRUG: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations),ALL,"ADULT, OLDER_ADULT",PHASE3,70,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-08-19,2022-10-11
COMPLETED,NO,"DIAGNOSTIC_TEST: Assessing antibody responses, neutralizing capacity and memory B-cell function",ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-07-31,2022-12-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: mRNA-1273.214,ALL,CHILD,PHASE3,931,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2022-06-21,2024-06-28
COMPLETED,NO,DIETARY_SUPPLEMENT: Viusid and Asbrip|DRUG: COVID-19 Standard Therapy,ALL,"ADULT, OLDER_ADULT",NA,80,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-01-08,2021-09-15
TERMINATED,NO,DRUG: Edoxaban Tablets|DRUG: Colchicine Tablets,ALL,"ADULT, OLDER_ADULT",PHASE3,60,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-21,2022-08-31
RECRUITING,NO,DRUG: Lopinavir-Ritonavir|DRUG: Corticosteroid|DRUG: Hydroxychloroquine|DRUG: Azithromycin|BIOLOGICAL: Convalescent plasma|DRUG: Tocilizumab|BIOLOGICAL: Immunoglobulin|DRUG: Synthetic neutralising antibodies|DRUG: Aspirin|DRUG: Colchicine|DRUG: Baricitinib|DRUG: Anakinra|DRUG: Dimethyl fumarate|DRUG: High Dose Corticosteroid|DRUG: Empagliflozin|DRUG: Sotrovimab|DRUG: Molnupiravir|DRUG: Paxlovid|DRUG: Baloxavir Marboxil|DRUG: Oseltamivir|DRUG: Low-dose corticosteroids: Dexamethasone|DRUG: Low-dose corticosteroids: Dexamethasone,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,70000,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-19,2036-06-30
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: 6-Week Self-Management Group,ALL,"ADULT, OLDER_ADULT",NA,51,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-18,2024-02
SUSPENDED,NO,OTHER: Sample Collection,ALL,"CHILD, ADULT, OLDER_ADULT",NA,2500,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-12-12,2024-06-30
UNKNOWN,NO,BIOLOGICAL: Coronavirus vaccination,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-02-11,2023-07-30
WITHDRAWN,NO,DRUG: ORTD-1 low dose|DRUG: ORTD-1 mid dose|DRUG: ORTD-1 high dose|OTHER: Vehicle control,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04,2021-07
RECRUITING,NO,BEHAVIORAL: Community Health Worker led curriculum,ALL,"CHILD, ADULT, OLDER_ADULT",NA,66,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-10-11,2023-05
COMPLETED,NO,OTHER: TR|OTHER: TSu,ALL,"ADULT, OLDER_ADULT",NA,74,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-03-26,2021-12-20
COMPLETED,NO,BIOLOGICAL: Prolastin|DRUG: Standard Medical Treatment,ALL,"ADULT, OLDER_ADULT",PHASE2,100,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-29,2021-06-10
WITHDRAWN,NO,DRUG: Nasal Spray,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: TREATMENT,2021-12-08,2022-08-08
COMPLETED,NO,DEVICE: Biosound Therapy System,ALL,"ADULT, OLDER_ADULT",NA,13,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-29,2022-01-19
RECRUITING,NO,BEHAVIORAL: Long COVID Coping and Recovery (LCCR) Intervention,ALL,"ADULT, OLDER_ADULT",NA,36,FED,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10-01,2024-09-30
RECRUITING,NO,BEHAVIORAL: manual-based group interventions,ALL,"ADULT, OLDER_ADULT",NA,96,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-11,2024-11
COMPLETED,YES,DRUG: Intermediate dose thromboprophylaxis|DRUG: Standard of Care thromboprophylaxis,ALL,"ADULT, OLDER_ADULT",PHASE4,176,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-06,2021-04-16
COMPLETED,NO,DIETARY_SUPPLEMENT: Zinc|DIETARY_SUPPLEMENT: Placebo,ALL,"ADULT, OLDER_ADULT",NA,460,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-02-15,2022-05-04
COMPLETED,NO,PROCEDURE: prolonged prone position ventilation,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-10-01,2022-01-01
COMPLETED,NO,"DRUG: Mixture 3,6% H2 in N2 (96.4%)",ALL,"ADULT, OLDER_ADULT",PHASE1,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-01,2023-05-23
ACTIVE_NOT_RECRUITING,NO,DRUG: Nitazoxanide|DRUG: Placebo|DIETARY_SUPPLEMENT: Vitamin Super B-Complex,ALL,"ADULT, OLDER_ADULT",PHASE3,1407,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-05-13,2024-05
COMPLETED,NO,BIOLOGICAL: Intravenous Immune Globulin|DRUG: Standard Medical Treatment,ALL,"ADULT, OLDER_ADULT",PHASE2,100,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-02,2021-03-03
ACTIVE_NOT_RECRUITING,NO,OTHER: Respicure®|OTHER: Standard of care,ALL,"ADULT, OLDER_ADULT",NA,480,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-10-27,2024-07
COMPLETED,NO,BIOLOGICAL: recombinant Ad5 vectored COVID-19 vaccine|BIOLOGICAL: RBD-based protein subunit vaccine (ZF2001) against COVID-19|BIOLOGICAL: trivalent split influenza vaccine,ALL,"ADULT, OLDER_ADULT",PHASE4,120,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-04-07,2022-03-04
UNKNOWN,NO,BIOLOGICAL: BNT162a1|BIOLOGICAL: BNT162b1|BIOLOGICAL: BNT162b2|BIOLOGICAL: BNT162c2,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,512,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-23,2023-04
NOT_YET_RECRUITING,NO,BIOLOGICAL: Blood sample (at inclusion and 6 months later)|OTHER: Patient questionnaires (at inclusion and 6 months later),ALL,"ADULT, OLDER_ADULT",NA,100,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-04,2024-01
COMPLETED,NO,"DRUG: NANOS1 , argent colloïdal ,",ALL,"ADULT, OLDER_ADULT",PHASE3,116,NETWORK,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-01,2022-02-20
RECRUITING,NO,OTHER: Intervention group,ALL,"ADULT, OLDER_ADULT",NA,66,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-04-24,2024-03
UNKNOWN,NO,DIETARY_SUPPLEMENT: Vitamin D,ALL,ADULT,NA,900,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-09-01,2021-04-28
COMPLETED,NO,DEVICE: Lucira COVID-19 & Flu Test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,1066,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-10-11,2023-02-16
RECRUITING,NO,DRUG: FB2001|DRUG: FB2001 placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1188,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-09-14,2023-12
WITHDRAWN,NO,OTHER: Real-time assessment using the VieCovid2020 smartphone application,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2021-12-15,2023-06-15
COMPLETED,YES,BIOLOGICAL: GAMUNEX-C|DRUG: Standard Medical Treatment,ALL,"ADULT, OLDER_ADULT",PHASE2,100,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-17,2021-10-25
UNKNOWN,NO,DRUG: Convalescent plasma,ALL,"ADULT, OLDER_ADULT",PHASE3,231,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06,2021-12
TERMINATED,NO,DRUG: Enzalutamide Pill,ALL,"ADULT, OLDER_ADULT",PHASE2,42,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-15,2021-05-29
COMPLETED,NO,OTHER: PRAYER,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2020-08-01,2022-01-01
COMPLETED,YES,BIOLOGICAL: BRII-196|BIOLOGICAL: BRII-198|BIOLOGICAL: Placebo|BIOLOGICAL: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE3,353,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-16,2022-10-10
RECRUITING,NO,DRUG: S-217622|DRUG: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,2200,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-06-09,2024-02-28
COMPLETED,YES,DRUG: Ruconest,ALL,"ADULT, OLDER_ADULT",PHASE2,38,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-11-30,2021-12-01
ACTIVE_NOT_RECRUITING,NO,COMBINATION_PRODUCT: Atorvastatin Calcium Tablets,MALE,"ADULT, OLDER_ADULT",PHASE1,1,INDIV,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-01,2023-07-31
WITHDRAWN,NO,DRUG: TCB008,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-13,2022-04-13
COMPLETED,NO,BIOLOGICAL: multipeptide cocktail,ALL,"ADULT, OLDER_ADULT",PHASE1,36,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-11-27,2021-12-02
COMPLETED,YES,DRUG: Favipiravir|DRUG: Placebo|OTHER: Standard of care treatment,ALL,"ADULT, OLDER_ADULT",PHASE2,149,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07-12,2021-04-16
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: AZD3152 (Cohort 1)|BIOLOGICAL: Placebo (Cohort 1)|BIOLOGICAL: AZD3152 (Cohort 2)|BIOLOGICAL: Placebo (Cohort 2)|BIOLOGICAL: AZD3152 (Cohort 3)|BIOLOGICAL: Placebo (Cohort 3),ALL,ADULT,PHASE1,24,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-07-31,2024-12-19
UNKNOWN,NO,DRUG: Drug COVID19-0001-USR|DRUG: normal saline,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-02,2021-08-30
UNKNOWN,NO,DRUG: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|DRUG: Telmisartan 40Mg Oral Tablet|DRUG: Atorvastatin 20 Mg Oral Tablet,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,294,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-27,2021-03-26
COMPLETED,NO,BIOLOGICAL: mRNA-1283|BIOLOGICAL: mRNA-1283.211|BIOLOGICAL: mRNA-1273|BIOLOGICAL: mRNA-1283.529,ALL,"ADULT, OLDER_ADULT",PHASE2,543,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-12-06,2023-03-23
COMPLETED,YES,BIOLOGICAL: CT-P59,ALL,ADULT,PHASE1,18,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-04,2021-04-05
TERMINATED,YES,DRUG: PF-07304814|DRUG: Placebo|BIOLOGICAL: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE3,58,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-09-15,2023-07-14
RECRUITING,NO,BIOLOGICAL: Convalescent Plasma 1 Unit|BIOLOGICAL: Convalescent Plasma 2 Units|OTHER: Standard of Care,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,240,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-16,2021-03-30
RECRUITING,NO,BIOLOGICAL: Nasopharyngeal swab for RT-PCR SARS-CoV-2,ALL,ADULT,NA,50,NETWORK,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-07-01,2024-07-01
RECRUITING,NO,DRUG: Synthetic Vitamin B1,ALL,"ADULT, OLDER_ADULT",PHASE4,480,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-01-08,2023-12-08
COMPLETED,NO,BIOLOGICAL: RUTI® vaccine|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,251,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-01-06,2021-11-11
WITHDRAWN,NO,DRUG: Vitamin D3 or Placebo|DEVICE: Doctella telehealth monitoring,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-01,2021-06-01
COMPLETED,NO,BIOLOGICAL: serology and ELISPOT test|BIOLOGICAL: serology,ALL,"ADULT, OLDER_ADULT",NA,539,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-06-02,2022-01-26
TERMINATED,YES,BIOLOGICAL: C19-IG 20%|DRUG: 0.9% Sodium chloride,ALL,"ADULT, OLDER_ADULT",PHASE3,465,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-28,2021-12-27
UNKNOWN,NO,BIOLOGICAL: Human COVID-19 immunoglobulin (pH4) for intravenous injection|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,180,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-30,2023-11-30
COMPLETED,NO,DRUG: pulse steroid and nanogam,ALL,"ADULT, OLDER_ADULT",PHASE4,178,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-03-30,2020-11-14
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: oral polio vaccine + information|BEHAVIORAL: Information,ALL,"ADULT, OLDER_ADULT",PHASE4,3400,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-15,2022-05
UNKNOWN,NO,BIOLOGICAL: SCTA01|BIOLOGICAL: SCTA01 Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,560,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-25,2021-11-25
WITHDRAWN,NO,DRUG: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|DRUG: Azithromycin 250 MG Oral Capsule|DRUG: Placebo oral tablet|DRUG: Placebo oral capsule,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-02,2020-09-02
COMPLETED,NO,"BIOLOGICAL: SARS-CoV-2 Vaccine (Vero Cell), Inactivated",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,1800,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-07-02,2022-04-29
COMPLETED,NO,DRUG: Tocilizumab,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,93,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-12,2020-06-12
WITHDRAWN,NO,DEVICE: Helmet Continuous Positive Airway Pressure (CPAP)|DEVICE: High Flow Nasal Oxygen (HFNO),ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-11-15,2022-12-15
COMPLETED,NO,DEVICE: Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours,ALL,"ADULT, OLDER_ADULT",NA,5,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2020-07-28,2020-09-20
COMPLETED,NO,DRUG: Losartan,ALL,"ADULT, OLDER_ADULT",PHASE1,34,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-04,2020-08-17
RECRUITING,NO,DRUG: Hydroxychloroquine|DIETARY_SUPPLEMENT: Vitamin C|DIETARY_SUPPLEMENT: Vitamin D|DIETARY_SUPPLEMENT: Zinc,ALL,"ADULT, OLDER_ADULT",PHASE2,600,OTHER,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-06-22,2025-07
COMPLETED,NO,DRUG: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|OTHER: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE3,99,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-21,2021-10-15
UNKNOWN,NO,DRUG: Favipiravir Combined With Tocilizumab|DRUG: Favipiravir|DRUG: Tocilizumab,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-08,2020-05
COMPLETED,NO,DRUG: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.,ALL,"ADULT, OLDER_ADULT",PHASE2,45,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-18,2020-09-29
NOT_YET_RECRUITING,NO,OTHER: COPERIA-REHAB,ALL,"ADULT, OLDER_ADULT",NA,56,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-12-14,2023-11-14
COMPLETED,NO,DIAGNOSTIC_TEST: Blood sample for serological test,ALL,"ADULT, OLDER_ADULT",NA,1466,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2020-04-17,2021-07-16
UNKNOWN,NO,DRUG: GNS561,ALL,"ADULT, OLDER_ADULT",PHASE2,178,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-18,2021-12-30
COMPLETED,NO,DEVICE: Transcranial direct-current stimulation|DEVICE: Transcranial direct-current stimulation|DEVICE: Sham Transcranial direct-current stimulation,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-10,2021-10-11
COMPLETED,NO,OTHER: Serology test follow-up,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-07-01,2022-05-23
RECRUITING,NO,"BIOLOGICAL: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)",ALL,"ADULT, OLDER_ADULT",PHASE3,480,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-02-18,2022-12-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: AdCLD-CoV19-1 OMI (Part A)|BIOLOGICAL: AdCLD-CoV19-1 OMI (Part B)|OTHER: Placebo (Part B),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,320,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-09-14,2024-02
COMPLETED,NO,DRUG: Melatonin 2mg|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,450,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-04-20,2020-12-01
COMPLETED,NO,BIOLOGICAL: BNT162b1|BIOLOGICAL: BNT162b2|OTHER: Placebo|BIOLOGICAL: BNT162b2SA,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,47079,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-04-29,2023-02-10
TERMINATED,NO,BEHAVIORAL: Personalized health education|BEHAVIORAL: General health education,ALL,"ADULT, OLDER_ADULT",NA,449,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-04-01,2021-09-30
RECRUITING,NO,DRUG: EDP-235|DRUG: Placebo,ALL,ADULT,PHASE2,200,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-11-10,2023-03
RECRUITING,NO,BEHAVIORAL: Health Education,ALL,CHILD,NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-06-13,2024-03-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Ad5-nCoV-IH|BIOLOGICAL: Ad5-nCoV-IM|BIOLOGICAL: CoronaVac,ALL,"ADULT, OLDER_ADULT",PHASE4,360,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-04-23,2023-03-20
COMPLETED,NO,DRUG: Proxalutamide|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,133,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-03-06,2021-04-15
COMPLETED,NO,DRUG: Emtricitabine/tenofovir disoproxil|DRUG: Hydroxychloroquine|DRUG: Placebo: Emtricitabine/tenofovir disoproxil Placebo|DRUG: Placebo: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE3,1002,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-04-15,2021-07-11
COMPLETED,NO,DRUG: REGN15160 (IV)|DRUG: Matching Placebo (IV)|DRUG: REGN15160 (SC)|DRUG: Matching Placebo (SC),ALL,ADULT,PHASE1,104,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-04-12,2023-01-26
COMPLETED,YES,DEVICE: Focal Mask,ALL,"ADULT, OLDER_ADULT",NA,201,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2021-09-06,2022-03-15
WITHDRAWN,NO,BIOLOGICAL: SCTV01C|BIOLOGICAL: SCTV01C|BIOLOGICAL: SCTV01C|BIOLOGICAL: SCTV01E|BIOLOGICAL: SCTV01E|BIOLOGICAL: SCTV01E|BIOLOGICAL: mRNA vaccine manufactured by Pfizer or Moderna|BIOLOGICAL: mRNA vaccine manufactured by Pfizer or Moderna|BIOLOGICAL: mRNA vaccine manufactured by Pfizer or Moderna|BIOLOGICAL: Sinopharm inactivated COVID-19 vaccine|BIOLOGICAL: Sinopharm inactivated COVID-19 vaccine|BIOLOGICAL: Sinopharm inactivated COVID-19 vaccine,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-04-01,2023-08-01
UNKNOWN,NO,PROCEDURE: biopsies of subcutaneous adipose tissue,ALL,"ADULT, OLDER_ADULT",NA,5,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-07-01,2021-07-09
COMPLETED,NO,BIOLOGICAL: LY3819253|DRUG: Placebo|BIOLOGICAL: Remdesivir|BIOLOGICAL: VIR-7831|BIOLOGICAL: BRII-196/BRII-198|BIOLOGICAL: AZD7442|DRUG: MP0420|DRUG: PF-07304814,ALL,"ADULT, OLDER_ADULT",PHASE3,2753,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-04,2023-07-14
NOT_YET_RECRUITING,NO,OTHER: Training in the management of functional disorders|OTHER: Reimbursement of 3 long consultations,ALL,"ADULT, OLDER_ADULT",NA,672,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-11,2025-03
COMPLETED,NO,BIOLOGICAL: Recombinant novel coronavirus vaccine (CHO cells),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,300,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-12-29,2022-07-19
WITHDRAWN,NO,DRUG: INO-4800|DRUG: INO-9112|DEVICE: CELLECTRA® 2000,ALL,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-10,2024-03
COMPLETED,NO,OTHER: Exercise & Nutrition|OTHER: Exercise & Nutrition,ALL,"ADULT, OLDER_ADULT",NA,216,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2020-11-30,2022-08-31
RECRUITING,NO,BEHAVIORAL: Education and Strategies Intervention|BEHAVIORAL: Mindfulness Skills Intervention,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,270,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-11-23,2022-09-01
COMPLETED,YES,BIOLOGICAL: Bacillus subtilis,ALL,"ADULT, OLDER_ADULT",NA,9,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-07-10,2021-11-01
COMPLETED,NO,BIOLOGICAL: Convalescent plasma,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,350,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-10,2021-01-10
COMPLETED,NO,DRUG: Hydroxychloroquine Oral Product|DRUG: Hydroxychloroquine + azithromycin,ALL,"ADULT, OLDER_ADULT",PHASE3,667,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-01,2020-06-02
UNKNOWN,NO,DEVICE: neuromuscular electrical stimulation,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-02-01,2021-12-31
UNKNOWN,NO,DRUG: Immunoglobulin of cured patients|DRUG: γ-Globulin,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-17,2020-05-31
RECRUITING,NO,BIOLOGICAL: Convalescent Plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-14,2021-12-31
COMPLETED,NO,DRUG: Ofatumumab,ALL,"ADULT, OLDER_ADULT",PHASE4,34,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-27,2023-06-13
UNKNOWN,NO,BIOLOGICAL: medium dosage inactivated SARS-CoV-2 vaccine|BIOLOGICAL: high dosage inactivated SARS-CoV-2 vaccine|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,1000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-10-27,2022-02-28
RECRUITING,NO,BIOLOGICAL: INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,400,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2024-01-29,2024-12-29
WITHDRAWN,NO,DRUG: Niclosamide Oral Tablet|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-20,2022-01-20
COMPLETED,NO,DRUG: mRNA-1273 (Moderna COVID-19 vaccine),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,19,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-03-10,2023-02-27
COMPLETED,NO,DRUG: leflunomide,ALL,"ADULT, OLDER_ADULT",PHASE3,178,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-16,2022-07-01
RECRUITING,NO,DRUG: Larazotide Acetate|DRUG: Placebo,ALL,"CHILD, ADULT",PHASE2,48,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-31,2026-03-31
COMPLETED,NO,DIETARY_SUPPLEMENT: High polyphenolic olive oil. (Early harvest olive oil).,ALL,"ADULT, OLDER_ADULT",NA,88,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-07-01,2022-09-30
COMPLETED,NO,BIOLOGICAL: SCB-2019,ALL,"ADULT, OLDER_ADULT",PHASE1,137,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2021-01-19,2021-12-16
UNKNOWN,NO,BIOLOGICAL: MSC,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05,2023-02
COMPLETED,NO,OTHER: plasma therapy using convalescent plasma with antibody against SARS-CoV-2|OTHER: Routine care for COVID-19 patients,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-19,2020-07-09
COMPLETED,NO,OTHER: Tele-exergaming Tablet,ALL,"ADULT, OLDER_ADULT",NA,54,FED,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-07-05,2023-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Sotrovimab,ALL,"ADULT, OLDER_ADULT",PHASE2,93,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-02-07,2023-04-01
COMPLETED,NO,BIOLOGICAL: MVC-COV1901|BIOLOGICAL: MVC-COV1901(Beta)-15|BIOLOGICAL: MVC-COV1901(Beta)-25,ALL,ADULT,PHASE1,107,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-05-06,2022-11-30
RECRUITING,NO,DRUG: Ozone,ALL,ADULT,PHASE1,100,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2023-05-18,2028-05
TERMINATED,NO,DRUG: Interferon-ß-1a|COMBINATION_PRODUCT: Standard of Care (SOC),ALL,"ADULT, OLDER_ADULT",PHASE2,56,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-02,2021-03-30
COMPLETED,YES,DRUG: PF-07321332|DRUG: Placebo for PF-07321332|DRUG: Placebo for Ritonavir|DRUG: Ritonavir,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,2954,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-09-09,2022-04-12
COMPLETED,NO,BIOLOGICAL: Mesenchymal Stromal Cells|OTHER: Supportive Care,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,28,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-12,2023-01-10
NOT_YET_RECRUITING,NO,DRUG: Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy;Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy,ALL,"ADULT, OLDER_ADULT",NA,114,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-04,2025-02
UNKNOWN,NO,DRUG: low-molecular-weight heparin,ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2020-08-01,2020-12-31
RECRUITING,NO,"BIOLOGICAL: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops|BIOLOGICAL: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops|BIOLOGICAL: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops|BIOLOGICAL: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops|BIOLOGICAL: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray",ALL,"ADULT, OLDER_ADULT",PHASE1,130,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-04-12,2022-10-31
COMPLETED,YES,DRUG: Sargramostim|DRUG: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE2,123,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-18,2021-05-19
COMPLETED,NO,DRUG: Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour|DRUG: Placebo of NICOTINE Transdermal patch,ALL,"ADULT, OLDER_ADULT",PHASE3,32,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-09,2021-11-05
TERMINATED,NO,DRUG: Dexamethasone,ALL,"ADULT, OLDER_ADULT",PHASE3,299,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-13,2020-07-22
COMPLETED,NO,PROCEDURE: prone positioning,ALL,"ADULT, OLDER_ADULT",NA,96,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-16,2022-08-03
COMPLETED,NO,DIAGNOSTIC_TEST: Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2,ALL,"ADULT, OLDER_ADULT",NA,182,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-10-01,2021-04-01
RECRUITING,NO,OTHER: blood sample and bronchoalveolar lavage,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-11-24,2025-02-23
COMPLETED,NO,DEVICE: nasal spray,ALL,"ADULT, OLDER_ADULT",NA,300,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-12-20,2021-08-30
UNKNOWN,NO,DRUG: Desferal 500 MG Injection,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-06-01,2020-12-31
NOT_YET_RECRUITING,NO,BIOLOGICAL: intravenous treatment with EVs|BIOLOGICAL: intravenous treatment with placebo solution,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,15,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-02-01,2025-06-01
UNKNOWN,NO,DEVICE: Acteev™ Masks|DEVICE: Comparison Masks,ALL,"ADULT, OLDER_ADULT",NA,1600,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-11-13,2022-02
COMPLETED,YES,DRUG: REGN10933+REGN10987 combination therapy|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,1149,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-15,2021-09-21
ACTIVE_NOT_RECRUITING,NO,DEVICE: Biofeedback training|DRUG: Treatment as usual,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: DEVICE_FEASIBILITY,2023-02-02,2024-06-02
COMPLETED,NO,OTHER: Methylene-Blue Photodisinfection,ALL,"CHILD, ADULT, OLDER_ADULT",NA,45,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-13,2021-10-19
UNKNOWN,NO,BIOLOGICAL: SCTV01E|BIOLOGICAL: Comirnaty|BIOLOGICAL: SCTV01E|BIOLOGICAL: Comirnaty,ALL,"ADULT, OLDER_ADULT",PHASE2,360,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-03-20,2023-05-01
COMPLETED,YES,DEVICE: Continuous Glucose Monitor (CGM),ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-03-03,2022-08-24
UNKNOWN,NO,BIOLOGICAL: Convalescent Plasma as Therapy for Covid-19 patients,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,44,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-01,2021-10-30
COMPLETED,NO,DRUG: Sofosbuvir and Ledipasvir|DRUG: Nitazoxanide,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,240,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-15,2020-10-30
COMPLETED,NO,DRUG: Dexamethasone,ALL,"ADULT, OLDER_ADULT",PHASE4,110,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-21,2022-03-04
RECRUITING,NO,DRUG: Atorvastatin|OTHER: Standard Care,ALL,"ADULT, OLDER_ADULT",PHASE3,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-03-10,2024-12
WITHDRAWN,NO,BIOLOGICAL: COVID-19 Vaccination|OTHER: Usual care,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-04-15,2021-12
UNKNOWN,NO,DRUG: Remdesivir-HU,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,2000,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-12,2021-11-30
COMPLETED,NO,DEVICE: Bio-Self COVID-19 Antigen Home Test|DEVICE: Standard of Care COVID-19 Test|DIAGNOSTIC_TEST: RT-PCR Test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,282,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-05-12,2022-07-25
UNKNOWN,NO,DEVICE: Oxygen Therapy|PROCEDURE: Physical Therapy,ALL,ADULT,NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-03-15,2020-06-23
COMPLETED,YES,"DRUG: ACE inhibitor, angiotensin receptor blocker",ALL,"ADULT, OLDER_ADULT",PHASE4,216,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-04-20,2021-02-24
RECRUITING,NO,DRUG: Nirmatrelvir/ritonavir|DRUG: Placebo/ritonavir,ALL,"ADULT, OLDER_ADULT",PHASE2,400,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-01,2024-03-31
RECRUITING,NO,DRUG: BIO 300 Oral Suspension|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,50,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-11,2024-03-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Rejuveinix (RJX) Active Comparator|DRUG: Placebo Comparator,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,237,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-25,2023-02
COMPLETED,NO,BEHAVIORAL: High intensity interval training|BEHAVIORAL: Standard care,ALL,"ADULT, OLDER_ADULT",NA,28,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-02-01,2022-02-10
TERMINATED,YES,BIOLOGICAL: Tocilizumab,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,1,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-05-28,2021-01-14
COMPLETED,NO,PROCEDURE: Awake Prone Positioning|PROCEDURE: Standard care,ALL,"ADULT, OLDER_ADULT",NA,13,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-15,2021-03-15
SUSPENDED,NO,DRUG: Hydroxychloroquine Sulfate|DRUG: Azithromycin Tablets,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,200,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-20,2023-07
RECRUITING,NO,DEVICE: high frequency chest wall oscillation with vest system|DEVICE: Lung flute (OPEP),MALE,ADULT,NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-10,2022-12
COMPLETED,NO,PROCEDURE: Muscle Biopsy,ALL,"ADULT, OLDER_ADULT",NA,22,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-01-02,2021-04-03
COMPLETED,NO,BIOLOGICAL: RQ3013|BIOLOGICAL: RQ3025|BIOLOGICAL: RQ3027,ALL,ADULT,NA,376,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2023-05-08,2023-11-23
UNKNOWN,NO,DIAGNOSTIC_TEST: Novel laser inferometry test for CORONA virus,ALL,"ADULT, OLDER_ADULT",NA,250,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-06,2021-12
UNKNOWN,NO,DRUG: Nivolumab Injection,ALL,"ADULT, OLDER_ADULT",PHASE2,92,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-15,2020-09-30
UNKNOWN,NO,BIOLOGICAL: ChAdOx1 nCoV-19|BIOLOGICAL: Normal saline 0.9%,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,2130,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-06-24,2021-12
WITHDRAWN,NO,DRUG: Olokizumab 64 mg|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-30,2021-01-29
UNKNOWN,NO,OTHER: severe acute respiratory syndrome CoV-2 serology,ALL,"CHILD, ADULT, OLDER_ADULT",NA,880,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-12-30,2022-09-10
WITHDRAWN,NO,DRUG: BI 767551 intravenous|DRUG: BI 767551 inhalation|DRUG: Placebo intravenous|DRUG: Placebo inhalation,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-17,2022-07-24
UNKNOWN,NO,BIOLOGICAL: Recombinant SARS-CoV-2 Fusion Protein Vaccine,ALL,"ADULT, OLDER_ADULT",NA,45,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-09-30,2023-09-30
RECRUITING,NO,DEVICE: Immunoadsorption|DEVICE: Sham-apheresis,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-05-08,2024-03
ACTIVE_NOT_RECRUITING,NO,OTHER: Pulmonary rehabilitation in primary care,ALL,"ADULT, OLDER_ADULT",NA,76,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-04-19,2024-09-01
WITHDRAWN,NO,DEVICE: Caption AI,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-07,2020-11-09
RECRUITING,NO,"DIETARY_SUPPLEMENT: 210 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK)",ALL,"ADULT, OLDER_ADULT",PHASE3,40,FED,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-12-01,2025-02-28
UNKNOWN,NO,DRUG: Pulmozyme|DRUG: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07-05,2021-12-31
WITHDRAWN,NO,BIOLOGICAL: VLA2001|DRUG: Active Comparator,ALL,CHILD,PHASE2|PHASE3,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-10-01,2025-08-30
RECRUITING,NO,DIETARY_SUPPLEMENT: Nicotinamide Riboside (NR)|BEHAVIORAL: Mind-body reprocessing therapy (MBRT)|BEHAVIORAL: Care as usual|DIETARY_SUPPLEMENT: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,310,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-30,2025-01
RECRUITING,NO,DRUG: Niagen,ALL,"ADULT, OLDER_ADULT",PHASE4,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-07-22,2023-12-31
WITHDRAWN,NO,DRUG: Famotidine|DRUG: Celecoxib|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-02-07,2023-02-07
COMPLETED,NO,BEHAVIORAL: Factual messages|BEHAVIORAL: Narrative message|BEHAVIORAL: Mixed message,ALL,"ADULT, OLDER_ADULT",NA,2409,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-09-21,2022-12-17
COMPLETED,NO,DIETARY_SUPPLEMENT: ADAPT-232 oral solution|OTHER: Placebo oral solution,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,100,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-19,2021-12-26
COMPLETED,YES,BIOLOGICAL: COVID-19 Convalescent Plasma,ALL,"ADULT, OLDER_ADULT",PHASE1,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-13,2021-03-08
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Mesenchymal stromal cells|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,9,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07-30,2023-12
COMPLETED,NO,OTHER: Aerobic Exercise Training|BEHAVIORAL: Patient Education|OTHER: Respiratory Exercise Training,ALL,"ADULT, OLDER_ADULT",NA,35,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2020-06-19,2021-02-17
COMPLETED,YES,DRUG: Sarilumab|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1912,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-03-18,2020-09-02
COMPLETED,NO,DRUG: kelavit,ALL,ADULT,PHASE1,150,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-02,2023-02-28
COMPLETED,NO,DIAGNOSTIC_TEST: CT-scan|DIAGNOSTIC_TEST: EEG|DIAGNOSTIC_TEST: EP|DIAGNOSTIC_TEST: Pulse oximetry|DIAGNOSTIC_TEST: Blood tests,ALL,ADULT,NA,51,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-05-22,2020-10-29
COMPLETED,YES,DRUG: Selinexor|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,190,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-04-17,2020-10-05
COMPLETED,NO,DIAGNOSTIC_TEST: ID Now™ COVID-19 Screening Test,ALL,"ADULT, OLDER_ADULT",NA,1265,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-11-09,2022-05-09
COMPLETED,NO,BIOLOGICAL: COVID-19 convalescent plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,58,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-04,2020-08-17
COMPLETED,YES,DRUG: Losartan,ALL,"ADULT, OLDER_ADULT",PHASE4,31,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-03-27,2020-06-13
COMPLETED,NO,DRUG: Bempegaldesleukin|DRUG: Standard of Care|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-13,2021-05-18
ENROLLING_BY_INVITATION,NO,"BEHAVIORAL: ILI Predictive Alerts, Reactive Content, and Proactive Content|BEHAVIORAL: ILI Predictive Alerts, Reactive Content|BEHAVIORAL: Proactive Content|BEHAVIORAL: No Intervention",ALL,"ADULT, OLDER_ADULT",NA,15000,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2024-02-12,2024-12
RECRUITING,NO,DEVICE: Hydroxy gas,ALL,"ADULT, OLDER_ADULT",NA,25,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-09-25,2024-05-31
RECRUITING,NO,OTHER: Exercise Prescription,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-04-22,2025-12-01
UNKNOWN,NO,BIOLOGICAL: BBV152|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,25800,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-11-16,2022-12
COMPLETED,YES,BIOLOGICAL: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|OTHER: Placebo|DRUG: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE3,593,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-08,2021-05-21
TERMINATED,NO,DRUG: casirivimab+imdevimab,ALL,CHILD,PHASE1,2,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-16,2022-06-09
COMPLETED,NO,DRUG: Interferon Beta-1B|DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-09,2020-07-07
COMPLETED,NO,DRUG: Dispersible NaCl powder 10 sessions|DRUG: Dispersible NaCl powder 5 sessions,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-01,2022-12-31
COMPLETED,YES,BIOLOGICAL: VIR-7831|BIOLOGICAL: Placebo|BIOLOGICAL: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE3,367,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-16,2022-10-04
UNKNOWN,NO,DEVICE: FFP2|DEVICE: Facial mask|DEVICE: MFS,ALL,ADULT,NA,10,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-05,2020-05
COMPLETED,NO,DRUG: Budesonide Nasal|OTHER: Physiological serum,ALL,"ADULT, OLDER_ADULT",PHASE3,120,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-05-18,2021-06-25
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 VLP Vaccine|BIOLOGICAL: Placebo,ALL,ADULT,PHASE1,38,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-03-27,2021-12-29
UNKNOWN,NO,BIOLOGICAL: COVID19,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-03-18,2022-11-30
COMPLETED,NO,OTHER: Physical Exercises,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-07-03,2020-10-03
WITHDRAWN,NO,DRUG: Selinexor,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-30,2020-08-30
COMPLETED,YES,BIOLOGICAL: CVnCoV Vaccine|DRUG: Placebo,ALL,ADULT,PHASE1,280,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2020-06-18,2021-12-21
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: CoronaVac|BIOLOGICAL: Turkovac,ALL,ADULT,PHASE3,4340,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-10-08,2023-12-31
TERMINATED,YES,DRUG: Brequinar Sodium|DRUG: Dipyridamole 75 MG|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,26,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-02-01,2022-06-04
UNKNOWN,NO,DRUG: Dapsone 85 mg PO BID|DRUG: Placebo 85 mg PO BID,ALL,"ADULT, OLDER_ADULT",PHASE3,3000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-22,2022-07-31
SUSPENDED,NO,DRUG: Sarilumab|DRUG: Azithromycin|DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,27,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-11,2020-08
COMPLETED,NO,DRUG: Oral,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,320,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-19,2021-08-28
TERMINATED,NO,DRUG: Budesonide dry powder inhaler,ALL,"ADULT, OLDER_ADULT",PHASE2,146,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-16,2021-01-12
WITHDRAWN,NO,BIOLOGICAL: BMS-986414|BIOLOGICAL: BMS-986413,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-11-29,2022-03-04
WITHDRAWN,NO,BEHAVIORAL: Doctorgram Patient Kit,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-01,2022-12
SUSPENDED,NO,OTHER: Leukapheresis,ALL,ADULT,NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-04-15,2023-12-31
COMPLETED,NO,COMBINATION_PRODUCT: Vitamin-D,ALL,"ADULT, OLDER_ADULT",PHASE3,500,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-12-05,2023-04-07
COMPLETED,NO,OTHER: Phone call,ALL,"ADULT, OLDER_ADULT",NA,129,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-06-12,2021-10-12
ENROLLING_BY_INVITATION,NO,DRUG: Experimental: Paxlovid 25 day dosing|DRUG: Experimental: Paxlovid 15 day dosing|DRUG: Placebo Comparator: Control,ALL,"ADULT, OLDER_ADULT",PHASE2,900,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-07-26,2024-07
UNKNOWN,NO,DRUG: Enoxaparin,ALL,"ADULT, OLDER_ADULT",PHASE3,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-06,2021-06
TERMINATED,NO,DRUG: T3 solution for injection|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,5,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-05-29,2021-04-19
TERMINATED,YES,DRUG: PF-07321332|DRUG: Ritonavir|DRUG: Placebo|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1440,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-25,2022-07-25
COMPLETED,NO,DRUG: mavrilimumab|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,815,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07-27,2022-01-14
UNKNOWN,NO,DRUG: COVID-globulin|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,376,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-04-12,2021-10-05
COMPLETED,NO,BEHAVIORAL: Intervention program,ALL,"ADULT, OLDER_ADULT",NA,102,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2020-05-25,2021-10-22
UNKNOWN,NO,BIOLOGICAL: Convalescent plasma|DRUG: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-18,2020-10-31
TERMINATED,NO,DRUG: Placebo|DRUG: Ivermectin|DRUG: Losartan,ALL,"ADULT, OLDER_ADULT",PHASE2,77,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-07-23,2022-06-30
TERMINATED,YES,BIOLOGICAL: Convalescent Plasma|OTHER: Best Supportive Care,ALL,"ADULT, OLDER_ADULT",PHASE2,21,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2020-11-06,2021-05-04
UNKNOWN,NO,DRUG: Dexamethasone|DRUG: Methylprednisolone,ALL,"ADULT, OLDER_ADULT",PHASE3,60,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-02,2020-11-30
COMPLETED,NO,DIAGNOSTIC_TEST: RT-qPCR test|DIAGNOSTIC_TEST: COVID-VIRO® test,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-10-13,2020-10-17
TERMINATED,YES,BIOLOGICAL: Convalescent Plasma|BIOLOGICAL: Standard Donor Plasma,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,82,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-08,2021-02-01
COMPLETED,NO,DRUG: PF-07817883|DRUG: Placebo,ALL,ADULT,PHASE2,239,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-05-24,2023-10-11
NOT_YET_RECRUITING,NO,BIOLOGICAL: Phase II:SWIM816;SARS-Cov-2;|BIOLOGICAL: Phase II:SW-BIC-213;SARS-Cov-2;|BIOLOGICAL: PhaseIII:SWIM816;SARS-Cov-2;|BIOLOGICAL: PhaseIII:Pfizer(Pfizer Bivalent vaccine);SARS-Cov-2；,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,800,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-06-20,2024-02-01
RECRUITING,NO,DRUG: Upamostat|DRUG: Placebo (PO),ALL,"ADULT, OLDER_ADULT",PHASE2,300,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2024-01-29,2024-10
COMPLETED,NO,BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml|BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml,ALL,"CHILD, ADULT",NA,2021,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2021-06-03,2022-07-31
COMPLETED,NO,BIOLOGICAL: COVID-19 Protein Subunit Recombinant Vaccine|BIOLOGICAL: Active Comparator,ALL,"ADULT, OLDER_ADULT",PHASE3,4050,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-06-07,2023-08-31
COMPLETED,NO,DRUG: 0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient|DRUG: 0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity|DRUG: 0.6% PVP-I Oral and nasal spray to healthy volunteer|OTHER: Oral and nasal spray by distilled water to control group,ALL,"ADULT, OLDER_ADULT",PHASE3,798,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-04-10,2021-05-30
COMPLETED,NO,DIETARY_SUPPLEMENT: L. reuteri DSM 17938 + vitamin D|DIETARY_SUPPLEMENT: Placebo + vitamin D,ALL,ADULT,NA,161,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2020-11-27,2021-09-13
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 Inactivated Vaccine|BIOLOGICAL: Placebo,ALL,CHILD,PHASE2,500,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-05-03,2022-06-20
WITHDRAWN,NO,BIOLOGICAL: One dose group|BIOLOGICAL: Two doses group|BIOLOGICAL: Aged 18-59 years|BIOLOGICAL: Aged 60 years old and above,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-01-07,2023-06-27
TERMINATED,YES,BIOLOGICAL: Lilly Bamlanivimab|BIOLOGICAL: Regeneron Casirivimab + Imdevimab|BIOLOGICAL: Lilly Bamlanivimab + Etesevimab|BIOLOGICAL: Sotrovimab|BIOLOGICAL: Bebtelovimab,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,4571,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-03-10,2022-06-16
UNKNOWN,NO,DRUG: Ivermectin Pill|DRUG: Combined ART/hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE4,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-07-13,2021-11
UNKNOWN,NO,BIOLOGICAL: SCTV01C|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,300,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-12-22,2023-01-01
RECRUITING,NO,BIOLOGICAL: Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine,ALL,"ADULT, OLDER_ADULT",PHASE2,80,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-02-20,2025-07
TERMINATED,NO,DRUG: Hydroxychloroquine|DRUG: Placebo of Hydroxychloroquine|DRUG: Lopinavir and ritonavir|DRUG: Placebo of LPV/r Tablets,ALL,"ADULT, OLDER_ADULT",PHASE3,118,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-04-14,2022-03-30
WITHDRAWN,NO,DRUG: Treatment with Dexmedetomidine,ALL,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-20,2020-11-20
COMPLETED,NO,BIOLOGICAL: CV0501 (3 μg)|BIOLOGICAL: CV0501 (6 μg)|BIOLOGICAL: CV0501 (12 μg)|BIOLOGICAL: CV0501 (25 μg)|BIOLOGICAL: CV0501 (50 μg)|BIOLOGICAL: CV0501 (75 μg)|BIOLOGICAL: CV0501 (100 μg)|BIOLOGICAL: CV0501 (150 μg)|BIOLOGICAL: CV0501 (200 μg),ALL,"ADULT, OLDER_ADULT",PHASE1,180,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2022-08-12,2023-08-18
COMPLETED,NO,DRUG: ATI-450|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-07-20,2021-06-01
UNKNOWN,NO,DRUG: SCTA01|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,795,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-27,2021-12-27
UNKNOWN,NO,DEVICE: therapeutic plasmaexchnage,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-06,2022-07
COMPLETED,NO,BIOLOGICAL: COVID Convalescent Plasma,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,86,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2023-03-23
RECRUITING,NO,DRUG: Angiotensin 1-7,ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-01-18,2024-04
UNKNOWN,NO,DRUG: Atazanavir|DRUG: Daclatasvir 60 mg|DRUG: Sofusbuvir + Daclastavir 60 mg|DRUG: Placebo Atazanavir|DRUG: Placebo Daclatasvir 60 mg|DRUG: Placebo Sofusbuvir + Daclatasvir 60 mg,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,256,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-15,2022-12-31
RECRUITING,NO,BIOLOGICAL: coadministration|BIOLOGICAL: COVID-19 vaccine|BIOLOGICAL: rabies vaccine,ALL,"ADULT, OLDER_ADULT",PHASE4,360,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-07-21,2023-06-30
WITHDRAWN,NO,DRUG: Recombinant human angiotensin-converting enzyme 2 (rhACE2),ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02,2020-04
UNKNOWN,NO,BIOLOGICAL: Biological: oral polio vaccine|BIOLOGICAL: Comparable Placebo|DRUG: NA-831|DRUG: Comparable Placebo of drug|COMBINATION_PRODUCT: Combination of oral polio vaccine and NA-831|COMBINATION_PRODUCT: Comparable Placebo of Oral Polio Vaccine and Placebo of drug,ALL,"ADULT, OLDER_ADULT",PHASE3,3600,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-11-01,2022-12-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: COVID-19 mRNA vaccine|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,150,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-05-20,2023-12-20
TERMINATED,YES,DRUG: Group 1 HCQ|DRUG: Group 2 Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,39,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-04-07,2020-07-11
RECRUITING,NO,OTHER: Exercise,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-09-04,2024-06-07
TERMINATED,NO,DRUG: 1: Naproxen|DRUG: 2: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE3,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-24,2020-12-15
COMPLETED,NO,BIOLOGICAL: Recombinant NDV Vectored Vaccine for SARS-CoV-2,ALL,ADULT,PHASE1,91,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-05-20,2022-09-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: AZD7442|BIOLOGICAL: Placebo|BIOLOGICAL: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE3,1455,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-02-05,2023-03-31
COMPLETED,NO,PROCEDURE: Stellate Ganglion Block,ALL,"ADULT, OLDER_ADULT",NA,1,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-15,2021-11-01
COMPLETED,NO,DIAGNOSTIC_TEST: VOX,ALL,"ADULT, OLDER_ADULT",NA,192,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-01-18,2023-01-18
RECRUITING,NO,DRUG: Ivermectin,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-16,2030-12-01
ACTIVE_NOT_RECRUITING,NO,DRUG: GLS-1027|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,132,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-05-07,2023-12
UNKNOWN,NO,DRUG: Fluticasone Propionate,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,500,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-22,2022-08-30
COMPLETED,NO,DIETARY_SUPPLEMENT: 1 week placebo(Week 1)|DIETARY_SUPPLEMENT: 1 week of probiotics(Week 1)|DIETARY_SUPPLEMENT: 1 week placebo(Week 2)|DIETARY_SUPPLEMENT: 1 week of probiotics(Week 2)|DIETARY_SUPPLEMENT: 1 week placebo(Week 3)|DIETARY_SUPPLEMENT: 1 week of probiotics(Week 3),ALL,ADULT,NA,44,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2022-02-27,2022-08-21
UNKNOWN,NO,BEHAVIORAL: Choices and judgements,ALL,"ADULT, OLDER_ADULT",NA,500,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2020-09-03,2021-08-02
COMPLETED,NO,OTHER: Structural and functional MRI|DRUG: Ethyl methyl hydroxypyridine succinate + Meldonium|DRUG: Placebo,ALL,ADULT,PHASE4,30,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-05-18,2022-12-20
COMPLETED,NO,DRUG: Tafenoquine Oral Tablet|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,86,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-19,2022-06-30
TERMINATED,NO,BEHAVIORAL: Digital cognitive behavioral intervention-RxWell|DRUG: Amphetamine-Dextroamphetamine,ALL,"ADULT, OLDER_ADULT",PHASE4,7,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-04,2023-05-18
COMPLETED,NO,DRUG: Nitazoxanide|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,500,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-04-19,2020-10-02
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: PIKA COVID-19 vaccine|BIOLOGICAL: Inactivated Covid-19 vaccine,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,5860,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-10-03,2024-03-11
TERMINATED,NO,DRUG: Favipiravir|DRUG: Favipiravir Placebo,ALL,OLDER_ADULT,PHASE2,67,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-10-16,2021-10-30
UNKNOWN,NO,OTHER: Assembled mask,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-05-20,2021-07-01
RECRUITING,NO,BIOLOGICAL: Prime-2-CoV_Beta,ALL,ADULT,PHASE1,60,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2022-06-24,2025-12-31
UNKNOWN,NO,BIOLOGICAL: Recombinant novel coronavirus vaccine (CHO cell),ALL,"ADULT, OLDER_ADULT",PHASE3,300,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-09-17,2022-10-12
TERMINATED,NO,DRUG: PRIME-2-CoV_Beta,ALL,"ADULT, OLDER_ADULT",PHASE1,103,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2022-06-20,2023-11-08
TERMINATED,NO,DRUG: Ivermectin|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,249,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-18,2021-07-21
NOT_YET_RECRUITING,NO,BIOLOGICAL: GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition,ALL,CHILD,PHASE3,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-10,2024-12
TERMINATED,YES,BIOLOGICAL: Hyperbaric Oxygen Therapy,ALL,"ADULT, OLDER_ADULT",PHASE4,1,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2021-01-31
TERMINATED,NO,DRUG: Amantadine,ALL,"ADULT, OLDER_ADULT",PHASE3,193,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-30,2022-03-10
COMPLETED,NO,PROCEDURE: Oral care with/without aerosolization,ALL,"ADULT, OLDER_ADULT",NA,18,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-03-22,2022-01-26
UNKNOWN,NO,DIETARY_SUPPLEMENT: Lactoferrin,ALL,"ADULT, OLDER_ADULT",NA,54,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-08,2021-04-30
COMPLETED,NO,OTHER: STOPCOV,ALL,"CHILD, ADULT, OLDER_ADULT",NA,114,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE,2020-09-14,2021-10-21
RECRUITING,NO,DIETARY_SUPPLEMENT: medium chain triglyceride oil|DIETARY_SUPPLEMENT: Safflower oil,ALL,ADULT,NA,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-10-01,2026-03-01
UNKNOWN,NO,DRUG: Cyproheptadine Hydrochloride 4 MG,ALL,"ADULT, OLDER_ADULT",PHASE3,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-10,2022-01-01
COMPLETED,NO,DRUG: Remdesivir|OTHER: Standard of care treatment,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-06-16,2020-12-01
TERMINATED,YES,BIOLOGICAL: MT-2766 High dose (3.75 µg)|DRUG: Placebo|BIOLOGICAL: MT-2766 Low dose,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,128,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-10-02,2023-01-29
COMPLETED,NO,DEVICE: hyperbaric oxygen therapy|DEVICE: breathing exercise|DRUG: medical treatment,ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-03-07,2023-06-01
WITHDRAWN,NO,DRUG: IIBR-100|DRUG: Active Comparator,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-09-30,2022-02-28
NOT_YET_RECRUITING,NO,BIOLOGICAL: PTX-COVID19-B|BIOLOGICAL: Comirnaty®,ALL,"ADULT, OLDER_ADULT",PHASE3,3800,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-02-03,2023-12-20
COMPLETED,NO,DIETARY_SUPPLEMENT: Echinochrome A|OTHER: Control,ALL,ADULT,NA,54,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-09-22,2022-12-18
COMPLETED,NO,OTHER: Specific exercise rehabilitation treatment|OTHER: No specific exercise rehabilitation treatment,ALL,"ADULT, OLDER_ADULT",NA,63,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-07,2023-04-30
UNKNOWN,NO,"BIOLOGICAL: SARS-CoV-2 Vaccine (Vero Cells), Inactivated|BIOLOGICAL: Placebo",ALL,CHILD,PHASE2,480,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-09,2023-04
RECRUITING,NO,BEHAVIORAL: Problem Management Plus|BEHAVIORAL: Services as Usual,ALL,"ADULT, OLDER_ADULT",NA,1500,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-11-07,2026-06-30
RECRUITING,NO,BIOLOGICAL: Influenza|BIOLOGICAL: MMR vaccines|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,2000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-05-01,2023-03
WITHDRAWN,NO,BIOLOGICAL: RUTI® vaccine|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12,2022-04
COMPLETED,NO,DRUG: Anakinra,ALL,"ADULT, OLDER_ADULT",PHASE2,1000,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-04-15,2022-04-15
NOT_YET_RECRUITING,NO,BIOLOGICAL: anti-SARS-CoV-2 human convalescent plasma,ALL,CHILD,PHASE1,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08,2024-12
WITHDRAWN,NO,DRUG: anti-SARS-CoV-2 plasma|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10,2021-12
COMPLETED,NO,"BIOLOGICAL: Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.|BIOLOGICAL: Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.",ALL,ADULT,PHASE4,480,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-03-23,2021-05-28
TERMINATED,NO,BIOLOGICAL: Low dose BCD-250 injection|BIOLOGICAL: High dose BCD-250 injection|BIOLOGICAL: Low dose or high dose BCD-250 injection|OTHER: Placebo injection,ALL,ADULT,PHASE1|PHASE2,50,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-08-10,2022-04-18
COMPLETED,YES,DRUG: Acalabrutinib,ALL,"ADULT, OLDER_ADULT",PHASE2,62,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-13,2020-11-16
RECRUITING,NO,OTHER: Chinese medicine nutritional supplement Cs4,ALL,"ADULT, OLDER_ADULT",PHASE2,110,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2023-04-17,2024-03-31
NOT_YET_RECRUITING,NO,"DIAGNOSTIC_TEST: SARS-COV-2, Influenza and RSV 8-Well MT-PCR Panel|DIAGNOSTIC_TEST: BioFire Respiratory Panel 2.1",ALL,"CHILD, ADULT, OLDER_ADULT",NA,1000,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-07,2024-02
COMPLETED,NO,BIOLOGICAL: mRNA-1073|BIOLOGICAL: mRNA-1010|BIOLOGICAL: mRNA-1273|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,553,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-13,2022-12-29
TERMINATED,NO,BIOLOGICAL: Spikevax|BIOLOGICAL: Comirnaty|BIOLOGICAL: Spikevax bivalent Original/Omicron BA.1|BIOLOGICAL: Spikevax bivalent Original/Omicron BA.4-5|BIOLOGICAL: Comirnaty Original/Omicron BA.1|BIOLOGICAL: Comirnaty Original/Omicron BA.4-5|BIOLOGICAL: Comirnaty Omicron XBB.1.5|BIOLOGICAL: Spikevax Omicron XBB.1.5,ALL,"ADULT, OLDER_ADULT",PHASE4,152,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-12-01,2024-01-08
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: mRNA-1273 SARS-CoV-2 vaccine from Moderna,ALL,"ADULT, OLDER_ADULT",NA,791,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-08,2025-04
COMPLETED,NO,DEVICE: High Flow Nasal Therapy|DEVICE: Conventional Oxygen Therapy,ALL,"ADULT, OLDER_ADULT",NA,364,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-10,2021-10-25
COMPLETED,NO,BIOLOGICAL: Convalescent Plasma (CP)|OTHER: Drugs and supportive care,ALL,"ADULT, OLDER_ADULT",NA,110,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-26,2020-10-10
UNKNOWN,NO,BIOLOGICAL: RUTI® vaccine|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,315,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-30,2020-12
UNKNOWN,NO,DRUG: recombinant human interferon Alpha-1b|DRUG: thymosin alpha 1,ALL,"ADULT, OLDER_ADULT",PHASE3,2944,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-01-21,2020-06
UNKNOWN,NO,DIAGNOSTIC_TEST: comparison of sample collection methods,ALL,"ADULT, OLDER_ADULT",NA,300,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-09,2022-09
TERMINATED,NO,DRUG: REGN14256|DRUG: imdevimab|DRUG: casirivimab + imdevimab|DRUG: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,25,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-08,2022-06-30
RECRUITING,NO,DIETARY_SUPPLEMENT: Flavonoids,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-08-01,2024-12-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: ChAdOx1 nCoV-19 (Abs 260)|BIOLOGICAL: MenACWY vaccine|BIOLOGICAL: ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost|BIOLOGICAL: Two dose MenACWY vaccine|BIOLOGICAL: ChAdOx1 nCoV-19 (qPCR)|BIOLOGICAL: ChAdOx1 nCoV-19 0.5mL prime plus boost|BIOLOGICAL: Two dose MenACWY vaccine min. 4 weeks apart|BIOLOGICAL: Two dose ChAdOx1 nCoV-19/Covishield 0.5mL|BIOLOGICAL: Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,12390,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-05-28,2024-03-31
WITHDRAWN,NO,DEVICE: Hydrogen peroxide|DEVICE: Placebo,ALL,"ADULT, OLDER_ADULT",NA,0,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-09,2021-07
TERMINATED,YES,DRUG: Camostat Mesilate|DRUG: Bicalutamide 150 mg,ALL,"ADULT, OLDER_ADULT",PHASE1,6,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-03,2021-09-15
WITHDRAWN,NO,DRUG: metformin glycinate|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02,2021-02
UNKNOWN,NO,DRUG: EXO 1 inhalation|DRUG: EXO 2 inhalation|DRUG: Placebo inhalation,ALL,"ADULT, OLDER_ADULT",PHASE2,90,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: OTHER",2020-10-01,2021-12-30
UNKNOWN,NO,DRUG: GX-19|DRUG: Saline,ALL,ADULT,PHASE1|PHASE2,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-06-17,2022-03-30
COMPLETED,NO,DEVICE: Acupuncture Therapy|DRUG: Budesonide|OTHER: Olfactory Training,ALL,"ADULT, OLDER_ADULT",NA,32,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-07,2023-06-09
COMPLETED,NO,BIOLOGICAL: COVIGEN C19 0.8 mg ID or Placebo ID|BIOLOGICAL: COVIGEN C19 2.0 mg IM or Placebo IM|BIOLOGICAL: COVIGEN C19 4.0 mg IM or Placebo IM|BIOLOGICAL: COVIGEN C20 1.0mg vaccine ID,ALL,"ADULT, OLDER_ADULT",PHASE1,68,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-06-21,2023-07-30
TERMINATED,NO,BEHAVIORAL: Gamification|BEHAVIORAL: Newsfeed function,ALL,"ADULT, OLDER_ADULT",NA,34,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-05-06,2020-08-26
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Aerosolized Ad5-nCoV|BIOLOGICAL: Inactivated SARS-CoV-2 vaccine,ALL,"ADULT, OLDER_ADULT",PHASE3,10420,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-01-22,2022-09-01
COMPLETED,NO,BIOLOGICAL: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|BIOLOGICAL: mRNA vaccine BNT162b2 (Pfizer),ALL,"ADULT, OLDER_ADULT",PHASE3,540,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2022-09-20,2023-05-02
WITHDRAWN,NO,DRUG: DAS181|DRUG: Placebo|DRUG: DAS181,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07-25,2020-11-30
UNKNOWN,NO,DRUG: Remdesivir,ALL,"CHILD, ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2020-11-30
COMPLETED,NO,BIOLOGICAL: EXG-5003|BIOLOGICAL: Placebo,ALL,ADULT,PHASE1|PHASE2,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-04-28,2023-01-24
UNKNOWN,NO,BIOLOGICAL: Tocilizumab,ALL,"ADULT, OLDER_ADULT",PHASE3,30,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-30,2021-06
COMPLETED,NO,BIOLOGICAL: VLA2001,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,178,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-05-09,2023-05-22
WITHDRAWN,NO,OTHER: PT Pal|OTHER: Exercise Manual,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-11,2022-12
ACTIVE_NOT_RECRUITING,NO,DIETARY_SUPPLEMENT: Active|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",NA,146,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-09-26,2024-01-30
COMPLETED,NO,BIOLOGICAL: anti-SARS-CoV-2 convalescent plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,131,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-11,2021-02-10
UNKNOWN,NO,"BIOLOGICAL: Candidate Vaccine, SCB-2019|OTHER: Placebo",ALL,"ADULT, OLDER_ADULT",PHASE2,766,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-08-10,2022-11-15
COMPLETED,NO,BEHAVIORAL: Physical activity behavioural modification,ALL,"ADULT, OLDER_ADULT",NA,32,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-11-01,2023-06-15
COMPLETED,NO,OTHER: Farmalarm,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-03-31,2020-05-18
UNKNOWN,NO,DRUG: Ruconest,ALL,"ADULT, OLDER_ADULT",PHASE4,40,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-12-30,2022-01
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose|BIOLOGICAL: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",NA,54,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-09-16,2024-03
TERMINATED,YES,BIOLOGICAL: HB-adMSC|OTHER: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,48,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-30,2021-09-30
COMPLETED,NO,DRUG: IV tPA (Activase),ALL,"ADULT, OLDER_ADULT",PHASE1,50,OTHER,"Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-01,2022-09-15
COMPLETED,NO,DRUG: Dexamethasone,ALL,"ADULT, OLDER_ADULT",PHASE3,445,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-27,2021-06-30
UNKNOWN,NO,DRUG: GX-19N,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-02-16,2022-03-31
COMPLETED,NO,BIOLOGICAL: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,508,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-04-12,2020-12-31
COMPLETED,NO,BIOLOGICAL: CoronaVac®|BIOLOGICAL: Omicron Vaccine|BIOLOGICAL: Trivalent Vaccine,ALL,"ADULT, OLDER_ADULT",PHASE2,551,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-11-28,2023-10-26
COMPLETED,YES,DRUG: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,29,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-05,2021-03-05
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: 20 μg dose of SYS6006|BIOLOGICAL: 30 μg dose of SYS6006|DRUG: Placebo,ALL,ADULT,PHASE1,40,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-04-27,2023-10-01
TERMINATED,NO,DRUG: Prednisone|OTHER: Control group,ALL,"ADULT, OLDER_ADULT",PHASE2,11,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-21,2020-08-18
RECRUITING,NO,DIAGNOSTIC_TEST: (NPS right - Nasal swab left - OPS)|DIAGNOSTIC_TEST: (NPS left - Nasal swab right - OPS)|DIAGNOSTIC_TEST: (Nasal swab right - NPS left - OPS)|DIAGNOSTIC_TEST: (Nasal swab left - NPS right - OPS)|DIAGNOSTIC_TEST: (NPS right - OPS - Nasal swab left)|DIAGNOSTIC_TEST: (NPS left - OPS - Nasal swab right)|DIAGNOSTIC_TEST: (Nasal swab right - OPS - NPS left)|DIAGNOSTIC_TEST: (Nasal swab left - OPS - NPS right)|DIAGNOSTIC_TEST: (OPS - NPS right - Nasal swab left)|DIAGNOSTIC_TEST: (OPS - NPS left - Nasal swab right)|DIAGNOSTIC_TEST: (OPS - Nasal swab left - NPS right)|DIAGNOSTIC_TEST: (OPS - Nasal swab right - NPS left),ALL,"ADULT, OLDER_ADULT",NA,250,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-03-03,2023-07-01
ENROLLING_BY_INVITATION,NO,BEHAVIORAL: Minimal-Dose Home-Based Resistance Exercise,ALL,"ADULT, OLDER_ADULT",NA,52,FED,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-31,2025-06-05
RECRUITING,NO,OTHER: Vitamin D|OTHER: Placebo,ALL,"CHILD, ADULT",NA,150,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-10-18,2025-09-30
UNKNOWN,NO,DRUG: Hydroxychloroquine 200 Mg Oral Tablet|DRUG: Azithromycin 500Mg Oral Tablet|DIETARY_SUPPLEMENT: Glucose tablets,ALL,ADULT,PHASE3,75,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-03-28,2020-06-28
UNKNOWN,NO,BEHAVIORAL: Experimental,FEMALE,ADULT,NA,74,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-04-11,2022-01-30
UNKNOWN,NO,OTHER: Alcohol based hand sanitizer,ALL,"CHILD, ADULT, OLDER_ADULT",NA,2000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-08,2022-09
RECRUITING,NO,BIOLOGICAL: Anti COVID 19 Intravenous Immunoglobulin (C-IVIG),ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,310,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-08-01,2022-12-02
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: COVID-19 mRNA vaccine|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,150,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-07-06,2023-12
NOT_YET_RECRUITING,NO,DRUG: mRNA- COVID-19|DRUG: Prevnar13,ALL,OLDER_ADULT,PHASE4,414,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-08-01,2022-12-31
RECRUITING,NO,DRUG: Nitazoxanide and Ciclésonide|DRUG: Telmisartan 20Mg Oral Tablet|DRUG: Paracetamol|DRUG: Fluoxétine and Budésonide,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,600,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-12,2023-08
COMPLETED,NO,BIOLOGICAL: Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-06,2021-09-01
UNKNOWN,NO,BIOLOGICAL: Triple dose vaccination by inactivated Covid19 vaccine,ALL,ADULT,PHASE2,200,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-09-20,2022-09-20
COMPLETED,NO,OTHER: Saline Nasal Irrigation|OTHER: Saline with Baby Shampoo Nasal Irrigation,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-01,2022-03-16
COMPLETED,NO,BIOLOGICAL: GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1|OTHER: Normal saline (0.9% sodium chloride solution) - Stage 1|BIOLOGICAL: GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1|OTHER: Normal saline (0.9% sodium chloride solution) - Stage 1|BIOLOGICAL: GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2|BIOLOGICAL: GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2|OTHER: Normal saline (0.9% sodium chloride solution)- Stage 2,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,260,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-01-20,2022-07-07
COMPLETED,NO,BIOLOGICAL: Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,12000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-09-09,2023-04-03
COMPLETED,NO,BIOLOGICAL: 3 doses of BNT162b2 vaccine|BIOLOGICAL: 2 dose of BNT162b2 vaccine,ALL,"ADULT, OLDER_ADULT",PHASE2,267,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-03-08,2023-12-02
COMPLETED,NO,OTHER: Pilates Exercises|OTHER: Home Exercise program,ALL,ADULT,NA,145,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-26,2023-02-23
RECRUITING,NO,DEVICE: solid microneedle skin patch|BIOLOGICAL: mRNA-1273|DEVICE: standard needle,ALL,ADULT,PHASE2,20,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-05-01,2023-05-01
COMPLETED,NO,DRUG: Nirmatrelvir|DRUG: Placebo|DRUG: Ritonavir,ALL,"ADULT, OLDER_ADULT",PHASE2,168,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-11-08,2023-09-12
NOT_YET_RECRUITING,NO,DIAGNOSTIC_TEST: COVID-19 Self testing and related messaging,ALL,"ADULT, OLDER_ADULT",NA,646,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-12,2023-05
COMPLETED,NO,BIOLOGICAL: TRV027|OTHER: sodium chloride 0.9%,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2020-10-09,2021-05-12
UNKNOWN,NO,DIAGNOSTIC_TEST: Rapid Diagnostic Test vs PCR,ALL,"ADULT, OLDER_ADULT",NA,1250,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-09-25,2020-12-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: AZD5156 (Parent study Sentinel Safety Cohort)|BIOLOGICAL: Placebo (Parent study Sentinel Safety Cohort)|BIOLOGICAL: EVUSHELD™ (Parent study Main Cohort)|BIOLOGICAL: AZD3152 (Parent study Main Cohort)|BIOLOGICAL: Placebo (Parent study Main Cohort)|BIOLOGICAL: AZD3152 (Sub-study)|BIOLOGICAL: AZD7442 - EVUSHELD™ (Sub-study)|BIOLOGICAL: AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,4038,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-12-16,2025-01-31
COMPLETED,NO,DRUG: Sildenafil|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-19,2021-06-30
COMPLETED,NO,DRUG: 150 mg 5-ALAPhosphate + SFC|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",NA,200,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-03-15,2022-06-18
RECRUITING,NO,DRUG: Nitazoxanide,ALL,"ADULT, OLDER_ADULT",PHASE3,160,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-08,2030-12-01
RECRUITING,NO,DRUG: HCQ01|OTHER: standard of care (SOC) for COVID-19,ALL,"ADULT, OLDER_ADULT",PHASE2,110,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-20,2022-07-20
COMPLETED,NO,DRUG: Convalescent Plasma Transfusion|OTHER: Supportive Care|DRUG: Random Donor Plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,29,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-20,2020-05-30
NOT_YET_RECRUITING,NO,BIOLOGICAL: SCTV01E|BIOLOGICAL: mRNA-1273,ALL,CHILD,PHASE2,300,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-07-01,2023-04-01
COMPLETED,NO,PROCEDURE: Biological samples specific to research|PROCEDURE: Clinical examination|PROCEDURE: Telephone follow-up,ALL,"ADULT, OLDER_ADULT",NA,73,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-04-27,2021-03-26
TERMINATED,YES,DRUG: CPI-006 2 mg/kg + SOC|DRUG: CPI-006 1 mg/kg + SOC|DRUG: Placebo + SOC,ALL,"ADULT, OLDER_ADULT",PHASE3,46,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-25,2021-08-18
TERMINATED,YES,DRUG: Apixaban 2.5 MG|DRUG: Apixaban 5MG|DRUG: Aspirin|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,657,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-09-07,2021-08-05
TERMINATED,NO,DRUG: Pemziviptadil (PB1046)|DRUG: Low Dose (10 mg) Control,ALL,"ADULT, OLDER_ADULT",PHASE2,54,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-15,2020-12-02
COMPLETED,NO,BIOLOGICAL: batch 1 of Ad5-nCoV|BIOLOGICAL: batch 2 of Ad5-nCoV|BIOLOGICAL: batch 3 of Ad5-nCoV,ALL,"ADULT, OLDER_ADULT",PHASE4,1050,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-03-08,2021-09-08
COMPLETED,NO,"DRUG: Methylprednisolone, Placebo",ALL,"ADULT, OLDER_ADULT",PHASE3,260,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-17,2021-07-12
NOT_YET_RECRUITING,NO,"DRUG: Amantadine|OTHER: Physical, Occupational, Speech Therapy|OTHER: Provider Counseling|OTHER: Medications for symptoms management",ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-04-01,2025-12-01
COMPLETED,NO,BIOLOGICAL: AZD1222|BIOLOGICAL: rAd26-S,ALL,"ADULT, OLDER_ADULT",PHASE2,100,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-03-05,2022-03-18
COMPLETED,NO,BIOLOGICAL: COVID-19 Vaccine HIPRA 40 ug/dose|BIOLOGICAL: Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection,ALL,"ADULT, OLDER_ADULT",PHASE2,26,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-03-25,2022-10-01
TERMINATED,YES,DRUG: SNDX-6352|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,1,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-05-30,2020-07-13
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: Nasal Swab|DIAGNOSTIC_TEST: Nasopharyngeal swab|DIAGNOSTIC_TEST: Throat swab|DIAGNOSTIC_TEST: Fingerstick|DIAGNOSTIC_TEST: Saliva specimen,ALL,"CHILD, ADULT, OLDER_ADULT",NA,1134,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-06-26,2024-03-31
RECRUITING,NO,OTHER: Access to Cue Health COVID-19 Remote testing and treatment for COVID-19,ALL,"ADULT, OLDER_ADULT",NA,10000,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-12-22,2024-01
UNKNOWN,NO,BIOLOGICAL: Covax-19™,ALL,ADULT,PHASE1,32,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-07,2021-12
COMPLETED,NO,BEHAVIORAL: Tele-interventions related to diabetes management and mental well-being,ALL,"ADULT, OLDER_ADULT",NA,149,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-04-17,2020-09-20
NOT_YET_RECRUITING,NO,BIOLOGICAL: RQ3013|BIOLOGICAL: Comirnaty,ALL,"ADULT, OLDER_ADULT",PHASE1,120,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-07,2023-07
COMPLETED,NO,DRUG: Vitamin D|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE4,218,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-11,2021-07-28
COMPLETED,NO,BIOLOGICAL: Recombinant NDV Vectored Vaccine for SARS-CoV-2|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,158,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-11-23,2023-07-24
UNKNOWN,NO,DIETARY_SUPPLEMENT: Manremyc|DIETARY_SUPPLEMENT: Placebo,ALL,"ADULT, OLDER_ADULT",NA,315,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-14,2021-12
RECRUITING,NO,OTHER: Triflow|OTHER: Control,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-12-21,2025-12-31
RECRUITING,NO,OTHER: Placebo Comparator: Sterile Water|OTHER: 27% Ethanol plus essential oils|OTHER: 0.075% Cetylpyridinium Chloride,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-20,2023-12-31
COMPLETED,NO,"DRUG: Nifedipine 30 MG|DIAGNOSTIC_TEST: Kangzhu BPCB0A-3A|BEHAVIORAL: Low Mobility|DRUG: Enalapril Maleate 10Mg Tab|DRUG: Lansoprazole 30Mg Ec Cap|DRUG: Metoprolol Succinate|DIETARY_SUPPLEMENT: Coenzyme Q10|DIETARY_SUPPLEMENT: d-alpha tocopherol acetate|DIETARY_SUPPLEMENT: Omega-3|DRUG: Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release|DRUG: Superoxide Dismutase",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,1,INDIV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-01-02,2023-01-12
NOT_YET_RECRUITING,NO,DRUG: S.opt.FL COVID-19 pDNA vaccine|DRUG: S.opt.FL COVID-19 pDNA vaccine|DRUG: S.opt.FL COVID-19 pDNA vaccine,ALL,ADULT,PHASE1,30,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2022-11-20,2023-07-01
COMPLETED,NO,DRUG: Ivermectin|DRUG: Azithromycin|DRUG: Cholecalciferol,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-15,2020-06-10
UNKNOWN,NO,DRUG: Nicotine patch|DRUG: Placebo patch,ALL,"ADULT, OLDER_ADULT",PHASE3,1633,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-22,2022-06
UNKNOWN,NO,DRUG: Hydroxychloroquine|DRUG: Hydroxychloroquine (placebo)|DRUG: Zinc|DRUG: Zinc (Placebo),ALL,"ADULT, OLDER_ADULT",PHASE3,660,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-05-04,2020-07-31
COMPLETED,YES,BIOLOGICAL: AZD1222|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,32450,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-28,2023-02-10
NOT_YET_RECRUITING,NO,BEHAVIORAL: Amygdala insula retraining,ALL,"CHILD, ADULT, OLDER_ADULT",NA,130,FED,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-15,2024-06-15
RECRUITING,NO,BIOLOGICAL: Pfizer-BioNTech mRNA COVID-19 vaccine|BIOLOGICAL: Moderna mRNA COVID-19 vaccine,ALL,"ADULT, OLDER_ADULT",PHASE4,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-21,2024-12-30
COMPLETED,YES,BIOLOGICAL: ABNCoV2 Vaccine,ALL,ADULT,PHASE1,45,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-03-11,2022-02-25
COMPLETED,NO,DRUG: Ivermectin,ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-01,2020-06-30
COMPLETED,NO,BIOLOGICAL: Convalescent Plasma of patients with COVID-19|OTHER: placebo (hartmann plus albumine),ALL,"ADULT, OLDER_ADULT",PHASE2,42,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-05-20,2020-12-10
COMPLETED,NO,BIOLOGICAL: AD17002|BIOLOGICAL: Placebo (Formulation buffer),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,30,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-21,2023-12-18
NOT_YET_RECRUITING,NO,DRUG: Dexamethasone,ALL,"ADULT, OLDER_ADULT",PHASE3,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-28,2023-12-01
COMPLETED,NO,DIAGNOSTIC_TEST: Take home saliva kit,ALL,"CHILD, ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-09-14,2022-06-30
COMPLETED,NO,PROCEDURE: Ophthalmologic exam,ALL,"ADULT, OLDER_ADULT",NA,23,NETWORK,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-04-27,2020-07-29
ACTIVE_NOT_RECRUITING,NO,"BIOLOGICAL: CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI ""Chumakov FSC R&D IBP RAS""",ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-07-01,2023-03-01
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: TNX-2110|BIOLOGICAL: TNX-2120|BIOLOGICAL: TNX-2130|BIOLOGICAL: CANDIN|BIOLOGICAL: Diluent,ALL,"ADULT, OLDER_ADULT",PHASE1,90,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-07,2022-08
ACTIVE_NOT_RECRUITING,NO,OTHER: questionnaire,ALL,"ADULT, OLDER_ADULT",NA,1800,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-11-25,2022-12
COMPLETED,NO,DRUG: INO-4800|DEVICE: CELLECTRA® 2000,ALL,"ADULT, OLDER_ADULT",PHASE1,120,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-04-03,2022-02-10
COMPLETED,NO,BIOLOGICAL: AZD1222|BIOLOGICAL: rAd26-S,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,100,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-09-15,2022-03-29
NOT_YET_RECRUITING,NO,BIOLOGICAL: PepGNP-COVID19 (One vaccination)|OTHER: Water for injection (One vaccination)|BIOLOGICAL: PepGNP-COVID19 (Two vaccinations)|OTHER: Water for injection (Two vaccinations),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,110,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-05-23,2024-10-23
COMPLETED,NO,DRUG: Nirmatrelvir/ ritonavir|DRUG: Nirmatrelvir/ritonavir|DRUG: Nirmatrelvir/ritonavir|DRUG: Nirmatrelvir/ ritonavir|DRUG: Nirmatrelvir/ ritonavir,ALL,"ADULT, OLDER_ADULT",PHASE1,15,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-08-31,2022-11-07
COMPLETED,NO,PROCEDURE: appendectomy,ALL,"CHILD, ADULT, OLDER_ADULT",NA,1945,OTHER,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-03-31,2021-10-01
COMPLETED,YES,"BIOLOGICAL: bamlanivimab 7000mg|BIOLOGICAL: BRII-196+BRII-198|BIOLOGICAL: AZD7442 (IV)|BIOLOGICAL: AZD7442 (IM)|DRUG: SNG001|DRUG: Camostat|BIOLOGICAL: BMS-986414 + BMS-986413|BIOLOGICAL: SAB-185 (3,840 Units/kg)|BIOLOGICAL: SAB-185 (10,240 Units/kg)|DRUG: CASIRIVIMAB + IMDEVIMAB|DRUG: Placebo for Bamlanivimab 7000mg|DRUG: Placebo for Bamlanivimab 700mg|DRUG: Placebo for BRII-196+BRII-198|DRUG: Placebo for SNG001|DRUG: Placebo for Camostat|DRUG: Placebo for SAB-185 (low dose)|DRUG: Placebo for BMS-986414 + BMS-986413|DRUG: Placebo for AZD7442 (IV)|DRUG: Placebo for AZD7442 (IM)|DRUG: Placebo for SAB-185 (high dose)|BIOLOGICAL: bamlanivimab 700mg",ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,4044,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-19,2023-06-20
ACTIVE_NOT_RECRUITING,NO,DRUG: Angiotensin converting enzyme inhibitor|DRUG: Angiotensin II Receptor Blockers,ALL,"ADULT, OLDER_ADULT",PHASE3,1155,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-27,2025-12
RECRUITING,NO,BIOLOGICAL: AD17002 + Formulation buffer|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,180,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-12-01,2025-03-31
COMPLETED,NO,BIOLOGICAL: Recombinant Novel Coronavirus vaccine (CHO Cells),ALL,CHILD,NA,240,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-04-29,2022-11-19
COMPLETED,NO,BIOLOGICAL: Convalescent Plasma (anti-SARS-CoV-2 plasma)|BIOLOGICAL: Non-convalescent Plasma (control plasma),ALL,"ADULT, OLDER_ADULT",PHASE2,223,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-21,2020-12-30
COMPLETED,NO,"DRUG: Hydroxychloroquine, Azithromycin|DRUG: Hydroxychloroquine, Doxycycline|DRUG: Hydroxychloroquine, Clindamycin|DRUG: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|DRUG: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|DRUG: Remdesivir|DRUG: Tocilizumab|DRUG: Methylprednisolone|DRUG: Interferon-Alpha2B|DRUG: Losartan|DRUG: Convalescent Serum",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,1800,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-04-11,2020-09-14
RECRUITING,NO,BEHAVIORAL: Heart Rate Variability Biofeedback (HRV-B),ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-24,2024-03-31
RECRUITING,NO,"BIOLOGICAL: COVID-19 mRNA Vaccine (ZSVG-02-O)|BIOLOGICAL: COVID-19 mRNA Vaccine (ZSVG-02-O)|BIOLOGICAL: COVID-19 Vaccine (Vero Cell) ,Inactivated",ALL,"ADULT, OLDER_ADULT",PHASE2,980,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-07-10,2024-10
COMPLETED,YES,BEHAVIORAL: Community health worker engagement,ALL,"ADULT, OLDER_ADULT",NA,56,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-10-05,2023-02-28
COMPLETED,NO,OTHER: SingStrong: Strong lungs through Song,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-29,2021-09-01
COMPLETED,NO,OTHER: Club event,ALL,ADULT,NA,1216,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-09-04,2022-02-26
UNKNOWN,NO,DRUG: Drug: NA-831|COMBINATION_PRODUCT: NA-831 and Atazanavir|COMBINATION_PRODUCT: NA-831and Dexamethasone|COMBINATION_PRODUCT: Atazanavir and Dexamethasone,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,525,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-06-15,2023-12-15
TERMINATED,NO,DRUG: Conestat alfa,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-06,2021-09-15
UNKNOWN,NO,DIAGNOSTIC_TEST: Low-field magnetic resonance imaging|DIAGNOSTIC_TEST: Blood sample,ALL,"CHILD, ADULT",NA,68,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-08-09,2022-01-01
RECRUITING,NO,"BIOLOGICAL: CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI ""Chumakov FSC R&D IBP RAS""|OTHER: The data from volunteers from the control group",ALL,ADULT,PHASE3,29000,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-07-07,2023-12-29
COMPLETED,NO,BIOLOGICAL: Human Amniotic Fluid,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-20,2020-06-09
COMPLETED,NO,DRUG: Enoxaparin Prophylactic Dose|DRUG: Heparin Infusion|DRUG: Heparin SC|DRUG: Enoxaparin/Lovenox Intermediate Dose,ALL,"ADULT, OLDER_ADULT",PHASE4,94,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-05-02,2021-05-12
COMPLETED,NO,OTHER: Educational moral injury video,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-05-31,2021-08-30
UNKNOWN,NO,OTHER: NaCl Solution,ALL,"ADULT, OLDER_ADULT",NA,405,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-23,2020-10-31
UNKNOWN,NO,DRUG: Previfenon®|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,524,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-09-30,2021-10-30
COMPLETED,NO,BEHAVIORAL: Residence-based testing participation pilot (SARS-CoV-2 testing with relaxed social distancing restrictions),ALL,"CHILD, ADULT, OLDER_ADULT",NA,152,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-04-01,2021-07-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: UB-612|BIOLOGICAL: BNT162b2 vaccine|BIOLOGICAL: ChAdOx1-S vaccine|BIOLOGICAL: Sinopharm BIBP,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,944,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-03-16,2023-09
COMPLETED,YES,BIOLOGICAL: Human Amniotic Fluid,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,47,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-28,2023-02-15
RECRUITING,NO,DIAGNOSTIC_TEST: Serological tests will be applied on patients blood sampling,ALL,"ADULT, OLDER_ADULT",NA,550,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-09,2024-04-09
UNKNOWN,NO,DRUG: Tofacitinib,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-10,2020-07-10
ENROLLING_BY_INVITATION,NO,BEHAVIORAL: MY-Skills for Long COVID,ALL,"ADULT, OLDER_ADULT",NA,16,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-02-01,2023-12-30
COMPLETED,NO,OTHER: Virtual Care and Remote Automated Monitoring,ALL,"ADULT, OLDER_ADULT",NA,905,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2020-04-23,2021-06-02
WITHDRAWN,NO,OTHER: Assisting to the event,ALL,ADULT,NA,0,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-05-01,2022-05-01
COMPLETED,NO,BIOLOGICAL: Mesenchymal Stem Cells (MSCs)|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,24,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-05-01,2021-10-28
COMPLETED,NO,DIETARY_SUPPLEMENT: Ayurveda|OTHER: Usual Care,ALL,ADULT,NA,32,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: SUPPORTIVE_CARE,2020-03-06,2020-04-12
RECRUITING,NO,DEVICE: transcutaneous electrical vagal neurostimulation,FEMALE,"ADULT, OLDER_ADULT",NA,45,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-03-22,2025-03-01
COMPLETED,NO,BIOLOGICAL: mRNA-1273.211|BIOLOGICAL: mRNA-1273|BIOLOGICAL: mRNA-1273.617.2|BIOLOGICAL: mRNA-1273.213|BIOLOGICAL: mRNA-1273.529|BIOLOGICAL: mRNA-1273.214|BIOLOGICAL: mRNA-1273.222|BIOLOGICAL: mRNA-1273.815|BIOLOGICAL: mRNA-1273.231,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,5404,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-05-28,2023-11-17
COMPLETED,YES,DRUG: Ivermectin and Doxycycline|DRUG: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE3,400,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-01,2020-09-10
UNKNOWN,NO,"BIOLOGICAL: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)",ALL,"ADULT, OLDER_ADULT",PHASE3,880,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-12-16,2022-10-30
RECRUITING,NO,BIOLOGICAL: SC-Ad6-1|BIOLOGICAL: SC-Ad6-1|BIOLOGICAL: SC-Ad6-1,ALL,ADULT,PHASE1,190,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-06-28,2023-12-31
UNKNOWN,NO,COMBINATION_PRODUCT: Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device),ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-04-14,2022-04
COMPLETED,NO,DRUG: Betadine© bucal 100 mg/ml|DRUG: Oximen® 3%|DRUG: Clorhexidine Dental PHB©|DRUG: Vitis Xtra Forte©|DRUG: Distilled Water,ALL,"ADULT, OLDER_ADULT",NA,160,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-06-15,2021-09-30
RECRUITING,NO,DIAGNOSTIC_TEST: Low-field magnetic resonance imaging|DIAGNOSTIC_TEST: Nailfold capillaroscopy|DIAGNOSTIC_TEST: Spiroergometry|DIAGNOSTIC_TEST: Realtime deformability cytometry,ALL,CHILD,NA,111,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-07-08,2023-03-31
UNKNOWN,NO,DRUG: P2Et (Caesalpinia spinosa extract)|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2020-09-30,2021-11-30
UNKNOWN,NO,BIOLOGICAL: UC-MSCs|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",NA,48,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-20,2022-02-15
RECRUITING,NO,BIOLOGICAL: SARS-CoV-2|BIOLOGICAL: Adenovirus (AdV)|BIOLOGICAL: Rhinovirus|BIOLOGICAL: No Intervention,ALL,CHILD,NA,200,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-10-28,2025-04-28
COMPLETED,NO,OTHER: blood sample,ALL,"ADULT, OLDER_ADULT",NA,18,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-05-20,2021-08-27
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Nanocovax|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,13000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-06-07,2022-12-07
NOT_YET_RECRUITING,NO,DRUG: Jaktinib hydrochloride tablets|DRUG: Jaktinib hydrochloride tablets|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,168,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-12,2024-06
TERMINATED,YES,DRUG: Hydroxychloroquine|OTHER: Placebo|RADIATION: Radiation therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,4,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-05-07,2021-04-21
TERMINATED,NO,BIOLOGICAL: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients,ALL,"ADULT, OLDER_ADULT",NA,9,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-15,2022-10-27
WITHDRAWN,NO,DRUG: Hydroxychloroquine and azithromycin treatment|OTHER: conventional management of patients,FEMALE,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-01,2021-04-01
COMPLETED,NO,DRUG: anti-SARS-CoV-2 IgY|DRUG: Placebo,ALL,ADULT,PHASE1,48,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-09-18,2020-12-14
UNKNOWN,NO,BIOLOGICAL: convalescent plasma,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,410,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-25,2020-12-31
TERMINATED,NO,BIOLOGICAL: Dose Finding Phase (MTD)|BIOLOGICAL: Partially HLA-matched SARS-CoVSTs|OTHER: Routine care (no SARS-CoVSTs),ALL,"ADULT, OLDER_ADULT",PHASE1,4,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-04,2021-10-12
WITHDRAWN,NO,BIOLOGICAL: GX-19N|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-10,2023-10
COMPLETED,NO,DRUG: Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate|DRUG: Colgate Peroxyl® -1.5% Hydrogen peroxide|OTHER: Oral-B® Gum & Enamel Care -Cetylpyridinium chloride|OTHER: No rinsing,ALL,"ADULT, OLDER_ADULT",NA,54,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: OTHER,2021-05-19,2021-10-25
COMPLETED,NO,OTHER: Antigenic tests (on saliva samples)|OTHER: Individual electronic sensor port|OTHER: Atmospheric measurements of CO2,ALL,"ADULT, OLDER_ADULT",NA,210,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-10-14,2022-01-14
UNKNOWN,NO,COMBINATION_PRODUCT: PurWet|COMBINATION_PRODUCT: FurFat|COMBINATION_PRODUCT: PurApo|COMBINATION_PRODUCT: PurPhl|COMBINATION_PRODUCT: PurClo|COMBINATION_PRODUCT: PurInf|COMBINATION_PRODUCT: Smoliv,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,2000,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2022-10-01
RECRUITING,NO,OTHER: Non-bloody dental procedures (control group)|PROCEDURE: Bloody dental procedures (study group),ALL,"CHILD, ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-20,2025-10-20
UNKNOWN,NO,DRUG: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2),ALL,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-07,2021-10
RECRUITING,NO,DIAGNOSTIC_TEST: Aptitude Medical Systems Metrix COVID/Flu Test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,1000,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-11-20,2024-05-14
COMPLETED,NO,DIETARY_SUPPLEMENT: Viusid and Asbrip,ALL,"ADULT, OLDER_ADULT",PHASE2,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-05-04,2020-10-01
COMPLETED,NO,DRUG: PF-07304814,ALL,ADULT,PHASE1,5,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-07,2021-12-10
COMPLETED,YES,DRUG: L-ascorbic acid,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,FED,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-16,2020-10-13
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Physiotherapy,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-04,2023-11-30
UNKNOWN,NO,DIAGNOSTIC_TEST: Resp-Aer-Meter|DIAGNOSTIC_TEST: Spirometry|DIAGNOSTIC_TEST: Qualitative and quantitative virus PCR of respiratory secretions in patients with high aerosol concentrations,ALL,"CHILD, ADULT, OLDER_ADULT",NA,525,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-01-18,2021-12-31
COMPLETED,NO,DIAGNOSTIC_TEST: Cognitive assessment|DIAGNOSTIC_TEST: Imaging|DIAGNOSTIC_TEST: Routine care|OTHER: Psychiatric evaluation|OTHER: Psychiatric evaluation,ALL,"ADULT, OLDER_ADULT",NA,76,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-08-23,2023-09-27
TERMINATED,NO,BIOLOGICAL: Convalescent plasma,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,86,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-08,2020-09-30
WITHDRAWN,NO,BIOLOGICAL: COVAC-1|BIOLOGICAL: Saline Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-06,2023-10
UNKNOWN,NO,BEHAVIORAL: Telepsychoeducation with personalized videos|BEHAVIORAL: Telepsychoeducation without personalized videos,ALL,"CHILD, ADULT, OLDER_ADULT",NA,2200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-11-05,2021-07-20
RECRUITING,NO,DRUG: Testofen|DRUG: Microcrystalline cellulose,ALL,"ADULT, OLDER_ADULT",PHASE3,150,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-10-25,2025-11-01
RECRUITING,NO,BIOLOGICAL: SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated,ALL,"ADULT, OLDER_ADULT",PHASE2,600,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-31,2023-09-30
COMPLETED,NO,OTHER: EEG based protocol for deep sedation,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-04,2021-09-23
UNKNOWN,NO,DIAGNOSTIC_TEST: SARS-CoV-2 screening by molecular biology|DIAGNOSTIC_TEST: Serological screening,ALL,"ADULT, OLDER_ADULT",NA,450,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-02-15,2022-09-30
ACTIVE_NOT_RECRUITING,NO,OTHER: Exercise|BEHAVIORAL: Psychological and Behaviour Change Support|OTHER: Nutrition,ALL,"ADULT, OLDER_ADULT",NA,1100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-04,2024-03-31
COMPLETED,YES,DEVICE: LifeSignals Biosensor 1AX*|OTHER: Standard of Care,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-09-01,2021-12-10
COMPLETED,NO,OTHER: Sampling by venipuncture (and eventually by nasopharyngeal swab),ALL,"ADULT, OLDER_ADULT",NA,187,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-08-27,2022-03-07
COMPLETED,NO,DRUG: PJS-539 Dose 1|DRUG: PJS-539 Dose 2|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,153,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-09-25,2022-03-04
COMPLETED,YES,DRUG: Placebo|DRUG: Nicotinamide riboside,ALL,"ADULT, OLDER_ADULT",PHASE2,28,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-06-11,2022-01-03
NOT_YET_RECRUITING,NO,DRUG: Manzi Guben granules,ALL,"ADULT, OLDER_ADULT",NA,360,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2023-06-01,2026-05-31
RECRUITING,NO,PROCEDURE: Lymph node aspiration / Blood sampling,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-07-05,2023-09
UNKNOWN,NO,DRUG: Hydroxychloroquine,ALL,ADULT,PHASE2|PHASE3,500,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-08-31,2021-12-31
NOT_YET_RECRUITING,NO,OTHER: Acupuncture,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-11,2023-11
TERMINATED,YES,DRUG: Placebo|DRUG: Ruxolitinib,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,211,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-05-24,2021-02-26
UNKNOWN,NO,DRUG: Hydroxychloroquine|DRUG: Remdesivir|OTHER: (Standard of Care) SoC,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,700,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-28,2020-11
RECRUITING,NO,DIAGNOSTIC_TEST: Sky Medical™ Rapid Antigen Test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,200,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-02-22,2023-01-11
COMPLETED,NO,DRUG: Chloroquine phosphate,ALL,"ADULT, OLDER_ADULT",PHASE2,10,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-07,2020-09-10
UNKNOWN,NO,DIAGNOSTIC_TEST: Lung impedance technique,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-28,2021-04-28
COMPLETED,NO,DRUG: ABBV-47D11|DRUG: Placebo for ABBV-47D11|DRUG: ABBV-2B04|DRUG: Placebo for ABBV-2B04,ALL,"ADULT, OLDER_ADULT",PHASE1,25,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-10,2021-08-24
COMPLETED,NO,"DEVICE: Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS)",FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-01,2023-01-06
COMPLETED,NO,"DIAGNOSTIC_TEST: COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)",ALL,"CHILD, ADULT, OLDER_ADULT",NA,500,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-07-12,2020-11-30
COMPLETED,NO,DIAGNOSTIC_TEST: Breath Biopsy Analysis,ALL,"CHILD, ADULT, OLDER_ADULT",NA,2558,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-11-12,2023-01-18
UNKNOWN,NO,BIOLOGICAL: Standard dosage inactivated vaccine|BIOLOGICAL: Double dosage inactivated vaccine,ALL,"ADULT, OLDER_ADULT",PHASE4,240,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-12-22,2023-03-10
ACTIVE_NOT_RECRUITING,NO,DRUG: Methylene Blue|DRUG: Control Test,ALL,"ADULT, OLDER_ADULT",PHASE2,64,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-05,2023-12-31
ACTIVE_NOT_RECRUITING,NO,OTHER: Cognitive Behavioral Therapy Group,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2022-05-10,2023-11-30
WITHDRAWN,NO,OTHER: Measurement of oxygen saturation,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-05-02,2022-05-02
UNKNOWN,NO,OTHER: CHEST CT SCAN,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-06-08,2022-12-24
UNKNOWN,NO,DRUG: Ozone plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,35,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-04,2022-12-21
NOT_YET_RECRUITING,NO,OTHER: Community Health Worker,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2024-03,2025-03
UNKNOWN,NO,BIOLOGICAL: GLS-5310|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,183,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-12-23,2022-12-31
COMPLETED,NO,DRUG: Vortioxetine|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-09-16,2023-02-22
COMPLETED,NO,BIOLOGICAL: AZD1222|BIOLOGICAL: AZD2816,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,2848,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-06-27,2022-08-02
COMPLETED,NO,DIAGNOSTIC_TEST: Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-06-30,2021-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: VYD222|DRUG: Normal saline,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,790,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-09-08,2024-11
COMPLETED,NO,BIOLOGICAL: COVID19 vaccine|BIOLOGICAL: Saline,ALL,"ADULT, OLDER_ADULT",PHASE1,40,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-06-30,2021-04-14
NOT_YET_RECRUITING,NO,BIOLOGICAL: Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine|BIOLOGICAL: Inactivated SARS-CoV-2 vaccine coadministered with MMR|BIOLOGICAL: Inactivated SARS-CoV-2 vaccine administered alone,ALL,CHILD,PHASE4,540,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-08,2024-12
NOT_YET_RECRUITING,NO,DRUG: Galactomannan|DRUG: PLACEBO,ALL,"ADULT, OLDER_ADULT",PHASE3,408,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-04-01,2022-09-25
ACTIVE_NOT_RECRUITING,NO,DRUG: nirmatrelvir|DRUG: ritonavir|DRUG: placebo for nirmatrelvir,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,436,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-10-19,2024-02-15
WITHDRAWN,NO,DRUG: Tofacitinib|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07-06,2020-10-18
COMPLETED,NO,BIOLOGICAL: DZIF-10c|BIOLOGICAL: DZIF-10c|DRUG: Placebo|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,45,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-14,2021-09-23
COMPLETED,NO,DIAGNOSTIC_TEST: GlowTest COVID-19 Antigen Home Test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,33,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-12-06,2021-12-17
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg|BIOLOGICAL: Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg|BIOLOGICAL: SARS-Cov-2 Vaccine Inactivated,ALL,"ADULT, OLDER_ADULT",PHASE2,150,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-11-10,2023-01-28
ENROLLING_BY_INVITATION,NO,OTHER: BrainHQ/Active Comparator Activity|OTHER: BrainHQ|OTHER: PASC CoRE|DEVICE: tDCS-active|DEVICE: tDCS-sham,ALL,"ADULT, OLDER_ADULT",NA,315,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-09-01,2024-12
RECRUITING,NO,BEHAVIORAL: AIR + Mindfulness|BEHAVIORAL: Relaxation condition,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-09-01,2024-03-31
COMPLETED,NO,DRUG: Ergoferon|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1057,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-10-06,2022-04-14
UNKNOWN,NO,OTHER: Treadmill Exercise|OTHER: Concentrated Oxygen|OTHER: Concentrated Air,ALL,ADULT,NA,24,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-01-21,2022-01-20
RECRUITING,NO,DRUG: DPA-714 PET/MRI,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,60,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-11-10,2026-06-01
NOT_YET_RECRUITING,NO,DRUG: Liraglutide Pen Injector [Saxenda]|OTHER: Medication Diary,ALL,ADULT,EARLY_PHASE1,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-04-01,2026-10-01
RECRUITING,NO,DRUG: Tianeptine|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,140,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-02-17,2027-10-31
UNKNOWN,NO,DEVICE: Patient Status Engine,ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-10-12,2021-04
UNKNOWN,NO,DRUG: Hydroxychloroquine Sulfate|DRUG: Bromhexine 8 MG,ALL,ADULT,EARLY_PHASE1,214,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-02-01,2021-06-30
COMPLETED,NO,"OTHER: hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint",ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-04-27,2021-01-11
UNKNOWN,NO,RADIATION: FDG-PET/CT,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-01-04,2022-01-04
COMPLETED,NO,BIOLOGICAL: Recombinant novel coronavirus vaccine (CHO cells),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,300,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-01-10,2022-12-06
COMPLETED,NO,BIOLOGICAL: COVI-VAC,ALL,"ADULT, OLDER_ADULT",PHASE1,20,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-04-14,2022-12-22
WITHDRAWN,NO,BIOLOGICAL: EQ001|BIOLOGICAL: EQ001 Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11,2021-06
RECRUITING,NO,DRUG: Shenlingcao Oral Liquid,ALL,"ADULT, OLDER_ADULT",PHASE2,152,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-30,2024-02-01
COMPLETED,NO,OTHER: community health worker support|OTHER: care as usual,ALL,"ADULT, OLDER_ADULT",NA,140,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: SUPPORTIVE_CARE,2020-05-21,2020-10-30
COMPLETED,YES,DRUG: Homeopathic Medication|OTHER: Placebo,ALL,ADULT,PHASE3,77,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-09-15,2022-04-22
RECRUITING,NO,BEHAVIORAL: NexJ Connected Wellness|OTHER: Usual Care,ALL,"ADULT, OLDER_ADULT",NA,152,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-02,2024-09
UNKNOWN,NO,DRUG: Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA]|DRUG: Baricitinib + dexamethasone|DRUG: Dexamethasone,ALL,"ADULT, OLDER_ADULT",PHASE3,2193,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-04,2022-11-30
COMPLETED,YES,OTHER: Placebo|DRUG: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE3,1062,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-02-21,2020-05-21
UNKNOWN,NO,"BIOLOGICAL: SARS-CoV-2 Vaccine (Vero Cells), Inactivated|BIOLOGICAL: Placebo",ALL,"ADULT, OLDER_ADULT",PHASE3,28000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-05,2022-11
TERMINATED,YES,DRUG: PLN-74809|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,6,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-22,2021-08-02
UNKNOWN,NO,BIOLOGICAL: Cell therapy protocol 1|BIOLOGICAL: Cell therapy protocol 2,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,60,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-05,2020-12-10
TERMINATED,NO,DRUG: BMS-986253,ALL,"ADULT, OLDER_ADULT",PHASE2,43,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-16,2021-03-01
COMPLETED,NO,DEVICE: Nasal Photodisinfection|DEVICE: Sham Comparator: Control,ALL,"ADULT, OLDER_ADULT",NA,100,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-12-20,2022-05-30
COMPLETED,YES,DEVICE: Saliva Assay,ALL,"CHILD, ADULT, OLDER_ADULT",NA,464,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-09-29,2021-03-31
COMPLETED,NO,BIOLOGICAL: BNT162b2|OTHER: Placebo|BIOLOGICAL: BNT162b2 OMI|BIOLOGICAL: Combination BNT162b2 and BNT162b2 OMI|BIOLOGICAL: Combination (Bivalent) BNT162b2 and BNT162b2 OMI,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,16385,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-07-01,2023-05-25
COMPLETED,NO,DEVICE: CogniFit's CCT Post COVID-19,ALL,"ADULT, OLDER_ADULT",NA,73,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-01,2022-02-28
COMPLETED,NO,DIAGNOSTIC_TEST: Take home saliva kits,ALL,"CHILD, ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-09-14,2022-06-30
RECRUITING,NO,DRUG: Trimodulin|DRUG: Placebo (human albumin 1%),ALL,"ADULT, OLDER_ADULT",PHASE3,390,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-12-22,2025-08-31
COMPLETED,NO,PROCEDURE: Therapeutic Plasma Exchange (TPE),ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-25,2021-01-20
COMPLETED,NO,DEVICE: Auricular transcutaneous vagus nerve stimulation,ALL,ADULT,NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-10-27,2023-01-04
COMPLETED,NO,DRUG: GX-03|DRUG: Petrolatum ointment,ALL,"ADULT, OLDER_ADULT",PHASE2,85,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-21,2021-05-30
COMPLETED,NO,DRUG: ADM03820|OTHER: Placebo,ALL,ADULT,PHASE1,48,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-04,2023-10-06
UNKNOWN,NO,BIOLOGICAL: IN-B009 (Low-dose)|BIOLOGICAL: IN-B009 (High-dose),ALL,ADULT,PHASE1,40,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-09-16,2023-02
COMPLETED,NO,BIOLOGICAL: CoronaVac|BIOLOGICAL: Turkovac,ALL,ADULT,PHASE2,222,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-07-12,2022-06-06
SUSPENDED,NO,DRUG: Fluvoxamine|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-01-16,2021-07-31
COMPLETED,NO,DRUG: Brazilian Green Propolis Extract (EPP-AF)|OTHER: Standard care,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-06-02,2020-08-30
COMPLETED,NO,OTHER: Standard interface|DEVICE: Double-Trunk Mask,ALL,"ADULT, OLDER_ADULT",NA,12,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-04-09,2020-05-01
WITHDRAWN,NO,DRUG: Azithromycin|DRUG: Hydroxychloroquine|DRUG: Lopinavir 200Mg/Ritonavir 50Mg Tab,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-07,2021-04-19
COMPLETED,YES,BIOLOGICAL: Dupilumab|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-05-25,2023-04-18
WITHDRAWN,NO,OTHER: Standard of care (SOC)|DRUG: Hydroxychloroquine|DRUG: Association of diltiazem and niclosamide,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-05,2023-05
COMPLETED,NO,OTHER: Virtual Care at Home,ALL,"ADULT, OLDER_ADULT",NA,817,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-17,2022-02-04
COMPLETED,NO,OTHER: tele-monitoring,ALL,"ADULT, OLDER_ADULT",NA,56,OTHER,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-01-01,2021-09-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Olokizumab|DRUG: Standard therapy,ALL,"ADULT, OLDER_ADULT",PHASE3,198,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-07-08,2023-04
COMPLETED,NO,DRUG: Honey|DRUG: Nigella Sativa / Black Cumin|DRUG: Placebos,ALL,"ADULT, OLDER_ADULT",PHASE3,313,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-30,2020-08-30
COMPLETED,NO,DIAGNOSTIC_TEST: Rapid Antigen Test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,592,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-11-23,2021-04-28
COMPLETED,NO,DRUG: XC221|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,274,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-06-26,2022-11-14
ACTIVE_NOT_RECRUITING,NO,DRUG: Placebo administration|DIAGNOSTIC_TEST: Confirm SARS-CoV-2 infection|PROCEDURE: Physical Examination|PROCEDURE: Vital Signs|DIAGNOSTIC_TEST: Hematology blood test|DIAGNOSTIC_TEST: Biochemistry blood test|OTHER: NEWS score|DIAGNOSTIC_TEST: PK test|DIAGNOSTIC_TEST: blood test for inflammatory markers|DIAGNOSTIC_TEST: D-dimer test|OTHER: VAS scale|DIAGNOSTIC_TEST: Urine pregnancy test for women of childbearing potential|PROCEDURE: ECG|OTHER: COVID-19-Impact on Quality of Life Questionnaire|DRUG: CimetrA-1|DRUG: CimetrA-2,ALL,"ADULT, OLDER_ADULT",PHASE3,252,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-11,2023-04
ACTIVE_NOT_RECRUITING,NO,OTHER: Functional Rehabilitation|OTHER: Neuromuscular Electrical Stimulation,ALL,"ADULT, OLDER_ADULT",NA,88,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-05-01,2022-12-01
COMPLETED,NO,BIOLOGICAL: NVX-CoV2373|BIOLOGICAL: BBIBP-CorV vaccine,ALL,"ADULT, OLDER_ADULT",PHASE3,1000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-03-18,2023-05-04
UNKNOWN,NO,RADIATION: Lung Low Dose Radiation,ALL,OLDER_ADULT,NA,41,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-01,2021-12-31
TERMINATED,NO,DRUG: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation,ALL,"ADULT, OLDER_ADULT",PHASE2,13,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2017-10-24,2021-06-30
COMPLETED,NO,DRUG: AZVUDINE|DRUG: AZVUDINE placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,312,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-15,2022-07-27
NOT_YET_RECRUITING,NO,"BIOLOGICAL: BIBP (CNBG, Sinopharm) WIV|BIOLOGICAL: CanSinoBIO|BIOLOGICAL: AstraZeneca ChAdOx",ALL,"ADULT, OLDER_ADULT",PHASE2,1680,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-01,2024-06-30
TERMINATED,NO,DRUG: Candesartan Cilexetil|DRUG: Repagermanium|DRUG: Candesartan Placebo|DRUG: Repagermanium Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,49,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-07,2023-01-28
ACTIVE_NOT_RECRUITING,NO,"BIOLOGICAL: Moderna mRNA-1273|BIOLOGICAL: BNT162b2|BIOLOGICAL: Ad26.COV2.S|DRUG: Continue IS (MMF or MPA)|DRUG: Continue IS (MTX)|BIOLOGICAL: Continue IS (B cell depletion therapy)|BIOLOGICAL: Monovalent [B.1.351] CoV2 preS dTM-AS03|DRUG: Withhold IS (MMF or MPA)|DRUG: Withhold IS (MTX)|DRUG: Withhold IS (B cell depletion therapy)|BIOLOGICAL: Moderna mRNA-1273, Bivalent|BIOLOGICAL: BNT162b2, Bivalent",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,257,NIH,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-08-13,2024-04-22
UNKNOWN,NO,DIAGNOSTIC_TEST: ELISA POCT vs RT-PCR,ALL,"ADULT, OLDER_ADULT",NA,1500,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-02-18,2021-12-30
TERMINATED,NO,DRUG: Colchicine|DRUG: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE2,116,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-27,2021-08-16
COMPLETED,NO,BIOLOGICAL: ChAdOx1-nCov-19 (Astra-Zeneca)|BIOLOGICAL: SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine,ALL,"ADULT, OLDER_ADULT",NA,499,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-07-06,2022-05-18
WITHDRAWN,NO,DRUG: Chloroquine Phosphate Tablets,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-03-10,2021-02-16
RECRUITING,NO,BEHAVIORAL: COVID Prevention Program (CPP),ALL,"ADULT, OLDER_ADULT",NA,256,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-04-11,2025-10-31
COMPLETED,YES,BEHAVIORAL: Biobehavioral Tele-rehabilitation Sessions,ALL,"ADULT, OLDER_ADULT",NA,49,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-12-11,2021-12-27
COMPLETED,NO,DRUG: NVX-Cov2373,ALL,ADULT,PHASE3,911,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-07-11,2022-09-01
RECRUITING,NO,DEVICE: Experimental group/ Active HD-tDCS|DEVICE: Control Group / Sham Group,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-09-14,2022-07-14
WITHDRAWN,NO,DRUG: Ivermectin|OTHER: Prophylaxis,ALL,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10,2022-06
COMPLETED,NO,DRUG: CORVax|DRUG: IL-12 plasmid|DEVICE: Cliniporator,ALL,"ADULT, OLDER_ADULT",PHASE1,16,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-12-30,2022-12-28
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: 202-CoV low adjuvant dose|BIOLOGICAL: 202-CoV low antigen dose|BIOLOGICAL: 202-CoV standard dose|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,72,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-07-12,2023-06
NOT_YET_RECRUITING,NO,BIOLOGICAL: 30μg dose of LYB002V14|BIOLOGICAL: 60μg dose of LYB002V14|BIOLOGICAL: placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,120,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-12-26,2024-12-31
RECRUITING,NO,DRUG: nirmatrelvir|DRUG: ritonavir,FEMALE,ADULT,PHASE1,8,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-12-12,2023-12-15
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: LYB002V14|BIOLOGICAL: LYB002V14A|BIOLOGICAL: LYB002CA,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,210,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-04-25,2023-11-30
COMPLETED,NO,DRUG: Hydroxychloroquine|DRUG: Lopinavir / Ritonavir|DRUG: Interferon Beta-1A|DRUG: Interferon Beta-1B,ALL,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-09,2020-04-27
COMPLETED,YES,DRUG: sodium pyruvate nasal spray,ALL,ADULT,PHASE2|PHASE3,22,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-27,2022-03-07
RECRUITING,NO,DEVICE: Transcranial Direct Current Therapy (tDCS),ALL,"CHILD, ADULT, OLDER_ADULT",NA,27,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-04-01,2023-07
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: VXCO-100|BIOLOGICAL: COVID-19 mRNA vaccine,ALL,"ADULT, OLDER_ADULT",PHASE1,130,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2023-08-04,2024-08-31
COMPLETED,NO,BEHAVIORAL: Occupational Therapy,ALL,CHILD,NA,52,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-12-13,2021-03-30
COMPLETED,NO,OTHER: Respiratory Training|OTHER: Aerobic training,ALL,ADULT,NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-07-02,2022-10-30
TERMINATED,NO,DRUG: Aviptadil 67μg|DRUG: Placebo 0.9% NaCl solution,ALL,"ADULT, OLDER_ADULT",PHASE2,83,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-05-18,2023-06-14
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|BIOLOGICAL: Saline placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,400,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-05-30,2021-12-30
TERMINATED,YES,DRUG: Camostat,ALL,"ADULT, OLDER_ADULT",PHASE2,34,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-23,2022-03-03
RECRUITING,NO,DRUG: Tozorakimab|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,2902,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-12-13,2025-03-17
NOT_YET_RECRUITING,NO,OTHER: Cardiopulmonary rehabilitation|OTHER: Health education,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-10-01,2024-12-31
UNKNOWN,NO,COMBINATION_PRODUCT: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid,ALL,ADULT,PHASE1,24,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-07,2021-10
COMPLETED,NO,DIETARY_SUPPLEMENT: Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C),ALL,"ADULT, OLDER_ADULT",NA,32,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2021-04-02,2022-02-14
UNKNOWN,NO,DRUG: Hydroxychloroquine|DRUG: Placebo oral tablet,ALL,ADULT,NA,374,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-05-15,2020-10-15
COMPLETED,YES,DRUG: Hydroxychloroquine|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1312,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-03-17,2020-05-20
UNKNOWN,NO,BEHAVIORAL: The PREPARE program,ALL,OLDER_ADULT,NA,372,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-06-15,2021-09-15
TERMINATED,NO,OTHER: Questionnaire Administration|BIOLOGICAL: Sotrovimab|PROCEDURE: Biospecimen Collection,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-01-25,2023-01-10
COMPLETED,NO,BEHAVIORAL: Intervention for TECC Model,ALL,"ADULT, OLDER_ADULT",NA,31,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-05-04,2022-06-30
COMPLETED,NO,DIAGNOSTIC_TEST: Psychological and Physiological Assessments,ALL,ADULT,NA,192,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-12-15,2023-06-30
COMPLETED,NO,BIOLOGICAL: mRNA-1273,ALL,"ADULT, OLDER_ADULT",PHASE2,19,NIH,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-04-28,2023-05-25
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03|OTHER: Normal saline,ALL,"ADULT, OLDER_ADULT",PHASE2,770,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-01-24,2023-11
UNKNOWN,NO,DRUG: Senicapoc,ALL,"ADULT, OLDER_ADULT",PHASE2,46,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-24,2021-12-31
TERMINATED,NO,BIOLOGICAL: TY027|BIOLOGICAL: TY027|OTHER: 0.9% saline,ALL,"ADULT, OLDER_ADULT",PHASE3,17,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-04,2022-03-04
WITHDRAWN,NO,DRUG: Stabilized hypochlorous acid|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-02-15,2021-08-15
TERMINATED,NO,DRUG: Zavegepant (BHV-3500)|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,44,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-25,2022-04-29
NOT_YET_RECRUITING,NO,DRUG: Baricitinib 4 MG|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,550,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-03-04,2029-12-30
RECRUITING,NO,BEHAVIORAL: ECA-ACE Vaccination Promotion Intervention,ALL,"ADULT, OLDER_ADULT",NA,600,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-12-12,2025-12-01
RECRUITING,NO,BIOLOGICAL: Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine|BIOLOGICAL: Cohort 2 RNA VACCINE MCTI CIMATEC HDT(HDT-301) vaccine|BIOLOGICAL: Cohort 3 VACCINE RNA MCTI CIMATEC HDT(HDT-301) vaccine|BIOLOGICAL: Placebo,ALL,ADULT,PHASE1,90,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-01-13,2022-10
TERMINATED,NO,DRUG: Triazavirin (Riamilovir)|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,74,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-08,2021-04-20
UNKNOWN,NO,DRUG: Atorvastatin 40 Mg Oral Tablet|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,220,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-14,2022-04
COMPLETED,NO,DRUG: IMU-838|DRUG: Oseltamivir,ALL,"ADULT, OLDER_ADULT",PHASE2,38,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-15,2022-09-21
COMPLETED,NO,BIOLOGICAL: Convalescent Plasma|OTHER: Standard of Care,ALL,"ADULT, OLDER_ADULT",PHASE3,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-14,2020-12-15
UNKNOWN,NO,DRUG: Favipiravir|DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE4,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-20,2020-05-05
ENROLLING_BY_INVITATION,NO,DRUG: 18F-αvβ6-BP,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-05-01,2024-06
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Narrative Intervention for Long COVID-19 (NICO),ALL,"ADULT, OLDER_ADULT",NA,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-10-11,2024-02-08
RECRUITING,NO,DRUG: SA55 nasal spray,ALL,"ADULT, OLDER_ADULT",PHASE1,80,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-05-31,2023-10-31
UNKNOWN,NO,BIOLOGICAL: Sample,MALE,ADULT,NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-10-02,2022-02
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: Pulmonary function testing,ALL,"ADULT, OLDER_ADULT",NA,140,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-05-18,2025-08-18
RECRUITING,NO,OTHER: NeuroFlex (computerized gamified tasks),ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-04-07,2024-12-01
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 VLP Vaccine-Wuhan|BIOLOGICAL: SARS-CoV-2 VLP Vaccine-Alpha (British) variant|BIOLOGICAL: SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant,ALL,ADULT,PHASE2,349,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-06-26,2022-01-16
COMPLETED,NO,BEHAVIORAL: Positive COVID Test Result - Hypothetical Scenario|BEHAVIORAL: Negative COVID Test Result - Hypothetical Scenario|BEHAVIORAL: Unavailable COVID Test Result - Hypothetical Scenario,ALL,"ADULT, OLDER_ADULT",NA,1400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2020-07-23,2020-07-29
COMPLETED,NO,BIOLOGICAL: BNT162b2,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,124,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-10-15,2023-07-23
COMPLETED,NO,BIOLOGICAL: BBV154 Vaccine|BIOLOGICAL: Placebo,ALL,ADULT,PHASE1,175,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-03-01,2021-11-30
COMPLETED,YES,DRUG: Placebo|DRUG: fostamatinib,ALL,"ADULT, OLDER_ADULT",PHASE2,59,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-08,2021-04-30
ACTIVE_NOT_RECRUITING,NO,DRUG: stellate ganglion block with 0.5% bupivacaine,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-01-03,2023-12-30
WITHDRAWN,NO,BIOLOGICAL: allogeneic marrow stromal cells (MSCs),ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-25,2024-05-01
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: BNT162b2,ALL,"ADULT, OLDER_ADULT",PHASE4,300,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-10-18,2024-12-31
UNKNOWN,NO,DIAGNOSTIC_TEST: Standard screening strategy|DIAGNOSTIC_TEST: New screening strategy,ALL,"CHILD, ADULT, OLDER_ADULT",NA,230,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-02,2020-03
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: mRNA-CR-04 vaccine 10μg|BIOLOGICAL: mRNA-CR-04 vaccine 30μg|BIOLOGICAL: mRNA-CR-04 vaccine 100μg|DRUG: Placebo,ALL,ADULT,PHASE1,72,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-08-07,2024-10-15
UNKNOWN,NO,BIOLOGICAL: Placebo|BIOLOGICAL: Inactivated vaccine booster|BIOLOGICAL: mRNA vaccine booster|DRUG: Viral vector vaccine booster,ALL,"ADULT, OLDER_ADULT",PHASE2,534,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-07-08,2022-06-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Baricitinib (janus kinase inhibitor)|DRUG: Remdesivir (antiviral) + barictinib (janus kinase inhibitor)|DRUG: Remdesivir (antiviral)|DRUG: Tocilizumab (interleukin 6 inhibitor),ALL,"ADULT, OLDER_ADULT",PHASE2,363,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-17,2024-04
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: Antibody testing for SARS-CoV-2 IgG|DIAGNOSTIC_TEST: Testing for SARS-CoV-2 RNA|DIAGNOSTIC_TEST: Testing for SARS-CoV-2 IgM/IgG,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,420,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-03-01,2024-08
UNKNOWN,NO,OTHER: Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors,ALL,"ADULT, OLDER_ADULT",NA,700,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-09,2020-12-01
TERMINATED,NO,BIOLOGICAL: Remestemcel-L|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,223,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-30,2022-01-02
COMPLETED,NO,BIOLOGICAL: sotrovimab|OTHER: Placebo to Biologic|BIOLOGICAL: sotrovimab|OTHER: Placebo to Biologic,ALL,"ADULT, OLDER_ADULT",PHASE1,48,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2021-07-06,2021-12-07
COMPLETED,NO,DIETARY_SUPPLEMENT: palmitoylethanolamide co-ultramicronized with antioxidant flavonoid luteolin (PEA-LUT)|DIETARY_SUPPLEMENT: Placebo,ALL,"ADULT, OLDER_ADULT",NA,34,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-08-16,2022-03-15
WITHDRAWN,NO,BIOLOGICAL: AV-COVID-19,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2023-01,2024-01
TERMINATED,NO,DRUG: Hyperbaric oxygen,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,34,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-03,2022-12-01
COMPLETED,NO,BIOLOGICAL: Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)|BIOLOGICAL: SARS-CoV-2 beta variant RBD mRNA vaccine|OTHER: Normal Saline,ALL,ADULT,PHASE1,76,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-04-05,2023-04-19
COMPLETED,NO,DRUG: BromAc,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-27,2022-08-25
RECRUITING,NO,DRUG: Placebo|DRUG: Anakinra 149 MG/ML Prefilled Syringe [Kineret],ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,182,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-09-06,2025-08
COMPLETED,NO,OTHER: NEURO +|OTHER: NEURO -,ALL,"ADULT, OLDER_ADULT",NA,99,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-04-02,2021-04-02
COMPLETED,NO,BIOLOGICAL: MVA-SARS-2-ST,ALL,ADULT,PHASE1,43,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-07-16,2022-11-08
COMPLETED,NO,"BIOLOGICAL: IIBR-100, low dose (prime)|BIOLOGICAL: IIBR-100 medium dose (prime)|BIOLOGICAL: IIBR-100 high-dose (prime)|BIOLOGICAL: IIBR-100 low-dose (prime-boost)|OTHER: Saline Placebo (single)|OTHER: Saline Placebo (double)|BIOLOGICAL: IIBR-100 medium-dose (prime-boost)|BIOLOGICAL: IIBR-100 high-dose (prime-boost)|BIOLOGICAL: IIBR-100 top-dose (prime-boost)",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,843,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-10-28,2022-10-03
COMPLETED,NO,BIOLOGICAL: TURCOVAC|BIOLOGICAL: CoronaVac,ALL,ADULT,PHASE3,1290,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-06-21,2023-04-27
UNKNOWN,NO,DEVICE: Vielight RX Plus,ALL,"ADULT, OLDER_ADULT",NA,295,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-02,2021-09-30
COMPLETED,NO,BIOLOGICAL: MVC-COV1901(S protein with adjuvant)|BIOLOGICAL: MVC-COV1901(Saline),ALL,"ADULT, OLDER_ADULT",PHASE2,3854,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-12-30,2021-10-29
NOT_YET_RECRUITING,NO,OTHER: Aerobic plus strength group|OTHER: Aerobic group,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-30,2023-08-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)|BIOLOGICAL: VidPrevtyn® Beta vaccine (Sanofi/GSK),ALL,"ADULT, OLDER_ADULT",PHASE3,248,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-05-16,2024-07-12
UNKNOWN,NO,"BIOLOGICAL: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)",ALL,"ADULT, OLDER_ADULT",PHASE3,432,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-12-18,2022-10-30
NOT_YET_RECRUITING,NO,BIOLOGICAL: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|BIOLOGICAL: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|BIOLOGICAL: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|BIOLOGICAL: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose,ALL,CHILD,PHASE1,120,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2024-01-31,2025-05-16
COMPLETED,NO,OTHER: Closed face shield with Surgical face mask use|OTHER: Surgical face mask use only,ALL,"ADULT, OLDER_ADULT",NA,233,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-01-16,2021-03-04
UNKNOWN,NO,BIOLOGICAL: LYB001|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,100,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-12,2023-04
COMPLETED,NO,DRUG: Evolocumab|DRUG: Saline solution,ALL,"ADULT, OLDER_ADULT",PHASE3,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-01,2022-05-17
TERMINATED,YES,OTHER: Standard of care|DRUG: Hydroxychloroquine|DRUG: Azithromycin,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,11,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-17,2020-06-26
WITHDRAWN,NO,DRUG: Hydroxychloroquine sulfate &Azithromycin|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-05,2021-04
UNKNOWN,NO,BIOLOGICAL: COVAX+PPV23;COVAX+IIV4|BIOLOGICAL: COVAX only (1st and 2nd dose)|BIOLOGICAL: PPV23 for the 1st dose and IIV4 for the 2nd dose,ALL,"ADULT, OLDER_ADULT",PHASE4,1404,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-05-06,2021-12
COMPLETED,YES,DRUG: Brequinar|OTHER: Standard of Care,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,25,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-19,2021-01-12
UNKNOWN,NO,"DRUG: Wharton's jelly derived Mesenchymal stem cells.|DRUG: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-01-13,2022-04
NOT_YET_RECRUITING,NO,DRUG: Low-Dose Naltrexone|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,160,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-12,2024-06
COMPLETED,NO,PROCEDURE: Blood sample,ALL,"CHILD, ADULT, OLDER_ADULT",NA,3541,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-07-15,2021-09-24
COMPLETED,NO,DRUG: Vitamin C|DRUG: Control,ALL,"ADULT, OLDER_ADULT",PHASE3,392,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-14,2022-12-06
TERMINATED,NO,BIOLOGICAL: PLX-PAD|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,66,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-01,2023-06-07
COMPLETED,YES,DRUG: Fluvoxamine|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,670,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-22,2021-09-28
UNKNOWN,NO,DRUG: hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,93,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-10-27,2021-01-31
COMPLETED,NO,OTHER: Tele-rehabillitation|OTHER: Prescribed Exercise Program,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-20,2023-08-01
COMPLETED,YES,DRUG: Raloxifene|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,61,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-01-22,2021-06-12
UNKNOWN,NO,DRUG: Tocilizumab,ALL,"ADULT, OLDER_ADULT",PHASE4,500,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-08,2021-05-08
WITHDRAWN,NO,DRUG: Tazemetostat,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01,2023-09-21
COMPLETED,NO,DEVICE: The standard Macintosh laryngoscope|DEVICE: The Vie Scope laryngoscope,ALL,"ADULT, OLDER_ADULT",NA,35,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-01-20,2020-02-25
RECRUITING,NO,DRUG: unfractionated heparin|DRUG: 0.9%sodium chloride,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,1100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-01-30,2026-06-01
UNKNOWN,NO,DRUG: Oral 25-Hydroxyvitamin D3,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1500,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-04-14,2021-03-15
COMPLETED,NO,DIETARY_SUPPLEMENT: 5-ALA-Phosphate + SFC (5-ALA + SFC),ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-15,2021-10-28
COMPLETED,NO,DRUG: Loratadine|DRUG: Famotidine,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,214,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-13,2022-07-30
UNKNOWN,NO,DRUG: Hydroxychloroquine|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1700,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-04-27,2021-06-01
COMPLETED,YES,DRUG: Interferon beta-1a|OTHER: Placebo|DRUG: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE3,969,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-05,2020-12-21
COMPLETED,NO,BEHAVIORAL: Non-Deceptive Placebo,ALL,ADULT,NA,64,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-02-04,2021-05-05
COMPLETED,NO,DEVICE: CPAP treatment,ALL,"ADULT, OLDER_ADULT",NA,68,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-01,2022-12-15
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 vaccine (inactivated)|BIOLOGICAL: Placebo,ALL,ADULT,PHASE3,1620,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-08-10,2021-08-31
COMPLETED,NO,BIOLOGICAL: Tetravalent influenza virus lysis vaccine|BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cell) group,ALL,"ADULT, OLDER_ADULT",PHASE3,299,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-09-03,2022-03-04
COMPLETED,NO,BIOLOGICAL: Recombinant SARS-CoV-2 Ad5 vectored vaccine|BIOLOGICAL: Inactive SARS-CoV-2 vaccine (Vero cell),ALL,ADULT,PHASE4,300,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-05-25,2021-12-25
COMPLETED,NO,DIAGNOSTIC_TEST: Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-11-02,2021-10-12
RECRUITING,NO,BIOLOGICAL: Full dose of Ad26.COV2. 5x10^10vp|BIOLOGICAL: Half dose of Ad26.COV2. 2.5x10^10vp|BIOLOGICAL: Full dose of Ad26.COV2. 5x10^10vp,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,690,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-12-20,2024-12
TERMINATED,YES,DRUG: USB002|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,21,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-07-27,2022-05-10
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: SARS-CoV-2 DNA Vaccine (ICCOV),ALL,"ADULT, OLDER_ADULT",PHASE2,31,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-06-15,2024-05-31
TERMINATED,NO,BIOLOGICAL: COVID-eVax|DEVICE: Cliniporator® and EPSGun,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,68,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2021-02-25,2021-12-07
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|BIOLOGICAL: Saline placebo,ALL,ADULT,PHASE3,16876,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-08-07,2022-03-10
UNKNOWN,NO,DRUG: Amantadine Hydrochloride|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,200,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-15,2022-05-31
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: ACT,ALL,"ADULT, OLDER_ADULT",NA,21,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-01,2023-02-15
COMPLETED,YES,DRUG: AZD1656|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,170,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-12,2021-05-12
COMPLETED,NO,OTHER: Concert|DIAGNOSTIC_TEST: Rapid nasopharyngeal antigen test for Sars-Cov-2|DIAGNOSTIC_TEST: Saliva Sample,ALL,ADULT,NA,6678,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-05-26,2021-06-13
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: 1x10^9 vp AZD1222|BIOLOGICAL: 5x10^9 vp AZD1222|BIOLOGICAL: 1x10^10 vp AZD1222,ALL,ADULT,PHASE1,28,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-10-10,2024-06
UNKNOWN,NO,BIOLOGICAL: Vaccinated with polio vaccine (IPV),ALL,"ADULT, OLDER_ADULT",PHASE4,300,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-11-15,2022-06-12
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: XBB.1.5 Vaccine (Booster)|BIOLOGICAL: XBB.1.5 Vaccine (single dose),ALL,ADULT,PHASE2|PHASE3,660,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2023-09-07,2024-07-31
COMPLETED,NO,DIETARY_SUPPLEMENT: Group A: oropharygeal spray and immunostimulant emulsion|DIETARY_SUPPLEMENT: Group D:Placebo oropharyngeal spray + Placebo taken PO,ALL,ADULT,NA,152,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-03-18,2021-07-05
COMPLETED,NO,BIOLOGICAL: TY027|OTHER: 0.9% Saline,ALL,ADULT,PHASE1,32,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-09,2021-01-20
UNKNOWN,NO,BIOLOGICAL: Mesenchymal stromal cells|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-09-15,2022-02
ACTIVE_NOT_RECRUITING,NO,OTHER: SARS-Cov-2 infection,ALL,"ADULT, OLDER_ADULT",NA,145,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-08,2024-11-12
COMPLETED,NO,DRUG: RAY1216|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1359,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-11-12,2023-03-28
COMPLETED,NO,BEHAVIORAL: Post-hospitalization nutritional monitoring,ALL,OLDER_ADULT,NA,34,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-07-27,2021-07-01
NOT_YET_RECRUITING,NO,DRUG: GamCoviMab,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03,2023-12
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Pain Neuroscience Education (PNE)+ Therapeutic Exercise (TE)|BEHAVIORAL: Active Comparator: Usual treatment,ALL,"ADULT, OLDER_ADULT",NA,89,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-02-20,2023-09-30
RECRUITING,NO,DRUG: Ibudilast|DRUG: Pentoxifylline|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-31,2025-12
RECRUITING,NO,DEVICE: Home-based telehealth exercise training program|BEHAVIORAL: Education and self-exercise,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-12,2024-10-08
COMPLETED,YES,DEVICE: Rapid SARS-CoV-2 Antigen Test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,99,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-10-07,2021-10-27
COMPLETED,NO,BIOLOGICAL: VBI-2902a|BIOLOGICAL: Placebo|BIOLOGICAL: VBI-2905a,ALL,ADULT,PHASE1,114,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-03-15,2022-11-14
COMPLETED,NO,OTHER: Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19,ALL,"ADULT, OLDER_ADULT",NA,377,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-04-16,2022-12-31
COMPLETED,NO,BIOLOGICAL: AdimrSC-2f,ALL,ADULT,PHASE1,68,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-08-24,2021-05-06
UNKNOWN,NO,BIOLOGICAL: AntiSARS-CoV-2 Serum|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,618,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-05,2022-05
COMPLETED,YES,BIOLOGICAL: CVnCoV Vaccine|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,2357,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-12-23,2022-06-08
COMPLETED,NO,DRUG: Carvacrol|OTHER: Control group,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,600,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-08-01,2020-12-15
TERMINATED,YES,DIAGNOSTIC_TEST: Quidel Sofia SARS Antigen FIA,ALL,"ADULT, OLDER_ADULT",NA,117,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-11-13,2021-03-10
COMPLETED,NO,DRUG: Povidone-Iodine,ALL,"ADULT, OLDER_ADULT",PHASE2,24,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-01,2020-10-23
TERMINATED,YES,BIOLOGICAL: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,12,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-18,2022-02-16
COMPLETED,NO,DRUG: Somatropin,ALL,"ADULT, OLDER_ADULT",PHASE3,83,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-08-06,2023-10-04
TERMINATED,NO,BIOLOGICAL: Convalescent anti-SARS-CoV-2 plasma|OTHER: Infusion placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,147,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-01,2021-03-16
COMPLETED,YES,BIOLOGICAL: TAK-019|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,200,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-02-12,2022-03-28
RECRUITING,NO,DRUG: Azvudine|DRUG: Paxlovid group,ALL,"ADULT, OLDER_ADULT",NA,540,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-18,2023-04-30
TERMINATED,NO,DRUG: PF-06650833|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,7,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-27,2021-10-06
UNKNOWN,NO,DRUG: FNC+Standard of Care|DRUG: FNC dummy tablet+Standard of Care,ALL,"ADULT, OLDER_ADULT",NA,342,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-12,2020-08-12
RECRUITING,NO,DRUG: FB2001|DRUG: FB2001 placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1336,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-04,2023-12
COMPLETED,NO,BIOLOGICAL: GRT-R910 10 mcg Dose (after AZ)|BIOLOGICAL: GRT-R910 30 mcg Dose (after AZ)|BIOLOGICAL: GRT-R910 10 mcg Dose (After Adenovirus based vaccine)|BIOLOGICAL: GRT-R910 10 mcg Dose (after mRNA based vaccine),ALL,"ADULT, OLDER_ADULT",PHASE1,40,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-09-16,2023-05-26
COMPLETED,NO,DRUG: Azithromycin 500 milligram (mg) oral Tablet|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,74,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-04-27,2021-06-15
WITHDRAWN,NO,DRUG: MRx-4DP0004|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08,2021-01
UNKNOWN,NO,DRUG: Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5),ALL,"ADULT, OLDER_ADULT",PHASE2,348,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-07-30,2021-09-06
WITHDRAWN,NO,DEVICE: CRP-apheresis,ALL,"ADULT, OLDER_ADULT",NA,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-05,2023-03-31
SUSPENDED,NO,DRUG: nirmatrelvir|DRUG: ritonavir,FEMALE,ADULT,PHASE1,49,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-22,2025-07-01
COMPLETED,NO,DRUG: Azithromycin Capsule,ALL,"ADULT, OLDER_ADULT",PHASE3,298,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-03,2021-04-20
COMPLETED,NO,BIOLOGICAL: LD Vehicle-GNP|BIOLOGICAL: LD PepGNP-Covid19|BIOLOGICAL: HD Vehicle-GNP|BIOLOGICAL: HD PepGNP-Covid19,ALL,ADULT,PHASE1,26,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-01-10,2022-09-15
UNKNOWN,NO,DRUG: Exosome-MSC Intravenous injection|DRUG: Placebo Intravenous Injection|DRUG: COVID-19 Standard Treatment,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-07-01,2022-12-30
COMPLETED,NO,DRUG: Hydroxychloroquine|DRUG: Placebo,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE3,129,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-13,2021-10-31
COMPLETED,NO,DIAGNOSTIC_TEST: Biochemistry blood test|DIAGNOSTIC_TEST: Hematology blood test|DIAGNOSTIC_TEST: D-Dimer test (coagulation)|DIAGNOSTIC_TEST: Inflammatory markers|DIAGNOSTIC_TEST: Vital signs|DIAGNOSTIC_TEST: VAS scale|DIAGNOSTIC_TEST: WHO Ordinal Score|DIAGNOSTIC_TEST: COVID-19-Related Symptoms assessment|DIAGNOSTIC_TEST: COVID-19-Impact on Quality-of-Life Questionnaire|DIAGNOSTIC_TEST: POST- COVID-19 Functional Status Scale:|DIAGNOSTIC_TEST: Pregnancy test|DIAGNOSTIC_TEST: Physical examination|DIAGNOSTIC_TEST: PK parameters|DIAGNOSTIC_TEST: SARS-CoV-2 test (PCR)|DIAGNOSTIC_TEST: ECG|DRUG: Treatment administration (twice a day),ALL,"ADULT, OLDER_ADULT",PHASE2,240,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-10-11,2023-03-01
COMPLETED,NO,OTHER: COVID-19 patients,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-08-07,2022-07-31
UNKNOWN,NO,BIOLOGICAL: IN01 vaccine,ALL,"ADULT, OLDER_ADULT",PHASE1,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-01,2022-06
UNKNOWN,NO,DRUG: Hydroxychloroquine 200 Mg Oral Tablet|DRUG: Azithromycin 250 MG,ALL,"ADULT, OLDER_ADULT",PHASE3,200,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-07,2021-03
COMPLETED,NO,DRUG: PF-07321332/ritonavir|DRUG: PF-07321332/ritonavir|DRUG: PF-07321332/ritonavir|DRUG: PF-07321332/ritonavir,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-03-10,2022-05-19
WITHDRAWN,NO,DRUG: Hypertonic Saturated Saline Mouth Rinse Active Arm|OTHER: Placebo Plain Water Mouth Rinse Arm,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-07,2021-12
COMPLETED,NO,DRUG: Methylprednisolone,ALL,"ADULT, OLDER_ADULT",NA,86,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-14,2020-04-15
COMPLETED,NO,DRUG: N-acetylcysteine,ALL,"ADULT, OLDER_ADULT",PHASE3,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-03-09,2022-04-01
NOT_YET_RECRUITING,NO,DRUG: N-acetylcysteine|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-03-31,2025-02-01
COMPLETED,NO,DRUG: FB2001|DRUG: FB2001 Placebo,ALL,ADULT,PHASE1,88,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-17,2022-08-12
WITHDRAWN,NO,BIOLOGICAL: Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2022-09-21
TERMINATED,NO,DRUG: Bovine Lactoferrin|DIETARY_SUPPLEMENT: Maltodextrin,ALL,ADULT,PHASE2,209,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-10-17,2021-02-10
UNKNOWN,NO,"OTHER: Oxygen-ozone therapy, probiotic supplementation and Standard of care|DIETARY_SUPPLEMENT: SivoMixx (200 billion)|DRUG: Azithromycin|DRUG: hydroxychloroquine",ALL,"ADULT, OLDER_ADULT",PHASE2,152,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-03-26,2020-12-31
TERMINATED,NO,DRUG: Anti-SARS-CoV-2 mAb,ALL,"ADULT, OLDER_ADULT",PHASE4,46,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-12,2022-01-31
RECRUITING,NO,BEHAVIORAL: Home office|BEHAVIORAL: Office,ALL,"ADULT, OLDER_ADULT",NA,2000,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2022-03-14,2023-09-30
RECRUITING,NO,DIETARY_SUPPLEMENT: VSL#3®|DIETARY_SUPPLEMENT: Placebo,ALL,"ADULT, OLDER_ADULT",NA,96,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-11-03,2023-11-03
COMPLETED,NO,DIAGNOSTIC_TEST: Sona Saliva C-19 Rapid Self-test,ALL,"ADULT, OLDER_ADULT",NA,500,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-04-19,2022-05-19
ACTIVE_NOT_RECRUITING,NO,DRUG: NVX-CoV2515|DRUG: NVX-Cov2373|DRUG: NVX-CoV2373 + NVX-CoV2515|DRUG: NVX-CoV2540|DRUG: NVX-CoV2373 + NVX-CoV2540,ALL,ADULT,PHASE3,1340,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-05-25,2024-02-11
COMPLETED,NO,DRUG: DAS181,ALL,"ADULT, OLDER_ADULT",NA,4,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-06,2020-04-30
RECRUITING,NO,OTHER: Acupuncture|OTHER: Active Control,ALL,"ADULT, OLDER_ADULT",PHASE2,160,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-19,2025-07-19
ACTIVE_NOT_RECRUITING,NO,DRUG: Temelimab 54mg/kg|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,200,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-29,2024-06-30
COMPLETED,NO,DRUG: Huashi Baidu granule|DRUG: compound pholcodine oral solution,ALL,"CHILD, ADULT",NA,108,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-01,2022-06-30
COMPLETED,NO,DRUG: Vit D,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-06-15,2021-04-10
UNKNOWN,NO,DRUG: Imatinib tablets|DRUG: Baricitinib Oral Tablet|OTHER: Supportive tratment,ALL,"ADULT, OLDER_ADULT",PHASE2,168,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-07,2021-09
UNKNOWN,NO,PROCEDURE: Plasma exchange and convalescent plasma,ALL,"ADULT, OLDER_ADULT",NA,220,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-16,2022-06-30
UNKNOWN,NO,BIOLOGICAL: The Pfizer mRNA-based BNT162b2 vaccine,ALL,"ADULT, OLDER_ADULT",PHASE4,504,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-10,2022-07
COMPLETED,NO,DRUG: TXA127|DRUG: TRV027|DRUG: Placebo|DRUG: Fostamatinib,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,871,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-07-15,2023-12-31
COMPLETED,NO,PROCEDURE: Human biological samples,ALL,"CHILD, ADULT, OLDER_ADULT",NA,245,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2020-03-23,2021-09-30
COMPLETED,NO,DRUG: FT516,ALL,"ADULT, OLDER_ADULT",PHASE1,5,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-14,2021-02-18
RECRUITING,NO,DRUG: Nirmatrelvir/ritonavir|DRUG: Placebo,ALL,ADULT,PHASE3,2000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-05-12,2026-04
TERMINATED,YES,DRUG: Oral-B Mouth Sore mouthwash|DRUG: Crest Pro-Health Multi-Protection mouthwash|DRUG: CloSYS Ultra Sensitive Rinse mouthwash|DRUG: Distilled water|DRUG: Listerine Zero Mouthwash Product,ALL,"ADULT, OLDER_ADULT",PHASE2,54,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-03-31,2022-09-10
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: mRNA-1083|BIOLOGICAL: Placebo|BIOLOGICAL: Influenza Vaccine|BIOLOGICAL: COVID-19 Vaccine,ALL,"ADULT, OLDER_ADULT",PHASE3,8075,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-10-19,2024-05-21
COMPLETED,NO,"BIOLOGICAL: SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)|DRUG: Normal Saline",ALL,OLDER_ADULT,EARLY_PHASE1,217,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2020-09-01,2023-05-19
TERMINATED,YES,DRUG: casirivimab+imdevimab,ALL,CHILD,PHASE2,7,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-13,2022-06-01
NOT_YET_RECRUITING,NO,BIOLOGICAL: Gam-COVID-Vac|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,400,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-03-08,2023-12-30
UNKNOWN,NO,DEVICE: Radius PPG Tetherless Pulse Oximetry (Masimo)|DEVICE: usual monitoring,ALL,"CHILD, ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-09-22,2021-11-15
COMPLETED,NO,DEVICE: Human IgG1 anti-SARS-CoV-2 antibody cocktail|DEVICE: Placebo,ALL,ADULT,NA,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-04-20,2022-07-01
ENROLLING_BY_INVITATION,NO,DRUG: Ebselen|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-27,2023-12-31
RECRUITING,NO,OTHER: Aerobic Exercise Training|OTHER: Education,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,90,NIH,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-01-22,2026-12-31
RECRUITING,NO,"BEHAVIORAL: Complementary and Integrative Medicine online intervention, routine care and book|BEHAVIORAL: Routine care and book",ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-04,2025-12
WITHDRAWN,NO,DRUG: Tadalafil Pill,ALL,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-20,2020-04-20
COMPLETED,NO,DRUG: Colchicine|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",NA,299,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07-14,2020-12-10
SUSPENDED,NO,DRUG: Hydroxychloroquine Sulfate|DRUG: Azithromycin Tablets,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,400,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-23,2023-06-30
COMPLETED,NO,BIOLOGICAL: Anti-SARS-CoV-2 Human Convalescent Plasma,ALL,"CHILD, ADULT",PHASE1,14,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-28,2021-12-13
TERMINATED,YES,BIOLOGICAL: COVID-19 convalescent plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,71,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-16,2020-11-28
COMPLETED,NO,PROCEDURE: Conventional oxygen therapy|PROCEDURE: High flow nasal cannula,ALL,"ADULT, OLDER_ADULT",NA,199,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-11,2021-02-10
WITHDRAWN,NO,COMBINATION_PRODUCT: 150 ppm Nitric Oxide delivered through LungFit Delivery System|COMBINATION_PRODUCT: 80 ppm Nitric Oxide delivered through LungFit Delivery System,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-15,2020-12-15
TERMINATED,NO,DRUG: ABX464|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,509,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07-01,2021-04-16
COMPLETED,NO,DRUG: Angiotensin-(1-7)|DRUG: Placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,112,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-05,2021-11-01
NOT_YET_RECRUITING,NO,BIOLOGICAL: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,100,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-09,2024-11
COMPLETED,NO,DRUG: Lopinavir/ritonavir|DRUG: Ribavirin|DRUG: Interferon Beta-1B,ALL,"ADULT, OLDER_ADULT",PHASE2,127,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-10,2020-03-31
RECRUITING,NO,BEHAVIORAL: COVID-19 Individual Awareness and Education.|BEHAVIORAL: COVID-19 Community Outreach & Health Promotion.|BEHAVIORAL: COVID-19 Individual Health Education & Linkages to Medical and Supportive Services.|BIOLOGICAL: Pop-up community vaccination sites,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,1054,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-07-16,2026-01-31
COMPLETED,NO,DRUG: CNM-ZnAg|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,296,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-01,2022-10-20
UNKNOWN,NO,BIOLOGICAL: Blood sample|BIOLOGICAL: Serum tube collection,ALL,"ADULT, OLDER_ADULT",NA,800,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-06-05,2020-12-15
COMPLETED,YES,DRUG: Ivermectin|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1459,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2022-02-16,2022-10-30
NOT_YET_RECRUITING,NO,BEHAVIORAL: Balance Acceptance and Commitment Therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,196,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-03,2025-09
UNKNOWN,NO,BIOLOGICAL: Normoxic Allogenic UCMSC|OTHER: Normal saline solution,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,42,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-17,2021-11
COMPLETED,NO,DRUG: Methylprednisolone sodium succinate 10 mg/kg intravenously|BIOLOGICAL: Human normal immunoglobulin (IVIg),ALL,"CHILD, ADULT",PHASE3,76,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-23,2022-11-20
NOT_YET_RECRUITING,NO,BEHAVIORAL: Mind Body Intervention #1,ALL,"ADULT, OLDER_ADULT",NA,180,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-10,2026-01
COMPLETED,NO,BIOLOGICAL: Multiple doses of anti-SARS-CoV-2 Convalescent Plasma,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-06,2020-10-14
COMPLETED,NO,DRUG: Convalescent plasma,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-29,2021-03-30
RECRUITING,NO,BIOLOGICAL: LVRNA009|OTHER: 0.9%NaCl,ALL,"ADULT, OLDER_ADULT",PHASE3,34000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-01-30,2025-12
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: BNT162b5 Bivalent (WT/OMI BA.2)|BIOLOGICAL: BNT162b2 Bivalent (WT/OMI BA.1)|BIOLOGICAL: BNT162b2 Bivalent (WT/OMI BA.4/BA.5)|BIOLOGICAL: BNT162b5 Bivalent (Original/OMI BA.4/BA.5)|BIOLOGICAL: BNT162b6 Bivalent (Original/OMI BA.4/BA.5)|BIOLOGICAL: BNT162b7 Bivalent (Original/OMI BA.4/BA.5)|BIOLOGICAL: BNT162b7 Monovalent (OMI BA.4/BA.5),ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,1424,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-07-26,2024-03-19
COMPLETED,NO,OTHER: Pulmonary and Motor Rehabilitation,ALL,"ADULT, OLDER_ADULT",NA,96,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-28,2020-12-31
COMPLETED,NO,BIOLOGICAL: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|BIOLOGICAL: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|BIOLOGICAL: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|BIOLOGICAL: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|BIOLOGICAL: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|BIOLOGICAL: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|BIOLOGICAL: Placebo on a 0- and 28-day schedule|BIOLOGICAL: Placebo on a 0- and 14-day schedule,ALL,ADULT,PHASE1|PHASE2,942,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-05-15,2021-08-31
COMPLETED,YES,DRUG: Brequinar|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,115,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-19,2021-04-28
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: COVAC-1|BIOLOGICAL: Saline Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,47,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-01-31,2024-05-30
COMPLETED,NO,"OTHER: Inhalation of N-acetylcysteine|OTHER: Inhalation of 5% sodium chloride|OTHER: Inhalation of 8,4% sodium bicarbonate",ALL,"ADULT, OLDER_ADULT",NA,175,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-10-01,2021-07-29
COMPLETED,NO,BIOLOGICAL: AG0301-COVID19|BIOLOGICAL: AG0301-COVID19,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,30,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-06-29,2021-08-12
COMPLETED,NO,OTHER: Colgate Periogard® mouthwash|OTHER: Colgate Peroxyl® mouthwash|OTHER: Colgate Total® Mouthwash|OTHER: Toothpaste with sodium monofluorophosphate|OTHER: Toothpaste with sodium fluoride and zinc|OTHER: Toothpaste with tin fluoride,ALL,"ADULT, OLDER_ADULT",NA,202,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-07-14,2021-09-30
COMPLETED,NO,DRUG: Rosuvastatin|DRUG: Nirmatrelvir/ritonavir,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-06-09,2023-08-10
WITHDRAWN,NO,DRUG: Pentoxifylline|DRUG: Placebo,ALL,ADULT,PHASE1|PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-11-13,2022-12-30
COMPLETED,NO,"BIOLOGICAL: SARS-CoV-2 rS - Phase 1|BIOLOGICAL: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1|OTHER: Normal saline solution (NSS), Placebo - Phase 1|OTHER: Normal saline solution (NSS), Placebo - Phase 2|BIOLOGICAL: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1|OTHER: Normal saline solution (NSS), Placebo, Day 21 - Phase 1|BIOLOGICAL: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,1419,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-05-25,2022-06-01
TERMINATED,NO,DRUG: Pegylated Interferon-α2b|OTHER: Standard of Care,ALL,"ADULT, OLDER_ADULT",PHASE2,7,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-11,2021-06-21
TERMINATED,YES,BIOLOGICAL: Convalescent plasma transfusion,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,109,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-06,2020-09-30
COMPLETED,NO,DIETARY_SUPPLEMENT: Dietary Supplement: Experimental|DIETARY_SUPPLEMENT: Dietary Supplement: Placebo,ALL,"ADULT, OLDER_ADULT",NA,32,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2022-10-01,2024-01-15
UNKNOWN,NO,DRUG: Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP,ALL,"ADULT, OLDER_ADULT",PHASE4,40,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-04-01,2021-07-01
RECRUITING,NO,DRUG: DAOIB,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-27,2025-02
ACTIVE_NOT_RECRUITING,NO,"BIOLOGICAL: 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated|BIOLOGICAL: 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated|BIOLOGICAL: 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated|BIOLOGICAL: 2 doses of vaccine",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,4400,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-04-29,2024-03-31
WITHDRAWN,NO,OTHER: Active tDCS|OTHER: Sham tDCS,ALL,ADULT,NA,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-02-01,2024-09-01
UNKNOWN,NO,BIOLOGICAL: Convalescent Plasma from COVID-19 donors,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,100,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-07,2021-04-06
UNKNOWN,NO,DRUG: Enoxaparin|DRUG: Methylprednisolone|DRUG: unfractionated heparin,ALL,"ADULT, OLDER_ADULT",PHASE3,210,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-25,2021-07-30
RECRUITING,NO,DIETARY_SUPPLEMENT: Bioarginina C,ALL,ADULT,NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-06-18,2022-11-18
TERMINATED,YES,DRUG: INO-4800|DEVICE: CELLECTRA® 2000|DRUG: Placebo|DEVICE: CELLECTRA® 2000,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1307,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-11-30,2022-09-13
TERMINATED,NO,DRUG: GIGA-2050,ALL,"ADULT, OLDER_ADULT",PHASE1,3,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-24,2022-01-11
COMPLETED,NO,DRUG: Piclidenoson|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,6,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-06,2022-04-21
COMPLETED,NO,DRUG: Trimodulin|OTHER: Placebo (human albumin 1%),ALL,"ADULT, OLDER_ADULT",PHASE2,166,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-06,2021-06-29
TERMINATED,NO,DRUG: Metoprolol Succinate,ALL,ADULT,EARLY_PHASE1,14,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-23,2023-09-12
UNKNOWN,NO,DRUG: Umifenovir|DRUG: Interferon-β 1a|DRUG: Lopinavir / Ritonavir|DRUG: Single Dose of Hydroxychloroquine|DRUG: Standards of Care,ALL,"ADULT, OLDER_ADULT",PHASE4,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-15,2020-04-24
COMPLETED,NO,DIAGNOSTIC_TEST: COVID-19 PCR and Serology,ALL,"ADULT, OLDER_ADULT",NA,111,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-05-13,2020-10-04
COMPLETED,NO,OTHER: Doppler Echo,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-04-24,2021-06-24
RECRUITING,NO,OTHER: MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS)|OTHER: Chalder Fatigue Scale|OTHER: Health Questionnaire (EQ-5D-5L)|OTHER: Hamilton Depression Rating Scale,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-12-09,2023-12-08
COMPLETED,NO,DRUG: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,26,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-27,2021-12-30
COMPLETED,NO,DIAGNOSTIC_TEST: saliva sample combined to an anterior nare self-swabbing (Self-samples)|DIAGNOSTIC_TEST: saliva sample (Self-sample)|OTHER: Survey of SARS-COV-19 knowledge|OTHER: Survey of acceptability of the different self-samples.,ALL,"CHILD, ADULT, OLDER_ADULT",NA,10000,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-02-22,2021-02-28
ACTIVE_NOT_RECRUITING,NO,DRUG: rSIFN-co Nasal Spray|DRUG: rSIFN-co Nasal Spray|DRUG: Placebo Nasal Spray|DRUG: Placebo Nasal Spray,ALL,"ADULT, OLDER_ADULT",PHASE2,188,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2022-07-01,2024-07-28
COMPLETED,NO,DRUG: XAV-19|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,416,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-01,2021-08-19
COMPLETED,NO,DRUG: Favipiravir|DRUG: Favipiravir|DRUG: Remdesivir,ALL,"ADULT, OLDER_ADULT",PHASE3,217,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-11,2021-12-30
COMPLETED,NO,BIOLOGICAL: Covigenix VAX-001 placebo|BIOLOGICAL: Covigenix VAX-001,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,268,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-04-07,2023-12-06
COMPLETED,YES,BIOLOGICAL: BNT162b2|OTHER: Placebo|BIOLOGICAL: Seasonal Inactivated Influenza Vaccine,ALL,ADULT,PHASE3,1134,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-04-20,2022-10-05
UNKNOWN,NO,DRUG: Prasugrel Hydrochloride 10 MG Oral Tablet|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,128,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-07,2021-01
COMPLETED,NO,BIOLOGICAL: VB10.2129|BIOLOGICAL: VB10.2210,ALL,ADULT,PHASE1|PHASE2,68,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-10-27,2023-05-30
COMPLETED,NO,DIAGNOSTIC_TEST: Anti-SARS-CoV2 Serology,ALL,"ADULT, OLDER_ADULT",NA,389,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-11-05,2021-03-15
COMPLETED,NO,DEVICE: LUS Twelve area|DEVICE: LUS Fourteen area,ALL,"ADULT, OLDER_ADULT",NA,59,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: DIAGNOSTIC,2021-01-01,2021-03-05
COMPLETED,NO,DIAGNOSTIC_TEST: Breath biopsy sampling using the ReCIVA Breath Sampler,ALL,ADULT,NA,50,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-09-22,2021-12-30
COMPLETED,NO,DRUG: L-ascorbic acid|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-18,2022-06-10
COMPLETED,NO,OTHER: PTSD evaluation of emergency room staff 9 and 12 months after the end of second lockdown in France during COvid-19 pandemic,ALL,"ADULT, OLDER_ADULT",NA,71,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-10-12,2022-01-16
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: mRNA-1273|BIOLOGICAL: Placebo|BIOLOGICAL: mRNA-1273.214,ALL,CHILD,PHASE2|PHASE3,11950,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-03-15,2024-04-05
COMPLETED,NO,OTHER: Collection of samples,ALL,"ADULT, OLDER_ADULT",NA,17,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-06-16,2022-01-18
WITHDRAWN,NO,DRUG: Hidroxicloroquina|DRUG: Control group,ALL,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-04-06,2021-08-27
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 rS/Matrix M1-Adjuvant|OTHER: Placebo|BIOLOGICAL: Licensed seasonal influenza vaccine,ALL,"ADULT, OLDER_ADULT",PHASE3,15138,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-09-28,2022-03-29
RECRUITING,NO,"OTHER: Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.",ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-11-16,2022-11
NOT_YET_RECRUITING,NO,PROCEDURE: Stellate Ganglion Block|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,44,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-01-15,2026-05-15
UNKNOWN,NO,BEHAVIORAL: Trial-Based Cognitive Therapy|BEHAVIORAL: Mindfulness-Based Health Promotion|BEHAVIORAL: Positive psychotherapy,ALL,ADULT,NA,135,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-23,2021-11-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: BCG Vaccine|BIOLOGICAL: Placebo Vaccine,ALL,"ADULT, OLDER_ADULT",PHASE4,1800,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-04-20,2023-05
COMPLETED,YES,DRUG: Dornase Alfa Inhalation Solution,ALL,"ADULT, OLDER_ADULT",PHASE3,30,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-06-19,2020-12-31
TERMINATED,NO,BIOLOGICAL: RAPA-501-Allo off-the-shelf Therapy of COVID-19|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,1,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-30,2021-09-13
COMPLETED,YES,DRUG: Antroquinonol|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,124,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-15,2021-12-23
WITHDRAWN,NO,DRUG: HLX70|OTHER: Placebo,ALL,ADULT,PHASE1,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2020-12-09,2021-09-18
UNKNOWN,NO,OTHER: Telerehabilitation,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-06-12,2023-06-12
COMPLETED,NO,BIOLOGICAL: INO-4800|DEVICE: CELLECTRA® 2000|OTHER: Saline-sodium citrate (SSC) buffer,ALL,ADULT,PHASE1|PHASE2,79,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-15,2022-05-25
ENROLLING_BY_INVITATION,NO,DRUG: Fisetin|DRUG: Placebo,ALL,OLDER_ADULT,PHASE2,150,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-04-29,2025-11-30
UNKNOWN,NO,DRUG: ASC09F+Oseltamivir|DRUG: Ritonavir+Oseltamivir|DRUG: Oseltamivir,ALL,ADULT,PHASE3,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-02-01,2020-07-01
COMPLETED,YES,BIOLOGICAL: pathogen reduced SARS-CoV-2 convalescent plasma|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,974,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-24,2021-08-06
COMPLETED,YES,BIOLOGICAL: Convalescent plasma,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-04,2020-08-01
COMPLETED,YES,DRUG: Theophylline Powder|DRUG: Placebo Comparator,ALL,"ADULT, OLDER_ADULT",PHASE2,51,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-15,2021-12-30
NOT_YET_RECRUITING,NO,OTHER: COVIDEx,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-12,2025-12
COMPLETED,NO,BIOLOGICAL: IBIO123|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,123,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-02-22,2023-06-27
COMPLETED,NO,"DIAGNOSTIC_TEST: Standard Q COVID-19 Ag - test, produced by SD Biosensor INC.",ALL,"ADULT, OLDER_ADULT",NA,4697,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-12-26,2021-03-25
COMPLETED,NO,DEVICE: GRIP Electronic Diagnostic Chip|DIAGNOSTIC_TEST: Laboratory-based nucleic acid amplification tests (NAATs),ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-02-01,2023-04-30
WITHDRAWN,NO,OTHER: Concert,ALL,ADULT,NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-06,2021-07
ACTIVE_NOT_RECRUITING,NO,DRUG: Nitric Oxide|DEVICE: Nasal spray with isotonic saline,ALL,"ADULT, OLDER_ADULT",PHASE3,1389,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-11-20,2024-04-30
COMPLETED,NO,DRUG: Ofatumumab|BIOLOGICAL: mRNA COVID-19 vaccine|DRUG: interferon or glatiramer acetate,ALL,ADULT,PHASE4,24,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-10,2023-04-14
WITHDRAWN,NO,DRUG: EP-7041 Injection,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10,2025-05
RECRUITING,NO,BIOLOGICAL: Umbilical cord mesenchymal stem cells implantation|OTHER: Comparator,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-01-28,2025-01
COMPLETED,NO,DRUG: Favipiravir,ALL,"ADULT, OLDER_ADULT",PHASE3,14,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-07,2020-12-28
RECRUITING,NO,BEHAVIORAL: Cognitive rehabilitation,ALL,ADULT,NA,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-14,2024-02
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Convalescent Plasma|OTHER: Standard of Care,ALL,"ADULT, OLDER_ADULT",PHASE2,475,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-11,2023-04
COMPLETED,NO,OTHER: decision science-based design,ALL,"ADULT, OLDER_ADULT",NA,360,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: OTHER,2021-03-13,2021-04-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Fostamatinib|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1600,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-10-27,2024-05
WITHDRAWN,NO,DIAGNOSTIC_TEST: Transpulmonary pressure measurements,ALL,CHILD,NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-05-21,2022-12
RECRUITING,NO,BEHAVIORAL: Yoga Therapy|BEHAVIORAL: Health Education,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-06-10,2024-11
RECRUITING,NO,DIAGNOSTIC_TEST: Cardiac Magnetic Resonance Imaging (CMR)|DIAGNOSTIC_TEST: Blood test|DIAGNOSTIC_TEST: 6-minute walk test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,112,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-09-01,2024-10-31
COMPLETED,NO,BIOLOGICAL: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|DRUG: COVID-19 standard care,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,146,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-04,2020-07-14
COMPLETED,YES,DRUG: Standard of Care (SOC) and Colchicine+Rosuvastatin,ALL,"ADULT, OLDER_ADULT",PHASE3,250,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-30,2022-03-30
NOT_YET_RECRUITING,NO,DRUG: RESP301,ALL,"ADULT, OLDER_ADULT",PHASE3,6400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-10-01,2026-05-14
RECRUITING,NO,DEVICE: Immunoadsorption,ALL,"ADULT, OLDER_ADULT",NA,66,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-10-01,2025-02
WITHDRAWN,NO,BIOLOGICAL: MVA-SARS-2-S|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-01-15,2022-11-02
RECRUITING,NO,DRUG: Azvudine|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,300,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-01-06,2023-05-15
WITHDRAWN,NO,DIETARY_SUPPLEMENT: 5-ALA-Phosphate + SFC (5-ALA+SFC),ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-08-15,2021-08-30
COMPLETED,YES,DRUG: Acalabrutinib,ALL,"ADULT, OLDER_ADULT",PHASE2,177,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-12,2020-11-17
RECRUITING,NO,BEHAVIORAL: COVID-19 Health Education Comic Books and Videos,ALL,"CHILD, ADULT, OLDER_ADULT",NA,900,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-01-17,2024-03
COMPLETED,YES,BIOLOGICAL: Biological: mRNA-1273|BIOLOGICAL: Placebo|BIOLOGICAL: mRNA-1273.351,ALL,"ADULT, OLDER_ADULT",PHASE2,660,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-05-29,2021-10-28
COMPLETED,NO,DRUG: GP30341 capsules 200 mg|DRUG: Standard therapy,ALL,"ADULT, OLDER_ADULT",NA,246,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-17,2022-07-20
COMPLETED,YES,DIAGNOSTIC_TEST: SARS-CoV-2 IgG Antibody Testing Kit,ALL,"ADULT, OLDER_ADULT",NA,571,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-01,2021-01-01
UNKNOWN,NO,BEHAVIORAL: Lifestyle change promotion program|BEHAVIORAL: Mindfullness based cognitive program|BEHAVIORAL: Written Information,ALL,"ADULT, OLDER_ADULT",NA,186,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-01-13,2022-07-12
COMPLETED,NO,DEVICE: non-invasive auricular vagus stimulation|DEVICE: Placebo Non Invasive Vagus Stimulation,ALL,ADULT,NA,44,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-03-09,2023-08-04
UNKNOWN,NO,BIOLOGICAL: COVID-19 convalescent plasma (CCP) plus standard of care (SOC)|BIOLOGICAL: Standard of care (SOC) plus placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,600,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-09-21,2022-07-31
COMPLETED,YES,DRUG: Fisetin|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-07-14,2022-09-27
RECRUITING,NO,DIAGNOSTIC_TEST: RT-PCR Test|DIAGNOSTIC_TEST: Real-time PCR Test,ALL,"ADULT, OLDER_ADULT",NA,550,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-11-28,2023-05
UNKNOWN,NO,BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cell) group,ALL,ADULT,PHASE3,1680,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-09-09,2022-12
UNKNOWN,NO,DRUG: Canrenoate Potassium|DRUG: Normal Saline,ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-01,2021-12-31
TERMINATED,NO,DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE3,148,OTHER,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-13,2020-07-20
UNKNOWN,NO,BIOLOGICAL: SCTV01C|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,300,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-12-22,2023-01-01
COMPLETED,NO,DEVICE: Application of CES via ear clips|DEVICE: Sham: No application of CES via ear clips,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-19,2022-03-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Pirfenidone|DRUG: Nintedanib,ALL,"ADULT, OLDER_ADULT",PHASE4,48,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-03-17,2022-11-30
COMPLETED,NO,BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|BIOLOGICAL: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,480,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-09-24,2022-01-19
NOT_YET_RECRUITING,NO,BEHAVIORAL: One day course|BEHAVIORAL: Individual follow-ups,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-11,2025-11
COMPLETED,NO,DIAGNOSTIC_TEST: Interlukein 6 and procalcitonin serum levels,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-01,2021-05-30
COMPLETED,NO,BIOLOGICAL: CoVAC-1,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,54,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-30,2023-04-30
COMPLETED,YES,DEVICE: NOWDx COVID-19 Test,ALL,"ADULT, OLDER_ADULT",NA,129,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-09-01,2020-12-31
COMPLETED,NO,OTHER: sensory re-education training|OTHER: traditional treatment,ALL,ADULT,NA,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-26,2023-10-30
UNKNOWN,NO,DRUG: Sofosbuvir 400 MG plus Daclatasvir 200mg,ALL,"ADULT, OLDER_ADULT",PHASE3,50,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-28,2021-09-03
ACTIVE_NOT_RECRUITING,NO,DRUG: EG-COVID-003|DRUG: EG-COVID-001|DRUG: A: EG-COVID|DRUG: B: EG-COVID|DRUG: C: EG-COVARo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,67,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-03-22,2024-08-01
UNKNOWN,NO,PROCEDURE: photobiomodulation and photodynamic therapy,ALL,"CHILD, ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-08-05,2022-02
UNKNOWN,NO,DRUG: IgIV,ALL,OLDER_ADULT,PHASE2,35,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-05,2021-05-05
COMPLETED,YES,DRUG: Canakinumab|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,454,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-04-30,2020-12-22
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2|BIOLOGICAL: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2|BIOLOGICAL: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2|BIOLOGICAL: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 3|BIOLOGICAL: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 3|BIOLOGICAL: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 3|BIOLOGICAL: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 1,ALL,CHILD,PHASE4,2520,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-07-27,2023-12-25
COMPLETED,NO,BIOLOGICAL: SARS-CoV-2 protein subunit recombinant vaccine|BIOLOGICAL: SARS-CoV-2 inactivated vaccine,ALL,"ADULT, OLDER_ADULT",PHASE1,175,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-02-16,2023-01-24
COMPLETED,YES,BIOLOGICAL: Thymic peptides,ALL,"ADULT, OLDER_ADULT",PHASE2,22,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-10,2021-05-14
COMPLETED,NO,DEVICE: STANDARD Q COVID-19 Ag Test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,1310,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-08-18,2022-12-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Moderna mRNA-1273|BIOLOGICAL: Vaccine 3 Dose|BIOLOGICAL: Vaccine 2 Dose,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,14232,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-12-01,2024-04-12
COMPLETED,NO,BIOLOGICAL: VLA2001,ALL,"ADULT, OLDER_ADULT",PHASE3,306,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-08-09,2022-11-18
RECRUITING,NO,DRUG: SP16 (6mg)|OTHER: Placebo|DRUG: SP16 (12 mg),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-01,2024-03
WITHDRAWN,NO,BIOLOGICAL: Mesenchymal stem cell|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-01,2023-03-31
RECRUITING,NO,"BIOLOGICAL: Placebo|BIOLOGICAL: COVID-19 Vaccine (Vero Cell) ,Inactivated|BIOLOGICAL: COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg|BIOLOGICAL: COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg|BIOLOGICAL: COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg",ALL,"ADULT, OLDER_ADULT",PHASE1,164,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-03-10,2024-06
RECRUITING,NO,DRUG: Imatinib|DRUG: Infliximab,ALL,"ADULT, OLDER_ADULT",PHASE4,400,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-06,2025-12
COMPLETED,YES,BIOLOGICAL: BNT162b2|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE4,160,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-10-21,2021-11-25
COMPLETED,NO,"COMBINATION_PRODUCT: Jinhua Qinggan (JHQG) Granules, Traditional Chinese Medicine|OTHER: Placebo Comparator",ALL,"ADULT, OLDER_ADULT",PHASE2,402,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-09-22,2021-08-23
RECRUITING,NO,BIOLOGICAL: COVID-19 Vaccine|OTHER: Diagnostic Laboratory Biomarker Analysis|BIOLOGICAL: Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1,ALL,"ADULT, OLDER_ADULT",PHASE2,240,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-09-27,2026-03-31
UNKNOWN,NO,OTHER: Pulmonary Rehabilitation,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-30,2021-01
COMPLETED,NO,DRUG: Molnupiravir (Esperavir)|DRUG: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE3,240,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-01,2022-03-11
COMPLETED,NO,DRUG: Cerebrolysin|OTHER: olfactory and gustatory trainings,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-30,2023-12-30
COMPLETED,NO,DRUG: Plitidepsin 1.5 mg / day|DRUG: Plitidepsin 2.0 mg / day|DRUG: Plitidepsin 2.5 mg / day,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,34,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-18,2022-03-16
RECRUITING,NO,OTHER: Generation of a biobank allowing the cryopreservation of leucocytes from COVID19 convalescent donors,ALL,"ADULT, OLDER_ADULT",NA,32,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-01,2024-01-15
COMPLETED,NO,DRUG: LSALT peptide|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,61,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-14,2022-06-02
RECRUITING,NO,DRUG: Echinaforce Forte tablets|DRUG: Echinaforce Chewable tablets|DRUG: Echinaforce tincture,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,75,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-11-15,2023-08
UNKNOWN,NO,OTHER: Blood sample,ALL,"CHILD, ADULT, OLDER_ADULT",NA,1000,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2020-07-15,2022-12-15
TERMINATED,YES,DRUG: Dociparstat sodium|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,27,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-08,2021-05-20
COMPLETED,NO,BEHAVIORAL: Self-management booklet (SWitCh: Stay well during COVID-19),ALL,"ADULT, OLDER_ADULT",NA,185,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-20,2021-10-01
COMPLETED,NO,DRUG: Hydroxychloroquine|DRUG: Oseltamivir|DRUG: Azithromycin,ALL,"ADULT, OLDER_ADULT",PHASE3,550,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-22,2020-11-22
COMPLETED,YES,DRUG: BGB-DXP593|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,181,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-02,2021-05-25
NOT_YET_RECRUITING,NO,DRUG: Amantadine,ALL,"ADULT, OLDER_ADULT",PHASE1,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-10-15,2025-05-15
COMPLETED,NO,BIOLOGICAL: COVAXIN(BBV152)|BIOLOGICAL: BBV154 Intranasal Vaccine,ALL,"ADULT, OLDER_ADULT",PHASE2,608,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-09-01,2022-07-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: CoronaVac|BIOLOGICAL: Placebo,ALL,ADULT,PHASE3,10214,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-09-14,2022-08-31
WITHDRAWN,NO,DRUG: Hydroxychloroquine as post exposure prophylaxis|OTHER: Others(No intervention),ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2020-04-01,2020-06-29
COMPLETED,NO,DRUG: Placebo|DRUG: Fluvoxamine,ALL,"ADULT, OLDER_ADULT",PHASE2,66,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-27,2022-05-31
RECRUITING,NO,BIOLOGICAL: TI-0010|BIOLOGICAL: Placebo,ALL,ADULT,PHASE1,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-07-10,2025-02-01
UNKNOWN,NO,DRUG: Ivermectin,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2020-04-25,2020-07-25
COMPLETED,NO,BIOLOGICAL: Convalescent plasma|DRUG: Hydroxychloroquin with Azithromycin,ALL,"ADULT, OLDER_ADULT",NA,49,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-03,2020-06-01
COMPLETED,YES,DRUG: EXO 1 inhalation|DRUG: EXO 2 inhalation|DRUG: Placebo inhalation,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: OTHER",2020-07-20,2020-10-20
ACTIVE_NOT_RECRUITING,NO,DIETARY_SUPPLEMENT: vitamin D|DIETARY_SUPPLEMENT: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,2024,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-28,2024-07-01
COMPLETED,NO,DIETARY_SUPPLEMENT: Vitamin D (cholecalciferol)|DIETARY_SUPPLEMENT: Herbal oil,ALL,"ADULT, OLDER_ADULT",NA,110,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-05-01,2022-01-31
COMPLETED,YES,BIOLOGICAL: mRNA-1273|BIOLOGICAL: mRNA-1273.351,ALL,"ADULT, OLDER_ADULT",PHASE1,135,NIH,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-03-31,2022-07-05
COMPLETED,NO,OTHER: Breathing exercise with the phone application|OTHER: Breathing exercise,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-02-25,2021-07-30
UNKNOWN,NO,BIOLOGICAL: Convalescent Plasma Infusion,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-01,2021-12-01
WITHDRAWN,NO,DEVICE: ensoETM device,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-10,2020-12
COMPLETED,NO,DIETARY_SUPPLEMENT: Probiotics|DIETARY_SUPPLEMENT: Placebo,ALL,"ADULT, OLDER_ADULT",NA,618,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-10-28,2022-12-04
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: 202-CoV low adjuvant dose|BIOLOGICAL: 202-CoV low antigen dose|BIOLOGICAL: 202-CoV standard dose|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,528,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-07-31,2023-11
UNKNOWN,NO,BIOLOGICAL: LYB001|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1900,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-01,2023-05
TERMINATED,NO,DRUG: Dexamethasone|DRUG: Methylprednisolone,ALL,"ADULT, OLDER_ADULT",PHASE4,127,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-01,2021-11-09
COMPLETED,NO,BIOLOGICAL: ChulaCov19 vaccine|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,192,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2021-05-03,2022-12-06
COMPLETED,NO,BIOLOGICAL: DS-5670a|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,142,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-03-15,2022-07-14
COMPLETED,NO,DRUG: Ruxolitinib Oral Tablet,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,77,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-01,2021-04-30
UNKNOWN,NO,DEVICE: Bedside lung ultrasound,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-05-10,2020-09-10
COMPLETED,NO,RADIATION: Low Dose Radiation Therapy (LD-RT)|OTHER: Sham irradiation,ALL,"ADULT, OLDER_ADULT",NA,22,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-11-02,2021-04-09
UNKNOWN,NO,BIOLOGICAL: SARS-Cov-2 mRNA vaccine immunization|BIOLOGICAL: Inactivated SARS-Cov-2 vaccine immunization,ALL,"ADULT, OLDER_ADULT",NA,112,UNKNOWN,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-07-02,2022-08-02
COMPLETED,NO,BIOLOGICAL: mRNA-1273|BIOLOGICAL: Ad26.COV2.S vaccine,ALL,"ADULT, OLDER_ADULT",PHASE4,336,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-10-21,2022-03-12
COMPLETED,NO,OTHER: convalescent plasma from recovered COVID 19 donor,ALL,"ADULT, OLDER_ADULT",PHASE2,575,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-18,2020-11-16
NOT_YET_RECRUITING,NO,DRUG: ACE2 Chewing Gum|OTHER: Placebo Chewing Gum,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2024-02,2024-04-01
COMPLETED,NO,OTHER: convalescent plasma application to SARS-CoV-2 infected patients,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-31,2020-06-30
UNKNOWN,NO,DRUG: Abidol hydrochloride|DRUG: Abidol Hydrochloride combined with Interferon atomization,ALL,"ADULT, OLDER_ADULT",PHASE4,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-02-01,2020-07-01
COMPLETED,NO,BIOLOGICAL: Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose|BIOLOGICAL: Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose|BIOLOGICAL: One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose|OTHER: Placebo,ALL,ADULT,PHASE1,90,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-08-10,2021-05-12
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: mRNA-1283.222|BIOLOGICAL: mRNA-1273.222,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,11471,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-03-28,2024-08-23
UNKNOWN,NO,DRUG: INC424 / Ruxolitinib,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2020-09-15
TERMINATED,YES,DRUG: Prazosin|OTHER: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE2,5,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-13,2022-03-31
RECRUITING,NO,BIOLOGICAL: A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray|OTHER: A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient,ALL,"ADULT, OLDER_ADULT",NA,108,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-05-01,2023-12-01
TERMINATED,NO,DRUG: OP-101|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,28,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-11,2022-08-12
COMPLETED,NO,DIAGNOSTIC_TEST: Brainstem Responses Assessment Sedation Score (BRASS)|DIAGNOSTIC_TEST: Electroencephalogram with EKG lead,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-09-14,2020-12-31
UNKNOWN,NO,DRUG: Hydroxychloroquine|DRUG: Indomethacin|DRUG: Zithromax Oral Product,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,80,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-16,2020-09-30
COMPLETED,NO,DRUG: XC221|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,118,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07-25,2020-10-29
COMPLETED,NO,DRUG: AZD 1222,ALL,"ADULT, OLDER_ADULT",PHASE3,10888,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-09-15,2022-12-30
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: serological testing,ALL,"ADULT, OLDER_ADULT",NA,500,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-03-22,2028-07
COMPLETED,NO,BIOLOGICAL: CoronaVac vaccine,ALL,"ADULT, OLDER_ADULT",NA,311,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-03-23,2022-02-25
RECRUITING,NO,DRUG: Remdesivir|DRUG: Imatinib Mesylate|DRUG: Dexamethasone|DRUG: Cenicriviroc|DRUG: Icatibant|DRUG: Apremilast|BIOLOGICAL: dornase alfa|DRUG: Celecoxib|DRUG: Famotidine|BIOLOGICAL: IC14|DRUG: Aviptadil|BIOLOGICAL: narsoplimab|DRUG: Cyproheptadine|DRUG: Cyclosporine,ALL,"ADULT, OLDER_ADULT",PHASE2,1500,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-31,2024-11-01
COMPLETED,NO,DRUG: Suspension of heat killed (autoclaved) Mycobacterium w|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",NA,40,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-30,2020-08-21
COMPLETED,NO,COMBINATION_PRODUCT: Plasma Exchange Procedure|OTHER: Sham Plasma Exchange Procedure,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-09-22,2023-06-06
COMPLETED,NO,DRUG: Anakinra 149 MG/ML Prefilled Syringe [Kineret],ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,179,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-08,2021-03-31
COMPLETED,NO,PROCEDURE: blood sample collection,ALL,"CHILD, ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-05-21,2023-05-21
WITHDRAWN,NO,OTHER: Olfactory retraining|DRUG: corticosteroid nasal irrigation|OTHER: smell household Items|OTHER: Nasal Irrigation,ALL,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-10,2022-03-10
COMPLETED,NO,BIOLOGICAL: Inactivated SARS-CoV-2 vaccine (Vero cell)|BIOLOGICAL: Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine,ALL,"ADULT, OLDER_ADULT",PHASE3,3000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-09-16,2021-12-13
RECRUITING,NO,OTHER: NIRS (Near-Infrared Spectroscopy),ALL,"ADULT, OLDER_ADULT",NA,37,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-06-22,2024-11-16
UNKNOWN,NO,DIETARY_SUPPLEMENT: CBDRA60 supplement|DIETARY_SUPPLEMENT: Placebo,ALL,"ADULT, OLDER_ADULT",NA,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-07-01,2022-12-28
UNKNOWN,NO,DRUG: EXO-CD24,ALL,"ADULT, OLDER_ADULT",PHASE1,35,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-25,2021-03-25
ENROLLING_BY_INVITATION,NO,DRUG: IV normal saline|DRUG: IV immunoglobulin,ALL,"ADULT, OLDER_ADULT",PHASE2,45,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-07-10,2024-04-06
WITHDRAWN,NO,DEVICE: geko T3,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-04,2022-11-08
NOT_YET_RECRUITING,NO,BIOLOGICAL: 50 μg Baiya SARS-CoV-2 Vax 2|OTHER: Placebo,ALL,ADULT,PHASE2,75,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-12,2024-08
COMPLETED,NO,DIAGNOSTIC_TEST: SARS-CoV-2 RNA detection,ALL,"CHILD, ADULT, OLDER_ADULT",NA,269,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-05-01,2021-09-30
COMPLETED,NO,BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cell),ALL,CHILD,PHASE2,400,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-11-04,2023-04-06
COMPLETED,NO,DRUG: 1: ILT101|DRUG: 2: Placebo Comparator,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-23,2021-04-05
COMPLETED,NO,"BIOLOGICAL: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|BIOLOGICAL: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|BIOLOGICAL: Two doses of placebo at the schedule of day 0,28|BIOLOGICAL: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,422,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-05-22,2022-05-31
COMPLETED,NO,OTHER: Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum,ALL,"ADULT, OLDER_ADULT",NA,16,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-03-20,2021-06-03
COMPLETED,YES,DRUG: HCQ|DRUG: HCQ+AZT|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,20,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-01,2020-07-27
COMPLETED,NO,BIOLOGICAL: Recombinant SARS-CoV-2 Fusion Protein Vaccine,ALL,"ADULT, OLDER_ADULT",PHASE1,43,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-08-07,2022-02-18
COMPLETED,YES,DRUG: Fluticasone|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1407,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-08-06,2022-05-18
TERMINATED,NO,BIOLOGICAL: blood samples,ALL,"ADULT, OLDER_ADULT",NA,2,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-05-19,2020-10-25
WITHDRAWN,NO,DRUG: Hydroxychloroquine|DIETARY_SUPPLEMENT: Vitamins and Minerals|DRUG: Azithromycin,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-11,2021-12
COMPLETED,NO,BIOLOGICAL: BNT162b2|BIOLOGICAL: BNT162b2 (B.1.1.7 + B.1.617.2)|BIOLOGICAL: BNT162b2 (B.1.1.7)|BIOLOGICAL: BNT162b2 (B.1.617.2)|BIOLOGICAL: BNT162b2 (B.1.1.529.1)|OTHER: Observational,ALL,"ADULT, OLDER_ADULT",PHASE2,1383,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-08-25,2023-10-04
WITHDRAWN,NO,DRUG: Ivermectin Pill|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-01,2021-06-30
COMPLETED,NO,BIOLOGICAL: AG0302-COVID19|BIOLOGICAL: AG0302-COVID19|BIOLOGICAL: AG0302-COVID19,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,30,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-08-31,2021-09-24
COMPLETED,YES,DEVICE: iCura COVID-19 Antigen Rapid Home Test|DEVICE: RT-PCR Test,ALL,"CHILD, ADULT, OLDER_ADULT",NA,332,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-12-09,2022-01-21
UNKNOWN,NO,DIAGNOSTIC_TEST: COVID-19 Swab,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2020-04-10,2020-06
NOT_YET_RECRUITING,NO,BIOLOGICAL: SCTV01E|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,10000,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-03,2024-10
UNKNOWN,NO,DRUG: Melphalan|OTHER: Standard of care,ALL,"ADULT, OLDER_ADULT",PHASE2,60,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-04-30,2020-10-30
ACTIVE_NOT_RECRUITING,NO,DIETARY_SUPPLEMENT: Omnibiotic AAD|DIETARY_SUPPLEMENT: Placebo,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-24,2023-12
COMPLETED,YES,DRUG: Hydroxychloroquine (HCQ),ALL,"ADULT, OLDER_ADULT",PHASE2,130,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-03,2020-10-01
COMPLETED,YES,DRUG: Molnupiravir 200 mg|DRUG: Molnupiravir 400 mg|DRUG: Molnupiravir 800 mg|DRUG: Placebo (PBO),ALL,"ADULT, OLDER_ADULT",PHASE2,204,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-19,2021-02-21
UNKNOWN,NO,DRUG: EgyVax Vaccine Candidate|DRUG: Placebo,ALL,ADULT,PHASE1,45,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2022-02-06,2023-06
UNKNOWN,NO,BIOLOGICAL: Natural Killer Cells infusion,ALL,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-02,2021-03-30
TERMINATED,YES,DRUG: Pegylated interferon lambda,ALL,"ADULT, OLDER_ADULT",PHASE2,14,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-06-22,2021-07-30
COMPLETED,NO,BIOLOGICAL: Blood sample|BIOLOGICAL: Low or upper respiratory tract sample|BIOLOGICAL: Stool collection or fecal swab|OTHER: phone call,ALL,"CHILD, ADULT",NA,140,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-05-05,2022-05-13
COMPLETED,YES,DRUG: Bromhexine Hydrochloride,ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-05-14,2020-08-31
COMPLETED,NO,DRUG: Danoprevir+Ritonavir,ALL,"ADULT, OLDER_ADULT",PHASE4,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-18,2020-04-15
UNKNOWN,NO,DRUG: PF-06650833|DRUG: Matching Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,68,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-01-06,2022-05-06
RECRUITING,NO,BIOLOGICAL: Novavax COVID-19 vaccine (2023-2024 formula XBB containing)|BIOLOGICAL: Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing),ALL,"ADULT, OLDER_ADULT",PHASE4,1500,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-11-22,2024-07-30
COMPLETED,NO,OTHER: CPC+ZN|OTHER: CPC|OTHER: Negative Control,ALL,"ADULT, OLDER_ADULT",NA,105,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-04-04,2021-10-30
WITHDRAWN,NO,BIOLOGICAL: vaccine BCG|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-08,2021-11
COMPLETED,NO,DRUG: Human immunoglobulin|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,146,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-04-11,2021-02-20
RECRUITING,NO,BEHAVIORAL: Web-based platform. (My Viva Plan),ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-08-25,2024-12-31
UNKNOWN,NO,DRUG: Apixaban|DRUG: Atorvastatin,ALL,"ADULT, OLDER_ADULT",PHASE3,2631,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-19,2024-01-31
TERMINATED,NO,DIAGNOSTIC_TEST: Rapid Diagnostic Test vs PCR,ALL,"ADULT, OLDER_ADULT",NA,192,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-01-27,2021-05-04
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: NDV-HXP-S 10μg|BIOLOGICAL: BNT162b2 30μg,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,4400,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-02-28,2024-09-25
UNKNOWN,NO,OTHER: Prone position,ALL,"ADULT, OLDER_ADULT",NA,248,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-05-13,2021-06
UNKNOWN,NO,DIETARY_SUPPLEMENT: Inflammation (I)|DIETARY_SUPPLEMENT: Inflammation (II)|DIETARY_SUPPLEMENT: Inflammation (III)|DRUG: Standard of care,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,120,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-02-01,2023-03
NOT_YET_RECRUITING,NO,DRUG: Vericiguat Oral Tablet,ALL,ADULT,PHASE2,104,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-02,2023-10
COMPLETED,YES,DRUG: Opaganib|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,475,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-21,2021-07-18
COMPLETED,NO,DEVICE: CanSwab,ALL,"ADULT, OLDER_ADULT",NA,169,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2020-12-22,2021-04-13
COMPLETED,YES,BIOLOGICAL: V110|BIOLOGICAL: V114|BIOLOGICAL: mRNA-1273|BIOLOGICAL: Placebo for V110|BIOLOGICAL: Placebo for V114,ALL,"ADULT, OLDER_ADULT",PHASE3,850,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-01-12,2023-02-21
COMPLETED,NO,DRUG: Famotidine 20 MG,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,208,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-01,2021-04-15
WITHDRAWN,NO,DRUG: Artemisinin / Artesunate|OTHER: placebo,ALL,ADULT,PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-01,2022-12
UNKNOWN,NO,DRUG: COVID-19 Convalscent Plasma,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,300,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-21,2020-12-30
RECRUITING,NO,OTHER: exercise programe,ALL,ADULT,NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-06-01,2025-09-01
RECRUITING,NO,DRUG: CDI-988|DRUG: Placebo,ALL,ADULT,PHASE1,56,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-09-27,2024-11
COMPLETED,NO,DRUG: Distilled Water|DRUG: 1% Povidone Iodine (PVP-I)|DRUG: 1.5% Hydrogen Peroxide (H2O2)|DRUG: 0.075% Cetylpyridinium Chloride (CPC)|DRUG: 0.1% Sodium Hypochlorite|OTHER: No rinse group,ALL,"ADULT, OLDER_ADULT",PHASE4,90,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-01-03,2021-12-10
COMPLETED,YES,BEHAVIORAL: Immediate vs. delayed provision of antibody test results,ALL,"ADULT, OLDER_ADULT",NA,1076,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SCREENING",2020-09-14,2020-11-11
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Offering SARS-CoV-2 test,ALL,"ADULT, OLDER_ADULT",NA,2389,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2023-02-06,2026-03
UNKNOWN,NO,BIOLOGICAL: intravenous immunoglobulin therapy,ALL,"ADULT, OLDER_ADULT",PHASE3,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-15,2020-11-15
COMPLETED,YES,DRUG: Mouth rinse,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-02-07,2022-07-13
TERMINATED,YES,DRUG: Pamrevlumab|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,22,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-20,2021-03-22
COMPLETED,NO,OTHER: Oxygen therapy,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-04-13,2021-08-27
TERMINATED,NO,DRUG: Evusheld (tixagevimab+cilgavimab) IM or IV,ALL,"ADULT, OLDER_ADULT",PHASE3,550,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-06-03,2023-06-30
COMPLETED,NO,DRUG: Almitrine|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,181,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-03,2021-12-17
UNKNOWN,NO,DRUG: Tocilizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,38,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-12,2020-05
UNKNOWN,NO,OTHER: whole body vibration training|OTHER: home based exercises,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-10-18,2022-12-20
RECRUITING,NO,BIOLOGICAL: MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray|OTHER: Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient,ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-12-17,2023-12-30
COMPLETED,NO,BIOLOGICAL: Gamma Variant RBD-based ARVAC-CG vaccine|BIOLOGICAL: Omicron Variant RBD-based ARVAC-CG vaccine|BIOLOGICAL: Bivalent RBD-based ARVAC-CG vaccine|OTHER: Placebo (Alum),ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,2014,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-02-06,2023-12-07
ACTIVE_NOT_RECRUITING,NO,DRUG: AZD7442,ALL,CHILD,PHASE1,46,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-21,2024-03-29
RECRUITING,NO,DRUG: Pycnogenol®|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,150,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-07,2025-06-01
ACTIVE_NOT_RECRUITING,NO,DRUG: agenT-797,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-21,2023-09-30
ACTIVE_NOT_RECRUITING,NO,DEVICE: Withings ScanWatch,ALL,"ADULT, OLDER_ADULT",NA,607,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-18,2023-06-30
UNKNOWN,NO,DRUG: Bromhexine and Spironolactone|DRUG: Base therapy,ALL,"ADULT, OLDER_ADULT",PHASE3,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-05-16,2020-08-23
NOT_YET_RECRUITING,NO,BEHAVIORAL: WATER+CT|BEHAVIORAL: Usual Care,ALL,"ADULT, OLDER_ADULT",NA,50,FED,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-04-01,2025-12-31
COMPLETED,NO,OTHER: Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol,ALL,"ADULT, OLDER_ADULT",NA,26,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-10-01,2021-09-20
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: COVID-19 Vaccine HIPRA|BIOLOGICAL: Cominarty (Pfizer-BioNtech),ALL,"ADULT, OLDER_ADULT",PHASE2,887,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-11-16,2023-06-01
COMPLETED,NO,OTHER: Counseling,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-05-05,2022-05-30
RECRUITING,NO,BIOLOGICAL: RegeneCyte|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,30,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-05-04,2024-10
COMPLETED,YES,BIOLOGICAL: VIR-7831 (sotrovimab)|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,1057,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-27,2021-09-02
ACTIVE_NOT_RECRUITING,NO,OTHER: sample blood,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-01-16,2024-01-15
COMPLETED,YES,BIOLOGICAL: SARS-CoV-2 convalescent plasma|BIOLOGICAL: Plasma from a volunteer donor,ALL,"ADULT, OLDER_ADULT",PHASE2,1225,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-03,2022-12-14
COMPLETED,YES,DRUG: BLD-2660,ALL,"ADULT, OLDER_ADULT",PHASE2,120,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-04,2021-06-21
RECRUITING,NO,DRUG: Nafamostat Mesilate|DRUG: Enoxaparin|DRUG: Dalteparin|DRUG: Tinzaparin|BIOLOGICAL: Hyperimmune globulin,ALL,"ADULT, OLDER_ADULT",PHASE3,2400,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-28,2024-12-31
COMPLETED,NO,DRUG: HFB30132A|OTHER: Placebo,ALL,ADULT,PHASE1,20,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-05-09,2022-02-22
UNKNOWN,NO,OTHER: Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-04-24,2022-10-24
COMPLETED,YES,BIOLOGICAL: Moderna COVID-19 Vaccine,ALL,ADULT,PHASE3,1923,NIH,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2021-03-24,2021-12-30
WITHDRAWN,NO,BIOLOGICAL: T regulatory cells,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03,2022-09
TERMINATED,NO,DRUG: RoActemra iv|DRUG: RoActemra sc|DRUG: Kevzara sc|OTHER: Standard medical care,ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-05,2020-10-08
NOT_YET_RECRUITING,NO,OTHER: wait-list|PROCEDURE: chiropractic adjustments,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-01-15,2025-01-15
RECRUITING,NO,DRUG: SA55 Injection,ALL,"ADULT, OLDER_ADULT",PHASE2,150,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-08-31,2024-08-30
COMPLETED,NO,COMBINATION_PRODUCT: Favipiravir and Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",NA,268,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-21,2021-04-26
ACTIVE_NOT_RECRUITING,NO,DRUG: Lambda 180 mcg S.C,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-07,2024-12-31
UNKNOWN,NO,BIOLOGICAL: medium dosage inactivated SARS-CoV-2 vaccine|BIOLOGICAL: high dosage inactivated SARS-CoV-2 vaccine|BIOLOGICAL: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,180,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-10-07,2022-02-28
COMPLETED,NO,OTHER: Convalescent SARS COVID-19 plasma|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",NA,333,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-15,2020-09-27
TERMINATED,NO,DRUG: DWJ1248|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,9,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-06-07,2021-10-06
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: SARS-CoV-2 Bivalent mRNA Vaccine|OTHER: Saline,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-08-10,2024-08-25
